# ESC Guidelines: Myocarditis Pericarditis (2025)

**Source**: `2025_Myocarditis_Pericarditis.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 90

---

## Table of Contents

- [2025 ESC Guidelines for the management of myocarditis and pericarditis](#2025-esc-guidelines-for-the-management-of-myocardi) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 7)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. What is new](#21-what-is-new) *(p. 8)*
  - [3. Epidemiology, classification, stages, diagnostic criteria and aetiology](#3-epidemiology,-classification,-stages,-diagnostic) *(p. 11)*
    - [3.1. Epidemiology](#31-epidemiology) *(p. 11)*
    - [3.2. Classification and stages](#32-classification-and-stages) *(p. 11)*
    - [3.3. Diagnostic criteria](#33-diagnostic-criteria) *(p. 12)*
      - [3.3.1. Diagnostic criteria for myocarditis](#331-diagnostic-criteria-for-myocarditis) *(p. 12)*
      - [3.3.2. Diagnostic criteria for pericarditis](#332-diagnostic-criteria-for-pericarditis) *(p. 15)*
    - [3.4. Aetiology of myocarditis and pericarditis](#34-aetiology-of-myocarditis-and-pericarditis) *(p. 15)*
      - [3.4.1. Aetiology of myocarditis](#341-aetiology-of-myocarditis) *(p. 15)*
      - [3.4.2. Aetiology of pericarditis](#342-aetiology-of-pericarditis) *(p. 15)*
  - [4. Clinical presentation of inflammatory myopericardial syndrome](#4-clinical-presentation-of-inflammatory-myopericar) *(p. 15)*
    - [4.1. General symptoms and signs](#41-general-symptoms-and-signs) *(p. 19)*
    - [4.2. Clinical stages of myocarditis](#42-clinical-stages-of-myocarditis) *(p. 19)*
      - [4.2.1. Acute myocarditis](#421-acute-myocarditis) *(p. 19)*
      - [4.2.2. Fulminant myocarditis](#422-fulminant-myocarditis) *(p. 20)*
      - [4.2.3. Subacute myocarditis](#423-subacute-myocarditis) *(p. 20)*
      - [4.2.4. Chronic myocarditis](#424-chronic-myocarditis) *(p. 20)*
    - [4.3. Clinical presentations of myocarditis](#43-clinical-presentations-of-myocarditis) *(p. 20)*
      - [4.3.1. Chest pain presentation](#431-chest-pain-presentation) *(p. 20)*
      - [4.3.2. Heart failure presentation](#432-heart-failure-presentation) *(p. 22)*
      - [4.3.3. Presentation with arrhythmias](#433-presentation-with-arrhythmias) *(p. 22)*
      - [4.3.4. Sudden cardiac death](#434-sudden-cardiac-death) *(p. 22)*
      - [4.3.5. Presentation of myocarditis with a potential genetic background](#435-presentation-of-myocarditis-with-a-potential-g) *(p. 22)*
    - [4.4. Clinical stages of pericarditis](#44-clinical-stages-of-pericarditis) *(p. 22)*
      - [4.4.1. Acute pericarditis](#441-acute-pericarditis) *(p. 22)*
      - [4.4.2. Subacute pericarditis](#442-subacute-pericarditis) *(p. 25)*
      - [4.4.3. Chronic pericarditis](#443-chronic-pericarditis) *(p. 25)*
    - [4.5. Clinical presentations of pericarditis](#45-clinical-presentations-of-pericarditis) *(p. 25)*
      - [4.5.1. Dry pericarditis](#451-dry-pericarditis) *(p. 25)*
      - [4.5.2. Effusive pericarditis](#452-effusive-pericarditis) *(p. 25)*
      - [4.5.3. Effusive–constrictive pericarditis](#453-effusive–constrictive-pericarditis) *(p. 25)*
      - [4.5.4. Pericarditis with cardiac tamponade](#454-pericarditis-with-cardiac-tamponade) *(p. 25)*
      - [4.5.5. Constrictive pericarditis](#455-constrictive-pericarditis) *(p. 26)*
      - [4.5.6. Transient constrictive pericarditis](#456-transient-constrictive-pericarditis) *(p. 27)*
        - [4.5.6.1. Constrictive pathophysiology](#4561-constrictive-pathophysiology) *(p. 27)*
      - [4.5.7. Pericarditis with polyserositis](#457-pericarditis-with-polyserositis) *(p. 28)*
      - [4.5.8. Inflammatory vs non-inflammatory pericarditis](#458-inflammatory-vs-non-inflammatory-pericarditis) *(p. 28)*
        - [4.5.8.1. Inflammatory phenotype of pericarditis](#4581-inflammatory-phenotype-of-pericarditis) *(p. 28)*
        - [4.5.8.2. Non-inflammatory phenotype of pericarditis](#4582-non-inflammatory-phenotype-of-pericarditis) *(p. 28)*
  - [5. Diagnosis and diagnostic work-up](#5-diagnosis-and-diagnostic-work-up) *(p. 28)*
    - [5.1. Electrocardiogram](#51-electrocardiogram) *(p. 29)*
    - [5.2. Biomarkers](#52-biomarkers) *(p. 29)*
      - [5.2.1. Biomarkers in clinical routine](#521-biomarkers-in-clinical-routine) *(p. 29)*
      - [5.2.2. Biomarkers beyond clinical routine](#522-biomarkers-beyond-clinical-routine) *(p. 29)*
    - [5.3. Genetics](#53-genetics) *(p. 30)*
    - [5.4. Multimodality imaging](#54-multimodality-imaging) *(p. 31)*
    - [5.5. Echocardiography](#55-echocardiography) *(p. 31)*
      - [5.5.1. Echocardiography in myocarditis](#551-echocardiography-in-myocarditis) *(p. 31)*
      - [5.5.2. Echocardiography in pericarditis](#552-echocardiography-in-pericarditis) *(p. 31)*
    - [5.6. Cardiovascular magnetic resonance](#56-cardiovascular-magnetic-resonance) *(p. 32)*
    - [5.7. Computed tomography](#57-computed-tomography) *(p. 32)*
    - [5.8. Nuclear medicine](#58-nuclear-medicine) *(p. 33)*
    - [5.9. Endomyocardial and pericardial biopsy](#59-endomyocardial-and-pericardial-biopsy) *(p. 33)*
      - [5.9.1. Endomyocardial biopsy](#591-endomyocardial-biopsy) *(p. 33)*
      - [5.9.2. Pericardial biopsy](#592-pericardial-biopsy) *(p. 35)*
    - [5.10. Role of autopsy](#510-role-of-autopsy) *(p. 35)*
    - [5.11. Role of cardiac catheterization and coronary angiography](#511-role-of-cardiac-catheterization-and-coronary-a) *(p. 35)*
    - [5.12. Electro-anatomical mapping](#512-electro-anatomical-mapping) *(p. 36)*
  - [6. Therapy](#6-therapy) *(p. 36)*
    - [6.1. Non-pharmacological therapy for inflammatory myopericardial syndrome](#61-non-pharmacological-therapy-for-inflammatory-my) *(p. 36)*
    - [6.2. Pharmacological therapy](#62-pharmacological-therapy) *(p. 36)*
      - [6.2.1. Pharmacological therapy for myocarditis](#621-pharmacological-therapy-for-myocarditis) *(p. 36)*
        - [6.2.1.1. General principles](#6211-general-principles) *(p. 36)*
        - [6.2.1.2. Fulminant myocarditis](#6212-fulminant-myocarditis) *(p. 38)*
        - [6.2.1.3. Acute myocarditis](#6213-acute-myocarditis) *(p. 38)*
        - [6.2.1.4. Subacute and chronic myocarditis](#6214-subacute-and-chronic-myocarditis) *(p. 39)*
      - [6.2.2. Pharmacological therapy for pericarditis](#622-pharmacological-therapy-for-pericarditis) *(p. 39)*
        - [6.2.2.1. General principles](#6221-general-principles) *(p. 39)*
          - [6.2.2.1.1. Acute pericarditis (first episode)](#62211-acute-pericarditis-(first-episode)) *(p. 39)*
        - [6.2.2.2. Incessant and recurrent pericarditis](#6222-incessant-and-recurrent-pericarditis) *(p. 39)*
    - [6.3. Interventional techniques including circulatory support](#63-interventional-techniques-including-circulatory) *(p. 42)*
      - [6.3.1. Myocarditis](#631-myocarditis) *(p. 42)*
        - [6.3.1.1. Short-term mechanical circulatory support](#6311-short-term-mechanical-circulatory-support) *(p. 42)*
        - [6.3.1.2. Intra-aortic balloon pump](#6312-intra-aortic-balloon-pump) *(p. 42)*
      - [6.3.2. Pericarditis](#632-pericarditis) *(p. 42)*
        - [6.3.2.1. Pericardiocentesis and pericardial drainage](#6321-pericardiocentesis-and-pericardial-drainage) *(p. 42)*
        - [6.3.2.2. Percutaneous balloon pericardiotomy](#6322-percutaneous-balloon-pericardiotomy) *(p. 43)*
        - [6.3.2.3. Intrapericardial drug administration](#6323-intrapericardial-drug-administration) *(p. 43)*
        - [6.3.2.4. Pericardioscopy](#6324-pericardioscopy) *(p. 43)*
        - [6.3.2.5. Pericardial fluid analysis, pericardial and epicardial biopsy](#6325-pericardial-fluid-analysis,-pericardial-and-e) *(p. 43)*
        - [6.3.2.6. Circulatory support](#6326-circulatory-support) *(p. 43)*
    - [6.4. Surgical therapy](#64-surgical-therapy) *(p. 43)*
      - [6.4.1. Myocarditis](#641-myocarditis) *(p. 43)*
      - [6.4.2. Pericarditis](#642-pericarditis) *(p. 43)*
        - [6.4.2.1. Surgical pericardiocentesis](#6421-surgical-pericardiocentesis) *(p. 43)*
        - [6.4.2.2. Pericardiotomy/pericardial window](#6422-pericardiotomy/pericardial-window) *(p. 43)*
        - [6.4.2.3. Pericardiectomy](#6423-pericardiectomy) *(p. 44)*
    - [6.5. Management of arrhythmias and prevention of sudden cardiac death in myocarditis](#65-management-of-arrhythmias-and-prevention-of-sud) *(p. 44)*
      - [6.5.1. Role of active devices (wearable and implanted devices) in acute myocarditis](#651-role-of-active-devices-(wearable-and-implanted) *(p. 45)*
  - [7. Prognosis](#7-prognosis) *(p. 45)*
    - [7.1. Complications and outcomes for myocarditis](#71-complications-and-outcomes-for-myocarditis) *(p. 45)*
      - [7.1.1. Sequela and mortality in myocarditis](#711-sequela-and-mortality-in-myocarditis) *(p. 46)*
      - [7.1.2. Follow-up](#712-follow-up) *(p. 46)*
    - [7.2. Complications and outcomes for pericarditis](#72-complications-and-outcomes-for-pericarditis) *(p. 47)*
  - [8. Inflammatory myopericardial syndrome overlapping types: myopericarditis and perimyocarditis](#8-inflammatory-myopericardial-syndrome-overlapping) *(p. 48)*
    - [8.1. Inflammatory myopericardial syndrome in systemic disorders](#81-inflammatory-myopericardial-syndrome-in-systemi) *(p. 49)*
      - [8.1.1. Rheumatoid arthritis](#811-rheumatoid-arthritis) *(p. 49)*
      - [8.1.2. Systemic lupus erythematosus](#812-systemic-lupus-erythematosus) *(p. 49)*
      - [8.1.3. Antiphospholipid syndrome](#813-antiphospholipid-syndrome) *(p. 49)*
      - [8.1.4. Sjögren's syndrome](#814-sjögren's-syndrome) *(p. 49)*
      - [8.1.5. Systemic sclerosis](#815-systemic-sclerosis) *(p. 49)*
      - [8.1.6. Polymyositis and dermatomyositis](#816-polymyositis-and-dermatomyositis) *(p. 49)*
      - [8.1.7. Vasculitis](#817-vasculitis) *(p. 49)*
    - [8.2. Inflammatory myopericardial syndrome in COVID-19 disease](#82-inflammatory-myopericardial-syndrome-in-covid-1) *(p. 49)*
  - [9. Specific types of myocarditis](#9-specific-types-of-myocarditis) *(p. 50)*
    - [9.1. Lymphocytic myocarditis](#91-lymphocytic-myocarditis) *(p. 50)*
      - [9.1.1. Presentation](#911-presentation) *(p. 50)*
      - [9.1.2. Diagnosis and therapy](#912-diagnosis-and-therapy) *(p. 50)*
    - [9.2. Eosinophilic myocarditis](#92-eosinophilic-myocarditis) *(p. 50)*
      - [9.2.1. Presentation](#921-presentation) *(p. 50)*
      - [9.2.2. Diagnosis](#922-diagnosis) *(p. 50)*
      - [9.2.3. Therapy](#923-therapy) *(p. 50)*
    - [9.3. Giant-cell myocarditis](#93-giant-cell-myocarditis) *(p. 50)*
      - [9.3.1. Presentation](#931-presentation) *(p. 51)*
      - [9.3.2. Diagnosis](#932-diagnosis) *(p. 51)*
      - [9.3.3. Therapy](#933-therapy) *(p. 51)*
    - [9.4. Myocarditis in sarcoidosis](#94-myocarditis-in-sarcoidosis) *(p. 52)*
      - [9.4.1. Presentation](#941-presentation) *(p. 52)*
      - [9.4.2. Diagnosis](#942-diagnosis) *(p. 52)*
      - [9.4.3. Therapy](#943-therapy) *(p. 52)*
    - [9.5. Specific infectious myocarditis (Viruses, Lyme, Chagas)](#95-specific-infectious-myocarditis-(viruses,-lyme,) *(p. 53)*
      - [9.5.1. Viruses](#951-viruses) *(p. 53)*
        - [9.5.1.1. Presentation](#9511-presentation) *(p. 53)*
        - [9.5.1.2. Diagnosis](#9512-diagnosis) *(p. 53)*
        - [9.5.1.3. Therapy](#9513-therapy) *(p. 53)*
          - [9.5.1.3.1. Influenza virus](#95131-influenza-virus) *(p. 53)*
          - [9.5.1.3.2. Human immunodeficiency virus](#95132-human-immunodeficiency-virus) *(p. 53)*
      - [9.5.2. Lyme carditis](#952-lyme-carditis) *(p. 53)*
        - [9.5.2.1. Presentation](#9521-presentation) *(p. 53)*
        - [9.5.2.2. Diagnosis](#9522-diagnosis) *(p. 53)*
        - [9.5.2.3. Therapy](#9523-therapy) *(p. 53)*
      - [9.5.3. Chagas disease](#953-chagas-disease) *(p. 54)*
        - [9.5.3.1. Presentation](#9531-presentation) *(p. 54)*
        - [9.5.3.2. Diagnosis](#9532-diagnosis) *(p. 54)*
        - [9.5.3.3. Therapy](#9533-therapy) *(p. 54)*
    - [9.6. Drug- or vaccine-induced myocarditis](#96-drug--or-vaccine-induced-myocarditis) *(p. 54)*
      - [9.6.1. Drug-induced myocarditis](#961-drug-induced-myocarditis) *(p. 54)*
        - [9.6.1.1. Immune checkpoint inhibitor-induced myocarditis](#9611-immune-checkpoint-inhibitor-induced-myocardit) *(p. 54)*
          - [9.6.1.1.1. Presentation](#96111-presentation) *(p. 54)*
          - [9.6.1.1.2. Diagnosis](#96112-diagnosis) *(p. 54)*
          - [9.6.1.1.3. Therapy](#96113-therapy) *(p. 54)*
        - [9.6.1.2. Other drugs associated with myocarditis](#9612-other-drugs-associated-with-myocarditis) *(p. 55)*
      - [9.6.2. Vaccine-induced myocarditis](#962-vaccine-induced-myocarditis) *(p. 55)*
    - [9.7. Pregnancy-associated myocarditis](#97-pregnancy-associated-myocarditis) *(p. 55)*
      - [9.7.1. Presentation](#971-presentation) *(p. 55)*
      - [9.7.2. Diagnosis](#972-diagnosis) *(p. 55)*
      - [9.7.3. Therapy](#973-therapy) *(p. 55)*
  - [10. Inflammatory cardiomyopathy](#10-inflammatory-cardiomyopathy) *(p. 55)*
    - [10.1. Presentation](#101-presentation) *(p. 56)*
    - [10.2. Diagnosis](#102-diagnosis) *(p. 56)*
    - [10.3. Therapy](#103-therapy) *(p. 56)*
  - [11. Specific types of pericarditis](#11-specific-types-of-pericarditis) *(p. 56)*
    - [11.1. Tuberculous pericarditis](#111-tuberculous-pericarditis) *(p. 56)*
      - [11.1.1. Presentation](#1111-presentation) *(p. 56)*
      - [11.1.2. Diagnosis](#1112-diagnosis) *(p. 56)*
      - [11.1.3. Therapy](#1113-therapy) *(p. 57)*
    - [11.2. Pericardial involvement in neoplastic disease](#112-pericardial-involvement-in-neoplastic-disease) *(p. 58)*
      - [11.2.1. Presentation](#1121-presentation) *(p. 58)*
      - [11.2.2. Diagnosis](#1122-diagnosis) *(p. 58)*
      - [11.2.3. Therapy](#1123-therapy) *(p. 58)*
    - [11.3. Post-cardiac injury syndrome](#113-post-cardiac-injury-syndrome) *(p. 58)*
      - [11.3.1. Diagnosis](#1131-diagnosis) *(p. 59)*
      - [11.3.2. Therapy](#1132-therapy) *(p. 59)*
    - [11.4. Pericarditis and autoinflammatory diseases](#114-pericarditis-and-autoinflammatory-diseases) *(p. 59)*
    - [11.5. Purulent pericarditis](#115-purulent-pericarditis) *(p. 59)*
      - [11.5.1. Presentation](#1151-presentation) *(p. 60)*
      - [11.5.2. Diagnosis](#1152-diagnosis) *(p. 60)*
      - [11.5.3. Therapy](#1153-therapy) *(p. 60)*
    - [11.6. Incessant and recurrent pericarditis](#116-incessant-and-recurrent-pericarditis) *(p. 60)*
    - [11.7. Inflammatory and non-inflammatory pericardial effusion](#117-inflammatory-and-non-inflammatory-pericardial-) *(p. 60)*
      - [11.7.1. Classification and aetiology](#1171-classification-and-aetiology) *(p. 60)*
      - [11.7.2. Presentation](#1172-presentation) *(p. 60)*
      - [11.7.3. Diagnosis](#1173-diagnosis) *(p. 61)*
      - [11.7.4. Therapy](#1174-therapy) *(p. 62)*
      - [11.7.5. Prognosis and follow-up](#1175-prognosis-and-follow-up) *(p. 62)*
    - [11.8. Cardiac tamponade](#118-cardiac-tamponade) *(p. 62)*
      - [11.8.1. Presentation](#1181-presentation) *(p. 62)*
      - [11.8.2. Aetiology and diagnosis](#1182-aetiology-and-diagnosis) *(p. 62)*
      - [11.8.3. Therapy](#1183-therapy) *(p. 63)*
      - [11.8.4. Outcomes and prognosis](#1184-outcomes-and-prognosis) *(p. 63)*
    - [11.9. Pericardial constriction and constrictive pericarditis (calcified and non-calcified)](#119-pericardial-constriction-and-constrictive-peri) *(p. 63)*
      - [11.9.1. Introduction](#1191-introduction) *(p. 63)*
      - [11.9.2. Presentation](#1192-presentation) *(p. 63)*
      - [11.9.3. Diagnosis](#1193-diagnosis) *(p. 63)*
      - [11.9.4. Therapy](#1194-therapy) *(p. 64)*
    - [11.10. Effusive–constrictive pericarditis](#1110-effusive–constrictive-pericarditis) *(p. 64)*
      - [11.10.1. Introduction](#11101-introduction) *(p. 64)*
      - [11.10.2. Aetiology](#11102-aetiology) *(p. 64)*
      - [11.10.3. Presentation](#11103-presentation) *(p. 64)*
      - [11.10.4. Diagnosis](#11104-diagnosis) *(p. 64)*
      - [11.10.5. Treatment](#11105-treatment) *(p. 64)*
  - [12. Age- and sex-related aspects in inflammatory myopericardial syndrome](#12-age--and-sex-related-aspects-in-inflammatory-my) *(p. 64)*
    - [12.1. Sex distribution](#121-sex-distribution) *(p. 64)*
    - [12.2. Paediatric patients](#122-paediatric-patients) *(p. 65)*
      - [12.2.1. Myocarditis](#1221-myocarditis) *(p. 65)*
      - [12.2.2. Pericarditis](#1222-pericarditis) *(p. 65)*
    - [12.3. Pregnancy, lactation, and reproductive issues](#123-pregnancy,-lactation,-and-reproductive-issues) *(p. 65)*
    - [12.4. The elderly](#124-the-elderly) *(p. 66)*
    - [12.5. Physical activity in inflammatory myopericardial syndrome](#125-physical-activity-in-inflammatory-myopericardi) *(p. 66)*
      - [12.5.1. Mental health effect of restricting exercise](#1251-mental-health-effect-of-restricting-exercise) *(p. 66)*
    - [12.6. Multidisciplinary teams for the management of inflammatory myopericardial syndrome](#126-multidisciplinary-teams-for-the-management-of-) *(p. 66)*
  - [13. Advice for patients](#13-advice-for-patients) *(p. 67)*
  - [14. Tertiary referral centres for inflammatory myopericardial syndrome: feature and volume of activity](#14-tertiary-referral-centres-for-inflammatory-myop) *(p. 67)*
    - [14.1. Tertiary care centres](#141-tertiary-care-centres) *(p. 67)*
    - [14.2. Inflammatory myopericardial syndrome in regional centres](#142-inflammatory-myopericardial-syndrome-in-region) *(p. 67)*
    - [14.3. Hub-and-spoke model](#143-hub-and-spoke-model) *(p. 67)*
    - [14.4. Teamwork, competencies, and advances in imaging techniques](#144-teamwork,-competencies,-and-advances-in-imagin) *(p. 68)*
  - [15. Key messages](#15-key-messages) *(p. 68)*
    - [15.1. Aetiology](#151-aetiology) *(p. 68)*
    - [15.2. Clinical presentation and diagnosis](#152-clinical-presentation-and-diagnosis) *(p. 68)*
    - [15.3. Therapy](#153-therapy) *(p. 68)*
    - [15.4. Prognosis and outcomes](#154-prognosis-and-outcomes) *(p. 68)*
    - [15.5. Multidisciplinary team](#155-multidisciplinary-team) *(p. 68)*
  - [16. Gaps in evidence](#16-gaps-in-evidence) *(p. 68)*
    - [16.1. Myocarditis](#161-myocarditis) *(p. 68)*
    - [16.2. Pericarditis](#162-pericarditis) *(p. 69)*
  - [17. Sex differences](#17-sex-differences) *(p. 69)*
  - [18. ‘What to do’ and ‘What not to do’ messages from the Guidelines](#18-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 69)*
  - [19. Evidence tables](#19-evidence-tables) *(p. 72)*
  - [20. Data availability statement](#20-data-availability-statement) *(p. 72)*
  - [21. Author information](#21-author-information) *(p. 72)*
  - [Appendix](#appendix) *(p. 73)*
    - [ESC Scientific Document Group](#esc-scientific-document-group) *(p. 73)*
  - [References](#references) *(p. 74)*
  - [References](#references) *(p. 74)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2025 ESC Guidelines for the management 
of myocarditis and pericarditis 
Developed by the task force for the management of myocarditis and 
pericarditis of the European Society of Cardiology (ESC) 
Endorsed by the Association for European Paediatric and 
Congenital Cardiology (AEPC) and the European Association 
for Cardio-Thoracic Surgery (EACTS) 
Authors/Task Force Members: Jeanette Schulz-Menger  
†,*, (Chairperson) 
(Germany), Valentino Collini  
‡, (Task Force Co-ordinator) (Italy), 
Jan Gröschel  
‡, (Task Force Co-ordinator) (Germany), Yehuda Adler (Israel), 
Antonio Brucato  
(Italy), Vanessa Christian (United Kingdom),  
Vanessa M. Ferreira  
(United Kingdom), Estelle Gandjbakhch  
(France), 
Bettina Heidecker  
(Germany), Mathieu Kerneis  
(France), Allan L. Klein  
(United States of America), Karin Klingel  
(Germany), George Lazaros  
(Greece), Roberto Lorusso  
(Netherlands), Elena G. Nesukay  
(Ukraine), 
Kazem Rahimi  
(United Kingdom), Arsen D. Ristić  
(Serbia), Marcin Rucinski  
(Poland), Leyla Elif Sade  
(United States of America), Hannah Schaubroeck 
(Belgium), Anne Grete Semb  
(Norway), Gianfranco Sinagra  
(Italy),  
Jens Jakob Thune  
(Denmark), Massimo Imazio  
†,*, (Chairperson) (Italy), and 
the ESC Scientific Document Group 
* Corresponding authors: Jeanette Schulz-Menger, Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, ECRC 
Experimental and Clinical Research Center, Berlin, Germany, and DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany, and Deutsches 
Herzzentrum der Charité Berlin, Germany, and Cardiology and Nephrology, HELIOS Hospital Berlin-Buch, Berlin, Germany. Tel: +4930450540611, E-mail: jeanette.schulz- 
menger@charite.de 
Massimo Imazio, Department of Medicine, University of Udine, and Cardiothoracic Department, University Hospital Santa Maria della Misericordia, ASUFC, Udine, Italy. Tel: +393296524271, 
E-mail: massimo.imazio@uniud.it 
† The two Chairpersons contributed equally to the document and are joint corresponding authors. 
‡ The two Task Force Co-ordinators contributed equally to the document. 
Author/Task Force Member affiliations are listed in author information. 
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix. 
ESC subspecialty communities having participated in the development of this document: 
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA). 
Councils: Council for Cardiology Practice, Council of Cardio-Oncology, Council on Basic Cardiovascular Science. 
Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Myocardial and Pericardial Diseases, Pulmonary Circulation and Right Ventricular Function. 
Patient Forum 
© The European Society of Cardiology 2025. All rights reserved.  
https://doi.org/10.1093/eurheartj/ehaf192 
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Elena Arbelo, (CPG Review Co-ordinator) (Spain), Cristina Basso, (CPG Review 
Co-ordinator) (Italy), Marianna Adamo (Italy), Suleman Aktaa (United Kingdom), Enrico Ammirati (Italy), 
Lisa Anderson (United Kingdom), Eloisa Arbustini (Italy), Emanuele Bobbio (Sweden), Giuseppe Boriani (Italy), 
Margarita Brida (Croatia), Robert A. Byrne (Ireland), Alida L.P. Caforio (Italy), Gh.-Andrei Dan (Romania), 
Fernando Domínguez (Spain), Suzanne Fredericks (Canada), Geeta Gulati (Norway), Borja Ibanez (Spain), 
Stefan James (Sweden), Alexander Kharlamov (Netherlands), Sabine Klaassen (Germany), Jolanda Kluin 
(Netherlands), Konstantinos C. Koskinas (Switzerland), Petr Kuchynka (Czech Republic), Vijay Kunadian (United 
Kingdom), Ulf Landmesser (Germany), Gregory Y.H. Lip (United Kingdom), Bernhard Maisch (Germany), 
Federica Marelli-Berg (United Kingdom), Pilar Martin (Spain), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Inge Moelgaard (Denmark), Saidi A. Mohiddin (United 
Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Giovanni Peretto (Italy), Kalliopi Pilichou 
(Italy), Nicolas Piriou (France), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), 
Xavier Rossello (Spain), Anna Sannino (Germany), Franziska Seidel1 (Germany), Felix C. Tanner (Switzerland), 
Witold Zbyszek Tomkowski (Poland), Ilonca Vaartjes (Netherlands), Sophie Van Linthout (Germany), 
Christiaan Vrints (Belgium), Romuald Wojnicz (Poland), and Katja Zeppenfeld (Netherlands) 
1 Representing the Association for European Paediatric and Congenital Cardiology (AEPC). 
All experts involved in the development of these guidelines have submitted declarations of interest, 
which are reported in a supplementary document to the guidelines. See the European Heart Journal online 
or https://www.escardio.org/Guidelines for supplementary documents as well as evidence tables. 
Disclaimer: The European Society of Cardiology (ESC) Guidelines represent the views of the ESC and were produced after careful 
consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in 
the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines 
issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals 
are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the 
implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way 
whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s 
health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC 
Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or 
guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data 
pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and 
regulations relating to drugs and medical devices prior to making any clinical decision and to check whether a more recent version of this 
document exists. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect. 
Permissions: The content of these ESC Guidelines has been published for personal and educational use only. No commercial use is 
authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. 
Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal 
and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).  
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
Keywords 
Guidelines • Myocarditis • Pericarditis • Myopericarditis • Perimyocarditis • Diagnosis • Therapy • 
Echocardiography • Cardiac magnetic resonance • Multimodality imaging • Endomyocardial biopsy  
Table of contents 
1. Preamble ...................................................................................................................... 7 
2. Introduction ............................................................................................................... 8 
2.1. What is new .....................................................................................................
8 
3. Epidemiology, classification, stages, diagnostic criteria and aetiology
11 
3.1. Epidemiology .................................................................................................. 11 
3.2. Classification and stages ............................................................................ 11 
3.3. Diagnostic criteria ........................................................................................ 12 
3.3.1. Diagnostic criteria for myocarditis ...............................................
12 
3.3.2. Diagnostic criteria for pericarditis ................................................
15 
3.4. Aetiology of myocarditis and pericarditis .......................................... 15 
3.4.1. Aetiology of myocarditis ..................................................................
15 
3.4.2. Aetiology of pericarditis ...................................................................
15 
4. Clinical presentation of inflammatory myopericardial syndrome .... 15 
4.1. General symptoms and signs ................................................................... 19 
4.2. Clinical stages of myocarditis .................................................................. 19 
4.2.1. Acute myocarditis ...............................................................................
19 
4.2.2. Fulminant myocarditis ........................................................................
20 
4.2.3. Subacute myocarditis .........................................................................
20


<!-- PAGE 3 -->

### Page 3

4.2.4. Chronic myocarditis ...........................................................................
20 
4.3. Clinical presentations of myocarditis ................................................... 20 
4.3.1. Chest pain presentation ...................................................................
20 
4.3.2. Heart failure presentation ................................................................
22 
4.3.3. Presentation with arrhythmias .......................................................
22 
4.3.4. Sudden cardiac death .........................................................................
22 
4.3.5. Presentation of myocarditis with a potential genetic 
background .........................................................................................................
22 
4.4. Clinical stages of pericarditis ................................................................... 22 
4.4.1. Acute pericarditis .................................................................................
22 
4.4.2. Subacute pericarditis ..........................................................................
25 
4.4.3. Chronic pericarditis ............................................................................
25 
4.5. Clinical presentations of pericarditis .................................................... 25 
4.5.1. Dry pericarditis .....................................................................................
25 
4.5.2. Effusive pericarditis .............................................................................
25 
4.5.3. Effusive–constrictive pericarditis ...................................................
25 
4.5.4. Pericarditis with cardiac tamponade ...........................................
25 
4.5.5. Constrictive pericarditis ....................................................................
26 
4.5.6. Transient constrictive pericarditis ................................................
27 
4.5.6.1. Constrictive pathophysiology ................................................
27 
4.5.7. Pericarditis with polyserositis .........................................................
28 
4.5.8. Inflammatory vs non-inflammatory pericarditis ......................
28 
4.5.8.1. Inflammatory phenotype of pericarditis ............................
28 
4.5.8.2. Non-inflammatory phenotype of pericarditis .................
28 
5. Diagnosis and diagnostic work-up ................................................................. 28 
5.1. Electrocardiogram ........................................................................................ 29 
5.2. Biomarkers ...................................................................................................... 29 
5.2.1. Biomarkers in clinical routine .........................................................
29 
5.2.2. Biomarkers beyond clinical routine .............................................
29 
5.3. Genetics ............................................................................................................ 30 
5.4. Multimodality imaging ................................................................................. 31 
5.5. Echocardiography ......................................................................................... 31 
5.5.1. Echocardiography in myocarditis ..................................................
31 
5.5.2. Echocardiography in pericarditis ...................................................
31 
5.6. Cardiovascular magnetic resonance ..................................................... 32 
5.7. Computed tomography ............................................................................. 32 
5.8. Nuclear medicine ......................................................................................... 33 
5.9. Endomyocardial and pericardial biopsy .............................................. 33 
5.9.1. Endomyocardial biopsy .....................................................................
33 
5.9.2. Pericardial biopsy .................................................................................
35 
5.10. Role of autopsy .......................................................................................... 35 
5.11. Role of cardiac catheterization and coronary angiography ..... 35 
5.12. Electro-anatomical mapping .................................................................. 36 
6. Therapy ..................................................................................................................... 36 
6.1. Non-pharmacological therapy for inflammatory 
myopericardial syndrome .................................................................................. 36 
6.2. Pharmacological therapy ........................................................................... 36 
6.2.1. Pharmacological therapy for myocarditis ..................................
36 
6.2.1.1. General principles .......................................................................
36 
6.2.1.2. Fulminant myocarditis ...............................................................
38 
6.2.1.3. Acute myocarditis .......................................................................
38 
6.2.1.4. Subacute and chronic myocarditis .......................................
39 
6.2.2. Pharmacological therapy for pericarditis ...................................
39 
6.2.2.1. General principles .......................................................................
39 
6.2.2.1.1. Acute pericarditis (first episode) .................................
39 
6.2.2.2. Incessant and recurrent pericarditis ...................................
39 
6.3. Interventional techniques including circulatory support ............. 42 
6.3.1. Myocarditis .............................................................................................
42 
6.3.1.1. Short-term mechanical circulatory support ....................
42 
6.3.1.2. Intra-aortic balloon pump .......................................................
42 
6.3.2. Pericarditis ..............................................................................................
42 
6.3.2.1. Pericardiocentesis and pericardial drainage .....................
42 
6.3.2.2. Percutaneous balloon pericardiotomy ...............................
43 
6.3.2.3. Intrapericardial drug administration ....................................
43 
6.3.2.4. Pericardioscopy ............................................................................
43 
6.3.2.5. Pericardial fluid analysis, pericardial and epicardial 
biopsy ...............................................................................................................
43 
6.3.2.6. Circulatory support ...................................................................
43 
6.4. Surgical therapy ............................................................................................. 43 
6.4.1. Myocarditis .............................................................................................
43 
6.4.2. Pericarditis ..............................................................................................
43 
6.4.2.1. Surgical pericardiocentesis ......................................................
43 
6.4.2.2. Pericardiotomy/pericardial window ....................................
43 
6.4.2.3. Pericardiectomy ...........................................................................
44 
6.5. Management of arrhythmias and prevention of sudden 
cardiac death in myocarditis ............................................................................. 44 
6.5.1. Role of active devices (wearable and implanted devices) in 
acute myocarditis .............................................................................................
45 
7. Prognosis .................................................................................................................. 45 
7.1. Complications and outcomes for myocarditis ................................ 45 
7.1.1. Sequela and mortality in myocarditis ..........................................
46 
7.1.2. Follow-up ................................................................................................
46 
7.2. Complications and outcomes for pericarditis ................................. 47 
8. Inflammatory myopericardial syndrome overlapping types: 
myopericarditis and perimyocarditis ................................................................. 48 
8.1. Inflammatory myopericardial syndrome in systemic disorders
49 
8.1.1. Rheumatoid arthritis ..........................................................................
49 
8.1.2. Systemic lupus erythematosus .......................................................
49 
8.1.3. Antiphospholipid syndrome ............................................................
49 
8.1.4. Sjögren’s syndrome .............................................................................
49 
8.1.5. Systemic sclerosis ................................................................................
49 
8.1.6. Polymyositis and dermatomyositis ...............................................
49 
8.1.7. Vasculitis ..................................................................................................
49 
8.2. Inflammatory myopericardial syndrome in COVID-19 disease
49 
9. Specific types of myocarditis ............................................................................ 50 
9.1. Lymphocytic myocarditis .......................................................................... 50 
9.1.1. Presentation ...........................................................................................
50 
9.1.2. Diagnosis and therapy .......................................................................
50 
9.2. Eosinophilic myocarditis ............................................................................ 50 
9.2.1. Presentation ...........................................................................................
50 
9.2.2. Diagnosis .................................................................................................
50 
9.2.3. Therapy ....................................................................................................
50 
9.3. Giant-cell myocarditis ................................................................................. 50 
9.3.1. Presentation ...........................................................................................
51 
9.3.2. Diagnosis .................................................................................................
51 
9.3.3. Therapy ....................................................................................................
51 
9.4. Myocarditis in sarcoidosis ......................................................................... 52 
9.4.1. Presentation ...........................................................................................
52 
9.4.2. Diagnosis .................................................................................................
52 
9.4.3. Therapy ....................................................................................................
52 
9.5. Specific infectious myocarditis (Viruses, Lyme, Chagas) ............. 53 
9.5.1. Viruses ......................................................................................................
53 
9.5.1.1. Presentation ..................................................................................
53 
9.5.1.2. Diagnosis .........................................................................................


<!-- PAGE 4 -->

### Page 4

9.5.1.3. Therapy ...........................................................................................
53 
9.5.1.3.1. Influenza virus .......................................................................
53 
9.5.1.3.2. Human immunodeficiency virus ...................................
53 
9.5.2. Lyme carditis ..........................................................................................
53 
9.5.2.1. Presentation ..................................................................................
53 
9.5.2.2. Diagnosis .........................................................................................
53 
9.5.2.3. Therapy ...........................................................................................
53 
9.5.3. Chagas disease ......................................................................................
54 
9.5.3.1. Presentation ..................................................................................
54 
9.5.3.2. Diagnosis .........................................................................................
54 
9.5.3.3. Therapy ...........................................................................................
54 
9.6. Drug- or vaccine-induced myocarditis ................................................ 54 
9.6.1. Drug-induced myocarditis ................................................................
54 
9.6.1.1. Immune checkpoint inhibitor-induced myocarditis ......
54 
9.6.1.1.1. Presentation ..........................................................................
54 
9.6.1.1.2. Diagnosis ................................................................................
54 
9.6.1.1.3. Therapy ...................................................................................
54 
9.6.1.2. Other drugs associated with myocarditis .........................
55 
9.6.2. Vaccine-induced myocarditis ..........................................................
55 
9.7. Pregnancy-associated myocarditis ......................................................... 55 
9.7.1. Presentation ...........................................................................................
55 
9.7.2. Diagnosis .................................................................................................
55 
9.7.3. Therapy ....................................................................................................
55 
10. Inflammatory cardiomyopathy ..................................................................... 55 
10.1. Presentation ................................................................................................. 56 
10.2. Diagnosis ....................................................................................................... 56 
10.3. Therapy .......................................................................................................... 56 
11. Specific types of pericarditis .......................................................................... 56 
11.1. Tuberculous pericarditis ......................................................................... 56 
11.1.1. Presentation ........................................................................................
56 
11.1.2. Diagnosis ...............................................................................................
56 
11.1.3. Therapy .................................................................................................
57 
11.2. Pericardial involvement in neoplastic disease ................................ 58 
11.2.1. Presentation ........................................................................................
58 
11.2.2. Diagnosis ...............................................................................................
58 
11.2.3. Therapy .................................................................................................
58 
11.3. Post-cardiac injury syndrome ............................................................... 58 
11.3.1. Diagnosis ...............................................................................................
59 
11.3.2. Therapy .................................................................................................
59 
11.4. Pericarditis and autoinflammatory diseases ................................... 59 
11.5. Purulent pericarditis ................................................................................. 59 
11.5.1. Presentation ........................................................................................
60 
11.5.2. Diagnosis ...............................................................................................
60 
11.5.3. Therapy .................................................................................................
60 
11.6. Incessant and recurrent pericarditis .................................................. 60 
11.7. Inflammatory and non-inflammatory pericardial effusion ........ 60 
11.7.1. Classification and aetiology ...........................................................
60 
11.7.2. Presentation ........................................................................................
60 
11.7.3. Diagnosis ...............................................................................................
61 
11.7.4. Therapy .................................................................................................
62 
11.7.5. Prognosis and follow-up ................................................................
62 
11.8. Cardiac tamponade ................................................................................... 62 
11.8.1. Presentation ........................................................................................
62 
11.8.2. Aetiology and diagnosis ..................................................................
62 
11.8.3. Therapy .................................................................................................
63 
11.8.4. Outcomes and prognosis ..............................................................
63 
11.9. Pericardial constriction and constrictive pericarditis 
(calcified and non-calcified) ............................................................................... 63 
11.9.1. Introduction .........................................................................................
63 
11.9.2. Presentation ........................................................................................
63 
11.9.3. Diagnosis ...............................................................................................
63 
11.9.4. Therapy .................................................................................................
64 
11.10. Effusive–constrictive pericarditis ...................................................... 64 
11.10.1. Introduction ......................................................................................
64 
11.10.2. Aetiology ............................................................................................
64 
11.10.3. Presentation ......................................................................................
64 
11.10.4. Diagnosis ............................................................................................
64 
11.10.5. Treatment ..........................................................................................
64 
12. Age- and sex-related aspects in inflammatory myopericardial 
syndrome ....................................................................................................................... 64 
12.1. Sex distribution ........................................................................................... 64 
12.2. Paediatric patients ..................................................................................... 65 
12.2.1. Myocarditis ...........................................................................................
65 
12.2.2. Pericarditis ............................................................................................
65 
12.3. Pregnancy, lactation, and reproductive issues ............................... 65 
12.4. The elderly .................................................................................................... 66 
12.5. Physical activity in inflammatory myopericardial syndrome .... 66 
12.5.1. Mental health effect of restricting exercise ...........................
66 
12.6. Multidisciplinary teams for the management of inflammatory 
myopericardial syndrome .................................................................................. 66 
13. Advice for patients ............................................................................................ 67 
14. Tertiary referral centres for inflammatory myopericardial 
syndrome: feature and volume of activity ....................................................... 67 
14.1. Tertiary care centres ................................................................................ 67 
14.2. Inflammatory myopericardial syndrome in regional centres .. 67 
14.3. Hub-and-spoke model ............................................................................. 67 
14.4. Teamwork, competencies, and advances in imaging 
techniques ................................................................................................................ 68 
15. Key messages ....................................................................................................... 68 
15.1. Aetiology ....................................................................................................... 68 
15.2. Clinical presentation and diagnosis .................................................... 68 
15.3. Therapy .......................................................................................................... 68 
15.4. Prognosis and outcomes ........................................................................ 68 
15.5. Multidisciplinary team .............................................................................. 68 
16. Gaps in evidence ................................................................................................. 68 
16.1. Myocarditis ................................................................................................... 68 
16.2. Pericarditis .................................................................................................... 69 
17. Sex differences .................................................................................................... 69 
18. ‘What to do’ and ‘What not to do’ messages from the Guidelines
69 
19. Evidence tables .................................................................................................... 72 
20. Data availability statement .............................................................................. 72 
21. Author information ........................................................................................... 72 
22. Appendix ................................................................................................................ 73 
ESC Scientific Document Group ........................................................................ 73 
23. References ............................................................................................................. 74 
Tables of Recommendations 
Recommendation Table 1 — Recommendations for clinical 
evaluation of myocarditis and pericarditis (see Evidence Table 1) ....... 28 
Recommendation Table 2 — Recommendations for genetic testing 
(see Evidence Table 2) ............................................................................................. 30


<!-- PAGE 5 -->

### Page 5

Recommendation Table 3 — Recommendations for the use of 
cardiovascular magnetic resonance imaging (see Evidence Table 3) ... 32 
Recommendation Table 4 — Recommendations for computed 
tomography (see Evidence Table 4) .................................................................. 32 
Recommendation Table 5 — Recommendations for nuclear 
medicine (see Evidence Table 5) ......................................................................... 33 
Recommendation Table 6 — Recommendations for 
endomyocardial biopsy (see Evidence Table 6) ............................................ 34 
Recommendation Table 7 — Recommendations for autopsy (see 
Evidence Table 7) ....................................................................................................... 35 
Recommendation Table 8 — Recommendations for 
electro-anatomical mapping (see Evidence Table 8) .................................. 36 
Recommendation Table 9 — Recommendations for medical 
therapy in myocarditis (see Evidence Table 9) ............................................. 39 
Recommendation Table 10 — Recommendations for medical 
therapy in pericarditis (see Evidence Table 10) ............................................ 42 
Recommendation Table 11 — Recommendations for interventional 
techniques including circulatory support in myocarditis (see 
Evidence Table 11) .................................................................................................... 42 
Recommendation Table 12 — Recommendations for interventional 
techniques in pericarditis (see Evidence Table 12) ..................................... 43 
Recommendation Table 13 — Recommendations for surgical 
therapy (see Evidence Table 13) ......................................................................... 44 
Recommendation Table 14 — Recommendations for management 
of arrhythmias and prevention of sudden cardiac death in 
myocarditis (see Evidence Table 14) ................................................................. 45 
Recommendation Table 15 — Recommendations for risk 
stratification, complications, and outcomes of inflammatory 
myopericardial syndrome (see Evidence Table 15) .................................... 47 
Recommendation Table 16 — Recommendations for giant-cell 
myocarditis (see Evidence Table 16) ................................................................. 51 
Recommendation Table 17 — Recommendations for myocarditis in 
sarcoidosis (see Evidence Table 17) .................................................................. 52 
Recommendation Table 18 — Recommendations for immune 
checkpoint inhibitor-associated myocarditis (see Evidence Table 18)
55 
Recommendation Table 19 — Recommendations for inflammatory 
cardiomyopathy (see Evidence Table 19) ....................................................... 56 
Recommendation Table 20 — Recommendations for tuberculous 
pericarditis (see Evidence Table 20) .................................................................. 57 
Recommendation Table 21 — Recommendations for neoplastic 
pericardial involvement (see Evidence Table 21) ......................................... 58 
Recommendation Table 22 — Recommendations for post-cardiac 
injury syndrome (see Evidence Table 22) ....................................................... 59 
Recommendation Table 23 — Recommendations for purulent 
pericarditis (see Evidence Table 23) .................................................................. 60 
Recommendation Table 24 — Recommendations for constrictive 
pericarditis (see Evidence Table 24) .................................................................. 64 
Recommendation Table 25 — Recommendations for pregnancy, 
lactation, and reproductive issues (see Evidence Table 25) .................... 65 
Recommendation Table 26 — Recommendations for physical 
activity and myocarditis/pericarditis (see Evidence Table 26) ................ 66 
Recommendation Table 27 — Recommendations for 
multidisciplinary teams in myopericardial syndromes (see Evidence 
Table 27) ........................................................................................................................ 66  
List of tables 
Table 1 Classes of recommendations .................................................................. 7 
Table 2 Levels of evidence ........................................................................................ 8 
Table 3 Terminology and stages .......................................................................... 11 
Table 4 Diagnostic criteria and classification for inflammatory 
myopericardial syndrome ....................................................................................... 13 
Table 5 Histopathological criteria for myocarditis ...................................... 13 
Table 6 Red flags for the clinical diagnosis of myocarditis and 
pericarditis ..................................................................................................................... 16 
Table 7 Clinical risk stratification to guide work-up in inflammatory 
myopericardial syndrome ....................................................................................... 16 
Table 8 Causes of cardiac tamponade .............................................................. 25 
Table 9 Basic and advanced level assessment ................................................ 29 
Table 10 Classification of pericardial effusion ............................................... 31 
Table 11 Parameters for reporting by endomyocardial biopsy ............. 35 
Table 12 Therapy for specific forms of myocarditis .................................. 37 
Table 13 Specific initial dosing and duration of therapy for acute and 
recurrent pericarditis ............................................................................................... 40 
Table 14 Tapering of corticosteroids ............................................................... 40 
Table 15 Follow-up in inflammatory myopericardial syndrome after 
discharge ........................................................................................................................ 47 
Table 16 Indicators of non-viral aetiologies and complications 
(high-risk features or red flags in acute pericarditis) .................................. 48 
Table 17 Echocardiographic signs of cardiac tamponade ..................................... 62 
Table 18 Definitions and therapy of main constrictive pericardial 
syndromes ..................................................................................................................... 63 
Table 19 ‘What to do’ and ‘What not to do’ ............................................... 69  
List of figures 
Figure 1 Central illustration of the ESC guidelines on myocarditis and 
pericarditis ........................................................................................................................ 9 
Figure 2 Paradigm change in the clinical diagnosis of myocarditis ........ 10 
Figure 3 Stages of inflammatory myopericardial syndrome .................... 12 
Figure 4 Diagnostic criteria by cardiovascular magnetic resonance 
based on the updated Lake Louise criteria ..................................................... 14 
Figure 5 Diagnostic algorithm and triage for inpatient myocarditis ..... 17 
Figure 6 Diagnostic algorithm and triage for outpatient myocarditis . 18 
Figure 7 Diagnostic algorithm and triage for pericarditis ......................... 19 
Figure 8 Spectrum of myocarditis presentations and outcomes .......... 20 
Figure 9 Diagnostic algorithm for acute chest pain presentation ......... 21 
Figure 10 Diagnostic algorithm for acute heart failure presentation .. 23 
Figure 11 Diagnostic algorithm for arrhythmia presentation ................. 24 
Figure 12 Management of cardiac tamponade .............................................. 26 
Figure 13 Management of constriction ............................................................. 27 
Figure 14 The different courses of inflammatory myopericardial 
syndrome and the interplay between genetic background 
inflammation and autoimmunity beyond the initial infectious trigger . 31 
Figure 15 Histopathological findings in myocarditis .................................... 34 
Figure 16 Proposed algorithm of medical therapy for pericarditis in 
adults (not including interventional therapies and pericardiectomy) .. 41 
Figure 17 Follow-up and risk stratification after acute myocarditis 
with arrhythmic presentation ............................................................................... 48 
Figure 18 Stages of tuberculous pericarditis .................................................. 57 
Figure 19 Triage and management of pericardial effusion ....................... 61 
Figure 20 Multidisciplinary teams for inflammatory myopericardial 
syndrome ....................................................................................................................... 67  
Abbreviations and acronyms 
ACC 
American College of Cardiology 
ACS 
Acute coronary syndrome  
ESC Guidelines                                                                                                                                                                                                 5


<!-- PAGE 6 -->

### Page 6

ADA 
Adenosine deaminase 
AF 
Atrial fibrillation 
AM 
Acute myocarditis 
AMI 
Acute myocardial infarction 
AP 
Acute pericarditis 
ARVC 
Arrhythmogenic right ventricular cardiomyopathy 
ATG 
Anti-thymocyte globulin 
AVB 
Atrioventricular block 
B19V 
Parvovirus B19 
CAD 
Coronary artery disease 
CD 
Chagas disease 
CI 
Confidence interval 
CK 
Creatinine kinase 
CK-MB 
Creatinine kinase muscle-brain type 
CMP 
Cardiomyopathy 
CMR 
Cardiovascular magnetic resonance 
CMV 
Cytomegalovirus 
COVID-19 
Coronavirus disease 2019 
CP 
Constrictive pericarditis 
CPB 
Cardiopulmonary bypass 
CRT 
Cardiac resynchronization therapy 
CS 
Cardiac sarcoidosis 
CT 
Computed tomography 
CTLA-4 
Cytotoxic T-lymphocyte antigen 4 
CTP 
Cardiac tamponade 
DCM 
Dilated cardiomyopathy 
DNA 
Deoxyribonucleic acid 
DSP 
Desmoplakin 
EAM 
Electro-anatomical mapping 
EBV 
Epstein–Barr virus 
ECG 
Electrocardiogram 
ECP 
Effusive–constrictive pericarditis 
ECV 
Extracellular volume 
EF 
Ejection fraction 
EGPA 
Eosinophilic granulomatosis with polyangiitis 
EM 
Eosinophilic myocarditis 
EMB 
Endomyocardial biopsy 
ESC 
European Society of Cardiology 
ESR 
Erythrocyte sedimentation rate 
FDG-PET 
Fluorodeoxyglucose positron emission 
tomography 
FM 
Fulminant myocarditis 
FMF 
Familial Mediterranean fever 
GCM 
Giant-cell myocarditis 
GDMT 
Guideline-directed medical therapy 
GLS 
Global longitudinal strain 
HAART 
Highly active antiretroviral therapy 
HCM 
Hypertrophic cardiomyopathy 
HCV 
Hepatitis C virus 
HES 
Hypereosinophilic syndrome 
HF 
Heart failure 
HHV-6 
Human herpesvirus 6 
HIV 
Human immunodeficiency virus 
HR 
Hazard ratio 
hs-TnI 
High-sensitivity troponin I 
hs-TnT 
High-sensitivity troponin T 
HT 
Heart transplantation 
IABP 
Intra-aortic balloon pump 
ICD 
Implantable cardioverter-defibrillator  
ICI 
Immune checkpoint inhibitor 
ICU 
Intensive care unit 
IFN 
Interferon 
IL 
Interleukin 
IL-1RA 
Interleukin-1 receptor antagonist 
IL-1RL1 
IL-1 receptor-like 1 
IMPS 
Inflammatory myopericardial syndrome 
i.v. 
Intravenous 
IVIG 
Intravenous immunoglobulins 
JVP 
Jugular venous pressure 
LA 
Left atrial 
LAG-3 
Lymphocyte activation gene 3 
LC 
Lyme carditis 
LGE 
Late gadolinium enhancement 
LLC 
Lake Louise criteria 
LM 
Lymphocytic myocarditis 
LV 
Left ventricle 
LVAD 
Left ventricular assist device 
LVEF 
Left ventricular ejection fraction 
MACE 
Major adverse cardiac events 
MCS 
Mechanical circulatory support 
miRNAs 
MicroRNAs 
NDLVC 
Non-dilated left ventricular cardiomyopathy 
NLRP3 
NLR family pyrin domain containing 3 
NSAID 
Non-steroidal anti-inflammatory drug 
NSVT 
Non-sustained ventricular tachycardia 
NT-proBNP 
N-terminal prohormone of brain natriuretic 
peptide 
OR 
Odds ratio 
P/LP 
Pathogenic/likely pathogenic 
PaM 
Pregnancy-associated myocarditis 
PCIS 
Post-cardiac injury syndrome 
PCR 
Polymerase chain reaction 
PD-1 
Programmed cell death protein 1 
PD-L1 
Programmed death ligand 1 
PEff 
Pericardial effusion 
PPCM 
Peripartum cardiomyopathy 
PPS 
Post-pericardiotomy syndrome 
PVS 
Programmed ventricular stimulation 
RA 
Rheumatoid arthritis 
RAP 
Right atrial pressure 
RCM 
Restrictive cardiomyopathy 
RCT 
Randomized controlled trial 
RNA 
Ribonucleic acid 
RP 
Recurrent pericarditis 
RV 
Right ventricle 
SARS-CoV-2 
Severe acute respiratory syndrome coronavirus 2 
SCD 
Sudden cardiac death 
SLE 
Systemic lupus erythematosus 
SSc 
Systemic sclerosis 
TB 
Tuberculosis 
TDI 
Tissue Doppler imaging 
TF 
Task Force 
TNF-α 
Tumour necrosis factor alpha 
TRAPS 
Tumour necrosis factor receptor-associated 
periodic syndrome 
TTE 
Transthoracic echocardiography 
uIFN-γ 
Unstimulated interferon gamma 
VA 
Ventricular arrhythmias


<!-- PAGE 7 -->

### Page 7

VA-ECMO 
Veno-arterial extracorporeal membrane oxygenation 
VAD 
Ventricular assist device 
VF 
Ventricular fibrillation 
VT 
Ventricular tachycardia 
WCD 
Wearable cardioverter-defibrillator 
WMA 
Wall motion abnormalities 
1. Preamble 
Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic 
approach for an individual patient with a given condition. ESC Guidelines 
are intended for use by health professionals but do not override their individual responsibility to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with the 
patient or the patient’s caregiver where appropriate and/or necessary. It is 
also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession. 
ESC Guidelines represent the official position of the ESC on a given 
topic. Guideline topics are selected for updating after annual expert review of new evidence conducted by the ESC Clinical Practice 
Guidelines (CPG) Committee. ESC Policies and Procedures for formulating and issuing ESC Guidelines can be found on the ESC website 
(https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/ 
Guidelines-development/Writing-ESC-Guidelines). 
This guideline updates and replaces the previous version of the ESC 
Guidelines on pericarditis from 2015. For the first time it also covers 
myocarditis. This Task Force was selected by the ESC to include professionals involved with the medical care of patients with this pathology 
and to include patient representatives and methodologists. The selection procedure included an open call for authors and aimed to include 
members from across the whole of the ESC region and from relevant 
ESC Subspecialty Communities. Consideration was given to diversity 
and inclusion. 
Guidelines Task Forces perform a critical review and evaluation of 
the published literature on diagnostic and therapeutic approaches including assessment of the risk–benefit ratio. Recommendations are 
based on major randomized trials and relevant systematic reviews 
and meta-analyses, when available. Systematic literature searches are 
conducted in cases of controversy or uncertainty to ensure that all 
key studies were considered. For recommendations related to diagnosis and prognosis, additional types of evidence are included, such as 
diagnostic accuracy studies and studies focused on the development 
and validation of prognostic models. The strength of each recommendation and the level of evidence supporting it are weighed and scored 
according to predefined criteria as outlined in Tables 1 and 2. 
Patient-reported outcome measures (PROMs) and patient-reported 
experience measures (PREMs) are also evaluated when available as 
the basis for recommendations and/or discussion in these guidelines. 
Evidence tables summarizing key information from relevant studies 
are generated to facilitate the formulation of recommendations, to enhance comprehension of recommendations after publication, and to 
reinforce transparency in the guidelines development process. The tables are published in their own section of ESC Guidelines and reference 
specific recommendation tables. 
After an iterative process of deliberations, a first Task Force vote 
on all recommendations is conducted prior to the initiation of rounds 
of review. A second Task Force vote on all recommendations is conducted after the final round of review and revision. For each vote, the 
Task Force follows ESC voting procedures and all recommendations 
require at least 75% agreement among voting members to be approved. Voting restrictions may be applied based on declarations of 
interests. 
Table 1 Classes of recommendations  
©



	





	
	










	



 
 	­

	




	

	


ESC Guidelines                                                                                                                                                                                                 7


<!-- PAGE 8 -->

### Page 8

The writing and reviewing panels provide declaration of interest 
forms for all relationships that might be perceived as real or potential 
sources of conflicts of interest. Their declarations of interest are reviewed according to the ESC declaration of interest rules, which can 
be found on the ESC website (http://www.escardio.org/doi) and are 
compiled in a report published in a supplementary document with 
the guidelines. Funding for the development of ESC Guidelines is derived entirely from the ESC with no involvement of the healthcare 
industry. 
The CPG Committee supervises and co-ordinates the preparation of 
new guidelines and approves their publication. In addition to review by 
the CPG Committee, ESC Guidelines undergo multiple rounds of 
double-blind peer review on a dedicated online review platform. The 
review is conducted by topic experts, including members from ESC 
National Cardiac Societies and from relevant ESC Subspecialty 
Communities. Guideline Task Forces consider all review comments 
and are required to respond to all those classified as major. After appropriate revisions, the Task Force and the CPG Committee members 
approve the final document for publication in the European Heart 
Journal. 
Unless otherwise stated, ESC Guidelines content refers to sex, 
understood as the biological condition of being male or female, defined 
by genes, hormones and sexual organs. Off-label use of medication may 
be presented in this guideline if a sufficient level of evidence shows that 
it can be considered medically appropriate for a given condition. 
However, decisions on off-label use must be made by the responsible 
health professional giving special consideration to ethical rules concerning healthcare, the specific situation of the patient, patient consent, and 
country-specific health regulations. 
2. Introduction 
Myocarditis and pericarditis are inflammatory diseases of the myocardium and pericardium, respectively, with potential overlap. These are 
the first ESC clinical practice guidelines covering the whole spectrum 
of these diseases. 
Herein, the Task Force (TF) introduces the term ‘inflammatory myopericardial syndrome’ (IMPS). IMPS is an umbrella term during the initial 
diagnostic process until a final diagnosis is made (Figure 1). It reflects the 
possible myocarditis–pericarditis overlap, aiming to increase the awareness of the spectrum of disease, and to allow timely diagnosis and better 
management. IMPS ranges from isolated myocarditis to isolated pericarditis through mixed forms with possible reciprocal involvement, such as 
myopericarditis and perimyocarditis. Both terms are commonly used in 
the medical literature, and defined in the 2015 ESC Guidelines for the 
diagnosis and management of pericardial diseases (see Section 8).1 
The rationale for the introduction of IMPS is that myocarditis and 
pericarditis have similar aetiologies and are anatomical contiguous 
structures with possible secondary involvement.2–5 
The field has experienced rapid growth, with position statements 
proposed by different cardiac societies.6–10 In the past, several consensus statements were provided, usually defining a proven myocarditis 
based on endomyocardial biopsy (EMB). Endomyocardial biopsy is 
able to detect the histological type, can identify some specific aetiologies, and can help to differentiate from non-inflammatory cardiomyopathies (CMPs).10 But nowadays multimodality imaging has become a 
cornerstone for the diagnosis of myocardial and pericardial inflammation and cardiovascular magnetic resonance (CMR) plays a crucial 
role, as reported in other ESC guidelines11–13 (Figure 2). 
The aim of these guidelines is to provide evidence-based guidance for 
clinical management of IMPS, to guide clinicians of all subspecialties 
from a clinical point of view, and to ensure qualified shared decision- 
making with patients (see Section 13 and Supplementary data online,  
Section 8). 
2.1. What is new 
Guidelines on pericarditis have been published twice before,1,15 while 
myocarditis will be covered for the first time in a guideline. The TF believes that combined guidelines with the recognition of the spectrum of 
disease are a step in a new direction, enabling a paradigm shift towards 
therapy based on the combined input from experts in inflammatory 
diseases of the myocardium and pericardium, with the support of a 
multidisciplinary team. In order to improve the awareness of the spectrum of disease, a new category, ‘inflammatory myopericardial syndrome (IMPS)’, will be introduced as an umbrella term to increase 
the understanding of the potential myocarditis–pericarditis overlap.  
Table 2 Levels of evidence  







	
		
	


		
							
					
©


<!-- PAGE 9 -->

### Page 9








	
















	








	





















	














 
 
 















 



­



­





­­























Figure 1 Central illustration of the ESC guidelines on myocarditis and pericarditis. ECG, electrocardiogram; EMB, endomyocardial biopsy; IMPS, 
inflammatory myopericardial syndrome; SCD, sudden cardiac death; TTE, transthoracic echocardiography.   
ESC Guidelines                                                                                                                                                                                                 9


<!-- PAGE 10 -->

### Page 10

It is introduced as an entering diagnostic term to lead to a tailored work- 
up and individualized therapy. Patient-oriented case management is proposed in different settings such as diagnosis and therapy, as well as return 
to work and play avoiding strict time definitions, since the remission pathway differs from patient to patient. In addition, a novelty in the field of 
IMPS is the improved knowledge on its possible genetic background 
and its link to specific inherited CMPs. Furthermore, a paradigm shift 
will be introduced in its diagnostic management. This is reflecting the 
new capabilities of multimodality imaging, especially CMR, as it has changed clinical workflow during recent years. A similar change was introduced in the American College of Cardiology (ACC) consensus 
statement in 2024.9 Endomyocardial biopsy has its place and is needed 
if specific decisions are warranted. 
In comparison with the last ESC Guidelines for the diagnosis 
and management of pericardial diseases,1 the current understanding 
of the pathogenesis of pericarditis has greatly improved with new evidence on the importance of the interplay between inflammation and 
autoinflammatory mechanisms, the role of genetic background, and 
immune responses in patients with multiple recurrences. The identification of a positive family history, a poor response to colchicine, and 
a clinical presentation with an inflammatory or non-inflammatory 
phenotype are useful tools to guide the selection of patients for genetic testing and specific pharmacological options. A new class of drugs 
targeting interleukin-1 (IL-1), the so-called anti-IL-1 agents, has become available and is used in recurrent cases with a poor response 
to other conventional therapies. Nevertheless, we need to further improve our understanding of the pathogenesis of non-inflammatory disease forms. 
Moreover, diagnostic capabilities have increased, thanks to the role 
of multimodality imaging, allowing improved diagnostic accuracy and 






	


		






	



		

Figure 2 Paradigm change in the clinical diagnosis of myocarditis. CMR, cardiovascular magnetic resonance; EMB, endomyocardial biopsy. Both EMB 
and CMR can provide a definitive clinical diagnosis but with different indications. Details are given in Section 5. 2013 Reference: Caforio et al.10 2021 and 
2023 References: Keren et al., Law et al.6,14


<!-- PAGE 11 -->

### Page 11

individualized duration of therapies according to clinical and imaging 
findings. 
The TF recommends establishing a multidisciplinary IMPS team to 
ensure optimal patient care in complicated cases. 
We firmly believe that recognizing IMPS will enhance the understanding of these inflammatory conditions and hope it will inspire further research to advance personalized diagnostic and therapeutic 
approaches. 
3. Epidemiology, classification, 
stages, diagnostic criteria and 
aetiology 
3.1. Epidemiology 
Population-based studies of the incidence or prevalence of IMPS are 
limited, and most epidemiological studies assess disease burden and 
sequelae in selected patient groups, such as those admitted to hospital. However, such studies might underestimate the true disease 
burden. For example, the rate of patients diagnosed with acute myocarditis (AM) increases from 5% to 13% with the use of CMR among 
patients with angina-like symptoms and increased high-sensitivity 
troponin T (hs-TnT).16 A different registry reported an incidence 
of 6.3–8.6 per 100 000 inhabitants, mostly in young men.17 The current global burden of cardiovascular disease data reports a prevalence of 4.2–8.7 per 100 000 in the age range between 35 and 
39 years.18 Men and younger patients are more likely to be diagnosed, although this could reflect the diagnostic bias towards these 
patient groups.19 
In children <2 years of age, the sex distribution is balanced; in adolescents there is a male prevalence (about two-thirds of cases),20,21 
which is also maintained in adult patients, suggesting the importance 
of hormonal factors. 
The incidence of acute pericarditis (AP) is estimated to be about 3– 
32 cases per 100 000 person-years.22,23 Similar to myocarditis, men and 
younger individuals are more likely to be diagnosed. Recurrence occurs 
in about 20%–30% of patients within 18 months after a first episode 
of AP.24 The recurrence rate increases up to 50% after the first recurrence.25 Pericarditis is diagnosed in 0.2% of all cardiovascular in-hospital 
admissions and is responsible for 5% of emergency room admissions for 
chest pain.23 In the observational Epidémiologie de la Douleur 
Thoracique (EPIDOULTHO) study, 3% of patients received a final diagnosis of IMPS.26 
3.2. Classification and stages 
The field of IMPS gained increasing awareness and interest during the 
coronavirus disease 2019 (COVID-19) pandemic.27 Research in the 
field of all forms of IMPS has a long history, and several terminologies 
exist. This is also reflected in the definition of stages. We are proposing 
a terminology from a clinical point of view with the intention of guiding 
the appropriate management of patients (Table 3). In addition, time 
frames for the stages (acute, subacute, and chronic) are suggested to 
be used for myocarditis and pericarditis. However, it is not always possible from a clinical point of view to identify the disease onset, for instance in subacute cases.1 
IMPS is characterized by different stages (see Figure 3). The course of 
the disease differs among patients. A patient may recover completely 
without any residuals, but others may develop complications, in some 
cases leading to death. Patients may not experience every stage. 
Complete remission can occur at every timepoint. However, a deep 
understanding of the respective stages is essential for appropriate 
therapeutic guidance. 
Table 3 Terminology and stages 
Terminology 
Definition  
IMPS 
Umbrella term for inflammatory myocardial 
and pericardial syndromes 
Myopericarditis 
Predominant pericarditisa 
Perimyocarditis 
Predominant myocarditisb 
Acute myocarditis 
Duration of symptoms ≤4 weeks 
Fulminant if: 
• Acute onset28 and haemodynamically 
unstable patients requiring inotropes or 
mechanical circulatory support  
Complicated myocarditis 
AM and ≥1 of the following:28 
• LVEF <50% on echocardiogram 
• Sustained ventricular arrhythmias 
• Advanced heart block 
• Heart failure 
• Cardiogenic shock 
Acute pericarditis 
Duration of symptoms ≤4 weeks 
Subacute/ongoing 
myocarditis 
Duration of symptoms >4 weeks to 
≤3 months 
Subacute/incessant 
pericarditisc 
Duration of symptoms >4 weeks to 
≤3 months 
Chronic myocarditis/ 
pericarditis 
Duration of symptoms >3 months 
Inflammatory 
cardiomyopathy 
Chronic myocarditis in association with cardiac 
dysfunction and ventricular remodelling with 
clinical phenotype of hypokinetic, either dilated 
or non-dilated cardiomyopathy with/without 
arrhythmogenic substrate 
Recurrent myocarditis/ 
pericarditis 
New symptoms or disease activity after clinical 
remission 
Remission without 
residuals 
Regression/absence of symptoms, 
normalization of ECG, biomarkers, imaging 
abnormalities (echocardiography and CMR) 
Remission with residuals 
Regression/absence of symptoms, persistence 
of abnormalities on ECG, biomarkers and/or 
imaging (functional and/or structural 
abnormalities in echocardiography or CMR) 
© ESC 2025
AM, acute myocarditis; CK-MB, creatine kinase muscle-brain type; CMR, cardiovascular 
magnetic resonance; ECG, electrocardiogram; IMPS, inflammatory myopericardial 
syndrome; LVEF, left ventricular ejection fraction. 
aPatients with definite criteria for pericarditis and elevated biomarkers of myocardial injury 
(high-sensitivity troponin I or T, CK-MB fraction) without newly developed regional or 
global impairment of left ventricular function in echocardiography or CMR. 
bPatients with definite criteria for pericarditis and elevated biomarkers of myocardial injury 
(high-sensitivity troponin I or T, CK-MB fraction) with newly developed regional or global 
impairment of left ventricular function in echocardiography or CMR. 
cIncessant/ongoing pericarditis: the term incessant pericarditis describes patients with 
persistent symptoms without a symptom-free interval of >4 weeks despite full-dose 
guideline-directed medical therapy (including corticosteroids), or those relapsing early 
during the tapering.   
ESC Guidelines                                                                                                                                                                                               11


<!-- PAGE 12 -->

### Page 12

3.3. Diagnostic criteria 
After the original proposed diagnostic criteria from the consensus paper 
in 2013,10 multimodality imaging, in particular CMR, has made a clinical, 
non-invasive diagnosis of myocarditis feasible. In accordance with the 
paradigm change (Figure 2), the TF proposes new diagnostic criteria and 
a new classification, following the system introduced in the 2023 ESC 
Guidelines for the management of endocarditis (Table 4).29 This clinically 
driven approach is based on a clinical presentation, with additional supportive findings, and positive CMR or EMB for myocarditis. Histopathological 
criteria and updated CMR Lake Louise criteria (LLC)30 are given in  
Table 5 and Figure 4, respectively. Similarly, diagnosis of pericarditis can 
be made with a clinical presentation, and more than one additional criterion. Cardiovascular magnetic resonance can also provide the non-invasive 
confirmation of the presence of pericarditis beyond clinical criteria. 
3.3.1. Diagnostic criteria for myocarditis 
Myocarditis can be clinically diagnosed as definite/possible with an 
appropriate clinical presentation and additional criterion, including 
CMR-proven or EMB-proven result (see details in Table 4). The additional criteria include common parameters in basic work-up, such as 
an electrocardiogram (ECG), which may show unspecific changes, including the whole spectrum of presentations from mimicking a myocardial infarction with ST elevation in non-coronary distribution, as well as 
rhythm abnormalities, or findings in echocardiography (see Section 5.5). 
Laboratory analysis of serum biomarkers usually shows elevation of 
markers of myocardial lesion, such as hs-TnT or high-sensitivity troponin I (hs-TnI). Biomarkers of heart failure (HF) (such as N-terminal prohormone of brain natriuretic peptide, NT-proBNP) are also needed to 
identify the severity of the disease, and suggest myocardial involvement. 
Depending on the individual case and risk (see Section 4), definitive 
diagnosis of myocarditis can be based on CMR (Figure 4) or EMB 
(Table 5). For EMB analysis quantitative immunohistochemistry criteria 
for inflammatory cells in lymphocytic myocarditis (LM) are under development. Asymptomatic cases may exist, e.g. vaccine- or drug-related 
cases, such as immune checkpoint inhibitor (ICI)-induced myocarditis, 
and are often underdiagnosed. 








	























 
­
 

­

 






























Figure 3 Stages of inflammatory myopericardial syndrome. AHA, anti-heart antibodies; AIDA, anti-intercalated disc antibodies.


<!-- PAGE 13 -->

### Page 13

Non-ischaemic myocardial inflammation can be diagnosed by CMR 
according to the updated LLC30 (see Figure 4). This is based on at least 
one T2-based criterion plus ideally one T1-based criterion. Having both 
a positive T2-based criterion and a T1-based criterion will increase specificity for diagnosing AM, but a diagnosis of possible myocarditis can 
still be made by having only one (i.e. T2-based or T1-based) criterion 
in an appropriate clinical scenario, although with less specificity. 
Supportive criteria include pericardial abnormalities (which, however, 
suggest concomitant pericarditis), and global or regional left ventricular 
(LV) systolic dysfunction on cine imaging. 
Table 4 Diagnostic criteria and classification for inflammatory myopericardial syndrome 
IMPS  
If diagnostic criteria for myocarditis and/or pericarditis are fulfilleda  
Myocarditis 
Pericarditis 
Definite 
Clinical presentationb and CMR- or EMB-proven 
Clinical presentationb with >1 additional criterion 
Possible 
Clinical presentationb with at least 1 additional criterion 
CMR- or EMB-uncertain or not available 
Clinical presentationb with 1 additional criterion 
Unlikely/rejected 
Only clinical presentationb without additional criteria 
Only clinical presentationb without additional criteria 
Additional criteria beyond clinical presentationsb  
Myocarditis 
Pericarditis 
Clinicalb 
Non-specific findings 
Pericardial rubs 
ECGc 
ST-T changes 
PR depression, widespread ST-segment elevation 
Biomarkers 
Troponin elevation 
C-reactive protein elevation 
Imagingd 
Abnormal strain, wall motion, reduced EF 
Myocardial oedema and/or LGE (CMR findings) 
New or worsening pericardial effusion 
Pericardial oedema and/or LGE (CMR findings) 
© ESC 2025
CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; EF, ejection fraction; EMB, endomyocardial biopsy; IMPS, inflammatory myopericardial syndrome; LGE, late gadolinium 
enhancement; LLC, Lake Louise criteria. 
Clinical presentations include chest pain or infarct-like symptoms, arrhythmias, heart failure, aborted sudden cardiac death. 
Cardiovascular magnetic resonance categories: proven = 2 out of 2 updated LLC fulfilled (Figure 4); uncertain = only 1 out of 2 updated LLC fulfilled; rejected = negative CMR. 
EMB categories: proven, uncertain, rejected (according to pathologist consensus). 
aOne condition may be leading (see Section 8). 
bSee detailed description of clinical presentation in Section 4; rarely asymptomatic cases may be detected (e.g. drug-related with a distinct history, such as immune checkpoint inhibitors). 
cIf ECG changes always consider/exclude myocarditis. 
dSee additional Sections 5.4–5.7 for detailed description of imaging findings.  
Table 5 Histopathological criteria for myocarditis 
Term 
Predominant inflammatory cells 
Myocyte necrosis 
Infections 
PCR positive (viruses, etc.)  
Active lymphocytic myocarditis 
CD3+ T lymphocytes 
>7/mm2, 
CD68+ macrophages 
yes 
yes/no 
Persistent lymphocytic myocarditis 
CD3+ T lymphocytes 
>7/mm2, CD68+ macrophages 
yes 
yes/no 
Resolved lymphocytic myocarditis 
– 
no 
yes/no 
Eosinophilic myocarditis (acute stage) 
Eosinophils, CD3+ T lymphocytes, 
CD68+ macrophages 
yes 
yes/no 
Giant-cell myocarditis (acute stage) 
Eosinophils, 
CD68+ giant cells, CD3+ T lymphocytes, 
CD68+ macrophages 
yes 
no 
Sarcoidosis 
CD68+ giant cells, granuloma, 
CD3+ T lymphocytes, 
CD68+ macrophages 
yes/no 
no 
© ESC 2025
PCR, polymerase chain reaction.   
ESC Guidelines                                                                                                                                                                                               13


<!-- PAGE 14 -->

### Page 14






	






	


		























 

		




	


 ­
­

 
	
	
		


	
		
 
	
	
 
		
		

	
	

		
­
	
	
	

		

	
	

	


	

	
 
	

 
	
­


­


	


 
	
	



	
­		




Figure 4 Diagnostic criteria by cardiovascular magnetic resonance based on the updated Lake Louise criteria. CMR, cardiovascular magnetic resonance; ECV, extracellular volume; LGE, late gadolinium enhancement; LLC, Lake Louise criteria; LV, left ventricle; LVEF, left ventricular ejection fraction; 
RVEF, right ventricular ejection fraction; SI, signal intensity ratio.30 Presence of pericardial effusion suggests concomitant pericarditis.


<!-- PAGE 15 -->

### Page 15

Histopathological Dallas criteria,31 in addition to immunohistological 
staining to detect CD3+ T cells and CD68+ macrophages, are required 
to identify specific histological subtypes of myocarditis and to differentiate from phenocopies [e.g. arrhythmogenic right ventricular cardiomyopathy (ARVC)].32,33 New quantitative criteria are presently 
required, since the ESC criteria of ≥14 leucocytes/mm2 including 
≥7 CD3+ T cells/mm2 have been questioned by cardiopathologists.10 
In addition, molecular analysis of EMB and blood [including assessment 
of viral deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in peripheral leucocytes and in plasma] using quantitative polymerase chain 
reaction (PCR) is necessary to identify the aetiopathogenesis of myocarditis and allow targeted therapies (antiviral or immunosuppressive/ 
immunomodulatory), if clinically useful.10,32,34 Examples are given in 
Section 5.9.1. 
3.3.2. Diagnostic criteria for pericarditis 
Pericarditis is an inflammatory pericardial syndrome with or without 
pericardial effusion (PEff). The definite clinical diagnosis can be made 
with a clinical presentation and more than one additional criterion 
(Table 4). The main presenting symptom is usually chest pain 
(85%–90% of cases), which is typically sharp and pleuritic, improves 
by sitting up and leaning forward, and is exacerbated by inspiration, 
lying down, and deglutition, due to increased attrition between inflamed pericardial layers. Dyspnoea can be reported by the elderly, 
or right HF signs and symptoms in the case of pericarditis with constriction. Arrhythmic presentations are rare and are usually associated with atrial fibrillation (AF). Additional criteria include a 
pericardial friction rub (≤33% of cases), which is a superficial scratchy 
or squeaking sound, caused by friction between the two inflamed 
pericardial layers. Electrocardiogram changes have been historically 
reported as a typical hallmark of AP; however, the pericardium is 
electrically silent, so ECG changes imply concomitant inflammation 
of the myocardium, warranting investigation for concurrent myocarditis.35 On imaging, new or worsening PEff (up to 60% of cases), 
which is generally mild, might be detected. As pericarditis classically 
manifests with an inflammatory syndrome, elevated laboratory markers of inflammation, such as C-reactive protein (79%–90%),36 
erythrocyte sedimentation rate (ESR), and neutrophilic leucocytosis,37,38 can provide additional supportive criteria. The inflamed 
pericardium is neovascularized and contrast-enhanced on computed 
tomography (CT) and CMR. Cardiovascular magnetic resonance is 
superior for tissue characterization and can reveal pericardial oedema and/or pericardial late gadolinium enhancement (LGE), providing additional imaging criteria for the diagnosis. 
3.4. Aetiology of myocarditis and 
pericarditis 
Myocardial and pericardial diseases share mostly similar aetiologies (see  
Supplementary data online, Table S1). The aetiology of IMPS can be either infectious or non-infectious. These can trigger IMPS in a genetically 
predisposed individual by inflammatory/autoimmune mechanisms. 
However, the prevalence of each aetiology and the impact of the causative agent on the clinical course, prognosis, and therapeutic approach 
may differ between the two entities.1,10 
3.4.1. Aetiology of myocarditis 
The most common infectious aetiology is presumed to be viral.10,39,40 
Enteroviruses, adenoviruses, parvovirus B19 (B19V) and some 
herpesviruses [Epstein–Barr virus (EBV), human herpesvirus 6 (HHV-6)], 
as well as influenza and coronaviruses, are the most common viruses 
associated with myocarditis (Supplementary data online, Table S1). 
Non-cytotoxic viruses trigger myocarditis indirectly by activating the immune system.41,42 Bacterial infection with Borrelia species [Lyme carditis 
(LC)] and parasitic infections, such as Trypanosoma cruzi [Chagas disease 
(CD)], are additional important aetiologies in specific regions of the globe. 
However, several non-infectious aetiologies should be recognized, 
including systemic diseases, autoimmune (or likely autoimmune) disorders [systemic lupus erythematosus (SLE), systemic sclerosis (SSc), 
rheumatoid arthritis (RA), eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES)], immune-mediated 
forms [such as LM, giant-cell myocarditis (GCM), eosinophilic myocarditis (EM), and cardiac sarcoidosis (CS)], inflammatory bowel disorders, drugs and toxic reactions (including ICI-associated myocarditis, 
see Section 9.6.1.1) and chest radiation, as well as genetic conditions 
such as inherited CMP (see Section 5.3);10,39 see Supplementary data 
online, Table S1.10 
3.4.2. Aetiology of pericarditis 
The aetiology largely depends on the epidemiological background, 
patient population, and clinical setting.1,10 Idiopathic or viral pericarditis is the most frequent aetiology in developed countries, 
ranging from 50% in inpatient settings to >80% in outpatient 
settings.43–48 Tuberculosis (TB) is responsible for about 70% of 
all cases, especially in human immunodeficiency (HIV)-infected patients, in regions where the disease is endemic. An increasing number of cases are related to interventional procedures and surgery 
[post-cardiac injury syndrome (PCIS)] due to the increased number 
of procedures performed and the ageing population.49 Other common causes include systemic inflammatory/autoimmune diseases 
and cancer (especially lung and breast cancer or lymphomas and 
leukaemia) (see Supplementary data online, Table S1).1 
About 5%–15% of patients with recurrence have genetic mutations, 
sometimes related to a monogenic autoinflammatory disease, mainly familial Mediterranean fever (FMF) and tumour necrosis factor receptor- 
associated periodic syndrome (TRAPS).50,51 A genetic predisposition 
and an autoinflammatory/immune-mediated pathogenesis are also suspected in patients with multiple recurrences. For additional information 
see Supplementary data online, Tables S2 and S3.50–52 
4. Clinical presentation of 
inflammatory myopericardial 
syndrome 
The term IMPS includes a spectrum of inflammatory diseases from 
isolated myocarditis to isolated pericarditis through a combination 
of both. IMPS should be used as an umbrella term during the initial 
diagnostic work-up until the final diagnosis is made. One of the major challenges for the diagnosis of IMPS is recognition itself, therefore the TF highlighted red flags (Table 6). These symptoms and 
signs should suggest IMPS. The red flags for IMPS are mainly clinical 
signs, accompanied by serological and/or imaging biomarkers, and 
are not equivalent to the risk. Red flags for IMPS are warning signs, 
aiming to raise the awareness of the disease. If there is a suspicion 
of IMPS, staging based on the risk assessment should be performed 
(Table 7).  
ESC Guidelines                                                                                                                                                                                               15


<!-- PAGE 16 -->

### Page 16

A fast and reliable diagnosis is crucial for proper management. The initial step involves triaging patients by assessing their risk factors and ruling 
out acute coronary syndrome (ACS), whenever indicated by the patient’s characteristics and clinical presentation. In addition, myocarditis 
warrants consideration whether the first contact was inpatient or 
outpatient.53,54 This approach is based on the different national 
healthcare systems, given that a patient may be first seen in an outpatient or inpatient setting (Figures 5–7). 
Table 7 Clinical risk stratification to guide work-up in inflammatory myopericardial syndrome 
Risk 
High risk 
Intermediate risk 
Low risk  
Myocarditis 
• Acute HF/cardiogenic shock 
• Dyspnoea NYHA III–IV refractory 
to medical therapy 
• Cardiac arrest/syncopea 
• Ventricular fibrillation/sustained 
ventricular tachycardiaa 
• High-level AV blocka 
• New/progressive dyspnoea 
• Non-sustained ventricular arrhythmias 
• Persistent release or relapsing troponin 
Stable symptoms or oligosymptomatic  
Imaging criteria: 
Imaging criteria: 
Imaging criteria:  
• Newly reduced LVEF (<40%)a 
• Extensive LGE on CMRa 
• Newly mildly reduced LVEF (41%–49%) 
and/or WMA 
• Preserved LVEF (≥50%) and  
LGE ≥2 segments on CMR 
• Preserved LVEF (≥50%) without LGE or limited 
LGE (<2 segments) on CMR 
Pericarditis 
• Signs and symptoms of cardiac 
tamponade 
• Fever (temperature >38°C) 
• Effusive–constrictive pericarditis 
• Failure of NSAID therapy 
• Incessant pericarditis 
• Signs and symptoms of right HF 
• Response to adequate therapy within 1–2 weeks  
Imaging criteria: 
Imaging criteria: 
Imaging criteria:  
• Large PEff (>20 mm end-diastole) 
• Cardiac tamponade 
• Extensive pericardial LGE on CMR 
• Moderate–large PEff  
(10–20 mm end-diastole) 
• Constrictive physiology regardless of the 
size of the effusion 
• Absence or mild PEff 
• Absence of pericardial LGE on CMR 
© ESC 2025
AV, atrioventricular; CMR, cardiovascular magnetic resonance; HF, heart failure; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; NSAID, non-steroidal 
anti-inflammatory drug; NYHA, New York Heart Association classification; PEff, pericardial effusion; WMA, wall motion abnormalities. 
aThese criteria do not lead directly towards endomyocardial biopsy; in these scenarios it is a case-by-case decision depending on the suspected underlying cause.  
Table 6 Red flags for the clinical diagnosis of myocarditis and pericarditis 
Myocarditis 
Pericarditis  
Recent or concomitant flu-like syndrome or gastroenteritis 
Infarct-like chest pain 
Palpitations 
HF symptoms 
ECG changesa 
Ventricular arrhythmias (isolated, complex) 
Syncope 
Haemodynamic instability 
Elevated markers of myocardial lesion (hs-Tn, CK-MB elevation) 
Elevated markers of HF (NT-proBNP) 
Abnormal wall motion, increased wall thickness and/or impaired systolic function 
on imaging 
CMR imaging with myocardial oedema and/or LGE 
Recent or concomitant flu-like syndrome or gastroenteritis 
Pleuritic/infarct-like chest pain 
Right HF symptoms and signs of constriction 
Fever 
Pericardial rubs 
C-reactive protein elevation 
Pericardial effusion 
Pleural effusion 
Polyserositis 
CMR imaging with pericardial oedema and/or LGE 
© ESC 2025
CK-MB, creatinine kinase muscle-brain type; CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; HF, heart failure; hs-Tn; high-sensitivity troponin; LGE, late gadolinium 
enhancement; NT-proBNP, N-terminal prohormone of brain natriuretic peptide. 
aSee Section 5.1.


<!-- PAGE 17 -->

### Page 17

Obstructive CADc
Treat CAD
High-risk clinical featuresd
Stay on ward/ICU
Establish HF/AA therapy and/or treatment of speciﬁc aetiology
Outpatient follow-up
Patient with symptoms and signsa of myocarditis presenting to the emergency room
First-line assessment with history, physical examination, ECG,
transthoracic echocardiography, chest X-ray, laboratory assessmentb 
(Class I)
Low risk
Intermediate risk
Stay on ward and discharge when possible
(Class I)
Cardiovascular magnetic 
resonancee
(Class I)
Endomyocardial biopsyf
(Class I)
Admit to ward/ICU
(Class I)
Cardiovascular magnetic resonance
(if not done before) 
Improvement
Multidisciplinary
IMPS team discussion
Discharge if possible
Diagnosis
Complete risk classiﬁcationd
Further work-up
Further assessmentg
Possible
Rejected/unlikely
Deﬁnitive
High risk
Figure 5 Diagnostic algorithm and triage for inpatient myocarditis. AA, anti-arrhythmic therapy; CAD, coronary artery disease; CRP, C-reactive protein; ECG, electrocardiogram; HF, heart failure; ICU, intensive care unit; IMPS, inflammatory myopericardial syndrome; N, no; NT-proBNP, N-terminal 
prohormone of brain natriuretic peptide; Y, yes. aSee Table 6. bLaboratory testing including troponin, NT-proBNP, C-reactive protein, differential blood 
count. cInvasive coronary angiography or computed tomography angiography depending on clinical likelihood/probability. dSee Table 7. eConsider endomyocardial biopsy. fConsider cardiovascular magnetic resonance. gSee Table 9.   
ESC Guidelines                                                                                                                                                                                               17


<!-- PAGE 18 -->

### Page 18

Elevated troponin
Admit to ward
(Class I)
See inpatient algorithmc
Outpatient follow-up
Patient with symptoms and signsa of myocarditis presenting to the outpatient clinic
First-line assessment with history, physical examination, ECG, transthoracic echocardiography,
laboratory assessmentb
(Class I)
Outpatient treatment
Cardiovascular magnetic resonancee
(Class I)
Refer to hospital
Obstructive CADd
Treat CAD
See inpatient algorithmc
Low risk
Diagnosis
Complete risk classiﬁcationg
Further work-up
Further assessmentf
Possible
Rejected/unlikely
Deﬁnitive
Intermediate risk
High risk
Figure 6 Diagnostic algorithm and triage for outpatient myocarditis. CAD, coronary artery disease; CRP, C-reactive protein; ECG, electrocardiogram; N, no; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; Y, yes. aSee Table 6. bLaboratory testing including troponin, 
NT-proBNP, C-reactive protein, differential blood count. cSee Figure 5. dInvasive coronary angiography or computed tomography angiography depending on clinical likelihood/probability. eDepending on clinical situation (heart failure, arrhythmias) admit to ward. fSee Table 9. gSee Table 7.


<!-- PAGE 19 -->

### Page 19

4.1. General symptoms and signs 
The most common symptom of myocarditis and pericarditis is chest 
pain (sometimes with infarct-like features, especially for myocarditis, 
or pleuritic with respiratory changes, especially for pericarditis). 
Other common presentations include dyspnoea (myocarditis with HF 
presentation, but it is also the most common symptom in the elderly 
with pericarditis) and/or arrhythmias of different degrees (mainly ventricular for myocarditis and supraventricular and AF for pericarditis) 
and, less frequently, syncope. Flow charts are provided for each type 
to guide the diagnostic pathway (see Section 4.3). 
Some patients may present with persistent symptoms without remission and are labelled as patients with incessant/ongoing IMPS. 
4.2. Clinical stages of myocarditis 
4.2.1. Acute myocarditis 
Acute onset is defined as symptoms and signs lasting ≤4 weeks.28 In myocarditis, this entails AM and the subtype fulminant myocarditis (FM). 
The presentation of AM can vary from very mild symptoms 
to a life-threatening condition.10 The typical symptoms and signs at 
presentation include chest pain in >80% of cases, and dyspnoea in 
20%–50%, while fatigue, palpitations, and syncope are less common 
and are reported in about 5%.28,32,55 In the majority of cases (80%), 
symptoms are preceded by prodromes, such as fever (60%), gastrointestinal complaints (30%), or respiratory symptoms (25%).28,55,56 
Other extracardiac symptoms, depending on the underlying disease, 
can be present. Electrocardiogram is normal in a minority of patients 
(about 15%); most frequently, ST-segment elevation is present 
(57.5%), but other ST/T-segment changes can be found (23.5%), as 
well as conduction blocks (10%).28,55 
In most patients with acute presentation, cardiac enzymes [troponin 
T/I and creatinine kinase muscle-brain type (CK-MB)] are elevated.28,55 
Echocardiography is important for clinical evaluation as it might reveal 
signs of myocarditis, including increased wall thickness and echogenicity 
due to myocardial oedema. PEff is seen in up to 25% of patients, reflecting concomitant pericarditis or related to haemodynamic factors.28,55 
Outpatient follow-up
Response to therapy after 1−2 week
Admission or close follow-up and aetiology search.
Patient with symptoms and signs of pericarditisa
First-line assessment with history, physical examination,
ECG, transthoracic echocardiography,
X-ray, routine blood test including CRP and troponin
(Class I)
High-risk featuresb
Low risk
Intermediate risk
High risk
Outpatient treatment
Admission,
aetiology search and anti-inﬂammatory therapy
Risk evaluationb
Figure 7 Diagnostic algorithm and triage for pericarditis. CRP, C-reactive protein; ECG, electrocardiogram; N, no; Y, yes. asee Table 6. bIf a patient has 
one or more prognostic predictors, as reported in Table 7, a high-risk patient must be admitted to hospital, and an aetiology search should be performed. Patients without high-risk features can be managed as outpatients without an aetiology search and admission if there is a good response to 
empirical anti-inflammatory therapy.   
ESC Guidelines                                                                                                                                                                                               19


<!-- PAGE 20 -->

### Page 20

4.2.2. Fulminant myocarditis 
Fulminant myocarditis (occurring in 3%–9%) is characterized by cardiogenic shock at presentation for which haemodynamic support is 
needed.28 Isolated right ventricle (RV) dysfunction is uncommon; however, biventricular failure occurs frequently in FM. Sustained ventricular 
arrhythmias (VA) may also occur in these patients (46.9%) and some 
present with sudden cardiac death (SCD) (25.8%).28,56,57 
In the majority of children with FM (usually <2 years of age), LV dysfunction with dilatation is present at initial presentation,40 while there is 
usually no LV dilatation in the early phase for adults. Concurrent viral 
infections can be common in these children. 
4.2.3. Subacute myocarditis 
The subacute stage refers to cases with symptoms lasting >1 month 
but ≤3 months. The symptoms are unspecific, and patients might either 
have a remission without residuals or might progress to chronic myocarditis or inflammatory CMP (see Section 10). 
4.2.4. Chronic myocarditis 
Chronic myocarditis is myocarditis persisting beyond 3 months.39 
Chronic myocarditis might reflect an intermediate stage possibly leading to inflammatory CMP, characterized by cardiac remodelling and 
some degree of ventricular dysfunction.10,39 
Milder forms may appear as hypokinetic non-dilated forms of CMP.39 
Moreover, an arrhythmogenic substrate, due to fibrosis, should be considered for the management of these patients.39,58 
Symptoms may be unremarkable in chronic myocarditis.10,39 
Dyspnoea and palpitations might be the leading symptoms.10,39 
Biomarkers of myocardial injury are usually within normal limits.59 
Notably, elevated C-reactive protein, hs-TnT, and impaired global longitudinal strain (GLS) have been associated with EMB-proven 
myocardial inflammation in patients with non-ischaemic HF.60 New 
quantitative CMR techniques have improved the diagnostic yield in patients with chronic myocarditis.61 
4.3. Clinical presentations of myocarditis 
Myocarditis is characterized by the heterogeneity of clinical manifestations (Figure 8); therefore, the diagnosis requires a high level of suspicion. The main patterns of clinical presentation are infarct-like chest 
pain (most frequent symptom), arrhythmias, and HF. Severity may 
range from asymptomatic/oligosymptomatic to severe life-threatening 
scenarios, such as severe HF or VA (potentially leading to SCD). A clinical classification based on presentation as high-risk or non-high-risk 
myocarditis (see Table 7) has been shown to meaningfully predict outcomes in large cohorts.28,62,63 Moreover, myocarditis, especially when 
recurrent, may represent the ‘hot phase’ of some CMPs [e.g. desmoplakin (DSP)-related ARVC].64 Details are given in Section 4.3.5. 
4.3.1. Chest pain presentation 
Chest pain is the most common form of clinical presentation (about 75% 
of unselected cases) in adolescents and adults.28 It is commonly associated 
with an increase in necrosis biomarkers, such as troponin, often with ECG 
alterations (especially ST-segment elevation), which may mimic ACS, despite the absence of significant obstructive coronary artery disease (CAD). 
These cases are often labelled as infarct-like.65 Patients with this presentation usually report a recent or concomitant viral infection, such as a respiratory tract infection or gastroenteritis, which often precedes 
myocarditis by several days to weeks (2–4 weeks). Usually, the presence 
of troponin release in the context of IMPS is not a negative prognostic 
marker, when associated with preserved biventricular function.4,66 
Patients presenting with chest pain and normal left ventricular ejection 
fraction (LVEF) without wall motion abnormalities (WMA), no VA, 
and complete resolution of ECG abnormalities in the short term can  





	






	



	



Figure 8 Spectrum of myocarditis presentations and outcomes. LGE, late gadolinium enhancement; SCD, sudden cardiac death. Image size correlates 
with presentation frequency (e.g. chest pain being the most common). Uncomplicated cases of myocarditis (about 75% of unselected cases) usually have 
spontaneous remission.28 In acute myocarditis diagnosed by endomyocardial biopsy, up to 50% of patients have spontaneous recovery, but up to 25% 
may have a persistent stable cardiac dysfunction, while 10%–25% have a progressive ventricular dysfunction, which could lead to end-stage dilated cardiomyopathy, heart transplantation, or death.9


<!-- PAGE 21 -->

### Page 21

be considered as having a low-risk presentation with an excellent long- 
term prognosis.4,28,62,66,67 There are possible exceptions to this general 
rule in a few cases with EM and GCM. Myocardial scarring as detected 
by CMR can be present in cases with preserved LVEF.3,68–70 Focal scarring 
of any cause was shown to be relevant for outcome, and small scars (e.g. 
<2 segments) after >6 months seemed to be more benign.71 
Nevertheless, long-term outcome data are missing. For a proposed workflow see Figure 9. 
Patient with acute chest pain
Clinical history and vital signs, 12-lead ECG, laboratory testinga, transthoracic echocardiography
(Class I)
CT angiography
(Class I)
Deﬁnite myocarditis
Suggestive of non cardiac causes or cardiomyopathies
Treat according to 
ACS GLc
Risk stratiﬁcationd
Further 
aetiological work-up
Endomyocardial biopsy
(Class I)
Cardiovascular magnetic resonanceg
(Class I)
Further aetiological work-up requiredh
No further work-up
Further work-upi
Red ﬂags for IMPSb
Aetiological work-up
Coronary artery disease
Normal ﬁndings
No further work-up
Invasive coronary angiography
(Class I)
Diagnostic criteria suggestive of myocarditis
Diagnostic criteria suggestive of pericarditis
Go to pericarditis algorithme
Clinical likelihood/probability of obstructive coronary artery disease
Clinical exclusion
Moderate
Low
High riskf
Non-high risk
If CAD not the sole explanation for the
 symptoms
Before discharge
High
Figure 9 Diagnostic algorithm for acute chest pain presentation. ACS, acute coronary syndrome; CAD, coronary artery disease; CRP, C-reactive 
protein; CT, computed tomography; ECG, electrocardiogram; GL, guideline; IMPS, inflammatory myopericardial syndrome; N, no; NT-proBNP, 
N-terminal prohormone of brain natriuretic peptide; Y, yes. aLaboratory testing including troponin, NT-proBNP, C-reactive protein, differential blood 
count. bSee Table 6. cReference: Byrne et al.72 dSee Table 7. eSee Figure 7. fConsider cardiovascular magnetic resonance. gConsider endomyocardial 
biopsy on a case-by-case basis. hDepending on the underlying cause and clinical need. iSee Sections 5, 8, 9, 10.   
ESC Guidelines                                                                                                                                                                                               21


<!-- PAGE 22 -->

### Page 22

4.3.2. Heart failure presentation 
Patients with myocarditis presenting with acute HF, in particular when 
associated with left ventricular dysfunction (LVEF ≤ 40%), should be 
considered as a high-risk group, and their prognosis largely depends 
on the short-term response to therapy.28,62 Clinical presentation 
may range from unexplained impaired ventricular function (with or 
without dilated LV), new onset or worsening HF (usually over 
2 weeks to 3 months), to rapidly progressive refractory HF and cardiogenic shock. Fulminant myocarditis presenting with HF has a higher 
rate of cardiac death and heart transplantation (HT) both in the short 
and long term, compared with patients with LV dysfunction without 
FM (see Section 4.2.2).56,73,74 In these scenarios, GCM and EM are independently associated with increased mortality.56,75 An algorithm 
for the proposed workflow is shown in Figure 10. As a central scheme, 
the workflow follows the CHAMPIT approach, provided in the 2021 
ESC Guidelines for the diagnosis and treatment of acute and chronic 
heart failure.12 One should be aware that arrhythmias can be a presentation of myocarditis, as well as an ‘alternative cause’ of HF outside 
the suspicion of myocarditis. 
4.3.3. Presentation with arrhythmias 
Patients with AM with new, recurrent, or unexplained arrhythmias 
may have a wide spectrum of symptoms, ranging from palpitations 
to syncope or life-threatening arrhythmias causing aborted 
SCD.10,76 Supraventricular arrhythmias, especially AF,63,77 are 
more common in the presence of concomitant pericarditis and 
PEff, while atrioventricular blocks (AVBs) or sustained VA are generally, but not exclusively, associated with LV dysfunction and HF. 
Patients with advanced AVB or sustained VA should be considered 
as high risk, even in the absence of LV dysfunction. Ventricular fibrillation (VF)/cardiac arrest occurs in about 2.5% of myocarditis-related 
hospitalizations.78 Patients with sustained VA during AM have a high 
risk of recurrence.79 
Patients with GCM (see Section 9.3) or CS (see Section 9.4) are at a 
high risk of VA, with a prevalence of >25%.80–82 
Scar-related VA can occur at any time during follow-up, even after 
inflammation resolution. However, polymorphic and irregular VA are 
more common during the active inflammatory phase, whereas monomorphic and regular VA are associated with healed myocarditis with residuals.83 Consistently, catheter ablation of ventricular tachycardia (VT) 
is more effective when performed in the post-inflammatory stage of the 
disease rather than during AM.84 
AVB is a common feature of myocarditis related to non-viral infections (i.e. CD, LC, diphtheria),85 and can also be an initial presentation 
of CS. In patients with arrhythmic presentation, genetic testing for CMP 
[ARVC/dilated CMP (DCM)/non-dilated left ventricular CMP 
(NDLVC)] should be considered (see Section 5.3). 
An algorithm for the proposed workflow is shown in Figure 11. 
4.3.4. Sudden cardiac death 
One of the causes of SCD in young adults is myocardial inflammation associated with fatal arrhythmias. Sudden cardiac death attributed to myocarditis among autopsied patients ranged from 1.1% to 
12%,87,88 and males show higher incidence rates of SCD than females, with an incidence rate ratio of 2.2.88 Most individuals are 
asymptomatic before SCD; however, between 18% and 48% of 
patients present with symptoms, including viral illness/malaise, syncope, nausea/abdominal pain, chest pain, and palpitations.87,88 Only 
5% show cardiac symptoms in conjunction with an infective process.87 These data highlight the need to suspect a diagnosis of myocarditis early enough. Late gadolinium enhancement in the mid-wall 
layer of the anteroseptal myocardial segments has been associated 
with higher rates of mortality and major VA, including SCD,3,89,90 
even in the presence of preserved LVEF. Septal involvement in myocarditis can be associated with a worse prognosis in the presence of 
a specific genetic background, such as pathogenic desmosomal gene 
variants (see Section 5.3).91,92 Further studies are necessary to confirm these data. 
4.3.5. Presentation of myocarditis with a potential 
genetic background 
A complex interaction between genetic background and inflammation 
might be responsible for the heterogeneity of the clinical presentation 
of myocarditis. An inflammatory stimulus of the heart might unveil an 
increased genetic susceptibility to develop overt LV dysfunction or arrhythmogenic phenotypes. In this setting it is important to consider 
additional features, such as a family history of myocarditis/pericarditis, 
CMP, or SCD. Autosomal dominant gene defects may be associated 
with myocarditis.93–95 Certain autosomal recessive defects in genes encoding various components of the cardiac structure can predispose 
young individuals to myocarditis.95,96 
Different studies reported that patients with myocarditis and evidence of pathogenic/likely pathogenic (P/LP) desmosomal gene variants (mostly with DSP variants) have a higher incidence of adverse 
cardiovascular events, especially myocarditis recurrence and VA, 
than patients without.91,94 Episodes of acute chest pain with troponin 
elevation and normal coronary arteries may occur in about 15% of 
patients with DSP mutations and are associated with LV LGE in about 
90% of cases.97 Specific genetic P/LP variants may increase the susceptibility to superimposed myocarditis in ARVC, which may be 
the first clinical presentation in the natural history of the disease.64,98 
The presence of so-called ‘hot phases’ (chest pain episodes accompanied by ECG changes and troponin release) represents a possible 
clinical presentation of ARVC, which often occurs in paediatric and 
young patients, as well as carriers of DSP genetic variants.99–101 
Currently, the role of ‘hot phases’ in disease progression, as well as 
in arrhythmic risk stratification, remains to be clarified. For more details see Section 5.3. 
4.4. Clinical stages of pericarditis 
4.4.1. Acute pericarditis 
Acute pericarditis is an inflammatory pericardial syndrome with or without 
PEff with an onset of ≤4 weeks. The clinical diagnosis is usually characterized by pleuritic and/or positional chest pain (>80% of cases). Dyspnoea is 
more common in the elderly.45,102 Physical examination may be characterized by pericardial friction rubs in up to one-third of cases, which could disappear with the presence of PEff. Pericardial effusion has been reported in 
up to 60% of cases, and it is usually mild. ECG changes, especially PR 
depression as an early sign and widespread ST-segment elevations, 
have been reported in up to 60% of cases, especially in young patients. 
This is suggestive of concomitant myocardial involvement, at least of 
mild degree.


<!-- PAGE 23 -->

### Page 23

Patient with signs and symptoms of acute heart failure
Clinical history and vital signs, 12-lead ECG, laboratory testinga, transthoracic echocardiography
(Class I)
Cardiogenic shock and/or respiratory failure
Admission to ICU 
acute Coronary syndrome
Hypertensive emergency
Arrhythmia
Mechanical
Pulmonary embolism
Infections 
Tamponade
Further 
work-up
Congestion/apparent HF
HF treatment
(Class I)
Red ﬂags for myocarditisb
Suspected fulminant myocarditis
Deﬁnite myocarditis
Suggestive of non cardiac causes 
or cardiomyopathies
Endomyocardial 
biopsy
(Class I)
Cardiovascular magnetic 
resonancee
(Class I)
Further aetiological 
work-up requiredf
No further work-up
Further work-up including geneticsg
Aetiological work-up
Normal
ﬁndings
No further 
work-up
Risk stratiﬁcationc
Before discharge
Simultaneously use CHAMPIT approach and whether congestion/apparent HF
High riskd
Non-high risk
Figure 10 Diagnostic algorithm for acute heart failure presentation. CRP, C-reactive protein; ECG, electrocardiogram; HF, heart failure; ICU, intensive care unit; N, no; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; Y, yes. aLaboratory testing including troponin, NT-proBNP, 
C-reactive protein, differential blood count. bSee Table 6. cSee Table 7. dConsider cardiovascular magnetic resonance. eIn stabilized heart failure patients, 
endomyocardial biopsy may be performed on a case-by-case basis. fDepending on the underlying cause and clinical need. gSee Sections 5, 8, 9, 10.   
ESC Guidelines                                                                                                                                                                                               23


<!-- PAGE 24 -->

### Page 24

Patient with new, recurrent or unexplained arrhythmias (any type)
Haemodynamic instability
Cardioversion/deﬁbrillation/
transcutaneous pacing/ALS
(Class I)
Clinical history and vital signs, 12-lead ECG, laboratory evaluationb, transthoracic echocardiography
(Class I)
Active myocarditis (based on initial CMR/EMB)
See speciﬁc sections
Type of initial arrhythmia at presentation
Repeat CMR 
within 6 months
(Class I)
Identify arrhythmia 
Risk stratiﬁcationd
Further aetiological 
work-up
Endomyocardial biopsy
(Class I)
Cardiovascular magnetic resonancef
(Class I)
Red ﬂags for myocardial involvementc
Deﬁnite myocarditis
Speciﬁc aetiology
ICD indicationsj
(Class I) (Class IIa) (Class IIb)
Further aetiological work-uph
Suggestive of non-cardiac causes 
or cardiomyopathies
Aetiological work-up
Normal ﬁndings
No further work-up
Non-high risk
Obstructive CADa
Treat CAD
PM indicationi
Further work-up depending on activity
 (genetics, systemic disorders)
Catheter ablation
(Class IIa)
High riske
Before discharge
Ventricular arrhythmiag
Conduction blocks
Figure 11 Diagnostic algorithm for arrhythmia presentation. ALS, advanced life support; CAD, coronary artery disease; CMR, cardiovascular magnetic resonance; CRP, C-reactive protein; ECG, electrocardiogram; EMB, endomyocardial biopsy; ICD, implantable cardioverter-defibrillator; N, no; 
NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PM, pacemaker; Y, yes. aInvasive coronary angiography or computed tomography 
angiography depending on clinical likelihood/probability. bLaboratory testing including troponin, NT-proBNP, C-reactive protein, differential blood 
count. cSee Table 6. dSee Table 7. eConsider cardiovascular magnetic resonance. fConsider endomyocardial biopsy on a case-by-case basis. gSee 
Section 6.5 for wearable cardioverter-defibrillator. hSee Sections 5, 8, 9, 10. iSee Section 6.5 and Reference Glikson et al.86 jSee Section 6.5,  
Recommendation Table 14 and Reference Zeppenfeld et al.58


<!-- PAGE 25 -->

### Page 25

An inflammatory syndrome is usually present with fever of >38°C 
(70%),37 elevated markers of inflammation (C-reactive protein) (80%– 
90%),36,37 ESR, neutrophil leucocytosis,37,38 and pericardial and/or pleural effusion (approximately 50%), often with lung atelectasis, leading to a 
possible diagnosis of pleuro-pneumonia,37,103 and less commonly, peritoneal involvement (13%).38 This presentation is labelled ‘inflammatory 
phenotype’ of AP. 
Cardiac enzymes are usually normal, but troponin may be elevated in 20%–30% of cases, due to concomitant myocarditis 
(myopericarditis).4 
4.4.2. Subacute pericarditis 
Subacute pericarditis refers to cases with persistent symptoms lasting 
>1 month and <3 months. This condition may directly progress to 
constrictive pericarditis (CP) within a few months and requires timely 
optimal medical therapy and close follow-up to prevent chronic 
evolution.104 
4.4.3. Chronic pericarditis 
Chronic pericarditis refers to cases lasting >3 months. In pericarditis, 
management of the patient during the acute phase is of paramount importance, not only for symptom relief but, most importantly, for prognostic purposes. Hospitalization of patients with AP and high-risk 
features allows the prompt identification and treatment of potentially 
life-threatening complications, such as cardiac tamponade (CTP).105 
Moreover, appropriate screening for specific aetiologies is the basis 
for tailored therapy. Progression of AP to subacute or chronic disease 
is sometimes unpredictable. Omission of colchicine administration and 
the use of high doses of corticosteroids with fast tapering are risk factors for recurrences or a chronic course of the disease.24,106–109 
Recently, scores that predict the individual risk of complicated pericarditis and chronicity have been proposed for the identification of subjects who require intensive therapy in terms of medication dose and 
length, as well as close follow-up.43,44,110 They require further validation 
in prospective, multicentre studies. 
In chronic forms, symptoms are similar to previous attack(s), 
but often milder.1 In unclear cases or in difficult-to-treat patients, 
CMR may be performed to assess the degree of inflammation and 
individualize medical therapy, especially before drug tapering or 
discontinuation.111,112 
Paradoxically, although chronic pericarditis significantly impairs quality of life, the rate of progression to CP is negligible (<1%) and is lower 
than the risk imposed by a single episode of AP, unless a specific aetiology is identified.105,113,114 
4.5. Clinical presentations of pericarditis 
Pericarditis is characterized by a wide spectrum of clinical presentations. 
The main presenting symptom of pericarditis is positional chest pain, 
which is reported in most affected individuals. Typical pericardial pain 
is sharp and is worse when coughing and taking a deep breath (pleuritic). 
Left trapezius ridge pain is a classic symptom of pericardial irritation and is 
transmitted through the phrenic nerve. Other less common symptoms 
include shortness of breath, fever, fatigue, and arrhythmia (e.g. AF). 
Pericardial effusion often accompanies pericarditis (>50% of cases). 
Other presentations include right HF-like symptoms [elevated jugular 
venous pressure (JVP), peripheral oedema, ascites] when constriction 
is present. Hypotension is a sign of CTP (which presents with Beck’s 
triad: hypotension, jugular venous distension, and muffled heart sounds). 
It is crucial to differentiate pericarditis from other diseases, such as ACS, 
congestive HF, pneumonia with pleuritis, pulmonary embolism, chronic 
obstructive pulmonary disease, and vasculitis. 
4.5.1. Dry pericarditis 
Dry pericarditis (40%–50% of cases), also referred to as ‘pericarditis sicca’, is a form of pericarditis that is characterized by inflammation of the 
pericardium without the presence of PEff. It can begin insidiously or 
abruptly. It is usually not associated with a specific cause or a worse 
prognosis. 
4.5.2. Effusive pericarditis 
Effusive pericarditis (50%–60% of cases) is characterized by the concurrent presence of effusion.115 A moderate to large PEff is more commonly associated with a non-idiopathic aetiology. 
4.5.3. Effusive–constrictive pericarditis 
Effusive–constrictive pericarditis (ECP) is characterized by the concurrent presence of PEff, along with thickening and constriction of 
the pericardium that restricts the normal filling of the heart.116 
Effusive–constrictive pericarditis occurs when constrictive physiology is uncovered following the drainage of a PEff with tamponade. 
The exact haemodynamic definition involves the right atrial pressure 
(RAP) failing to fall by ≥50% or to a level of <10 mmHg despite intrapericardial pressure being lowered to near 0 mmHg with removal of 
pericardial fluid via pericardiocentesis.110,116,117 Current multimodality imaging allows a clinical diagnosis of ECP without cardiac 
catheterization. 
4.5.4. Pericarditis with cardiac tamponade 
The two most serious complications of pericarditis are CTP and CP. 
Pericarditis with CTP is a life-threatening condition where inflammation 
of the pericardium leads to the accumulation of compressive pericardial 
fluid (Table 8).110,115 Symptoms may include chest discomfort, fatigue, 
and dyspnoea. Clinical signs include hypotension, tachycardia, raised 
JVP, pulsus paradoxus, muffled heart sounds, electrical alternans with 
decreased ECG voltage, and an enlarged cardiac silhouette on chest 
X-ray. The magnitude of clinical and haemodynamic abnormalities depends on the amount of pericardial fluid and rate of accumulation, 
the distensibility of the pericardium, and the compliance and filling pressures of the cardiac chambers118 (Figure 12). 
Table 8 Causes of cardiac tamponade  
Common causes (in order of relative frequency):  
(1) 
Neoplasm/malignancy  
(2) 
Iatrogenic/trauma  
(3) 
Pericarditis  
(4) 
Tuberculosis (most common in developing countries) 
Less common causes (in order of relative frequency):  
(1) 
Collagen vascular diseases (systemic lupus erythematosus, rheumatoid 
arthritis, scleroderma)  
(2) 
Pericardial injury syndrome  
(3) 
Acute myocardial infarction  
(4) 
Aortic dissection  
(5) 
Uraemia  
(6) 
Bacterial infection  
(7) 
Pneumopericardium 
© ESC 2025   
ESC Guidelines                                                                                                                                                                                               25


<!-- PAGE 26 -->

### Page 26

4.5.5. Constrictive pericarditis 
Pericardial constriction is a chronic condition characterized by a thickened, fibrotic, and often calcified pericardium that leads to impaired diastolic filling of the heart. It should be named CP when associated with 
pericarditis. Constrictive pericarditis is a consequence of chronic pericardial inflammation and is characterized by scarring, fibrosis, and loss 
of elasticity of the pericardium. The main symptoms are dyspnoea, 
oedema, orthopnoea, and fatigue. The classic clinical picture is usually 
characterized by isolated right HF with normal or nearly normal natriuretic peptide levels. Venous congestion, hepatomegaly, pleural effusions, and ascites may occur.110,115,119 Constrictive pericarditis should 
be treated empirically with anti-inflammatory therapy. Cases after failure of medical therapy and pericardial constriction without pericarditis 
should be referred for pericardiectomy without delay (Figure 13). 
Patient with deﬁnite diagnosis of cardiac tamponade
High-risk features 
(with cumulative score ≥6) 
Outpatient follow-up
Pericardial window
Improvement 
Postpone pericardiocentesis
Empiric anti-inﬂammatory therapy
Pericardiocentesis with drainage
Criteria for triage for patients with pericardial eﬀusion at risk for progression to cardiac tamponade
Imaging
Clinical presentation
Aetiology
Malignant disease 
2
Tuberculosis 
2
Recent radiotherapy 
1
Recent viral infection 
1
Recurrent PEﬀ 
1
Chronic terminal renal failure 
1
Immunosuppression 
1
Dysthyroidism 
 -1
Systemic autoimmune disease 
-1
Dyspnoea/tachypnoea                                     1
Orthopnoea                                                         3
Hypotension (CBP <95 mmHg)                  0.5
Progressive sinus tachycardia                         1
Oliguria                                                                 1
Pulsus paradoxus (>10 mmHg)                      2
Pericardial chest pain                                    0.5
Pericardial friction rub                                  0.5
Rapid worsening of symptoms                      2
Slow disease evolution                                  -1 
Cardiomegaly on chest x-ray 
1
Electrical alternans on ECG 
0.5
Microvoltage on ECG 
1
Circumferential large PEﬀ  
3
Moderate PEﬀ 
1
Small PEﬀ  
 -1
Right atrial collapse 
1
IVC dilated not collapsible 
1.5
Right ventricular collapse  
1.5
Left atrial collapse 
2
Mitral/tricuspid respiratory 
ﬂow variations 
1
Swinging heart 
1
Figure 12 Management of cardiac tamponade. CBP, central blood pressure; ECG, electrocardiogram; IVC, inferior vena cava; N, no; PEff, pericardial 
effusion; Y, yes. Criteria are listed for the evaluation of patients by immediate or delayed pericardiocentesis based on expert consensus. Immediate 
pericardiocentesis should be considered if there are >6 points from at least two categories.


<!-- PAGE 27 -->

### Page 27

4.5.6. Transient constrictive pericarditis 
Transient constriction is CP with ongoing inflammation that can be reversed following anti-inflammatory treatment or that heals spontaneously. 
It develops with pericarditis with or without PEff (about 10% of 
cases) and resolves with anti-inflammatory therapy in >50% of 
cases.120,121 A trial of 3–6 months of anti-inflammatory therapy is recommended in patients with newly diagnosed CP before referral for 
pericardiectomy.122,123 Biomarkers (e.g. elevated C-reactive protein) 
and multimodality imaging, including CMR, are mandatory to detect 
pericardial inflammation. 
4.5.6.1. Constrictive pathophysiology 
It is important to distinguish constrictive pathophysiology from actual 
HF symptoms.115,120,121,124 There may be features of septal bounce, 
Concomitant pericarditis
Pericardiectomy
(Class I)
Persistence of constriction
Outpatient follow-up
Close follow-up within 1 month
Pericardiectomy
(Class I)
Patient with symptoms and signs of constrictiona
First-line assessment with history, physical examination,
ECG, transthoracic echocardiography, laboratory assessment,
CT (calciﬁcations) and CMR (inﬂammation)
(Class I)
Deﬁnite diagnosis of constriction
Admission and cardiac catheterization
Low riskb
Intermediate riskb
High risk
Outpatient treatment
Improvement
Outpatient follow-up
Admission
(Class I)
Empiric anti-inﬂammatory therapy for at least 3–6 months
(Class IIa)
Figure 13 Management of constriction. CMR, cardiovascular magnetic resonance; CT, computed tomography; ECG, electrocardiogram; N, no; Y, yes. 
Empirical anti-inflammatory therapy is warranted only for those with evidence of pericarditis (by clinical criteria, biomarkers, and/or imaging). Low risk: 
clinical remission after therapy/normalization of imaging findings. Intermediate risk: improved symptoms without complete remission/partial regression. 
High risk: persistent symptoms/persistent imaging signs of constriction. aSee Table 6. bSee Table 7.   
ESC Guidelines                                                                                                                                                                                               27


<!-- PAGE 28 -->

### Page 28

respiratory phase-dependent shift of the ventricular septum, and 
Doppler features of constriction without HF symptoms (see  
Supplementary data online, Section 2.4 and Figure S1). 
4.5.7. Pericarditis with polyserositis 
Pericarditis with polyserositis is characterized by inflammation of the 
pericardium and concurrent inflammation of other serous membranes 
lining major body cavities, such as the pleura and peritoneum.37,103,125,126 
4.5.8. Inflammatory vs non-inflammatory pericarditis 
In the context of pericarditis, the terms ‘inflammatory’ and ‘non- 
inflammatory’ phenotype refer to two distinct clinical presentations 
based on the underlying pathophysiological mechanisms. 
4.5.8.1. Inflammatory phenotype of pericarditis 
The inflammatory phenotype is characterized by inflammation of the 
pericardium with evidence of systemic inflammation. This phenotype 
is often associated with fever, and/or elevated systemic inflammatory 
markers (e.g. C-reactive protein), PEff, and/or pleural effusion. These 
forms typically respond well to targeted anti-inflammatory therapies, 
including colchicine and anti-IL-1 agents.37,127 
4.5.8.2. Non-inflammatory phenotype of pericarditis 
The non-inflammatory phenotype refers to the manifestation of pericarditis without C-reactive protein elevation or low elevation of markers of 
systemic inflammation (e.g. high-sensitivity C-reactive protein).127 This occurs in 10%–20% of patients with pericarditis.36 The pathogenesis of pericarditis with normal C-reactive protein is unknown and these cases are 
often difficult to treat. C-reactive protein is a sensitive albeit unspecific biomarker of inflammation mainly driven by IL-6. Moreover, in autoimmune 
diseases characterized by the type I interferon (IFN) gene signature, 
C-reactive protein appears to be an unreliable marker of inflammation.52 
5. Diagnosis and diagnostic 
work-up 
The diagnostic work-up in patients with suspected IMPS should be tailored based on the severity of clinical presentation, response to medical 
therapy, and individual risk (Table 7). It includes medical history, clinical/ 
physical exam, biomarkers (myocardial injury, systemic inflammation, 
and HF), ECG, and multimodality imaging. Endomyocardial biopsy has 
its place in dedicated clinical scenarios. For IMPS, routine viral serology 
is not recommended,1 except for HIV and hepatitis C virus (HCV), as 
well as for suspected bacterial infections (such as Borrelia spp., rickettsial, and T. cruzi infections). Echocardiography is the basic imaging method, followed by other techniques. Cardiovascular magnetic resonance 
is an advanced imaging test of increasing importance for detection of 
myocardial as well as pericardial injury.115,128 Most important is a 
patient-tailored approach, usually driven by the dominant symptoms. 
Flow charts (Figures 5–7 and 9–13) illustrate the proposed workflow 
in different clinical scenarios. If a patient presents with clinical symptoms suggestive of IMPS (Table 6), basic and advanced diagnostic assessments are recommended (see Table 9). 
Recommendation Table 1 — Recommendations for 
clinical evaluation of myocarditis and pericarditis (see  
Evidence Table 1) 
Recommendations 
Classa 
Levelb  
Complete clinical evaluation, including history, 
physical examination, chest X-ray, biomarkersc, ECG, 
and echocardiography is recommended in all patients 
with a suspicion of myocarditis and/or pericarditis for 
the initial diagnostic assessment. 
I 
C 
CMR is recommended in patients with the clinical 
suspicion of myocarditis (using updated LL criteria)30 
and/or pericarditis for the non-invasive diagnosis of 
inflammatory reaction.110,115,129 
I 
B 
Hospital admission is recommended for patients 
with high-risk pericarditisd for monitoring and 
treatment.105,130 
I 
B 
Hospital admission is recommended for patients 
with moderate- to high-risk myocarditisd for 
monitoring and treatment. 
I 
C 
EMBe is recommended in patients with high-risk 
myocarditisd and/or haemodynamic instability, 
and/or in patients with intermediate-risk myocarditis 
not responding to conventional therapy in order to 
detect a specific histologic subtype and to assess the 
presence of viral genome for treatment.34,63,73,131 
I 
C 
Invasive coronary angiography or coronary CT, 
depending on clinical likelihood, is recommended in 
patients with IMPS if an acute coronary syndrome is 
suspected to rule out obstructive coronary artery 
disease. 
I 
C 
Hospital admission should be considered for patients 
with low-risk myocarditisd for monitoring and 
treatment. 
IIa 
C 
Pericardial or epicardial biopsy may be considered in 
relapsing pericardial effusion as part of the diagnostic 
work-up when the diagnosis cannot be reached with 
multimodality imaging and laboratory examinations. 
IIb 
C 
Routine serology is not recommended in patients 
with myocarditis and/or pericarditis for the 
evaluation of viral aetiology except for hepatitis C, 
HIV, and Lyme disease. 
III 
C 
© ESC 2025
CMR, cardiovascular magnetic resonance; CT, computed tomography; ECG, 
electrocardiogram; EMB, endomyocardial biopsy; HIV, human immunodeficiency virus; 
hs-TnI, high-sensitivity troponin I; hs-TnT, high-sensitivity troponin T; IMPS, 
inflammatory myopericardial syndrome; LL, Lake Louise; NT-proBNP, N-terminal 
prohormone of brain natriuretic peptide. 
aClass of recommendation. 
bLevel of evidence. 
cIncluding hs-TnT or hs-TnI, C-reactive protein, NT-proBNP. 
dSee Table 7. 
eContemporary evaluation of EMB should be based on histology, immunohistology, and 
molecular pathology for detection of viral infections in myocardial and blood samples 
(see also Table 11).


<!-- PAGE 29 -->

### Page 29

5.1. Electrocardiogram 
Dynamic changes in the ST segment are classic hallmarks of pericarditis and myocarditis. The most typical pattern includes widespread 
ST-segment elevation, reported in 20%–60% of cases (see  
Supplementary data online, Table S4). In pericarditis, ECG changes 
suggest concomitant myocardial involvement, and are indicative of 
inflammation of the subepicardium.35 These changes are more common in the initial phase and may be more frequent in younger patients. ST-segment depression and T-wave inversion may also be 
present, albeit less frequently than in patients with acute myocardial 
ischaemia,132 and may be related to the extent of myocardial 
damage.133,134 Diffuse depression of the PR segment is a classic early 
finding in AP. 
A decrease in the amplitude of QRS complexes on ECG can be 
observed in cases of AP and/or AM, especially with large effusions or 
extensive myocardial injury. Electrical alternans of the QRS complexes 
has been reported, attributed to fluctuation of the heart within a 
large effusion (swinging heart). Lengthening of the QT interval might occur in AM. 
Atrial fibrillation can occur in AP, especially in predisposed patients, 
in whom pericardial inflammation may be a trigger for supraventricular 
arrhythmias.77 In contrast, VA are more common in myocarditis. 
AVBs and intraventricular conduction defects, particularly right bundle branch blocks, are not uncommon (see Section 4.3.3, and  
Supplementary data online, Table S4) and may be associated with 
more severe presentations.135–137 
Electrocardiogram changes are highly dynamic and may evolve over a 
span of hours or days, with temporal progression varying significantly 
among patients. Typically, ST changes resolve; however, it is important 
to note that a normal ECG at presentation does not exclude the possibility of IMPS. 
5.2. Biomarkers 
5.2.1. Biomarkers in clinical routine 
Recommended biomarkers in IMPS include: 
• Markers of inflammation (e.g. C-reactive protein): C-reactive 
protein is often increased in patients with pericarditis (up to 80%) 
and AM (up to 80%), and contributes to the diagnosis.28,36,138 
Negative results, however, do not exclude the diagnosis. In pericarditis, C-reactive protein is a marker of disease activity that could be 
used to guide the duration of anti-inflammatory therapy.36 
D-dimers are currently being investigated for their diagnostic and 
prognostic relevance.36,139,140 
• Markers of myocardial lesions (e.g. troponin): Troponin is elevated in myocardial involvement, usually indicating cardiomyocyte 
necrosis. Assessment of baseline troponin is crucial to diagnose the 
severity of myocarditis. It is typically increased in infarct-like 
myocarditis. 
• Markers of HF (BNP or NT-proBNP): Assessment of baseline level 
is recommended among patients with suspected myocarditis. This 
measurement can be repeated at discharge and during follow-up in 
an outpatient setting to assess the risk of clinical events. 
NT-proBNP can be used in patients with myocarditis as a predictive 
marker of HF among patients with normal or impaired LVEF.12  
5.2.2. Biomarkers beyond clinical routine 
Different biomarkers may help to identify a specific aetiology and to 
guide risk stratification. Most of them are not part of clinical routine, 
Table 9 Basic and advanced level assessment 
Basic assessment:  
History: potential causes and triggers (viral infection of upper respiratory or 
gastrointestinal tract, toxins, drug use, medications), recurrent symptoms, 
family history of IMPS/cardiomyopathy/SCD, and systemic 
inflammatory/autoimmune diseases 
Physical examination: assess clinical stability, symptoms (chest pain, HF 
symptoms, palpitations, syncope), malaise, general weakness and fatigue, 
pericardial friction rub, clinical symptoms/signs of CTP 
ECG: PR-segment depression, ST/T-wave changes, AVB, and ventricular 
arrhythmias 
Chest X-ray 
Basic laboratory data: 
Markers of myocardial lesion (e.g. hs-TnT/TnI) 
Markers of systemic inflammation (e.g. C-reactive protein, ESR, WBC count) 
Markers of heart failure (e.g. NT-proBNP) 
Complete blood count (including eosinophilic count) 
Renal function and electrolytes (e.g. sodium, potassium, creatinine) 
Thyroid function (e.g. TSH) 
Hepatic function and additional testing (e.g. lactate dehydrogenase, aspartate 
aminotransferase, alanine aminotransferase) 
Echocardiography including strain imaging 
Advanced assessment usually after admission: 
Coronary anatomy evaluation (if needed for differential diagnosis by invasive 
coronary angiography or coronary CT depending on the clinical likelihood of 
ACS) 
CMR to assess signs of myocardial and pericardial inflammation and/or fibrosis 
Arrhythmia screening depending on risk stratification (e.g. Holter-ECG) 
Additional laboratory parameters guided by clinical suspicion (e.g. if 
therapeutic consequences are expected) 
Dedicated genetic testing if indicated 
CT to assess concomitant pleuropulmonary diseases 
Specific myocarditis: EMB in high-risk cases and in intermediate-risk 
cases on a case-by-case decision to detect specific histology and some 
aetiologies if needed 
Specific pericarditis: diagnostic pericardiocentesis when indicateda 
© ESC 2025
ACS, acute coronary syndrome; AVB, atrioventricular block; CMR, cardiovascular magnetic 
resonance; CT, computed tomography; CTP, cardiac tamponade; ECG, electrocardiogram; 
EMB, endomyocardial biopsy; ESR, erythrocyte sedimentation rate; HF, heart failure; 
hs-TnT/TnI, high-sensitivity troponin T/I; IMPS, inflammatory myopericardial syndrome; 
NT-proBNP, N-terminal prohormone of brain natriuretic peptide; SCD, sudden cardiac 
death; TSH, thyroid-stimulating hormone; WBC, white blood cell. 
aSee Recommendation Table 12   
ESC Guidelines                                                                                                                                                                                               29


<!-- PAGE 30 -->

### Page 30

but could help based on a strong clinical suspicion,73 e.g. miR721 was 
shown to have a discriminatory capacity.141 
In specific circumstances, tumour necrosis factor alpha (TNF-α), IL-1β, 
IL-6, and IL-17A may be of value. Similarly, in some cases, evaluation of 
cardio-specific antibodies may be helpful, according to the local laboratory availability. These include organ-specific anti-heart autoantibodies 
and anti-intercalated disc autoantibodies, as well as non-organ-specific 
serum autoantibodies.10 These autoantibodies, especially if found at 
high titres, may have a negative prognostic value.73,142 
Furthermore, a specific serum biomarker, i.e. the soluble form of the 
IL-1 receptor-like 1 (IL-1RL1), also known as ST2, was associated with a 
higher risk of severe HF among male myocarditis patients.143 Other 
biomarkers have been studied in myocarditis, including procollagen 
type III, gelsolin, soluble VCAM-1, galectin-3, serum alarmin S100A8/ 
S100A9, immunoglobulin free light chain, and heparin-binding protein, 
for both diagnostic and prognostic purposes. However, these biomarkers were evaluated among limited small cohorts and are clinically not 
routinely used.144,145 
5.3. Genetics 
Genetic testing is relatively new in the field of IMPS. There is a potential 
overlap with CMPs. Myocarditis and pericarditis will be discussed 
separately. 
There has been increasing evidence that gene variants coding for structural proteins, particularly desmosomal and sarcomeric proteins, may 
overlap with acute and recurrent myocarditis and affect disease severity.94,95 Furthermore, it has been shown that there is an overlap of gene 
variants predisposing to myocardial inflammation and inherited CMP 
(ARVC and NDLVC).13 In particular, myocardial inflammation may be detected in patients with inherited CMP using serum and imaging biomarkers.13 There is evidence that these patients are at higher risk for 
complicated myocarditis (Section 4.3.5).13,91,93,94 In a meta-analysis, the 
pooled prevalence of P/LP variants was 4.2% for uncomplicated myocarditis, whereas for complicated myocarditis the pooled prevalence was 22% 
and 45% in adults and children, respectively.95 Pathogenic/likely pathogenic 
variants in desmosomal genes were more common in uncomplicated 
myocarditis (64%), while variants in sarcomeric genes were more prevalent in complicated myocarditis (58% in adults and 71% in children).95 
A case series demonstrated a high proportion of definite or probable pathogenic variants in patients with myocarditis with RV involvement or sustained VA.146 Furthermore, DSP variants have 
been reported in familial recurrent myocarditis.147 Another study 
demonstrated overlap of gene variants in myocarditis and inherited 
CMP.96 
Identifying such gene variants has several clinical implications: 
(1) While in myocarditis there is a recommendation to defer on implantable cardioverter-defibrillator (ICD) placement during the 
acute phase of the disease, the threshold for ICD placement is lower in ARVC in cases of primary prevention.58 
(2) Gene variants predisposing to myocarditis have relevant implications for patients.147,148 Details are given in the 2023 ESC 
Guidelines for the management of cardiomyopathies.13 
(3) Cascade clinical and genetic screening for relatives and familial genetic counselling should be offered.93,149 
As scientific knowledge about gene variants and their potential 
pathophysiological role has been continuously increasing over recent years, comprehensive screening includes desmosomal and sarcomeric genes and some DCM-associated genes.64,91,96,146,150 For 
details, see 2023 ESC Guidelines for the management of cardiomyopathies.13 Nevertheless, it is not clear whether the inflammatory 
process acts as a trigger or is fully part of the pathophysiological process in inherited CMP.151 
Pathogenic/likely pathogenic variants have been identified in patients 
with recurrent pericarditis (RP), especially young patients, with a family 
history, multiple recurrences, inflammatory phenotype, and refractory 
or dependent on medical treatments. Recurrent pericarditis has been 
associated with genetic variants for monogenic autoinflammatory diseases (e.g. FMF, TRAPS), but also with genes related to the inflammatory response (Figure 14).50,51,152,153 
A recent study performed whole-exome sequencing in 108 patients 
with RP. Overall, about 15% of patients had variants in genes related to 
the inflammatory response, while up to 30% of patients carried variants 
in different cardiac genes, worthy of a deeper investigation.51 These 
data suggest a genetic predisposition in at least a subset of patients 
(positive family history of pericarditis or periodic fever, poor response 
to colchicine, multiple recurrences with inflammatory phenotype), and 
counselling may be offered.51,152 In these clinical scenarios, prolonged 
therapy with specific biological agents (e.g. anti-IL-1 agents) should be 
considered. 
Recommendation Table 2 — Recommendations for 
genetic testing (see Evidence Table 2) 
Recommendations 
Classa 
Levelb  
It is recommended to obtain family history 
including pedigrees in cases of recurrent IMPS 
to provide clues to the underlying aetiology, 
determine inheritance pattern, and identify 
relatives at risk. 
I 
C 
Genetic testing should be considered in patients 
with definite myocarditis/pericarditis in 
cases of:50,51,64,94,150 
• family history of IMPS, inherited or suspected 
cardiomyopathy 
• severe ventricular arrhythmiac 
• significant left/right LGE (e.g. ring-like pattern or 
septal LGE) or persistent LVEF systolic dysfunction 
• recurrent myocarditis or persistent troponin 
elevation 
• recurrent pericarditis with an inflammatory 
phenotype, refractory to conventional treatmentd, 
with the aim to detect an underlying genetic cause. 
IIa 
B 
© ESC 2025
IMPS, inflammatory myopericardial syndrome; IL, interleukin; LGE, late gadolinium 
enhancement; LVEF, left ventricular ejection fraction. 
aClass of recommendation. 
bLevel of evidence. 
cSee Section 4. 
dEspecially poor response to colchicine and anti-IL-1 agents.


<!-- PAGE 31 -->

### Page 31

5.4. Multimodality imaging 
The non-invasive diagnosis of IMPS relies on advanced cardiovascular imaging. An overview of the capabilities of different imaging modalities for 
the identification of pathophysiological components is provided in  
Supplementary data online, Table S5. Echocardiography is usually the 
first-step imaging modality and provides functional and morphological information. Cardiovascular magnetic resonance can better differentiate 
myocardial tissue and shows myocardial and pericardial inflammation, 
as well as different patterns of fibrosis. Fluorodeoxyglucose positron 
emission tomography (FDG-PET) is useful to detect disease activity, especially for CS (see Section 5.8). Computed tomography allows detection 
of calcification of the pericardium and its extent, as well as exclusion of 
CAD. The application of non-invasive imaging should guide therapeutic 
decision-making (see Section 4). 
5.5. Echocardiography 
Transthoracic echocardiography (TTE) is usually the initial imaging modality of choice for individuals with suspected IMPS, given its ability to 
identify myocardial and pericardial abnormalities, as well as concomitant valvular disease.115,124 
5.5.1. Echocardiography in myocarditis 
Patients with a suspicion of myocarditis should usually undergo standard 
TTE including speckle tracking or tissue Doppler imaging (TDI) at presentation. Transthoracic echocardiography helps monitor changes in cardiac chamber size, ventricular function, wall thickness, and PEff. In 
myocarditis, global ventricular dysfunction, diastolic dysfunction with 
preserved ejection fraction (EF), and regional WMA may occur.154,155 
Tissue Doppler imaging or strain imaging can be used in the setting of 
myocarditis and may indicate myocardial injury.156,157 Recent studies 
have shown that global longitudinal and circumferential strain (GLS 
and GCS) and strain rate were decreased in patients with AM, even 
with preserved EF.156 Strain may provide important prognostic information in AM.157 Regional GLS can be associated with scarring on 
CMR and can predict VA and outcomes in patients with AM.157 
Abnormal RV strain158 and left atrial (LA) strain159 have been detected 
in AM with preserved EF. 
5.5.2. Echocardiography in pericarditis 
Transthoracic echocardiography can detect the presence of PEff and 
assess its haemodynamic importance, as well as constrictive pathophysiology (Supplementary data online, Figure S1 and Table S6). 












	










	


Figure 14 The different courses of inflammatory myopericardial syndrome and the interplay between genetic background inflammation and autoimmunity beyond the initial infectious trigger. IMPS, inflammatory myopericardial syndrome.  
Table 10 Classification of pericardial effusion  
Onset 
Acute (≤4 weeks) 
Subacute (>4 weeks to ≤3 months) 
Chronic (>3 months) 
Sizea 
Mild: <10 mm 
Moderate: 10–20 mm 
Large: >20 mm 
Distribution 
Circumferential/loculated 
Composition 
Transudate/exudate 
© ESC 2025
aMaximal end-diastolic diameter.   
ESC Guidelines                                                                                                                                                                                               31


<!-- PAGE 32 -->

### Page 32

Acute pericarditis patients may have a normal-appearing TTE (40%– 
50% of cases in first episodes); however, the presence of new or worsening PEff is a diagnostic criterion for pericarditis.24,115,160 The size of 
PEff is assessed by the end-diastolic distance of the echo-free space between the epicardium and parietal pericardium (Table 10).115,128 It is recommended that images should include the extent and location of each 
effusion measurement, as this allows follow-up studies. Transthoracic 
echocardiography enables the recognition of CTP and the presence 
of constriction.115 
5.6. Cardiovascular magnetic resonance 
Cardiovascular magnetic resonance is the accepted gold standard for 
the quantification of biventricular function and detection of WMA. 
Cardiovascular magnetic resonance has the advantage of tissue differentiation, non-invasively detecting myocardial and pericardial inflammation, as well as fibrosis.30 The diagnostic targets in non-ischaemic 
myocardial inflammation include myocardial oedema, hyperaemia and 
capillary leak, and necrosis/fibrosis (see Supplementary data online,  
Figure S2).161–164 The diagnostic accuracy of CMR is higher if performed 
early in the time course of disease (best within the first 2 weeks). 
Myocardial oedema and changes due to inflammation lead to increased 
tissue water content that can be detected as increased signal intensities 
on T2-weighted imaging and/or T2 mapping; increased tissue free- 
water content will also lead to an increased signal in T1 mapping and 
extracellular volume (ECV) quantification. Myocyte necrosis and fibrosis can result in non-ischaemic (e.g. mid-wall, subepicardial, patchy) patterns of LGE, which do not typically follow a coronary artery 
distribution. The identification of myocarditis with chest pain presentation is less challenging than in HF and arrhythmic scenarios. The updated LLC, which include parametric mapping methods (T1/T2/ECV), 
should be applied for diagnosis, as the combined approach increases 
the diagnostic accuracy (see Figure 4).30 It is important to note that imaging evidence of myocardial inflammation does not provide the underlying histotype (see Supplementary data online, Figure S2). 
In the case of pericarditis, CMR detects thickening, oedema, and LGE 
of the pericardium.110,129,165 It is important to note that pericardial 
LGE may imply ongoing inflammation and neovascularization rather 
than simple scarring (see Supplementary data online, Figure S2). 
Cardiovascular magnetic resonance is helpful for an objective assessment of the degree of inflammatory involvement of the pericardium, 
either for first diagnoses or follow-up (for details see Figure 7 and  
Table 9). 
Given its physical properties, CMR is affected by ferromagnetic objects, such as valvular prosthesis and implants, resulting in artefacts. 
The same holds true for active MR-conditional devices, such as pacemakers, ICDs, and cardiac resynchronization therapy (CRT) pacemakers/defibrillators (P/Ds), but dedicated techniques are now 
available to achieve better diagnostic image quality in many cases.166 
Cardiovascular magnetic resonance could also be used in patients 
with non-conditional devices with a clear clinical indication if other imaging modalities are not helpful. In all cases, programming of the implanted device before and after the scan is warranted, as well as 
patient monitoring. 
Even in intubated patients, CMR scans are feasible in order to detect 
inflammation.167 If breath-hold capacities are reduced or the patient is 
uncooperative, fast imaging techniques and/or motion-corrected imaging have to be applied.168 
5.7. Computed tomography 
Computed tomography is an established tool for excluding CAD depending on the risk score and can be used in the diagnostic work-up 
according to current ESC guidelines.65,72,195 
Contrast-enhanced CT may be very useful to make an aetiological 
diagnosis in patients presenting with large PEff including tamponade.196 
Computed tomography is important before pericardiectomy for constriction to evaluate the anatomy and extent of calcifications as a higher 
burden of pericardial calcification has been associated with a better 
post-surgical outcome.197 Furthermore, anatomical abnormalities, 
such as pectus excavatum, can be identified.198 Meanwhile, CT in combination with FDG-PET plays a crucial role in the detection of CS 
(Section 9.4). 
Recommendation Table 3 — Recommendations for the 
use of cardiovascular magnetic resonance imaging (see  
Evidence Table 3) 
Recommendations 
Classa 
Levelb  
Myocarditis 
CMR is recommended in patients with suspected 
myocarditis to reach a clinical diagnosis and to 
determine the cause of acute myocardial injury, 
including assessment of oedema, ischaemia, and 
necrosis/fibrosis/scarring.115,164,169–183 
I 
B 
CMR is recommended for follow-up at least within 
the first 6 months in patients with myocarditis to 
identify a healed or ongoing process, for risk 
stratification and personalized therapy, and to enable 
a return to exercise.10,62,184–186 
I 
C 
Pericarditis 
CMR is recommended in patients with suspected 
pericarditis when a diagnosis cannot be made using 
clinical criteria to assess evidence of pericardial 
thickening, oedema, LGE, and to assess the 
persistence of disease during follow-up in selected 
cases.110,129,165,187–194 
I 
B 
© ESC 2025
CMR, cardiovascular magnetic resonance; LGE, late gadolinium enhancement. 
aClass of recommendation. 
bLevel of evidence.  
Recommendation Table 4 — Recommendations for 
computed tomography (see Evidence Table 4) 
Recommendations 
Classa 
Levelb  
CT is recommended to evaluate pericardial 
thickness, calcifications, masses, and loculated 
pericardial effusions, as well as concomitant 
pleuropulmonary diseases and chest 
abnormalities.193,197,199,200 
I 
C 
© ESC 2025
CT, computed tomography. Remaining recommendations for CT can be found in  
Recommendation Table 1. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 33 -->

### Page 33

5.8. Nuclear medicine 
Fluorodeoxyglucose uptake reflects metabolically active inflammatory 
cells in AM.201 
Fluorodeoxyglucose positron emission tomography can be considered as an alternative in patients when CMR is unsuitable because of 
an irregular heartbeat or device-related artefacts.202 Simultaneous/hybrid 
cardiac PET-CT/CMR imaging complement each other in the assessment of myocarditis compared with either approach alone.201,203 
Fluorodeoxyglucose positron emission tomography is also a powerful 
tool to detect and assess the extent of extracardiac involvement in sarcoidosis (see Section 9.4). 
Appropriate fasting before FDG-PET is a must to obtain reliable results.204 Typical preparation protocols include a high-fat and low- 
carbohydrate diet for 12–24 h followed by complete fasting other 
than water for the 6–12-h period prior to FDG injection. 
The role of nuclear imaging in pericarditis is less well established. The 
use of FDG-PET/CT in pericarditis is generally complementary and is 
most often implemented in cases where CMR cannot be used.205 
5.9. Endomyocardial and pericardial biopsy 
5.9.1. Endomyocardial biopsy 
Endomyocardial biopsy enables the identification of the underlying 
histological subtype of cardiac inflammation.10,34,207,208 However, non- 
invasive imaging methods have significantly improved, allowing the diagnosis of myocarditis by CMR. Therefore, the role of EMB in clinical 
practice has changed. Endomyocardial biopsy remains important for 
high-risk patients and in some intermediate cases when the knowledge 
of the histological subtype and the identification of a possible viral aetiology are important for targeted therapies (Figure 15).207,209 
Endomyocardial biopsy has potential complications (e.g. cardiac perforation/tamponade, thromboembolism, valvular trauma, severe arrhythmias, and death).9,210 Rates depend on the setting and centre experience 
and range between 0.6% and 5%,63,211 and increase up to 26% in FM 
cases on mechanical circulatory support (MCS).212 Children may have 
higher complication rates depending on age, the experience of the centre, and the site of the biopsy (LV or RV).63,213 On this basis, the clinical 
use of EMB should be tailored according to the risk–benefit ratio. 
Histological and immunohistological investigations, as well as viral genome analysis, allow the identification of viral or immune-mediated LM, EM, 
GCM, and sarcoidosis.33,214,215 Moreover, EMB allows the identification of 
the inflammatory stages in association with the degree of myocardial necrosis and fibrosis. Endomyocardial biopsy is useful in the differential diagnosis of infiltrative/storage diseases (amyloidosis, haemochromatosis, 
glycogenosis), different CMPs, and genetic heart diseases33,216 if non- 
invasive imaging is inconclusive. This approach is consistent with other 
international position statements.9,210 Endomyocardial biopsy can be useful in cases of chronic CMP that is progressive or unresponsive to standard therapy. When FM, GCM or EM are suspected, early EMB is required 
to start immunosuppressive therapy rapidly and improve outcomes.57 In 
GCM, EMB has high sensitivity (80%–93%) and a positive predictive value 
(71%), especially if performed within 2–4 weeks from symptom onset.217 
In CS, EMB may have a low sensitivity (20%–30%) due to the focal nature 
of inflammatory lesions, but can be improved by guiding the EMB using 
CMR or electro-anatomical mapping (EAM).218–222 
Historically, diagnosis by EMB was based on the histological Dallas criteria in HE-stained heart tissue sections revealing myocytolysis and interstitial immune cells.223 However, since there is high interobserver 
variability, immunohistochemical detection of lymphocytes (CD3) and 
macrophages (CD68) can definitely increase sensitivity for the diagnosis 
of myocarditis.10,224–226 A recent meta-analysis indicates that the use of 
immunohistochemistry can increase the detection rate of inflammation 
in EMB specimens to ∼51%.227 A value of ≥14 leucocytes/mm2 with T 
lymphocytes of ≥7 cells/mm2 has been considered as the cut-off for 
the diagnosis of myocarditis.10 In acute LM, the number of T lymphocytes 
is generally higher (>25 cells/mm2).228 Additionally, the expression of 
MHC class II molecules in antigen-presenting macrophages and endothelial cells is routinely observed in EMB with myocarditis.33 Endomyocardial 
biopsy also enables the detection of viruses, such as enteroviruses, 
B19V,228 and herpesviruses, e.g. EBV and HHV-6, using quantitative real- 
time (RT)-PCR and in situ hybridization. It is likely that advances in molecular diagnostic techniques, such as next-generation sequencing, will 
help to identify potential new pathogens. Positive PCR results obtained 
on EMB have to be accompanied by a parallel investigation of blood samples collected at the time of the EMB to exclude acute systemic virus infection. In cases of acute cardiac and systemic virus infection, 
immunosuppressive therapy must be avoided. 
The most common site of EMB is the RV septum, but occasionally LV 
or biventricular EMB may be needed. The decision of the EMB site should 
be based on the clinical indication, findings of pre-procedural imaging, and 
operator expertise.229 A study of 755 patients with suspected myocarditis and non-ischaemic CMP (including infiltrative and storage disorders) 
indicated that biventricular EMB can increase diagnostic accuracy compared with selective LV or RV EMB.211 Sampling error is the major limitation of the diagnostic accuracy of EMB. The minimal number of 
required EMB samples for each technique is reported in Table 11.33 
It should be emphasized that PCR in EMB tissue and in situ hybridization can be used for identification of the viral agent, because viral serology concurs with the results of PCR in a minority of patients 
(∼4%) with myocarditis.230 With PCR, the rate of viral sequences detected in EMB specimens is up to 67%, although the rate varies widely 
among studies.63,228,231 The PCR tests for the detection of infectious 
agents must be performed in laboratories that are accredited and certified for the identification of viruses, bacteria, and parasites. The evaluation of these PCR results must be done in the context of histological/ 
immunohistological findings by pathologists with expertise in cardiovascular diseases. 
The timely communication of biopsy results is crucial for optimal 
therapeutic guidance. 
Targeted biopsies of an inflamed heart diagnosed using histology, immunohistochemistry, and molecular virology could be correlated with modern technologies, such as genomics, epigenomics, proteomics, and 
metabolomics to improve the diagnosis and therapy. Recommendations 
for EMB can be found in Recommendation Table 1. 
Recommendation Table 5 — Recommendations for nuclear medicine (see Evidence Table 5) 
Recommendations 
Classa 
Levelb  
Carb-free 18F-FDG-PET or 18F-FDG-PET/CT should 
be considered for the diagnostic work-up in patients 
with suspected myocarditis and/or pericarditis in 
whom echocardiography and CMR are inconclusive 
for the clinical diagnosis.201,206 
IIa 
C 
© ESC 2025
CMR, cardiovascular magnetic resonance; CT, computed tomography; 18F-FDG-PET, 
[18F]-fluorodeoxyglucose positron emission tomography. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               33


<!-- PAGE 34 -->

### Page 34

Recommendation Table 6 — Recommendations for endomyocardial biopsy (see Evidence Table 6) 
Recommendations 
Classa 
Levelb  
EMBc is recommended in patients with high-risk myocarditisd, and/or haemodynamic instability, and/or in patients with intermediate-risk 
myocarditis not responding to conventional therapy in order to detect a specific histologic subtype and to assess the presence of viral 
genome for treatment.34,63,73,131 
I 
C 
© ESC 2025
EMB, endomyocardial biopsy. 
aClass of recommendation. 
bLevel of evidence. 
cContemporary evaluation of EMB should be based on histology, immunohistology, and molecular pathology for detection of viral infections in myocardial and blood samples (see also  
Table 11). 
dSee Table 7.  

















	




	


	







µm




Figure 15 Histopathological findings in myocarditis. HE, haematoxylin eosin. (A–C) Endomyocardial biopsy for acute lymphocytic myocarditis reveals 
cardiomyocyte necrosis (A, HE stain) and severe focal infiltration of CD3+ T cells (B) and CD68+ macrophages (C), as detected by immunohistochemistry. (D–F) In chronic lymphocytic myocarditis, no cardiomyocyte injury is observed, but there is focal replacement fibrosis (D, HE) in the presence of 
CD3+ T cells (E) and CD68+ macrophages (F). (G–I) In acute eosinophilic myocarditis, necrosis of cardiomyocytes is associated with numerous eosinophilic granulocytes (G, Giemsa stain), some CD3+ T cells (H), and numerous CD68+ macrophages (I). (J–L) Areas with severe cardiomyocyte necrosis in 
the presence of extensive focal and diffuse infiltration of eosinophilic granulocytes (J, Giemsa stain), CD3+ T cells (K), and CD68+ macrophages and 
CD68+ giant cells (L) are typical of giant-cell myocarditis. (M–O) Cardiac sarcoidosis is histologically characterized by the presence of granulomas, usually in the absence of cardiomyocyte necrosis (M, Giemsa stain), but with focal infiltration of CD3+ T cells (N) and numerous CD68+ macrophages and 
CD68+ giant cells (O).


<!-- PAGE 35 -->

### Page 35

5.9.2. Pericardial biopsy 
In clinical practice, pericardial biopsy is rarely indicated in complicated 
cases not responding to conventional anti-inflammatory therapy and 
with a high suspicion of a specific aetiology (e.g. primary pericardial tumours and metastases), which cannot be determined by non-invasive 
diagnostic methods. Pericardial biopsy can be performed by pericardioscopy (an endoscopic study of the pericardium that is available in a limited number of tertiary referral centres). It is more commonly 
performed with a thoracoscopic or surgical approach, usually during 
a pericardial drainage or a pericardial window.1,232 
5.10. Role of autopsy 
In autopsy studies of SCD, myocarditis has been described as a common finding, with incidences of myocarditis in children and adults ranging from 0.3% to 14.8%.87,88,233–235 In the majority of these studies, the 
incidence of myocarditis in SCD was higher in people aged under 
35 years.236,237 A nationwide unselected cohort of 14 294 deaths in 
Denmark suggested that 6% of all autopsied SCD was caused by myocarditis. Males have a significantly higher incidence.88 In the UK, between 1994 and 2022, myocarditis was reported as a rare cause of 
SCD in non-hospitalized individuals (1.1%) in 7702 consecutive cases 
of SCD. Here, the most common reported form was LM (56%), which 
corresponds well with data obtained from EMBs of patients with suspected myocarditis.10,63,87,238 
In the guidelines for the histopathological diagnosis of myocarditis, 
‘fulminant’ or ‘multifocal’ myocarditis can be generally considered as a 
reliable or acceptable cause of death, especially when inflammation is 
the only substantial histopathological finding. This approach is endorsed 
by the Association of European Cardiovascular Pathology.239 
In addition to LM, other types of cardiac inflammation are observed 
in autopsies. In 558 of 49 612 (1.1%) forensic autopsies, myocarditis 
was detected by histology. In a Finnish study consisting of 351 patients 
with CS, 14% experienced fatal and aborted SCD as a presenting manifestation. In 64%, undiagnosed granulomas in the heart were the cause 
of fatalities.240 The likelihood that a case of unexplained SCD is caused 
by an underlying inherited disorder has led to the emerging role of genetic testing of DNA obtained at autopsy (also called molecular autopsy 
or post-mortem genetic testing).239 Therefore, pathologists play an important role in the identification of families at risk by reporting whether 
it is recommended to refer first-degree family members for clinical 
screening and/or to perform additional post-mortem genetic testing 
to identify the underlying cause of cardiac inflammation.241,242 Legal 
and ethical issues related to genetic testing in deceased subjects who 
did not give their consent are not universally regulated by law. 
5.11. Role of cardiac catheterization and 
coronary angiography 
Given the overlap of symptoms (especially chest pain), as well as the 
elevation of biomarkers (such as troponin in the case of myocardial involvement and NT-proBNP) and ECG changes, ACS is the main differential diagnosis for IMPS. Depending on the initial clinical assessment, 
ACS should be ruled out according to current guidelines (Figure 9). 
The recommended methods are coronary CT or invasive coronary 
angiography depending on likelihood of obstructive CAD.72,248 
Coronary angiography is preferable in patients with a high likelihood 
of ACS. It should be noted that CAD may coexist with myocarditis 
in particular scenarios, including EM and ICI-induced myocarditis.249–251 
Cardiac catheterization is also indicated to monitor and guide HF 
therapy, as well as the early need for more advanced support (HT or 
MCS) in the case of refractory haemodynamic deterioration.12 
Table 11 Parameters for reporting by endomyocardial 
biopsy 
Criteria 
Parameters for reporting  
Histology (paraffin-embedded EMB, 
at least 3 EMB) 
Presence and extent of 
cardiomyocyte necrosis, 
inflammation, fibrosis 
Immunohistology 
(paraffin-embedded EMB, at least 3 
myocardial samples) 
Presence, extent, localization, and 
typing of immune cells in the 
myocardium: CD3+ T lymphocytes, 
CD68+ macrophages 
(≥14 leucocytes/mm2 with T 
lymphocytes ≥7 cells/mm),10 
HLA-DR expression in immune 
cells and endothelial cells 
Molecular pathology [infections: 
RNAlater, snap-frozen tissue (1–2 
EMB), paraffin-embedded EMB]     
Blood 
Presence, typing, and quantification 
of DNA/RNA from infectious 
agents by q(RT)-PCR 
Viruses: mainly enteroviruses, 
parvovirus B19, human herpesvirus 6, 
Epstein–Barr virus; Borrelia spp., 
Trypanosoma cruzia 
q(RT)-PCR for detection of 
systemic infections 
Molecular pathology (genetics: 
RNAlater, frozen tissue, 
paraffin-embedded EMB, blood) 
NGS for detection of pathogenic 
variants in cardiac genes, 
traditionally associated with 
cardiomyopathies (especially 
desmosomal and sarcomeric/ 
cytoskeletal genes) 
© ESC 2025
DNA, deoxyribonucleic acid; EMB, endomyocardial biopsy; HLA-DR, human leucocyte 
antigen—DR isotype; NGS, next-generation sequencing; q(RT)-PCR, quantitative 
(real-time) polymerase chain reaction; RNA, ribonucleic acid. 
aSee Supplementary data online, Table S1.  
Recommendation Table 7 — Recommendations for 
autopsy (see Evidence Table 7) 
Recommendations 
Classa 
Levelb  
Comprehensive autopsy is recommended in all 
patients <50 years of age with SCD to evaluate the 
presence of acute myocarditis as a cause and to 
detect potential underlying inherited cardiac 
diseases.87,243–246c 
I 
B 
Retaining samples suitable for DNA extraction and 
consulting a cardiac pathologist is recommended in 
cases of SCD, when an inherited cause is suspected, 
or the cause of death remains unexplained.243,247c 
I 
B 
© ESC 2025
DNA, deoxyribonucleic acid; SCD, sudden cardiac death. 
aClass of recommendation. 
bLevel of evidence. 
cIn line with the 2022 ESC Guidelines for the management of patients with ventricular 
arrhythmias and the prevention of sudden cardiac death.58   
ESC Guidelines                                                                                                                                                                                               35


<!-- PAGE 36 -->

### Page 36

For pericarditis, specific indications for cardiac catheterization include the differential diagnosis between restrictive CMP (RCM) or 
CP,252 when this differentiation cannot be done by multimodality imaging (see Supplementary data online, Section 2.6). 
5.12. Electro-anatomical mapping 
The diagnostic yield of traditional fluoroscopy-guided EMB in patients 
with suspected myocarditis may decrease with segmental or patchy 
myocardial involvement, as seen in CS. Electro-anatomical mapping, 
using bipolar and unipolar voltage mapping, allows the identification 
of low-voltage areas, which reflects abnormal myocardial tissue (scarring, inflammation), and therefore guides EMB.218–222 Unipolar 
EAM-guided EMB demonstrated a higher diagnostic yield than bipolar 
EAM (83% compared with 63%), consistent with the epicardial 
substrate.84,218,221 
A meta-analysis of 148 patients showed a higher diagnostic performance of EAM-guided EMB in CS compared with other forms of myocarditis. The sensitivity of any abnormal electrogram for a positive EMB 
was high (92%) but was associated with moderate specificity (58%).221 
Electro-anatomical mapping has demonstrated good sensitivity and 
specificity compared with CMR for the detection of pathological areas 
of the myocardium.218 The value of EAM to guide biopsy may be lower 
in AM as low-voltage areas correlate well with LGE, but not with oedema.253 There may also be discordance between low-voltage areas 
and LGE on CMR. However, the combination of unipolar/bipolar EAM 
with CMR findings increased the diagnosis yield of EMB,218 especially in 
CS.220 The EAM pattern may also help to differentiate between differential diagnoses, especially between CS and ARVC,254 as CS often involves 
the basal septum and exhibits a higher bipolar/unipolar low-voltage area 
ratio. The reported complication rate of EAM-guided EMB is <5%.218,221 
Programmed ventricular stimulation (PVS) has not been evaluated in 
the acute setting and should not be performed in the acute phase. It 
could be useful for arrhythmia stratification in selected patients with 
non-active myocarditis, with LGE and risk factors for ventricular arrythmias (Section 6.5).255 
6. Therapy 
The aim of medical therapy for IMPS is to relieve symptoms and to prevent complications, especially recurrences and mortality in complicated 
cases. Medical therapy targets include: (i) infectious agents; (ii) inflammation; (iii) immune-mediated processes; (iv) HF and ventricular 
dysfunction (in cases of myocarditis); (v) arrhythmias; and (vi) 
constriction (in cases of pericarditis). Treatments are individualized according to the specific case and the presumed or diagnosed pathogenesis, and specific therapeutic concepts will be discussed in the section 
covering specific causes. There may be differences depending on 
whether an isolated or a combined form is present. The current evidence is more focused on the isolated cases. For combined conditions, 
the leading one (myopericarditis or perimyocarditis) should guide the 
therapeutic decision-making and subsequent follow-up. 
6.1. Non-pharmacological therapy for 
inflammatory myopericardial syndrome 
An important non-pharmacological concept is the restriction of physical 
activity beyond sedentary activities until symptom resolution and clinical 
remission with normalization of inflammatory markers. This temporary 
limitation of physical activities should be individualized according to each 
patient, and the response to therapy until clinical remission. According 
to clinical presentation, at least 1 month is needed to reach clinical remission, but it can last longer. Depending on the stage and risk of the 
IMPS, physical activity should be tailored, and temporary restriction of 
physical activity is necessary in the acute phase of the disease (see 
Section 7). Previous consensus statements and guidelines11 have tried 
to provide a fixed time interval. This TF suggests personalizing the treatment until clinical remission based on a multiparametric assessment, 
which was also supported by the 2024 ACC expert consensus paper.9 
Clinical remission is defined as full regression of symptoms, as well as 
normalization of laboratory results (e.g. C-reactive protein, troponin levels) and investigations (ECG, evidence of PEff, CMR evidence of active 
inflammation) (Table 3). Additional testing (e.g. exercise testing and 
Holter monitoring) is recommended for patients with myocarditis for 
the detection of clinical remission. After a prolonged rest period, a gradual, monitored return to work and physical activity may be helpful, if necessary, guided by a qualified rehabilitation. Currently, evidence-based 
data are missing on this topic, and the decision must be individualized. 
6.2. Pharmacological therapy 
6.2.1. Pharmacological therapy for myocarditis 
6.2.1.1. General principles 
This section will focus on general aspects and non-aetiology-directed 
therapy. It should be recognized that evidence is very limited in this field 
and this document will provide guidance for clinical practice. 
Medical therapy of myocarditis is based on clinical presentation, case severity, and aetiology. It includes general supportive, non-aetiology-directed 
therapy (e.g. HF therapy),12,259 anti-arrhythmic therapy, and specific therapy (aetiology-directed therapy).58,260,261 Corticosteroids are considered 
for autoimmunity-associated cases to suppress the immune system, as first- 
line therapy in most cases. Severe cases are considered for MCS and HT. 
Uncomplicated cases of myocarditis usually present with chest pain 
and can be empirically treated with aspirin or non-steroidal anti- 
inflammatory drugs (NSAIDs) for the control of chest pain, if needed. 
This is supported by a small study showing no harm for patients treated 
with anti-inflammatory drugs.262 Concomitant use of colchicine is safe 
in patients with myopericarditis, preventing recurrences.263 In clinical 
practice, β-blockers are often used in patients with myocarditis. In a 
small study, β-blockers were associated with better outcomes, defined 
as freedom from cardiac death or HT.264 
Recommendation Table 8 — Recommendations for 
electro-anatomical mapping (see Evidence Table 8) 
Recommendations 
Classa 
Levelb  
Electro-anatomical mapping should be considered in 
cases of suspected myocarditis (especially cardiac 
sarcoidosis) to guide endomyocardial 
biopsy.218,220,221,253,256–258 
IIa 
C 
© ESC 2025
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 37 -->

### Page 37

Several viruses can cause myocarditis and are mentioned in 
Section 3.4. The specific therapies for viral aetiologies can be found in 
Section 9.5 for influenza-, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-, and HIV-associated myocarditis. For specific 
aetiologies, refer to the subsections on LM (Section 9.1), EM 
(Section 9.2), GCM (Section 9.3), CS (Section 9.4), LC (Section 9.5.2), 
CD (Section 9.5.3), and ICI-associated myocarditis (Section 9.6.1.1). 
Specific medical therapies are summarized in Table 12. 
Table 12 Therapy for specific forms of myocarditis 
Lymphocytic myocarditis (virus-negative)  
1st line therapy 
Non-severe: prednisone 1 mg/kg/day p.o. then tapered 
Severe: i.v. methylprednisolone 7–14 mg/kg/day for 3 days, then 1 mg/kg/day p.o. 
2nd line therapy 
Oral corticosteroids + azathioprinea or mycophenolate mofetilb, cyclosporinec, methotrexated 
3rd line therapy 
IVIGe or plasmapheresisf 
Eosinophilic myocarditis 
1st line therapy 
Same as lymphocytic myocarditis + Treat EM-associated condition if identified 
2nd line therapy 
Same as lymphocytic myocarditis + Treat EM-associated condition if identified 
3rd line therapy 
– 
Giant-cell myocarditis 
1st line therapy 
Non-severe: prednisone 1 mg/kg/day p.o. then tapered 
Severe: i.v. methylprednisolone 7–14 mg/kg/day for 3 days, then 1 mg/kg/day p.o. + immunosuppressive 
(azathioprinea or mycophenolate mofetilb, cyclosporinec) 
2nd line therapy 
Antithymocyte Globulin (ATG)g cyclophosphamideh, rituximabi 
3rd line therapy 
– 
Cardiac sarcoidosis 
1st line therapy 
Non-severe: prednisone 1 mg/kg/day p.o., tapering from 40–60 mg daily 
Severe: i.v. methylprednisolone 7–14 mg/kg/day for 3 days, then 1 mg/kg/day p.o. 
2nd line therapy 
Methotrexated (1st choice), or azathioprinea mycophenolate mofetilb, cyclophosphamideh 
3rd line therapy 
Infliximabj or adalimumabk, rituximabi 
Lyme carditis 
1st line therapy 
(a) Oral antibiotics (mild cases): 
– Doxycycline 100 mg b.i.d. (14–21 days) 
– Amoxicillin 500 mg t.i.d. (14–21 days) 
– Cefuroxime axetil 500 mg b.i.d. (14–21 days) 
(b) i.v. antibiotics (severe cases): 
– Ceftriaxone 2 g/day (14–21 days) 
2nd line therapy 
i.v. antibiotics: 
Cefotaxime (2 g q8h × 14–21 days) or Penicillin G (18–24 MU/day i.v. q4h × 14–21 day) 
3rd line therapy 
– 
Chagas disease 
1st line therapy 
Benznidazole 5–7 mg/kg/day in 2 doses for 60 days 
Nifurtimox 8–10 mg/kg/day in 3 doses for 60–90 days 
2nd line therapy 
– 
3rd line therapy 
–                                                                                                                                                                    
Continued  
ESC Guidelines                                                                                                                                                                                               37


<!-- PAGE 38 -->

### Page 38

6.2.1.2. Fulminant myocarditis 
Fulminant myocarditis is a rare and severe presentation of myocarditis 
and a cause of cardiogenic shock, and should be treated accordingly 
with inotropic or vasopressor support or, if needed, MCS (see 
Section 6.3).265 It is crucial to be aware of the condition and, when 
needed, to refer patients to tertiary referral centres that can institute 
temporary MCS and perform early EMB. Early EMB has been independently associated with a lower rate of death or HT/left ventricular assist 
device (LVAD) at 1 year.57 The timely communication of biopsy results 
is crucial. Specific subtypes of FM (e.g. biopsy-proven non-infectious 
forms) may respond to immunosuppressive therapy in addition to 
guideline-directed medical care.12,34 An ongoing trial is evaluating corticosteroids for FM (ClinicalTrials.gov Identifier: NCT05150704). 
6.2.1.3. Acute myocarditis 
Acute myocarditis has a high rate of spontaneous recovery, especially in 
uncomplicated cases. In cases of AM diagnosed by EMB, up to 50% of 
patients have spontaneous recovery and up to 25% may have a persistent stable cardiac dysfunction. Only 10%–25% have a progressive ventricular dysfunction, which could lead to end-stage DCM, HT, or 
death.9 Treatment of AM depends on severity and clinical presentation. 
Risk stratification of these patients is mandatory to assess the required 
level of care. 
The acute phase of viral myocarditis (e.g. induced by cytolytic enteroviruses) is characterized by intense virus replication and myocyte necrosis and usually lasts for only a few days.266 Thus, early antiviral 
therapy directed against an identified virus is a potential therapeutic 
avenue to stop the development of viral myocarditis. The evidence 
on clinical application of antiviral agents is limited, and antiviral treatments should be agreed upon with an infectious disease expert as 
part of the IMPS team. 
Patients with AM show significant activation of the NLR family pyrin 
domain containing 3 (NLRP3) inflammasome in the heart, thus it is a 
potential therapeutic target in the acute phase of myocarditis.267 
Activation of NLRP3 functions as a rapid inducer of an inflammatory response through the production of IL-1β and IL-18. Theoretically, promising agents are anti-IL-1 agents (anakinra, rilonacept, canakinumab) and 
colchicine,267 although human data on the effect of such agents in myocarditis are still limited. 
In humans, the first evidence has been reported using anakinra, an 
IL-1 receptor antagonist (IL-1RA) that improved heart function in selected cases of AM refractory to standard treatment. However, in 
the ARAMIS trial, anakinra failed to demonstrate a benefit in patients 
with suspected AM without a specific aetiology (NCT03018834).268 
The primary endpoint was the number of days alive free from any complication due to AM. The study had potential limitations related to the 
limited sample size, the inclusion of a low-risk population, and the short 
follow-up, but it proved that anakinra was safe in this setting. 
Regarding modulation of the immune response, further randomized 
studies are needed to assess treatment with intravenous immunoglobulins (IVIG) in AM for adults,269 since case series and retrospective analyses suggest a benefit in terms of transplant-free survival. Intravenous 
immunoglobulins are commonly prescribed in paediatric patients.269 In 
general, treatment of AM with corticosteroids is controversial, with the 
exception of ICI-induced myocarditis270 and EM.271 
ICI-induced myocarditis 
1st line therapy 
Withdraw ICI, reassess 
Non-severe: methylprednisolone 500–1000 mg/day × 3 days, then taper with oral prednisone 
Severe: i.v. methylprednisolone 7–14 mg/kg/day × 3 days, then 1 mg/kg/day 
2nd line therapy 
If no response in 24–48 h: mycophenolate mofetilb, ATGg abataceptl, alemtuzumabm 
3rd line therapy 
Infliximabj or adalimumabk, rituximabi 
© ESC 2025
ATG, anti-thymocyte globulins; b.i.d., twice daily; CTLA-4, cytotoxic T-lymphocyte antigen 4; EM, eosinophilic myocarditis; ICI, immune checkpoint inhibitor; IgG, immunoglobulin; IL, 
interleukin; i.v., intravenous; IVIG, intravenous immunoglobulins; p.o., by mouth; s.c., subcutaneous; t.i.d., three times daily; TNF-α, tumour necrosis factor alpha. 
aAzathioprine (immunosuppressant purine analog): 1–2 mg/kg per day p.o. (typically 100–150 mg daily, in 1–2 divided doses, main target: lymphocytes). 
bMycophenolate mofetil (immunosuppressant that inhibits inosine monophosphate dehydrogenase, main target: lymphocytes): 500–1000 mg p.o. b.i.d. (total 1–2 g/day). 
cCyclosporine (calcineurin inhibitor that prevents IL-2 transcription in activated T-cells): ∼3–5 mg/kg/day p.o. (divided b.i.d.) adjusted to target trough levels ∼150–250 ng/mL. 
dMethotreaxate (antimetabolite that inhibits dihydrofolate reductase and other folate-dependent steps, reducing proliferation of active lymphocytes): 15–20 mg/week p.o. or s.c. (low-dose 
weekly, with folic acid supplementation). 
eIVIG (immunomodulatory therapy providing pooled IgG antibodies) = standard dose off-label 2 g/kg total dose, typically administered over 1 to 2 days; alternative dosing: 0.4 g/kg/day for 5 
consecutive days (less commonly used in myocarditis but sometimes used in autoimmune settings). 
fPlasmapheresis (therapeutic plasma exchange that filters out and removes circulating autoantibodies, immune complexes, and inflammatory mediators) 3–5 sessions in 5–10 days. 
gAntithymocyte Globulin (ATG; polyclonal anti-T-lymphocyte antibody that causes profound T-cell depletion): ∼1 mg/kg i.v., often given daily for 3–5 days. 
hCyclophosphamide (cytotoxic alkylating agent that crosslinks DNA in rapidly dividing cells, main target: lymphocytes): 600 mg/m² i.v. bolus on days 1, 15, and 30 (pulse therapy). 
iRituximab (monoclonal antibody against CD20 on B cells): 375 mg/m² i.v. weekly × 4 doses (1 month). 
jInfliximab (monoclonal antibody against TNF-α): 5 mg/kg i.v. at weeks 0, 2, 6, then every ∼8 weeks (maintenance). 
kAdalimumab (anti-TNF-α fully human monoclonal antibody) 40 mg SC every week (or every 2 weeks, per clinical response). 
lAbatacept (CTLA-4 Ig fusion protein that binds CD80/86 on antigen-presenting cells, blocking the CD28 co-stimulatory signal required for full T-cell activation): 500 mg i.v. every 2 weeks × 5 
doses (approximately 10 weeks). 
mAlemtuzumab (monoclonal antibody against CD52 on lymphocytes): 30 mg i.v. once (alternative: 15 mg i.v. daily for 2 days).  
Main mechanisms of action:  
• T-cell suppression (e.g., corticosteroids, cyclosporine, abatacept)  
• B-cell depletion (rituximab)  
• Cytokine inhibition (TNF-α blockers like infliximab, adalimumab)  
• DNA synthesis inhibition (azathioprine, mycophenolate, methotrexate)  
• Immunoglobulin replacement/modulation (IVIG)  
• Plasma filtration (plasmapheresis)


<!-- PAGE 39 -->

### Page 39

The efficacy of combined immunosuppression (prednisone with either cyclosporine or azathioprine), compared with placebo, was assessed in a single randomized controlled trial (RCT) in patients with 
biopsy-proven AM of unspecified aetiology, since infectious causes 
were not excluded by PCR.272 The trial was designed to determine 
whether immunosuppressive therapy improved LV function in patients 
with AM. There was no significant difference in survival between the 
two groups (P = 0.96). The study had several limitations, such as small 
sample size and incomplete analysis of EMB based only on histopathology. However, in specific histopathological forms of AM, such as 
GCM, immunosuppressive drugs are recommended (see Sections 9.2 
and 9.3). 
6.2.1.4. Subacute and chronic myocarditis 
Chronic myocarditis may represent an intermediate stage between 
subacute myocarditis and inflammatory CMP. During chronic myocarditis, HF may develop, and guideline-directed medical therapy 
(GDMT) for HF is the cornerstone in the treatment of chronic myocarditis.12,259 Antiviral therapy has little benefit in the subacute and 
chronic stages of myocarditis,273 and the effects of immunomodulatory drugs on chronic myocarditis of unspecified aetiology are still 
controversial. 
6.2.2. Pharmacological therapy for pericarditis 
6.2.2.1. General principles 
The aims of medical therapy for pericarditis are to provide: (i) symptomatic care (mainly control of pericarditis chest pain); (ii) clinical remission; and (iii) prevention of complications, especially recurrences 
and constriction. 
Exercise restriction limits the heart rate and may be useful to reduce 
pericardial friction, which can be improved using drugs that reduce it 
(e.g. β-blockers or ivabradine for those who cannot receive or tolerate 
β-blockers) for patients with a resting heart rate of >75 b.p.m., and 
symptoms despite empirical anti-inflammatory therapy.274 
6.2.2.1.1. Acute pericarditis (first episode). The mainstay of medical 
therapy is empirical anti-inflammatory therapy using aspirin or NSAIDs 
at full anti-inflammatory doses with appropriate time intervals of administration (usually every 8 h) plus colchicine to reduce the risk of recurrences.24,25,108,275–278 Gastroprotection with a proton pump 
inhibitor is recommended using NSAIDs.279 
When aspirin and NSAIDs are contraindicated, or for specific indications, corticosteroids should be considered at low to moderate doses 
plus colchicine (see Tables 13 and 14). 
In cases of incomplete response to aspirin/NSAIDs and colchicine, 
corticosteroids may be added at low to moderate doses as triple therapy.1 In cases of recurrence, every effort should be made not to increase the dose or to reinstate corticosteroids. 
The use of colchicine on top of empirical anti-inflammatory therapy 
is supported by most of the published evidence, with the single exception of a small open-label trial that was probably underpowered to 
test the study hypothesis for patients with AP.281 Specific dosing 
and duration of therapy are summarized in Table 13. Monitoring of 
serum C-reactive protein and CMR imaging is recommended to assess 
clinical remission, guide the treatment length, and evaluate the response to therapy in more complicated and difficult-to-treat cases. 
In uncomplicated cases, clinical follow-up with/without echocardiography is sufficient. 
6.2.2.2. Incessant and recurrent pericarditis 
In patients with incessant pericarditis or RP, the mainstay of therapy 
is always colchicine in association with aspirin/NSAID or low to 
moderate doses of corticosteroids. For more difficult cases, chest 
pain can be controlled by a combination of aspirin or an NSAID 
plus corticosteroids at low to moderate doses and colchicine (triple 
therapy). The i.v. route should be considered to ensure a clinical response or to control symptoms in more difficult or resistant cases. 
Recommendation Table 9 — Recommendations for 
medical therapy in myocarditis (see Evidence Table 9) 
Recommendations 
Classa 
Levelb  
Management of symptoms 
NSAIDs (together with proton pump inhibition) 
should be considered in patients with associated 
symptoms of pericarditis to reduce symptoms. 
IIa 
C 
Colchicine should be considered in patients with 
myopericarditis to reduce recurrences.263 
IIa 
B 
Management of heart failure 
Adherence to the ESC HF guidelines is 
recommended in cases of myocarditis with LV 
systolic dysfunction and/or HF to reduce symptoms 
and to improve LV function.12 
I 
C 
HF therapy should be considered in patients with 
myocarditis and LV systolic dysfunction for at least 
6 months upon complete LV functional recovery to 
stabilize LV function. 
IIa 
C 
Management of arrhythmias 
β-Blockers, with a continuation for at least 6 months, 
should be considered in patients with acute 
myocarditis, especially those with troponin elevation, 
to control symptoms and prevent arrhythmias. 
IIa 
C 
Anti-arrhythmic treatment should be considered in 
post-myocarditis patients with recurrent, 
symptomatic VT to reduce arrhythmic burden.58 
IIa 
C 
Immunosuppressive therapy 
Corticosteroids should be considered in patients 
with fulminant, non-infectious forms of myocarditis 
to stabilize the patients. 
IIa 
C                                                                                                   
Continued 
Corticosteroids may be considered in patients with 
acute myocarditis with impaired LVEF if refractory to 
standard HF therapy to stabilize patients. 
IIb 
C 
Routine use of immunosuppressive therapy is not 
recommended in acute myocarditis with preserved 
LV function because no outcome benefit has been 
shown. 
III 
C 
© ESC 2025
ESC, European Society of Cardiology; HF, heart failure; LV, left ventricle; LVEF, left 
ventricular ejection fraction; NSAID, non-steroidal anti-inflammatory drug; VT, 
ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               39


<!-- PAGE 40 -->

### Page 40

Patients who develop a recurrence during corticosteroid tapering 
should continue colchicine and receive an NSAID on top of this treatment instead of increasing the dose of corticosteroids. Which medication should be tapered first (corticosteroids or NSAID) depends on the 
specific clinical scenario (age, kidney function, haemorrhagic risk, and 
use of oral anticoagulants). 
For patients with corticosteroid dependence, colchicine resistance, 
and evidence of elevated C-reactive protein (baseline or subsequent 
episode), clinical trials and an international registry supported the use 
of an anti-IL-1 agent (anakinra or rilonacept).108,275,282–284 An 
advantage of these agents is the rapid onset of action and the possibility 
of rapid withdrawal of corticosteroids.285 There is evidence of efficacy 
with anti-IL-1 agent (anakinra or rilonacept) monotherapy.108,275,282–284 
However, concomitant use of colchicine could be helpful to reduce recurrences and prolong recurrence-free survival, providing a sequential 
block of the pro-inflammatory pathway leading to the generation of 
IL-1.286 Colchicine should be maintained and withdrawn as the last 
drug only after stable remission. Moreover, colchicine has the safest cardiovascular profile and is now proposed to prevent major adverse cardiac 
events (MACE) in patients with atherosclerotic cardiovascular diseases.248 In patients obtaining stable remission with a chronic low dose 
of corticosteroids (e.g. prednisone ≤5 mg or equivalent) plus colchicine, 
the decision of switching to IL-1 blocker treatment should be tailored to 
the patient on an individualized basis, taking into account several parameters (such as tolerability, age and sex issues, patient preference). 
The use of anti-IL-1 agents may be associated with a moderate increase 
in the overall risk of mild to moderate infections. Safety data on anti-IL-1 
agents are reassuring when considering new malignancy risk, whereas 
their safe administration in patients with known active malignancies has 
not been well investigated to date. 
There is limited evidence for other drugs for pericarditis. 
Azathioprine has been empirically used in patients with recurrences 
and a lack of response to first- and second-level options such as aspirin/NSAID, colchicine, and corticosteroids.287 However, this drug 
seems more appropriate as a steroid-sparing agent, and has limited efficacy for those with acute pain. Intravenous immunoglobulins have 
also been tested in patients with refractory RP after failure of first 
and second options, as well as anti-IL-1 agents. These drugs may be 
efficacious either for infectious or non-infectious aetiologies, since 
they are able to clear infectious agents and modulate the immune 
response.288 Both corticosteroids and immunoglobulins have been  
Table 13 Specific initial dosing and duration of therapy for acute and recurrent pericarditis 
Therapy 
Dosing 
Durationa 
Taperinga  
Aspirinb 
750–1000 mg 3 times daily 
1–2 weeks 
Decrease by 250 mg every 1–2 weeks 
Ibuprofenb 
600–800 mg 3 times daily 
1–2 weeks 
Decrease by 200 mg every 1–2 weeks 
Indomethacin 
25–50 mg 3 times daily 
1–2 weeks 
Decrease by 25 mg every 1–2 weeks 
Colchicineb 
0.5 mg once daily (<70 kg or severe renal impairment) or 0.5 mg 
twice daily 
3–6 months 
Not required 
Prednisone 
0.2–0.5 mg/kg/day 
2–4 weeks 
Several months 
Treatment for recurrences only: 
Azathioprine 
Starting with 1 mg/kg/day then gradually increased to 2–3 mg/kg/day 
Several months 
Several months 
IVIG 
400–500 mg/kg i.v. daily for 5 days 
5 days 
Not required 
Anakinra 
1–2 mg/kg/day up to 100 mg/day in adults 
At least 6 months/ 
>12 months 
Needed (at least 3–6 months)/ 
unknown 
Rilonaceptc 
320 mg once daily followed by 160 mg weekly 
© ESC 2025
IVIG, intravenous immunoglobulins; NSAID, non-steroidal anti-inflammatory drug. 
Treatment for recurrences only is highlighted in grey. 
aTherapy duration as initial dosing; for all treatments the attack dose is maintained until symptom resolution and normalization of inflammatory markers (e.g. C-reactive protein) and other 
investigations (electrocardiogram, echocardiogram) then tapering is recommended. It should be tailored to the single patient according to disease severity and patient response. Tapering is 
especially important for corticosteroids where tapering is particularly slow, especially below 15 mg/day, the common threshold for recurrences (see Table 14). Monitoring is essentially based 
on the assessment of blood count, creatinine, creatine kinase, transaminases, C-reactive protein, echocardiography. Anakinra should be tapered after clinical remission. Different schemes are 
adopted: e.g. reducing one dose per week every month; every other day full dose for at least 3 months then half-dose every other day for at least 3 months. 
bAspirin and ibuprofen are common first-level treatments for the first episode of pericarditis (acute pericarditis) associated with colchicine for at least 3 months. Aspirin is the preferred 
choice for patients with ischaemic heart disease. Indomethacin is usually considered for incessant/recurrent cases. In incessant/recurrent cases, colchicine is maintained for at least 
6 months. Aspirin/NSAID full dose is recommended for patients with normal or mildly reduced renal function. For those with moderate to severe renal impairment, dose adjustment or 
use of corticosteroids is recommended. 
cRilonacept is registered in the USA but is not currently available in Europe. Anakinra, due to its short half-life, may be the preferable choice in patients at increased risk of infections.  
Table 14 Tapering of corticosteroids 
Prednisone 
dosea 
Starting dose 
0.20–0.50 mg/ 
kg/daya 
Taperingb  
Prednisone 
daily dose 
>50 mg 
10 mg/day every 1–2 weeks  
50–25 mg 
5–10 mg/day every 1–2 weeks  
25–15 mg 
2.5 mg/day every 2–4 weeks  
<15 mg 
1.25–2.5 mg/day every 2–6 weeks 
© ESC 2025
aAvoid higher doses except for special cases, and only for a few days, with rapid tapering to 
25 mg/day. Prednisone 25 mg is equivalent to methylprednisolone 20 mg. 
bEvery decrease in prednisone dose should be done only if the patient is asymptomatic and 
C-reactive protein is normal, particularly for doses of <25 mg/day. 
Calcium intake (supplement plus oral intake) of 1200–1500 mg/day and vitamin D 
supplementation of 800–1000 IU/day should be offered to all patients receiving 
glucocorticoids. Moreover, bisphosphonates are recommended to prevent bone loss in 
all men aged ≥50 years and postmenopausal women in whom long-term treatment with 
glucocorticoids is initiated at a dose of ≥5.0–7.5 mg/day of prednisone or equivalent.280


<!-- PAGE 41 -->

### Page 41

proposed for a non-inflammatory presentation (so-called non- 
inflammatory phenotype).288,289 
More recently, hydroxychloroquine has shown a steroid-sparing effect and increased flare-free survival in RP in patients with colchicine resistance and corticosteroid dependence.290 Treatment duration with 
aspirin/NSAIDs and steroids should be extended in an individualized 
manner, and the tapering process should be slower than for a first episode of AP.1 
The dosing and duration of most common drugs used for pericarditis 
is summarized in Table 13, while the proposed algorithm of medical 
therapy for pericarditis (not including interventional therapies and pericardiectomy) is illustrated in Figure 16. 
Patient with acute pericarditis
Exercise-restriction and ﬁrst level therapya:
ASA or NSAID (usually ibuprofen or indomethacin) plus colchicine
(Class I)
Tapering of ASA/NSAID
and colchicineb for 3–6 months to reduce recurrence risk
Incessant/recurrent
If ASA/NSAID 
contraindicated 
or not tolerated
Response to medical therapy
Low to moderate doses of corticosteroids plus colchicine or triple medical therapy with corticosteroids, NSAID and colchicinec
(Class IIa)
Incessant/recurrent
Response to medical therapy
Tapering of corticosteroids and colchicineb for at least 6 months to reduce recurrence risk
Anti-IL-1 agents
(Anakinra or Rilonacept)
(Class I)d
If corticosteroids 
contraindicated 
or not tolerated
Figure 16 Proposed algorithm of medical therapy for pericarditis in adults (not including interventional therapies and pericardiectomy). ASA, acetyl 
salicylic acid; IL-1, interleukin-1; CRP, C-reactive protein; CMR, cardiovascular magnetic resonance; LOE, level of evidence; N, no; NSAID, non-steroidal 
anti-inflammatory drug; Y, yes. aASA is the first option if patients are already on antiplatelet therapy with ASA. Ibuprofen is usually preferred as the first 
NSAID. Try more than one agent to evaluate response. Gastroprotection with a proton pump inhibitor is always recommended with use of aspirin/ 
NSAID. bColchicine is recommended to prevent recurrence. Consider at least 3 months for the first episode of pericarditis and at least 6 months for 
incessant/recurrent cases. Colchicine to be withdrawn as last drug only after stable remission. Tapering is recommended to reduce the persistence/ 
recurrence of symptoms. Tapering is slower for corticosteroids. Colchicine tapering is usually not performed due to the duration of >3–6 months 
of therapy. Suggested schemes of tapering are reported in Table 12. For response to therapy we considered clinical remission. cLow to moderate 
dose of corticosteroids (e.g. prednisone 0.2–0.5 mg/kg/day or equivalent doses of an alternative corticosteroid). dClass I LOE A, Class IIa LOE C regardless of C-reactive protein levels if CMR evidence of pericardial inflammation.   
ESC Guidelines                                                                                                                                                                                               41


<!-- PAGE 42 -->

### Page 42

6.3. Interventional techniques including 
circulatory support 
6.3.1. Myocarditis 
6.3.1.1. Short-term mechanical circulatory support 
Myocarditis patients who present with rapid deterioration in haemodynamic status and rapidly progressive myocardial dysfunction are 
amongst those who respond best to temporary MCS.293 Among temporary MCS, veno-arterial extracorporeal membrane oxygenation 
(VA-ECMO) represents the most frequently applied or recommended 
approach, ranging from 75% to 85% of AM cases.75,294–296 Despite the 
high risk and markedly compromised state of patients undergoing 
VA-ECMO support for FM, the prognosis is rather favourable, with a 
high rate of myocardial recovery and patient survival. Several national 
and international multicentre studies showed in-hospital survival ranging from 61% to 72%,297–300 but no freedom from HT in patients 
with giant-cell FM.294 Temporary MCS should be performed early 
and in a timely manner in patients with FM with refractory cardiogenic 
shock because of the high likelihood of recovery. 
6.3.1.2. Intra-aortic balloon pump 
As mentioned, EMB should be performed as soon as possible, even in 
the presence of temporary MCS,212,295 and specific immunosuppressive therapy should be considered at least as an initial option, while determining the myocardial response.295 An intra-aortic balloon pump 
(IABP) should be considered in cardiogenic shock as first-line MCS 
with prompt escalation to more powerful MCS if haemodynamic and 
end-organ perfusion improvement is not observed within a short 
time (1 h maximum).295 
6.3.2. Pericarditis 
Pericardium-related interventional procedures are increasingly applied 
and require specific expertise.1,301 The use of percutaneous interventional techniques for pericarditis is not limited to perform percutaneous drainage, but also to obtain fluid samples for cytology and other 
pathological examinations (see Supplementary data online, Table S7). 
Moreover, interventional techniques are used to provide alternative 
treatment, such as balloon pericardiotomy or, less commonly, intrapericardial drug administration (e.g. corticosteroids or chemotherapy). 
6.3.2.1. Pericardiocentesis and pericardial drainage 
Percutaneous pericardiocentesis guided by echocardiography or fluoroscopy is indicated for CTP and symptomatic moderate to large PEffs 
Recommendation Table 10 — Recommendations for 
medical therapy in pericarditis (see Evidence Table 10) 
Recommendations 
Classa 
Levelb  
Colchicine is recommended as first-line therapy 
in patients with pericarditis as an adjunct 
to aspirin/NSAID or corticosteroid therapy 
to reduce subsequent recurrences.24,25,108,275–278 
I 
A 
Anti-IL-1 agents (anakinra or rilonacept) are 
recommended for patients with recurrent 
pericarditis after failure of first-line therapies and 
corticosteroids and elevation of C-reactive protein 
levels to reduce recurrences and allow 
corticosteroid withdrawal.108,275,282–284 
I 
A 
High-dose aspirin or NSAIDs with proton pump 
inhibitors are recommended as first-line therapy in 
patients with pericarditis to control symptoms and 
reduce recurrences.291,292 
I 
B 
A β-blocker should be considered in symptomatic 
patients, despite full anti-inflammatory therapy, and 
heart rate at rest >75 b.p.m. in order to improve 
symptom control.274 
IIa 
C 
Anti-IL-1 agents (anakinra or rilonacept) should be 
considered in cases of incessant/recurrent 
pericarditis with evidence of pericardial inflammation 
on CMR after failure, contraindications, and 
intolerance to first-line therapies and corticosteroids 
regardless of C-reactive protein levels to reduce 
recurrences and allow corticosteroid withdrawal. 
IIa 
C 
Low- to medium-dosec corticosteroids should be 
considered for patients with pericarditis only in cases 
of contraindication/failure of aspirin/NSAIDs and 
colchicine, or when there is a specific indication to 
control symptoms and reduce recurrencesd. 
IIa 
C 
Hydroxychloroquine may be considered in patients 
with recurrent pericarditis refractory to standard 
therapy (including corticosteroids and anti-IL-1 
agents) to prolong recurrence-free survival.290 
IIb 
B 
Corticosteroids are not recommended as the first 
option for patients with pericarditis therapy without 
a specific indicationd. 
III 
C 
© ESC 2025
b.p.m., beats per minute; CMR, cardiovascular magnetic resonance; IL, interleukin; NSAID, 
non-steroidal anti-inflammatory drug. 
aClass of recommendation. 
bLevel of evidence. 
cSee Table 13. 
dFor example, systemic inflammatory disease on maintenance therapy with corticosteroids, 
post-pericardiotomy syndromes, post-vaccine pericarditis, severe renal failure, 
concomitant therapies interacting with NSAIDs such as oral anticoagulant.  
Recommendation Table 11 — Recommendations for 
interventional techniques including circulatory support 
in myocarditis (see Evidence Table 11) 
Recommendations 
Classa 
Levelb  
A timely and dedicated Shock Team discussion is 
recommended in patients with myocarditis in the 
presence of haemodynamic compromise, to decide 
on the need for escalation to MCS and to determine 
a long-term management plan. 
I 
C 
Temporary MCSc should be considered in patients 
with myocarditis and cardiogenic shock or acute 
decompensation in chronic myocarditis to stabilize 
the patients. 
IIa 
C 
© ESC 2025
IABP, intra-aortic balloon pump; MCS, mechanical circulatory support; PLVAD, 
percutaneous left ventricular assist device; VA-ECMO, veno-arterial extracorporeal 
membrane oxygenation. 
aClass of recommendation. 
bLevel of evidence. 
cIABP, PLVAD, VA-ECMO.


<!-- PAGE 43 -->

### Page 43

not responding to medical therapy, or when a search for aetiological 
agents is needed (e.g. suspicion of cancer, bacterial infection). 
Whenever possible, pericardiocentesis should not drain a large amount 
of pericardial fluid (usually <500 mL) to prevent pericardial decompression syndrome. Complete drainage of the PEff can be achieved, 
leaving a drain to be removed when the daily drainage is <30 mL. 
Surgical drainage is required when percutaneous pericardiocentesis is 
not feasible or purulent effusion is present, to allow complete drainage 
of the effusion and prevent its organization. Clinical triage has been proposed to indicate urgent management.118 An overall score of >6 indicates the need for urgent pericardiocentesis, whereas a lower score 
suggests delaying the intervention (see Figure 12). 
Imaging is an essential component for guiding percutaneous pericardiocentesis. Under echocardiography, CT, or fluoroscopic guidance, 
a needle (usually 16–20 gauge) should be introduced into the sub- 
xyphoid space, although an apical or left-lateral approach might be 
used. The catheter should usually remain in situ for a few days, also 
based on the type and efficacy of concomitant systemic and/or topic 
pharmacological treatment.1 
6.3.2.2. Percutaneous balloon pericardiotomy 
Percutaneous balloon pericardiotomy represents a percutaneous alternative to the endoscopic or surgical pleuro-pericardial window, which allows relapsing pericardial fluid to be absorbed through the ample pleural 
serosa, especially as palliative and temporary relief.1 It should not be used 
as a first- or second-line intervention, but rather reserved for very rare 
cases, such as recurrent neoplastic PEff and CTP, as well as for absolute 
contraindications for surgery or in the case of a very poor quality of life in 
terminal patients (see Supplementary data online, Table S8).1 
6.3.2.3. Intrapericardial drug administration 
Percutaneous access to the pericardium is done using an intrapericardial 
catheter following pericardial drainage. It may be used to deliver drugs 
targeting different conditions. Anti-inflammatory agents have been delivered with some efficacy. Intrapericardial crystalloid triamcinolone, 
300 mg/m2 of body surface, can be used for autoreactive or recurrent 
PEffs that do not respond to other conventional therapies, and to avoid 
or limit systemic side effects of oral corticosteroids. Chemotherapeutics 
have also been delivered, such as cisplatin and thiotepa (usually for lung 
and breast cancer, respectively), with demonstrated reduction of PEff relapse.302–304 Currently, due to improved chemotherapy, the systemic 
route is favoured, and therapeutic planning should involve a multidisciplinary team with cardiologists and oncologists. 
Sclerosing agents, such as talc, to enhance pericardium–epicardium 
adherence and to reduce relapsing PEff, should not be used, because 
of reduced efficacy compared with a pericardial window or pericardiectomy, and the risk of inducing constriction.305,306 
6.3.2.4. Pericardioscopy 
This procedure is sometimes considered as part of the diagnostic work- 
up, allowing pericardial biopsy. Pericardial access is also increasingly 
used for mapping and ablation of the epicardial substrates of VA, 
with an improved success rate and avoidance of a surgical procedure. 
6.3.2.5. Pericardial fluid analysis, pericardial and epicardial biopsy 
Percutaneous pericardial access may be used also to provide fluid samples 
for pathological and pathogen examinations (bacterial or viral aetiology), 
and/or to perform pericardial as well as epicardial biopsies, particularly 
in cancer screening (see Supplementary data online, Table S7).1 
6.3.2.6. Circulatory support 
Mechanical circulatory support has been shown to be applied in up to 
12% of pericardiectomy patients with pre-procedural RV dilatation/ 
dysfunction,307–309 and is sometimes considered peri-operatively.307– 
309 The association of pre-procedural RV dilatation/dysfunction and reduced LV function also represent risk factors for a peri-procedural risk 
of early mortality, calling for timely and prophylactic MCS.308 
6.4. Surgical therapy 
6.4.1. Myocarditis 
The surgical treatment of myocarditis mainly accounts for HT, when there 
is no myocardial recovery. In addition to infective or autoimmune aetiologies, radiation-induced myopericarditis (usually secondary to haematological cancer) may contribute to the indications for such an 
intervention. Limited series of HTs due to radiation-induced myocarditis 
have been described with satisfactory results. Secondary malignancy, lung 
and kidney failure are negative prognostic factors for post-operative morbidity and mortality.310 A durable ventricular assist device (VAD) or a total 
artificial heart are other alternatives for advanced cardiac support.295 
6.4.2. Pericarditis 
6.4.2.1. Surgical pericardiocentesis 
Surgical pericardiocentesis is rarely performed for urgent/emergency 
conditions, but for large PEff requiring expeditious drainage, not achievable with percutaneous-based drainage (e.g. for purulent PEff or clot 
aspiration). 
6.4.2.2. Pericardiotomy/pericardial window 
These surgical procedures are carried out to create a connection, namely 
a pleuro-pericardial window, usually between the lateral or left posterior 
pericardium and the left pleura. The indication is relapsing PEff with 
haemodynamic compromise despite conservative treatment or percutaneous drainage. The pleuro-pericardial window is meant to promote drainage from the pericardium to the left pleural space.1 Such a window may be 
created by a small thoracotomy or endoscopically. In selected cases, a 
pericardial window can also be created in the peritoneal cavity. 
Recommendation Table 12 — Recommendations for 
interventional techniques in pericarditis (see Evidence 
Table 12) 
Recommendations 
Classa 
Levelb  
Pericardiocentesis (echocardiography-, CT-, or 
fluoroscopy-guided) is recommended for cardiac 
tamponade, or suspected bacterial or neoplastic 
pericarditis, or symptomatic moderate to large 
pericardial effusion despite medical therapy. 
I 
C 
Surgical pericardial drainage is recommended in 
patients with pericardial effusion when percutaneous 
pericardiocentesis is not feasible or with purulent 
pericardial effusion to allow complete drainage and 
to prevent constriction. 
I 
C 
Surgical pleuro-pericardial window is recommended 
in patients with relapsing pericardial effusion despite 
medical therapy. 
I 
C 
© ESC 2025
CT, computed tomography. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               43


<!-- PAGE 44 -->

### Page 44

6.4.2.3. Pericardiectomy 
Pericardiectomy is the mainstay treatment for chronic constriction or 
CP not responding to anti-inflammatory therapy.311 Complete pericardiectomy is recommended for the management of CP, as it offers superior long-term outcomes and significantly reduces the risk of 
recurrences compared with partial anterior or anterophrenic pericardiectomy, which may leave residual constrictive tissue and contribute 
to persistent or recurrent symptoms. Due to the relative rarity of 
the condition, and the complexity of patients, pericardiectomy should 
be performed at high-volume centres that have the required expertise. 
Early pericardiectomy within 6 months after the onset of symptoms is 
associated with the lowest operative mortality.312,313 The occurrence of 
refractory RP and/or pericardial fluid formation, despite optimal medical 
and interventional therapy, is also considered a possible indication for 
surgical pericardiectomy. In the absence of a surgical plane for proper decortication, a pragmatic approach, named the waffle procedure, can be 
considered. This technique utilizes longitudinal and horizontal incisions 
to allow some relief of constriction. However, it usually offers only temporary improvement, with a high rate of recurrent constriction.314,315 
Extracorporeal circulation may be required in difficult operative conditions, such as extensive calcifications with a high risk of marked bleeding 
during pericardiectomy. Previous 2015 ESC guidelines recommended resection ‘of as much as possible’ of the pericardium with avoidance of cardiopulmonary bypass (CBP), using this only in circumstances of difficult 
control of bleeding.1 Cardiopulmonary bypass can play an important 
role in enabling safe and complete pericardiectomy, particularly in selected complex or high-risk cases. 
Pericardiectomy is commonly performed without CPB. However, 
CPB may be necessary in specific clinical scenarios. These include 
dense adhesions between the pericardium and the myocardium, 
particularly involving the posterior surface of the heart. CPB is 
also indicated in cases of haemodynamic instability during dissection. 
This is especially relevant when heart lifting is required to access the 
diaphragmatic or posterior pericardium. Additional indications 
include calcific constrictive pericarditis with myocardial involvement, challenging anatomical conditions, or the need for concomitant cardiac procedures, such as valve surgery or coronary artery 
bypass grafting. 
Possible benefits of CPB include providing a bloodless field and improved visibility for complete pericardial resection, especially posteriorly, avoiding myocardial injury by decompressing the heart during 
dissection, maintaining haemodynamic stability, particularly in patients 
with borderline cardiac output or tamponade physiology. However, 
the full heparinization required to perform CPB may, in some cases, 
favour bleeding generated by pericardial resection. Therefore, the 
indication for the use of CPB must always be taken into consideration 
intra-operatively and according to the anatomical as well as haemodynamic conditions encountered during the surgical procedure. It is, 
however, self-explanatory that a radical pericardiectomy, including 
also the posterior site of the pericardium, would be usually possible 
and advisable with the application of CPB. However, diaphragmatic 
pericardial resection may often be performed without CPB use, taking 
care to perform resection in a stepwise manner, without prolonging 
heart lifting and avoiding marked haemodynamic compromise. 
Heart transplantation is very rarely indicated in patients with CP. 
However, it may be considered as a last-resort option in highly selected, 
exceptional cases. This applies when pericardiectomy is not feasible or 
cannot be completed due to extensive pericardial calcification with myocardial involvement, prior surgeries, radiation therapy, or infections that 
have caused severe adhesions and scarring. Surgical inaccessibility of 
critical regions, such as the posterior pericardium, may also preclude 
complete resection. In some patients, persistent heart failure symptoms 
and progressive functional deterioration may occur despite maximal 
medical therapy and attempted pericardiectomy. In these cases, heart 
transplantation might be considered. 
It is also an option when coexistent myocardial disease or a mixed constrictive–restrictive physiology is present, where pericardial resection 
would not be expected to improve symptoms or haemodynamic function. 
In CP, tricuspid regurgitation (TR) is a common finding due to chronic elevated right-sided pressures, annular dilation secondary to longstanding volume overload and atrial enlargement, tethering of leaflets 
due to pericardial constraint. When TR is present in patients undergoing pericardiectomy, leaving the valve unrepaired can lead to persistent 
right HF symptoms (e.g. oedema, ascites, fatigue), poorer functional recovery post-operatively, and higher long-term mortality, as shown in 
retrospective observational studies. During pericardiectomy, the tricuspid valve is accessible, and repair (usually annuloplasty) can be safely 
performed with minimal added risk—especially when CP surgery is 
done under CPB. Thus, repair is recommended when TR is more 
than mild, and anatomy is suitable, and the patient is already undergoing 
pericardiectomy (i.e. no added surgery is required beyond access). 
Supporting evidence is limited. While RCTs are lacking, the recommendation is based on retrospective findings showing improved symptom 
relief and outcomes with combined surgery, and surgical principles in 
valve disease management but also the practicality and safety of valve 
repair when the chest is already open.311 
Contraindications for pericardiectomy may include severe hepatic 
dysfunction with cirrhosis and ascites, uncontrolled infection or sepsis, 
and other life-limiting diseases. In some situations, advanced therapy, 
such as HT, might be the only solution due to unfeasible cardiac decortication, because of extensive calcifications or a high risk of cardiac and 
major vascular injury during pericardiectomy (for predictors of outcomes after pericardiectomy see also Supplementary data online, 
Table S8 and Section 3.2). 
6.5. Management of arrhythmias and 
prevention of sudden cardiac death in 
myocarditis 
Patients with myocarditis are known to be vulnerable to life-threatening 
arrhythmias, and careful observation and management of patients according to the risk stratification is needed. In the 2022 ESC Guidelines 
for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, significant attention was paid to active 
Recommendation Table 13 — Recommendations for 
surgical therapy (see Evidence Table 13) 
Recommendations 
Classa 
Levelb  
Surgical pericardiectomy is recommended in patients 
with chronic pericardial constriction or persistent 
constrictive pericarditis despite medical therapy to 
improve symptoms and survival.312,313 
I 
C 
Tricuspid valve repair is recommended in patients 
with pericardial constriction and severe tricuspid 
valve regurgitation to improve symptoms and 
survival.316 
I 
C 
© ESC 2025
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 45 -->

### Page 45

and chronic myocarditis.58 In addition to these guidelines, our aim is to 
provide a special focus on several selected scenarios. 
6.5.1. Role of active devices (wearable and implanted 
devices) in acute myocarditis 
In AM, AVB may be reversible, and temporary pacing is often necessary in 
cases of haemodynamic compromise as a bridge to recovery.317 In this 
setting, temporary transvenous external pacing with an active lead can 
be used for patients who require prolonged temporary pacing.86,318– 
320 In the absence of recovery within a clinically reasonable period, definitive cardiac pacing is usually necessary in patients with persistent high- 
degree AVB. In patients with LV dysfunction needing frequent ventricular 
pacing, CRT or conduction system pacing may be helpful.86,321 
Permanent pacemaker placement can be considered in patients with 
AM for persisting high-degree AVB despite medical therapy. 
Sustained VA in the context of AM is a rare phenomenon,79 yet it 
poses a substantial risk of recurrence, persisting even after resolution 
of the acute phase. Studies indicate a high recurrence rate ranging 
from 28% to 60%, which appears higher in patients with monomorphic 
VT, chronically active myocarditis, anteroseptal LGE, and reduced 
LVEF.71,79,89,222,322–325 In myocarditis patients, polymorphic and irregular 
VA are more common during the active inflammatory phase, whereas 
monomorphic and regular VA are associated with healed myocarditis 
and scars.79,83,325 An arrhythmic presentation may raise suspicion of an 
underlying inherited CMP.95 GCM is associated with a high risk of life- 
threatening VA and ICD implantation can be considered.326 The use of 
a wearable cardioverter-defibrillator (WCD) is feasible in selected patients with AM at higher risk of VA, when waiting for recovery or with 
a temporary contraindication for ICD.327–330 The resolution of inflammation does not necessarily indicate the absence of risk, because myocardial fibrosis may constitute an arrhythmogenic substrate, 
predisposing a patient to VA long after the acute episode. On this basis, 
arrhythmia risk stratification should be performed in patients with persistent LGE after the acute phase.325 In patients with prior myocarditis, 
sustained or non-sustained VT during an exercise test performed 
6 months after the acute episode was found to be more common among 
those with an arrhythmic presentation, and was associated with subsequent adverse events, including malignant VA.331 Late gadolinium enhancement was also identified as a significant predictor of adverse 
events, including malignant arrhythmias, irrespective of LVEF, especially 
in an anteroseptal location.332–334 Implantable loop recorders can be useful for early detection of VA in selected patients.89 Details regarding oral 
anticoagulation can be found in the 2019 ESC Guidelines for the management of patients with supraventricular tachycardia, the 2022 ESC 
Guidelines for the management of patients with ventricular arrhythmias 
and the prevention of sudden cardiac death, and the 2024 ESC 
Guidelines for the management of atrial fibrillation.58,260,261 
7. Prognosis 
The current literature focuses on the single condition, but one could 
expect that a patient with concomitant involvement of the myocardium 
and pericardium will have a worse prognosis. However, current published evidence suggests that patients with uncomplicated pericarditis 
and myopericarditis have a good overall prognosis, despite combined 
involvement of the pericardium and myocardium.4,337 The TF expects 
that the introduction of the term IMPS will increase awareness and will 
lead to dedicated studies in this regard. 
7.1. Complications and outcomes for 
myocarditis 
One of the main prognostic factors is the initial clinical presentation of 
myocarditis (Figure 8). Low-risk myocarditis (about 75% of unselected 
cases) usually has a chest pain presentation with preserved biventricular 
function, and an overall benign short- and long-term prognosis.28 Acute 
complicated myocarditis with arrhythmic presentation, and especially 
HF presentation, has a worse prognosis.56 There is conflicting evidence 
Recommendation Table 14 — Recommendations for 
management of arrhythmias and prevention of sudden 
cardiac death in myocarditis (see Evidence Table 14) 
Recommendations 
Classa 
Levelb  
Pacing in myocarditis 
Temporary transvenous external pacing should be 
considered in patients with acute myocarditis and 
high-degree conduction disorders as a bridge to 
recovery.86,317,335 
IIa 
C                                                                                                   
Continued 
WCD in myocarditis 
A WCD should be considered for 3–6 months in 
patients with sustained ventricular arrhythmia during 
the acute phase of myocarditis as a bridge to 
recovery.323,325,327–330 
IIa 
C 
Ablation in myocarditis 
Catheter ablation, performed in specialized centres, 
should be considered in post-myocarditis patients 
with recurrent symptomatic SMVT or ICD shocks in 
whom AAD are ineffective, not tolerated, or not 
desired.58 
IIa 
C 
ICD in myocarditis 
Secondary prevention 
ICD implantation is recommended in patients with 
non-activec myocarditis and haemodynamically 
not-tolerated sustained VT to prevent 
SCD.78,79,322,336 
I 
C 
ICD implantation should be considered in patients 
with non-activec myocarditis and haemodynamically 
tolerated sustained VT to prevent SCD.78,79,322,336 
IIa 
C 
ICD implantation may be considered in patients with 
acute myocarditis and sustained VA (VT/VF) in the 
acute phase to prevent SCD.71,79,89,222,323–325 
IIb 
C 
Primary prevention   
ICD implantation may be considered in patients 
with myocarditis after the acute phase (3–6 months) 
and persistent risk factors for VAd to prevent 
SCD.89,332–334,336. 
IIb 
C 
© ESC 2025
AAD, anti-arrhythmic drugs; CMR, cardiovascular magnetic resonance; ICD, implantable 
cardioverter-defibrillator; LGE, late gadolinium enhancement; LVEF, left ventricular 
ejection fraction; NSVT, non-sustained ventricular tachycardia; PVS, programmed 
ventricular stimulation; SCD, sudden cardiac death; SMVT, sustained monomorphic 
ventricular tachycardia; VA, ventricular arrhythmias; VF, ventricular fibrillation; VT, 
ventricular tachycardia; WCD, wearable cardioverter-defibrillator. 
aClass of recommendation. 
bLevel of evidence. 
cNon-active based on CMR evidence of activity (T2), see Figure 4. 
dNSVT, extensive LGE, unexplained syncope, positive PVS, reduced LVEF <50%.   
ESC Guidelines                                                                                                                                                                                               45


<!-- PAGE 46 -->

### Page 46

on the role of sex in the prognosis of IMPS.73 Women seem to have a 
more favourable prognosis than men in myocarditis.338 Young age and a 
previous myocarditis were independent relapse predictors. Fulminant 
onset, lower LVEF at presentation, distinct autoimmune features, especially in women, and high-titre organ-specific anti-heart autoantibodies 
and antinuclear autoantibodies were independent predictors of death 
and HT.73 Genetic predisposition may also increase the risk (see 
Section 5.3). 
The aetiology also plays a relevant role, e.g. EM, GCM and CS are 
associated with a worse prognosis (Sections 9.2–9.4). Outcomes are 
worse in patients with FM, in the case of late diagnosis and delayed 
interventions.57 Factors associated with increased mortality or HT 
are GCM, QRS duration of >120 ms on initial ECG, or the need 
for temporary MCS other than IABP.56 Biventricular dysfunction 
has been described as the main predictor of death or HT in 
myocarditis.63,66,73 
Multimodality imaging contributes to the assessment of prognosis. 
For example, myocarditis patients with normal CMR have a good 
prognosis.339 Late gadolinium enhancement on CMR at initial presentation is an important prognostic finding.340 In a multicentre study 
with AM and preserved EF, the presence of anteroseptal LGE in 
the mid-wall layer was the best independent predictor of the combined endpoint of cardiac death, appropriate ICD interventions, resuscitated cardiac arrest, and hospitalization for HF [odds ratio 
(OR) 2.73; 95% confidence interval (CI) 1.2–5.9; P = .01]. At a median 
follow-up of 4.3 years, 7.7% of these patients reached the combined 
endpoint.3 Anteroseptal LGE was the best independent predictor 
of SCD [hazard ratio (HR) 4.59; 95% CI 1.38–15.24; P = .01]. 
Myocardial fibrosis was present in 95% of patients with SCD, compared with 41% in patients without SCD.341 Additionally, major arrhythmic onset (sustained VT or VF), presence of fibrosis at EMB, 
and induction of major VA on PVS all predicted major arrhythmic 
events.63,73,255 
In another study, including patients with AM and life-threatening 
arrhythmias, positive LGE in two or more myocardial segments 
and absence of oedema on initial CMR were associated with an increased risk for recurrent major arrhythmic events, including SCD 
[HR 4.51 (95% CI 2.39–8.53) and HR 2.59 (95% CI 1.40–4.79), 
respectively].71 
Large studies are needed in the future to develop a risk stratification 
with a high negative predictive value for SCD and the need for ICD implantation. Variables for risk stratification for the progression to DCM 
are given in Supplementary data online, Table S9. 
7.1.1. Sequela and mortality in myocarditis 
The main long-term complications are evolution to DCM with subsequent HF and (recurrence of) VA, including SCD.76 LVEF recovery after myocarditis can be complete or partial. Recovery rates 
vary from 50% to 94% depending on the initial presentation.74 
These patients usually have a gradual deterioration of LVEF and 
subsequent dilation and might remain unrecognized and asymptomatic until development of overt HF. Myocarditis can cause 
about 10% of DCM.66 Patients with B19V AM present most often 
with an infarct-like syndrome, and may have a favourable long-term 
prognosis,342 but there is evidence describing cases with severe 
fatal outcomes.228 In contrast, patients with HHV-6 myocarditis 
(and especially those with B19V and HHV-6 co-infection) usually 
present with acute HF symptoms, and frequently progress to 
chronic HF.342 
Arrhythmias during myocarditis range from mild conduction abnormalities to life-threatening VT or VF, requiring medication and/ 
or device therapy (refer to Section 6.5). The risk of VA is independent 
of LVEF.83,343 
Myocarditis may have a significant mortality. Initial complicated 
presentation and histological subtype predict the risk. Outcomes 
are worse in patients with FM, with a reported mortality at 60 days 
of 24%.56,73 Mortality also depends on the underlying cause of FM. 
In a study of GCM survivors beyond 1 year, the combined rate of 
death, HT, VAD implantation, or GCM recurrence was 47% at 
5 years.344 Reported in-hospital mortality and long-term outcomes 
after an episode of AM vary.345 In a multicentre registry of patients 
with AM, complicated AM occurred in 27%, including 9% cases of 
FM. In-hospital mortality was 8.5%, compared with 0% in uncomplicated cases. Heart transplantation or LVAD was required in 
3% and 4% of patients, respectively. Heart transplantation or death 
occurred in 18% of complicated cases after 5 years. Recurrences 
or VA occurred in approximately 3%–9% of cases over a period 
of 19–90 months.28 In the recently reported contemporary ESC 
multicentre myocarditis registry of 581 patients with myocarditis, 
2.7% of patients died, 1.7% received a HT, 0.7% underwent VAD 
implantation, and 3.9% underwent ICD implantation at 1-year 
follow-up.62,63,73 
7.1.2. Follow-up 
Patients with low-risk myocarditis with chest pain presentation can be 
discharged when cardiac enzymes tend towards normalization. Time 
to recovery in AM varies from a few days to a few months. Relapses 
occur in about 10% of cases, with a 1-year recurrence rate of around 
5%.10,73,346 
Follow-up is recommended in all patients with myocarditis, with 
clinical assessment, ECG, Holter-ECG registration, exercise test (if 
no signs of ongoing inflammation), echocardiography, and CMR within 
at least 6 months after the index hospitalization (see Table 15).10,62 
The prognosis is determined by baseline and 6-month LV function, regardless of the initial clinical presentation.62,63,73 Cardiovascular magnetic resonance should be performed at least within the first 
6 months in patients with definite myocarditis to guide the timepoint 
for return to work, based on the individual case. 
It is generally accepted to wait 3–6 months after an acute episode 
of myocarditis to evaluate the need for an ICD. In some patients at 
high risk for VA (see Section 6.5.1),71 a WCD should be considered 
during follow-up as a bridge to recovery.58 Subsequently, after 
3–6 months of follow-up, the decision on whether or not to implant 
a definitive ICD is based on the individual patient, with increasing indication based on risk factors including genetic predisposition (see 
Section 5.3, Section 6.5.1; see Figure 17). In patients presenting with 
symptomatic VA, or heart block in GCM or CS, early consideration 
of an ICD is warranted.58 Recommendations concerning arrhythmias 
and SCD in specific forms of myocarditis are discussed in Section 6.5.58 
In uncomplicated cases, a follow-up at 6, 12, and 24 months is sufficient, while it should be prolonged and be lifelong in complicated cases 
or with residuals. 
See Supplementary data online, Section 8 for patient communication 
advice.


<!-- PAGE 47 -->

### Page 47

7.2. Complications and outcomes for 
pericarditis 
Risk stratification of patients with pericarditis must be performed at the 
initial presentation at the emergency department or in an ambulatory 
setting. Admission is recommended in high-risk cases.105,130 
Non-high-risk cases can be managed as outpatients with a close follow- 
up within 1 to 2 weeks (Figure 7). ECG changes (mainly widespread 
ST-segment elevation) and troponin elevation were usually not negative 
prognostic markers in this setting with an infarct-like presentation and 
preserved biventricular function.4,35 
In the real world, approximately 25% of patients diagnosed with AP 
present with at least one predictor of poor prognosis and require hospitalization.130 The in-hospital mortality rate for AP is around 1% on 
average, but can be higher in older patients and those with severe 
co-infections.23 
According to the clinical presentation, additional diagnostic work-up 
should be performed only for a specific clinical suspicion, the presence 
of high-risk features, or a lack/incomplete response to empirical anti- 
inflammatory therapy (Table 16). 
The usual course of AP is characterized by clinical remission 
after medical therapy within 4–6 weeks. The most common and 
problematic complication of pericarditis is RP, which affects 
20%–30% of patients not treated with colchicine. About 10% of 
patients may present with continued symptoms without clinical remission. Such cases have been labelled as ‘incessant’, and may directly progress to constriction in few months,104 while this 
complication is extremely rare in idiopathic RP.114,347 A course 
with multiple recurrences is possible, but not usual in simple presumed viral pericarditis, and should prompt a search for an underlying cause (Figure 14). 
Cardiac tamponade is relatively rare in AP, as well as CP (<1% of 
cases). The risk for complications is related to the aetiology. For instance, the risk of CP is low after presumed viral/idiopathic pericarditis, 
intermediate for immune-mediated aetiologies, as well as PCIS and neoplastic pericarditis (2%–5%), and high for bacterial pericarditis (20%– 
30%), especially if purulent.347 
At least three scores43,44,348 have been proposed recently to identify patients at increased risk of developing complicated pericarditis 
and chronicity, requiring close follow-up (see Supplementary data 
online, Tables S2 and S3). However, these scores have not been validated or replicated in additional larger studies, and remain 
investigational. 
Recommendation Table 15 — Recommendations for 
risk stratification, complications, and outcomes of inflammatory myopericardial syndrome (see Evidence 
Table 15) 
Recommendations 
Classa 
Levelb  
Follow-up with clinical assessment, biomarkersc, 
ECG, exercise test, Holter-ECG monitoring, 
echocardiography, and CMR at least within 6 months 
after the index hospitalization is recommended in all 
patients with myocarditis to identify a potential 
progression or new risk factors.62 
I 
C 
Long-term follow-up is recommended for patients 
with complicated myocarditisd to identify a potential 
progression or new complications.28,74 
I 
C 
Long-term follow-up is recommended for patients 
with incessant or recurrent pericarditis to identify a 
potential progression and new complications.104,347 
I 
C 
© ESC 2025
CMR, cardiovascular magnetic resonance; ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence. 
cAt least troponin. 
dSee definition of complicated myocarditis in Table 3.  
Table 15 Follow-up in inflammatory myopericardial syndrome after discharge   
Within 1 month 
Within 3–6 months 
12 months 
>1 year and long-term FUa  
Clinical evaluation and ECG 
Myocarditis 
X 
X 
X 
X 
Pericarditis 
X 
X 
X 
X 
Biomarkers (TnI, C-reactive protein) 
Myocarditis 
X 
X 
(X) 
(X) 
Pericarditis 
X 
X 
(X) 
(X) 
Rhythm 
(stress and/or Holter-ECG) 
Myocarditis 
– 
X 
(X) 
(X) 
Pericarditis 
– 
– 
– 
– 
Imaging myocarditis 
TTE 
Xb 
Xc 
Xc 
CMR 
Xb 
Xc 
Xc 
Imaging pericarditis 
TTE 
Xb 
Xc 
X 
CMR 
(X)b 
(X)d 
(X)d 
© ESC 2025
CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; FU, follow-up; IMPS, inflammatory myopericardial syndrome; TnI, troponin I; TTE, transthoracic echocardiography. 
All follow-ups should be adapted to the clinical situation and severity. In round brackets, optional testing according to clinical presentation [(X), case-by-case decision]. 
aA long-term FU, e.g. after 2 years, is suggested only for complicated cases of IMPS, usually myocarditis. 
bIn complicated cases or if abnormal at 1 month, imaging should be repeated between 3 and 6 months. 
cIf abnormal at 6 months, imaging should be repeated within the next 6 months and/or in the next 12 months. 
dFollow-up proposed for uncomplicated cases of acute pericarditis. Long-term follow-up, tailored to the single patient, is recommended for high-risk cases.   
ESC Guidelines                                                                                                                                                                                               47


<!-- PAGE 48 -->

### Page 48

### 8 Inflammatory myopericardial

syndrome overlapping types: 
myopericarditis and 
perimyocarditis 
IMPS includes a spectrum of inflammatory diseases from isolated myocarditis to isolated pericarditis through a combination of both. IMPS 
should be used as an umbrella term, also covering overlapping forms 
of myocarditis and pericarditis.1 The diagnosis of predominant pericarditis with myocardial involvement, or ‘myopericarditis’, can be clinically 
established if patients with definite criteria for AP show elevated biomarkers of myocardial injury, without newly developed focal or diffuse 
impairment of LV function on TTE or CMR. The term myopericarditis 
indicates a primarily pericarditic syndrome with minor myocardial involvement, which describes the majority of combined pericarditis and 
myocarditis cases encountered in clinical practice. On the other 
hand, evidence of new-onset focal or diffuse reduction of LV function 
in patients with elevated myocardial biomarkers, and clinical criteria 
for AP, suggests predominant myocarditis with pericardial involvement,  








	















Figure 17 Follow-up and risk stratification after acute myocarditis with arrhythmic presentation. ICD, implantable cardioverter-defibrillator; LGE, 
late gadolinium enhancement; LV, left ventricle; LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular tachycardia; PVS, programmed 
ventricular stimulation; WCD, wearable cardioverter-defibrillator. Rarely for a high risk, cardioverter-defibrillator implantation may be considered before discharge (see text for detailed discussion). aAdditional risk factors (at least 1, increasing risk and indication with >1 or more): NSVT, extensive 
LGE, unexplained syncope, positive PVS, reduced LVEF of <50%.327–329  
Table 16 Indicators of non-viral aetiologies and 
complications (high-risk features or red flags in acute 
pericarditis) 
Major  
Fever >38°C (HR 3.56) 
Subacute onset (HR 3.97) 
Large pericardial effusion (>20 mm on echocardiography) (HR 2.15) 
Cardiac tamponade (HR 2.15) 
Lack of response to aspirin or NSAID after at least 1 week of therapy 
(HR 2.50) 
Minor 
Pericarditis associated with myocarditis 
Immunodepression 
Trauma 
Oral anticoagulant therapy 
© ESC 2025
HR, hazard ratio; NSAID, non-steroidal anti-inflammatory drug. Major features have been validated 
in multivariable analysis in a prospective cohort study of patients with acute pericarditis.105


<!-- PAGE 49 -->

### Page 49

termed ‘perimyocarditis’. The clinical management and outcomes of 
mixed forms follow the predominant involvement. At present, patients 
with myopericarditis can be treated as patients with pericarditis, while 
patients with perimyocarditis should be managed as patients with pure 
myocarditis. The knowledge in the field is rapidly evolving and ongoing 
trials and evidence will provide more updated guidance for clinical 
management. 
A common scenario with overlapping forms of myocarditis and pericarditis is represented by systemic immune disorders, which can affect 
either the myocardium or pericardium, or both. 
Several systemic inflammatory and autoimmune diseases may present 
with myocarditis, pericarditis, mixed forms, or PEff without pericarditis. 
Main conditions include RA, SLE, Sjögren’s syndrome, SSc, polymyositis 
and dermatomyositis, and vasculitis (e.g. particularly EGPA). 
8.1. Inflammatory myopericardial 
syndrome in systemic disorders 
Inflammatory myopericardial syndrome may complicate several types 
of systemic diseases, generally immune-mediated,349,350 either with 
myocardial (myocarditis) or pericardial involvement (pericarditis and/ 
or PEff). Symptoms and signs that may raise the suspicion of a rheumatic autoimmune disease are family history, history of low-grade fever, 
joint symptoms, dry eyes and mouth, headache, lymphadenopathy, 
Raynaud phenomenon, skin rash, oral and genital aphthae, deep or 
superficial vein thrombosis, recurrent foetal losses, lymphopenia, and 
chronic increase of CK and other inflammatory markers. Targeted 
therapy should be applied, if a specific diagnosis is reached during the 
diagnostic work-up. 
8.1.1. Rheumatoid arthritis 
Pericarditis can be seen as part of the inflammatory activity in RA, and is 
often present concurrently with pleuritis. It is the most common cardiac 
manifestation, affecting up to 50% of patients, as detected on post- 
mortem examination. Myocarditis may also be present, and generally resolves if the disease is controlled.351 Anakinra, already registered for the 
treatment of RA, can be used also for related pericardial involvement. 
8.1.2. Systemic lupus erythematosus 
Pericarditis is the most common cardiac manifestation of SLE, reported 
in approximately 25% of patients, and it is included in the American 
Rheumatism Association/American College of Rheumatology (ARA/ 
ACR) classification criteria.352 Myocardial involvement in SLE affects 
about 5% of patients.353,354,355 Symptoms of IMPS are often non- 
specific, including elevated troponin, alterations on the ECG, LVEF abnormalities, and PEff. These manifestations are usually associated with 
typical symptoms of SLE, including fever, arthritis, nephritis, and skin 
rashes.356,357 The diagnosis can be supported by specific laboratory 
markers, as well as multimodality imaging, to guide the therapy.358,359 
Endomyocardial biopsy could be rarely considered in selected cases.349 
Cardiac tamponade occurs in less than 2% of cases, and CP is extremely 
rare. Cardiomyopathy is uncommon clinically, but autopsy studies 
found myocardial involvement in 40%–50% of patients. 
8.1.3. Antiphospholipid syndrome 
Antiphospholipid syndrome is associated with the presence of 
anti-cardiolipin and/or anti-β2-glycoprotein antibodies, and/or lupus 
anticoagulant, and may be the cause of myocardial dysfunction through 
various mechanisms. While myocarditis can manifest in this syndrome, 
mediated by autoimmune mechanism, myocardial damage can be also 
caused by microthrombotic phenomena.360,361 
8.1.4. Sjögren’s syndrome 
In Sjögren’s syndrome, the most common clinical manifestation of cardiac 
damage is pericarditis, which has been reported in less than one-third of 
cases. Myocarditis and myocardial fibrosis are also possible,362 and may 
occur associated with rhythm disturbances. Specific antibodies 
(anti-Ro/SSA) could also be identified in unexplained heart blocks.363 
8.1.5. Systemic sclerosis 
Inflammatory myopericardial syndrome is frequent in SSc,364 often clinically occult and, when symptomatic, the prognosis is poor. It may be 
related to ventricular dysfunction and/or structural damage of the 
microvascular bed, leading to repeated focal ischaemic injuries and irreversible myocardial fibrosis. It can be also due to a primary systemic 
myositic disease.349,365 Damage usually follows two pathways.366 The 
first one is linked to the production of collagen by activated fibroblasts 
at the myopericardial level, especially at the subepicardial level, with 
consequent fibrosis, valve stenosis, coronary spasms, and ischaemic 
events. The second pathway is caused by renal and pulmonary involvement, with severe cardiac consequences.367,368 Further research is 
needed to improve the understanding of IMPS in SSc.364 
8.1.6. Polymyositis and dermatomyositis 
The myocardium can be affected in inflammatory myopathies, such as 
polymyositis and dermatomyositis,369 with consequent myocardial 
hypertrophy, ischaemia, cardiac enlargement, and systolic and diastolic 
ventricular dysfunction.370 Cardiac involvement in inflammatory myopathies is clinically occult in most patients, but may be suspected by multimodality imaging371,372 and is related to poor outcome.370,372 
Myocarditis occurs in up to 30% of autopsied patients, with or without 
concomitant coronary or vessel vasculitis. Pericarditis is rarely reported 
in these patients. 
8.1.7. Vasculitis 
Myocardial involvement is prognostically relevant in vasculitis, particularly EGPA. In EGPA, about 15%–60% of patients present with cardiac 
disease350 including PEff, conduction disturbances, and motion abnormalities, as well as ACS, often due to coronary spasm, and EM (see 
Section 9.2). While cardiac involvement in EGPA often occurs early, it 
can be late in the course of the disease, and mainly affects anti- 
neutrophil cytoplasmic antibody (ANCA)-negative patients with high 
eosinophil counts. Myocardial and pericardial involvement is also possible in other vasculitis, especially in Kawasaki’s disease, where myocarditis is a common cardiovascular complication (see Supplementary data 
online, Figure S3).373 
Cooperation with specialists is important in all these systemic conditions to reach the correct diagnosis and to plan appropriate treatment. 
The diagnosis of EGPA may be particularly challenging.349 
8.2. Inflammatory myopericardial 
syndrome in COVID-19 disease 
The COVID-19 pandemic raised the awareness of IMPS, as in many patients the myocardium as well as the pericardium were affected. It is not 
proven whether the SARS-CoV-2 virus can directly damage cardiomyocytes or pericardiocytes, as it was suggested in cultivated human cardiomyocytes.374 Autopsy studies could only detect small amounts of virus  
ESC Guidelines                                                                                                                                                                                               49


<!-- PAGE 50 -->

### Page 50

in the myocardium and pericardium.375–379 The true estimate of 
COVID-19-associated IMPS is variable depending on CMR/ 
EMB-derived diagnosis ranging from 0.1–4.5/1000 cases380,381 up to 
2%–8% of cases in symptomatic patients.382 Symptoms as well as diagnostic work-up are similar to those described for general IMPS (see 
Sections 4 and 5). 
The predominant management of symptomatic complicated 
SARS-CoV-2-related IMPS is antiviral treatment for SARS-CoV-2 virus 
together with supportive therapy. Several immunosuppressive therapies, such as anti-IL-1 (anakinra and canakinumab) and anti-IL-6 (tocilizumab and sarilumab), have demonstrated promising results in critically ill 
patients hospitalized for COVID-19.383–385 In less severe cases, the key 
elements for treatments are those recommended for IMPS. More details can be found in Supplementary data online, Section 5.1.2. 
9. Specific types of myocarditis 
9.1. Lymphocytic myocarditis 
The diagnosis of LM is based on pathological criteria and reflects an inflammatory disease that may be caused by viruses, but also by other infectious agents, including bacteria (such as Borrelia spp.) and protozoa 
(such as T. cruzi).10 Furthermore, contemporary single-centre and multicentre cohort studies suggest that LM is more commonly non-infectious 
or immune-mediated/autoimmune.63,73 It is important to note that the 
aetiopathogenesis and outcome of viral LM varies considerably, based 
on the different infections. Cytolytic viruses, such as enteroviruses (e.g. 
coxsackieviruses and echoviruses), destroy cardiomyocytes and induce 
severe infiltration by macrophages and lymphocytes.386 In contrast to enteroviruses, vasculotropic B19V, which infects cardiac endothelial cells, 
but not cardiomyocytes, can also induce severe LM, especially in young 
children.228,387 High viral copy numbers (>500 viral DNA copies/µg of 
cardiac DNA) were found to be associated with cardiac inflammation 
and/or systemic infection.228,388 Low B19V DNA copy numbers in cardiac tissue rather reflect virus persistence, and are usually not related 
to cardiac inflammation. Lymphotropic viruses of the Herpesviridae family 
[HHV-6, EBV, human cytomegalovirus (CMV)], as well as HCV, influenza 
viruses, and SARS-CoV-2 may indirectly trigger myocarditis by activating 
the immune system.389 Regarding the aetiology and pathogenesis of myocarditis, microRNAs (miRNAs) may be promising diagnostic markers, as 
well as prognostic and therapeutic targets in myocarditis.141,390 
However, the precise role of miRNAs in myocarditis remains to be determined.391 In addition to infectious agents, organ-specific autoimmunity to heart autoantigens,66 different systemic immune-mediated 
diseases, toxic substances, and drugs, including ICIs, are known to induce 
different forms of acute and chronic LM.66 Immune-mediated myocarditis may occur with exclusive cardiac involvement or in the context of systemic immune-mediated diseases, such as SLE, SSc, and others.349,392 
Interestingly, genetic host susceptibilities have also been linked to cardiac 
dysfunction following myocarditis.91,150 
9.1.1. Presentation 
Since LM can be induced by various causes, there is no universal, specific 
clinical presentation. Instead, it must be considered in the context of 
the different diseases, in line with the stages of myocarditis. 
9.1.2. Diagnosis and therapy 
The diagnostic pathways were described above and vary depending on 
the cause. The diagnostic and therapeutic approach has to follow the 
clinical situation and the stages as described in Section 4 (see Table 12). 
9.2. Eosinophilic myocarditis 
Eosinophilic myocarditis is a rare form of myocarditis, characterized by 
eosinophilic infiltration of the myocardium. Underlying disorders that 
should be evaluated during the work-up of EM include: hypersensitivity 
and allergic reactions;271 immune-mediated disorders, in particular 
EGPA; undefined complex HES or its myeloproliferative variant; parasitic infections; and cancer.349 A meta-analysis of single cases or small 
case series reported a rate of in-hospital death of up to 22%, and a significantly increased occurrence of the hypersensitivity form, up to 
36%.271 
9.2.1. Presentation 
The clinical presentation of EM can be variable, ranging from oligosymptomatic to acute FM, or chronic RCM (Loeffler CMP or endomyocarditis).271 Nevertheless, prior study demonstrates that EM often has a 
fulminant presentation with abrupt impairment of LVEF, a high risk of 
malignant arrhythmias, and a high risk of thromboembolic complications, related to the formation of ventricular thrombi.271 Although 
EM is often accompanied by peripheral eosinophilia, it should be noted 
that this finding is absent in up to 25% of patients with EM, and may contribute to the underdiagnosis of EM. 
9.2.2. Diagnosis 
The diagnosis of EM can be established by either the EMB-proven presence of eosinophilic infiltration of the myocardium, or the presence of 
CMR-proven myocarditis with pathognomonic findings associated with 
peripheral eosinophilia (Supplementary data online, Figure S3). 
Furthermore, general clinical signs related to EGPA or HES disorders 
should be evaluated, such as an increased number of eosinophilic cells, 
history of asthma and sinusitis, and characteristic skin lesions. Left ventricular function may be preserved, and DCM can occur, but often the 
phenotype of RCM is present. On echocardiography, a typical finding is 
Loeffler endocarditis. In the diagnostic work-up, systemic screening for 
the above-mentioned aetiologies should be carried out systematically. 
9.2.3. Therapy 
The first-line therapy for EM is the administration of i.v. corticosteroids, 
but caution should be exercised if EM is caused by an infectious agent. 
The optimal dose and duration of corticosteroids are unclear, but it is 
proposed to administer a daily i.v. bolus of corticosteroids followed by 
dosage tapering in severe forms, while oral steroid administration (see  
Table 12) can be considered in patients with mild LV dysfunction.39,271 
The identification of an EM-associated condition is crucial to administer 
specific treatments, such as cyclophosphamide or IL-5 inhibitors in 
EGPA-related EM,34 imatinib in the myeloproliferative variant of 
platelet-derived growth factor receptor alpha (PDGFRA)-associated 
HES, or albendazole in Toxocara canis infection. In hypersensitivity/allergic EM, first-line therapy is to withdraw the potential cause of 
eosinophilia. 
Since endocavitary thrombi were reported in 12% of EM cases, the 
use of anticoagulation during the acute phase could be considered for 
the prevention of endocavitary thrombi.271 
9.3. Giant-cell myocarditis 
Giant-cell myocarditis is a very rare, but often rapidly progressive disease with a poor prognosis, with an ∼85% rate of death or HT at 
3 years.56,82 The incidence of GCM was reported to range from 
0.007% to 0.051% in autopsy studies; however, this number might


<!-- PAGE 51 -->

### Page 51

underestimate the true disease burden.393,394 Giant-cell myocarditis 
generally affects young and middle-aged adults without a sex predominance. In a large multicentre registry of GCM cases, patients were aged 
from 16 to 69 years at the time of diagnosis.82 
Giant-cell myocarditis is recognized as a non-infectious myosin-induced 
autoimmune form, as experimental models suggest,395 and an association 
with autoimmune disorders has been reported in ∼20% of cases.82 
9.3.1. Presentation 
Early symptoms of GCM might not differ from other types of myocarditis and vary widely at the time of presentation. In an international 
registry of 63 GCM patients, HF was the presenting symptom in 75% 
of cases.82 The initial manifestations might be progressive haemodynamic deterioration or cardiogenic shock, intractable arrhythmias, 
and SCD. The condition often progresses rapidly to death, often within 
days to months. A systematic analysis including 51 patients with GCM 
showed that the cumulative incidence of SCD (fatal or aborted) was 
22% at 1 year and 26% at 5 years after presentation, and the composite 
incidence of SCD or VT was 41% at 1 year and 55% at 5 years.326 
Other early GCM manifestations include bradyarrhythmias and cardiac 
conduction abnormalities, including complete AVB. In a study from 
Finland, 25% of individuals <55 years of age with clinically idiopathic 
heart block had GCM or CS on heart biopsy.396 The presence of AM 
complicated by treatment-resistant HF or cardiogenic shock, VA, and 
AVB should increase the clinical suspicion of GCM. 
9.3.2. Diagnosis 
Endomyocardial biopsy remains the gold-standard diagnostic modality 
for GCM and can identify these patients at an early stage.397,398 Patients 
diagnosed with GCM through EMB had a shorter symptom-onset-to- 
diagnosis time and milder heart damage than those diagnosed during 
HT.398 
The presence of multinucleated giant cells in the absence of well- 
organized granulomatous lesions in the myocardial biopsy specimen 
is the hallmark of GCM. The giant cells are typically located in the interstitium or around blood vessels and are characterized by their large size, 
multinucleation, and cytoplasmic granules. 
Giant-cell myocarditis is characterized by myocardial destruction 
mediated by a large number of T cells, macrophages, multinucleated 
giant cells, and eosinophils in EMB.39 Generally, the histological diagnosis of GCM is guided by myocyte necrosis, diffuse infiltration of inflammatory cells, and interstitial fibrosis.399,400 The severity of necrosis and 
fibrosis in EMB predicts the outcome.401 It is important to understand 
that one set of non-diagnostic EMB samples does not exclude GCM. 
The sensitivity of the first biopsy is 68% and increases to 93% when 
the biopsy is performed up to three times. Thus, repeated EMB should 
be considered when there is a high clinical suspicion of GCM.217 In a 
single-centre case series of GCM, LGE on CMR was present in 96% 
of cases, and its distribution correlated with the histology.401 Prompt 
EMB in the setting of suspected GCM can affect the choice of MCS, 
leading to an early listing for HT and consideration of cyclosporine- 
based immunosuppression.402 Administration of i.v. steroids prior to 
EMB may reduce the diagnostic yield of EMB. There should be an agreement in specialized centres to prioritize the evaluation of EMB, and to 
provide the results at least within 3 days, optimally within 8 h. 
9.3.3. Therapy 
As soon as GCM is suspected, immunosuppressive therapy should be initiated promptly to avoid disease progression and delay HT. It is crucial 
that the therapy should be initiated based on a strong clinical suspicion. 
Historically, the survival of patients with GCM without immunosuppression was about 3 months from symptom onset to death or HT. Many 
studies have shown that immunosuppression is useful for the treatment 
of GCM. Immunosuppressive therapy typically involves two or three 
drugs, including corticosteroids, and at least one, and usually two additional immunosuppressive agents (see Table 12). In GCM patients, immunosuppression with corticosteroid monotherapy is not associated 
with a prolongation of transplant-free survival.82 
Patients with GCM should receive the same guideline-based treatment for HF and arrhythmias as patients with heart disease from other 
causes.12,58 
Cyclosporine is the most commonly used immunosuppressant. In 
multiple retrospective and prospective studies, concomitant use of 
cyclosporine was associated with improved prognosis. Combining immunosuppressive therapy with corticosteroids and cyclosporine, 
azathioprine, or both improved transplant-free survival on average to 
12 months, while patients treated with corticosteroids alone survived 
on average 4 months.82 A cases series of GCM reported that 1-year 
transplant-free survival was 73% in patients who received corticosteroids and cyclosporine with or without muromonab-CD3, with a reported decrease of the degree of necrosis, cellular inflammation, and 
giant cells after 4 weeks of treatment.403 A systematic review of 27 
studies with 43 biopsy-proven GCM cases requiring MCS showed 
that the administration of immunosuppressive therapy prior to MCS 
implantation was associated with significantly better survival than treatment with MCS alone. Immunosuppression may reduce the severity of 
HF in these patients by preventing further autoimmune destruction of 
the myocardium.404 
Cessation or reduction of immunosuppression is associated with 
GCM recurrence as long as 8 years after diagnosis.344,403 
In a single-centre study, the risk of life-threatening VA in GCM patients exceeded 50% at 5 years after admission. Permanent ICD effectively terminated life-threatening ventricular tachyarrhythmias, and no 
GCM patient with the device suffered from a SCD.326 
Transplantation could be considered for GCM patients who fail to 
respond to GDMT and immunosuppression. A recent systematic review and meta-analysis of 499 patients with CS and 69 with GCM 
who underwent HT found that 1- and 5-year survival rates in GCM patients were similar to those in transplant recipients with other HF 
aetiologies.405 
Recommendation Table 16 — Recommendations for 
giant-cell myocarditis (see Evidence Table 16) 
Recommendations 
Classa 
Levelb  
EMB is recommended in patients with suspected 
GCM due to unexplained new-onset HF of up to 
2 weeks associated with a normal or dilated left 
ventricle and new ventricular arrhythmias, second- 
or third-degree AVB, or failure to respond to usual 
care within 1 to 2 weeks to initiate specific 
treatment.402 
I 
C 
Combined immunosuppressive therapy is 
recommended in patients with a diagnosed GCM.217 
I 
C 
© ESC 2025
AVB, atrioventricular block; EMB, endomyocardial biopsy; GCM, giant-cell myocarditis; HF, 
heart failure. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               51


<!-- PAGE 52 -->

### Page 52

9.4. Myocarditis in sarcoidosis 
Cardiac sarcoidosis is a form of inflammatory heart disease, coexisting 
with systemic sarcoidosis in 5%–10% of cases,406 or rarely, in isolation. 
The aetiology of sarcoidosis is not well understood, but may involve an 
autoimmune response after certain trigger(s) and genetic predisposition, 
which leads to the formation of non-caseating granulomas in multiple organs, typically in the lungs.407 On histopathology, the granuloma consists 
of CD68+ macrophages, CD68+ giant cells, CD3+ T lymphocytes, and 
CD20+ B lymphocytes. It is characterized by inflammation, oedema, 
lymphocytic infiltration, and replacement fibrosis.408 Cardiac sarcoidosis 
is often subclinical, with an estimated cardiac involvement in around 25% 
of cases on autopsy series in patients with sarcoidosis.409,410 
9.4.1. Presentation 
Manifestations of CS may range from cardiac inflammation, conduction 
system disease, frequent ectopy, tachyarrhythmia, and HF, to SCD.407 
Cardiac sarcoidosis may mimic different cardiac phenotypes, including 
ARVC,254,411–413 DCM, and hypertrophic CMP (HCM), but may also 
occur in patients with normal cardiac function.414 Symptoms are non- 
specific, and often related to arrhythmias, especially AVBs and VTs. The 
challenge is to identify patients at risk, since SCD due to malignant arrhythmia is common.415,416 
9.4.2. Diagnosis 
The diagnostic algorithm of CS is different in patients with or without 
known extracardiac sarcoidosis. Pathognomonic findings in non- 
invasive imaging are sufficient for the diagnosis of CS in cases with 
known systemic sarcoidosis.417 In contrast, the diagnostic pathway in 
primary CS is more challenging, but typical multimodality imaging patterns are usually sufficient. Cardiac sarcoidosis can manifest as abnormalities on ECG, echocardiography, CMR, PET, EMB, and cardiac and 
inflammatory blood biomarkers (see Section 5.4). Electrocardiogram 
or cardiac rhythm monitoring may demonstrate conduction system abnormalities (such as AVB or bundle-branch block) and arrhythmias, including VT.418 Echocardiography may reveal regional WMA in a 
non-coronary distribution, septal thinning, and ventricular aneurysms. 
Endomyocardial biopsy may be helpful in selected patients, but negative 
results do not rule out CS due to potential sampling errors.419 
Endomyocardial biopsy guided by imaging or EAM may improve the 
diagnostic yield (see Section 5.12). 
Multimodality advanced cardiac imaging, such as CMR and FDG-PET, 
plays an increasing role in the management of suspected CS. Overall, 
compared with FDG-PET, CMR has higher sensitivity of 89%–95% vs 
84%, respectively, but similar specificity of 78%–85% vs 82%, respectively, for the diagnosis of CS.408,420–428 
On CMR, CS has a wide range of potential findings, and is often considered the ‘great mimicker’ of various cardiac conditions, but the interventricular septum is often involved408 and the ‘hook sign’429 is 
recognized to be associated with a high probability of CS. For more details, see Supplementary data online, Figure S3. A heavy burden of LGE is 
associated with a poorer prognosis and predisposes to VA, HF, and death 
in CS, and may guide clinical decision-making.430–436 Aside from LGE, the 
identification of ongoing myocardial inflammation is possible.30,437–441 
Fluorodeoxyglucose-positron emission tomography also allows detection of cardiac inflammation in CS.426 It requires careful patient preparation to suppress physiological 18F-FDG uptake. The classical finding is 
focal 18F-FDG uptake in the basal septum, with a concordant perfusion 
defect. Perfusion defects in the active stage of CS may be due to microvascular obstruction by inflammatory oedema, necrosis, or both, and are 
not necessarily located in the same region as the 18F-FDG uptake.427 
Hybrid PET-CMR may enable better detection of cardiac inflammation 
in a more comprehensive manner,440,442,443 but its availability is limited. 
Both CMR and PET may be used for imaging-guided EMB. 
The intensity and extent of FDG uptake on PET is of prognostic relevance.443–449 In a meta-analysis of 37 studies of patients with CS, LGE on 
CMR and FDG uptake on PET were both predictive of MACE (all-cause 
death, cardiac death and aborted SCD, VA, and HF hospitalization). 
Fluorodeoxyglucose-positron emission tomography has proved to 
be useful in predicting and monitoring the anti-inflammatory therapy 
response in sarcoidosis;204,450 however, the optimal timing for repeating PET studies for the assessment of treatment response is not well 
established. 
In addition to clinical assessment, imaging modalities should be used 
for the short- and long-term management of patients with CS. 
9.4.3. Therapy 
The treatment of CS is currently not standardized, and is based on 
patient-tailored assessment, often with multidisciplinary input.451 
Treatment is targeted at controlling cardiac inflammation, myocardial 
scarring and dysfunction.13,431–436 First-line therapy includes corticosteroids (see Table 12). 
Since resolution of conduction abnormalities with anti-inflammatory 
treatment remains unpredictable, definitive cardiac pacing is usually 
needed. AVB and the need for cardiac pacing are associated with a higher risk of sustained VA, which reached 31% at 5 years in the Finnish 
registry.416,452,453 Thus, it appears reasonable to propose an ICD 
with pacing ability rather than a pacemaker in CS patients with pacing 
indications. The risk of VA during follow-up is high in observational 
studies, in patients with low LVEF,416,452,454,455 presence of LGE on 
CMR,434,456–459 and positive PVS.456,460–464 There is a lack of data on 
the relationship between scarring extent and arrhythmia risk. 
Positron emission tomography-computed tomography may also help 
to stratify patients.465 
Heart transplantation could be considered in a subgroup of patients 
with CS, similarly to GCM.405 
Recommendation Table 17 — Recommendations for 
myocarditis in sarcoidosis (see Evidence Table 17) 
Recommendations 
Classa 
Levelb  
Diagnosis 
CMR, using tissue characterization techniques, is 
recommended in patients with suspected CS to 
assess cardiac inflammation and myocardial 
involvement.408,421–425 
I 
B 
18F-FDG-PET is recommended for the diagnostic 
work-up, including detection of inflammation, as well 
as for follow-up and assessment of therapeutic 
response in patients with CS.426–428 
I 
B 
Therapy 
ICD implantation is recommended in patients with 
CS and sustained ventricular arrhythmia (VT/VF) or 
aborted CA to prevent SCD.58,396,416,454,455,466 
I 
B 
ICD implantation is recommended in patients with 
CS and LVEF ≤35% to prevent SCD.416,452,454,455 
I 
C                         
Continued


<!-- PAGE 53 -->

### Page 53

9.5. Specific infectious myocarditis 
(Viruses, Lyme, Chagas) 
9.5.1. Viruses 
A large variety of infectious agents (Supplementary data online, Table S1) 
can cause myocardial inflammation, but viruses are considered the most 
common cause among infectious forms of myocarditis. Data on the true 
prevalence of viral myocarditis are difficult to determine, since EMB is 
performed only in a subgroup of high-risk patients and in complicated 
cases. Moreover, a positive viral serological test does not imply myocardial infection and is not routinely recommended. Exceptions are HIV and 
HCV and for specific infections such as Lyme disease.10 The epidemiology of viral myocarditis has changed during the past three decades; 
while enteroviruses and adenoviruses have been considered the most 
common causes of viral myocarditis,468 vasculotropic viruses such as 
B19V,63,66,468 and lymphotropic viruses such as HHV-6 are increasingly 
found in EMB samples.342,469 The prognostic relevance of persistent 
B19V infection with low viral copy numbers remains controversial because its presence in myocardial tissue may not have direct pathogenetic 
significance,470,471 in contrast to acute B19V infection.228 
9.5.1.1. Presentation 
Symptoms vary according to the underlying cause and severity of disease. However, it generally follows the presentation of acute and 
chronic stages, as presented in Section 4. 
9.5.1.2. Diagnosis 
The diagnostic approach should follow the description outlined in 
Section 4 (Figures 5 and 6). The presence of more than 500 copies/μg 
of DNA in EMB is considered as the threshold for virus-related myocardial inflammation, and usually guides therapeutic choices (e.g. starting 
immunosuppression). Viral PCR analysis in EMB samples is performed 
to better characterize the pathological substrate causing myocarditis. 
If immunosuppression is needed, viral presence has to be ruled out 
by EMB.10 Contemporary PCR analysis for viral presence in EMB specimens and blood samples is utilized to rule out possible tissue 
contamination.10,469 
9.5.1.3. Therapy 
Data are insufficient to support antiviral therapy for AM, as well as treatment with IVIG for presumed viral myocarditis.472 Anti-herpesvirus 
drugs in patients with CMV or HHV-6 infection can be considered, although their efficacy has not been directly studied in patients with 
myocarditis.10 Treatment with type I IFN in patients with enterovirus 
has been suggested to increase viral clearance, but large trials are missing.273,473–475 Antiviral therapies have to be prescribed and managed in 
collaboration with an infectious diseases expert with shared decision- 
making in the IMPS team.1,472 
9.5.1.3.1. Influenza virus. Supportive management is the backbone of 
severe influenza treatment. Myocardial involvement is rare, but should 
be considered in patients of any age with chest pain, tachycardia, and 
haemodynamic instability within 2–4 weeks from symptom onset. 
The effect of antiviral therapy on myocarditis is not clear, although oseltamivir is utilized in both inpatient and outpatient settings. Peramivir 
and zanamivir are used only for hospitalized patients. There are individual case reports of successful treatment with neuraminidase inhibitors.476–479 Peramivir has often been used in combination with either 
oseltamivir480,481 or zanamivir.482 
9.5.1.3.2. Human immunodeficiency virus. The pathogenesis of 
HIV-associated myocarditis involves direct viral infection, co-infection 
with other viruses or bacteria, cytokine activity, side effects of highly 
active antiretroviral therapy (HAART), immune system dysregulation, 
and/or ischaemia. If HIV-associated myocarditis is diagnosed, therapy 
for HIV infection has to be started or continued. Highly active antiretroviral therapy has been reported to significantly decrease the incidence of cardiac involvement, especially pericarditis, arrhythmias, 
and DCM compared with patients treated with nucleoside reverse 
transcriptase inhibitors in a retrospective study of 1042 patients.483 
9.5.2. Lyme carditis 
Lyme carditis may be an early manifestation of Lyme borreliosis, a tick- 
borne disease, caused by Borrelia spp., which is one of the most common vector-borne diseases in the northern hemisphere. 
9.5.2.1. Presentation 
In cases of early disseminated infection, AM with possible associated 
pericarditis may occur, but LC is typically characterized by varying degrees of AVB, with third-degree AVB in approximately 25% of cases.484 
Chronic LC often shows manifested persistent symptoms and signs, 
such as fatigue, cognitive dysfunction, headaches, sleep disturbance, 
neuropsychiatric and musculoskeletal symptoms, electrical conduction 
delays, and DCM. 
9.5.2.2. Diagnosis 
The suspicious index in LC score has been proposed to evaluate the likelihood of high-degree AVB to be caused by LC. It allows categorization 
of patients into low-, intermediate- and high-risk categories.485 
Continuous ECG monitoring is required for patients presenting with 
syncope or with a PR interval of >300 ms, since this is a high-risk marker 
of progression to complete AVB.484 Serological tests are recommended 
for patients presenting with high-degree AVB and suspected LC. 
9.5.2.3. Therapy 
Atrioventricular block is often transient and typically resolves within 
1–2 weeks of antibiotic treatment, therefore permanent pacemaker 
placement is not warranted for AVB associated with LC before starting 
therapy. Intravenous therapy with ceftriaxone is the recommended 
first-line treatment for patients with LC and AV disturbances,486 followed by oral antibiotics (doxycycline, amoxicillin, or cefuroxime) for 
ICD implantation should be considered in patients 
with CS and LVEF >35% after resolution of the active 
phase with significant LGE, a history of arrhythmias, 
unexplained syncope, inducible sustained VA at PVS, 
or with persistent high-degree AVB to prevent 
SCD.416,434,452,453,456–464,467 
IIa 
C 
© ESC 2025
AVB, atrioventricular block; CA, cardiac arrest; CMR, cardiovascular magnetic resonance; 
CS, cardiac sarcoidosis; 18F-FDG-PET, [18F]-fluorodeoxyglucose positron emission 
tomography; ICD, implantable cardioverter-defibrillator; LGE, late gadolinium 
enhancement; LVEF, left ventricular ejection fraction; PVS, programmed ventricular 
stimulation; SCD, sudden cardiac death; VA, ventricular arrhythmias; VF, ventricular 
fibrillation; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               53


<!-- PAGE 54 -->

### Page 54

at least 14 days and up to 21 days (total antibiotic course), depending 
on the severity of clinical presentation and response to treatment. 
The prognosis for early-treated disseminated LC is favourable, 
with complete recovery occurring in most patients treated with 
antibiotics.484,487 
Although LC may resolve spontaneously, antibiotic therapy shortens 
the disease duration and prevents further complications. 
9.5.3. Chagas disease 
Chagas disease (CD) is a systemic disorder caused by the protozoan 
parasite T. cruzi, which is transmitted through a haematophagous triatomine insect vector in endemic areas, such as Latin America, and 
can be transmitted transplacentally, by infected blood, or even orally 
through ingestion of contaminated food and drinks. Current migration 
has made CD a global disease, and congenital transmission has become 
relevant in non-endemic areas, including Europe. 
9.5.3.1. Presentation 
Acutely infected individuals remain asymptomatic or show mild and 
non-specific symptoms. Intense direct tissue parasitism may result in 
AM in less than 5% of cases. Chagas disease may evolve into CMP in 
20%–30% of cases. Common findings in patients with Chagas CMP include brady- or tachyarrhythmias, dilated ventricles with regional 
(mainly inferior, inferolateral, or apical) or global systolic dysfunction, 
and thromboembolism. 
9.5.3.2. Diagnosis 
Diagnosis of CD requires a high clinical suspicion. Polymerase chain 
reaction testing is the most sensitive test in acute infection while, 
for diagnosing chronic CD, the combination of two serological tests 
with antigens that detect different antibodies against T. cruzi is preferable. Multimodality imaging is able to support the diagnosis, as often 
apical aneurysms with and without thrombi can be detected by 
CMR.488 
9.5.3.3. Therapy 
Eradication of the parasite is a target in early phases, and anti-parasitic 
treatment should be provided as soon as possible, following detection 
of an acute infection. In the BENEFIT (Benznidazole Evaluation for 
Interrupting Trypanosomiasis) trial, 2854 patients with Chagas CMP 
were randomized to either benznidazole or placebo for 80 days. 
Benznidazole significantly reduced serum parasite detection, but there 
was no significant reduction in clinical cardiac deterioration at 
5 years.489 Therefore, anti-trypanosomal treatment should not be routinely used in adult patients with chronic CMP, but it can be considered 
in early and mild forms490,491 (see Table 12). Patients with Chagas CMP 
should be treated according to HF guidelines. Chagas disease is associated with high morbidity and mortality, with an annual rate of cardiovascular death of 6%.492 In this population, the benefit of ICD in primary 
and secondary prevention is controversial, since observational studies 
did not demonstrate a mortality benefit compared with amiodarone.493 
However, a systematic review and meta-analysis showed that, in patients with previous VT, appropriate ICD interventions and electric 
storms were frequent, occurring at a rate of 25% and 9% per year, respectively, with an overall mortality of 9% per year.494 A case-based decision is warranted. 
9.6. Drug- or vaccine-induced myocarditis 
9.6.1. Drug-induced myocarditis 
9.6.1.1. Immune checkpoint inhibitor-induced myocarditis 
Immune checkpoint inhibitors have revolutionized cancer treatment 
and are approved in multiple cancer types. These agents are monoclonal antibodies blocking specific molecules that inhibit the immune 
response—CTLA-4 (cytotoxic T-lymphocyte antigen 4), PD-1 (programmed cell death protein 1) and its ligand PD-L1 (programmed 
death ligand 1), and LAG-3 (lymphocyte activation gene 3)—strongly 
enhancing T-cell responses against cancer. By activating the immune 
system, ICIs may induce immune-related adverse events, which can affect any organ. Myocarditis is one of the most feared complications,495–497 although rare, as it affects approximately 1% of treated 
patients, within the first weeks following the initiation of therapy.495 
Since a growing number of patients are eligible for ICI treatment, 
the absolute number of cases is increasing. One of the largest case series, including 122 patients with ICI-associated myocarditis, recorded 
early onset after treatment initiation (median 30 days), and up to 
50% mortality.496 A systematic analysis of the World Health 
Organization (WHO) pharmacovigilance database confirmed a high 
mortality rate up to 33%.498 
The main risk factor for ICI-induced AM is combination therapy with 
two types of ICI, such as an anti-CTLA-4, e.g. ipilimumab, combined 
with an anti-PD-1, e.g. nivolumab.499 
This complication affects mostly men495 and older patients (median 
age 65 years) with more comorbidities.28,495 Furthermore, if ICIs are 
combined with other cancer therapies, their toxicity aggravates. 
9.6.1.1.1. Presentation. Immune checkpoint inhibitor-induced myocarditis is especially arrhythmogenic, including a risk of conduction 
disorders, and HF with reduced EF occurs in about half of patients.500 
Myocarditis is frequently associated with peripheral myositis, which, 
when associated with respiratory failure, can negatively affect 
survival. 
9.6.1.1.2. Diagnosis. When suspected, rapid diagnostic triage is 
needed.495–497 Early diagnosis is extremely important, usually including laboratory tests and multimodality imaging (Section 5). The detection of a 
coexisting CAD in older patients should not refrain from further work-up 
for myocarditis (Table 4). In inconclusive cases an EMB can be necessary. 
For more details, see the 2022 ESC cardio-oncology guidelines.501 
9.6.1.1.3. Therapy. After diagnosis, immediate discontinuation of ICI 
and early (within the first 24 h) initiation of corticosteroids is warranted. Up to 50% of patients will be refractory to corticosteroids. In 
this situation, second-line immunosuppression treatments are necessary (see Table 12).502 In a prospective registry, the combination of ruxolitinib and high doses of abatacept, and screening for concurrent 
respiratory muscle failure, was associated with improved survival.502 
Long-term cardiovascular effects of ICIs become more and more relevant since a growing number of cancer patients are exposed to this 
therapy.503,504 Rechallenge with an ICI has to be considered following 
a multidisciplinary team discussion, based on factors such as the severity 
of the myocarditis, cancer prognosis, oncology treatment options, and 
patient preference.504,505 Details are given in the 2022 ESC guidelines 
for cardio-oncology.501


<!-- PAGE 55 -->

### Page 55

9.6.1.2. Other drugs associated with myocarditis 
Many drugs have been associated with myocarditis (see Supplementary 
data online, Table S10), especially clozapine.506 The reported incidence 
of clozapine-associated myocarditis ranges from 0.1% to 5%.507,508 
Drug-induced myocarditis may be associated with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.509 Treatment is 
based on discontinuation of the drug and use of corticosteroids. 
9.6.2. Vaccine-induced myocarditis 
In 2002 the ‘Brighton collaboration’ was established with the aim to provide standards for the definition of adverse events after vaccination.510 
In a clinical context, different vaccines, apart from the SARS-CoV-2 
vaccine, have been associated with myocarditis. The main association 
is with smallpox vaccine,511 with data deriving mainly from the US military population. 
A systematic review reported cardiac events including IMPS after influenza vaccination, pneumococcal vaccine, and tetanus toxoid.512 
Few data reported myocarditis after receiving different vaccines (e.g. 
meningococcus, hepatitis A and B, diphtheria, poliovirus) (see  
Supplementary data online, Table S11).513–518 
A recent multicentre study reported good mid-term outcomes after 
COVID-19 vaccine-associated myocarditis without death or need for 
HT.519 More detailed information can be found in Supplementary 
data online, Section 5.1.2. 
9.7. Pregnancy-associated myocarditis 
Peripartum CMP (PPCM) is sometimes associated with myocardial inflammation, more common particularly in patients presenting with arrhythmias.520 Pregnancy-associated myocarditis (PaM) is a rare 
condition, and its incidence and prognosis varies regionally.521–523 
Nutritional deficiencies, viral myocarditis, and autoimmune processes 
have been postulated as triggers. Recent data support the role of 
neurohormonal changes of late pregnancy and delivery, as well as the 
role of genetic predisposition.524 
9.7.1. Presentation 
There is no clear distinction between the phenotype of PaM and PPCM. 
Women develop symptoms of HF during late pregnancy or after delivery, with the majority being diagnosed after delivery, typically in the first 
month post-partum. A minority of patients may present with pulmonary oedema, cardiogenic shock, severe arrhythmias,525 cardio- 
pulmonary arrest, thromboembolic complications, and brain injury. 
9.7.2. Diagnosis 
There are no specific studies for PaM, therefore the guidance for PPCM 
should be followed. Transthoracic echocardiography should be performed in any suspected case. In PPCM, LVEF is typically <45%.526 
Careful examination should be undertaken to clearly view the LV 
apex to detect intracardiac thrombi. Brain natriuretic peptide/ 
N-terminal prohormone of brain natriuretic peptide are usually markedly elevated.527–529 
Cardiovascular magnetic resonance imaging is an advanced imaging 
modality if echocardiogram is inadequate, but gadolinium-based contrast 
agents should be avoided during pregnancy.530–532 Cardiovascular magnetic resonance is crucial to differentiate underlying causes.533 The detection of active inflammation can be performed without application of 
contrast media in CMR (Figure 4). 
Peripartum CMP has been associated with a higher rate of recovery 
than other forms of HF with reduced EF,534 and remission frequently 
occurs within the first 3 to 6 months.535 Delayed recovery can also occur after 2 years.536,537 
9.7.3. Therapy 
There are no dedicated studies for PaM, so advice is based on published 
literature for PPCM. 
Treatment of HF is essential, with modifications to ensure foetal 
safety during pregnancy.521,538–540 
Low-molecular-weight heparins do not cross the placenta, and are 
preferred during pregnancy if the thromboembolic risk is high.541 
Direct oral anticoagulants are less well studied in pregnancy, and should 
be avoided. Anticoagulation should be continued until recovery of LV 
function. 
Bromocriptine has been shown to improve LVEF at 6 months, but 
the results are contradictory.521,542–545 
Following delivery, most HF medications are compatible with breastfeeding. Many patients may also relapse. Treatment withdrawal and incomplete recovery of LV function are risk factors for recurrences.546,547 
Lifelong treatment has not been proven to be necessary. 
Pre-conception counselling should include discussion of the potential 
risks of recurrent myocardial dysfunction, even after recovery.547 
Multidisciplinary teams are warranted for patient management.548,549 
10. Inflammatory cardiomyopathy 
Inflammatory CMP is defined by chronic myocarditis in association with 
cardiac dysfunction and ventricular remodelling, with a clinical hypokinetic phenotype, either dilated or non-dilated, with or without arrhythmogenic substrate. It can also manifest as the evolution of a prior 
myocarditis, whether treated or untreated. Inflammatory CMP is involved in the pathogenesis of DCM. It includes immune-mediated/autoimmune forms and infectious subtypes.12,550 A genetic predisposition is 
Recommendation Table 18 — Recommendations for 
immune checkpoint inhibitor-associated myocarditis 
(see Evidence Table 18) 
Recommendations 
Classa 
Levelb  
Diagnostic triage within 24 h is recommendedc in 
patients with suspected myocarditis induced by ICI 
to initiate treatment rapidly.495,496,501,504 
I 
C 
Immediate disruption of ICI and administration of 
high-dosage corticosteroids are recommended in 
patients with ICI-associated myocarditis in order to 
stop the inflammatory reaction and stabilize the 
patient.504 
I 
C 
Second-line immunosuppression treatment should 
be considered in patients with steroid-refractory 
ICI-associated myocarditis.501,504 
IIa 
C 
Second-line immunosuppression treatment may be 
considered in patients with fulminant/severe 
ICI-associated myocarditis.501,504 
IIb 
C 
© ESC 2025
ICI, immune checkpoint inhibitor. 
aClass of recommendation. 
bLevel of evidence. 
cSee Figure 5.   
ESC Guidelines                                                                                                                                                                                               55


<!-- PAGE 56 -->

### Page 56

also important for the pathogenesis of inflammatory CMP.9 However, 
the rates, risk factors, and other characteristics of cases progressing 
from AM to chronic myocarditis or inflammatory CMP remain unknown. 
10.1. Presentation 
Patients with inflammatory CMP may present with new-onset/acute, 
subacute, or chronic HF. Although myocarditis resolves in >50% of 
cases, even spontaneously, approximately 25% of cases may present 
with persistent ventricular dysfunction, and more severe cases may 
progress to DCM.10 
10.2. Diagnosis 
A variety of clinical assessment, ECG, multimodality imaging, and, if 
needed, EMB can be used to reach a diagnosis. Persistent or chronic 
myocardial inflammation should be suspected in cases with non- 
ischaemic ventricular dysfunction associated with low QRS voltages, 
and persistent mild elevation of hs-TnT/TnI. The absence of significant 
remodelling may be observed in the early phase of the disease. This suspicion can be confirmed by multimodality imaging (echocardiography 
and CMR) and EMB, especially in the presence of myocardial oedema 
observed at CMR. Inflammatory CMP may be familial in rare cases. In 
these patients, genetic testing should be discussed. 
10.3. Therapy 
Guideline HF treatment is recommended in patients with inflammatory 
CMP.12,259 Medical therapy should be tailored to the underlying cause 
in case of systemic disorders, especially in autoimmune diseases. Only 
one RCT showed an improvement of cardiac function with immunosuppressive treatment in patients with virus-negative inflammatory 
CMP.551 Other non-randomized studies, often derived from single- 
centre and/or retrospective studies,34,131,551–555 suggest the efficacy 
of immunosuppression on top of optimized HF therapy, and support 
its safety. In patients with different immune-mediated myocarditis 
and HF, immunosuppressive therapy was safe.34,131,552–555 Therefore, 
the treatment should be based on histological/immunohistological 
and viral PCR examination of the biopsy specimens. 
In untreated cases, progression to DCM and transplantation or death 
are observed.10,39 
11. Specific types of pericarditis 
11.1. Tuberculous pericarditis 
In high-income countries, TB pericarditis accounts for up to 4% of pericardial disease, but it is increasing due to immigration. On the other hand, TB 
is the cause of clinically significant PEff in approximately 90% of 
HIV-infected and 50%–70% of non-HIV-infected individuals living in developing countries with a high prevalence of TB.556 It should be emphasized 
that most of the information on TB pericarditis comes from endemic 
areas in low-income countries and immunosuppressed patients.1 
Notably, the disease can occur at any age, and men are affected more frequently than women.48 Tuberculous pericarditis has an overall mortality 
rate of 17%–40% at 6 months after diagnosis.557 
11.1.1. Presentation 
Clinical presentations of TB pericardial involvement include AP (most 
commonly with PEff), ECP, and CP, with these manifestations representing consecutive stages of a unique process rather than independent 
conditions.558,559 Specifically, the evolution of TB pericarditis encompasses four stages (Figure 18). The first stage or dry stage of AP is without effusion, the second stage with PEff (this is the form most 
commonly encountered in clinical practice) in up to 80% of cases, the 
third stage with progressive absorption of effusion, and the fourth stage 
with pericardial constriction. In the effusive phase, pericardiocentesis 
usually yields bloody effusion, and effusive–constrictive physiology 
may emerge after pericardial drainage. At this stage, lymphocytic exudate is mainly observed.560 The duration of each stage varies and depends on individual factors (e.g. HIV status), and early treatment may 
prevent progression. 
11.1.2. Diagnosis 
The diagnosis of TB pericarditis is challenging and in 15%–20% of cases 
the diagnosis may be missed.561 A ‘definite’ diagnosis of TB is based on 
the presence of tubercle bacilli in the pericardial fluid or on a histological sample of the pericardium, by culture or by PCR (Xpert MTB/RIF and 
RIF ultra) testing. A ‘probable’ diagnosis is made when there is proof of 
TB elsewhere in a patient with unexplained pericarditis, a lymphocytic 
pericardial exudate with elevated unstimulated IFN-γ (uIFN-γ), adenosine deaminase or lysozyme levels, and/or an appropriate response to 
antituberculosis therapy in endemic areas.558 In a meta-analysis, the 
sensitivity and specificity of adenosine deaminase, which is probably 
the most widely used biomarker, were 90% and 86%, respectively, 
for the diagnosis of TB pericarditis.562 Xpert MTB/RIF is highly specific 
(100%); however, it has a sensitivity of 64%, which increases to 78% 
when pericardial biopsy samples are employed.563,564 Pericardial fluid 
culture shows low sensitivity (53%–75%) and it is also time-consuming, 
needing more than 3 weeks to yield results. Interferon gamma offers superior accuracy for the diagnosis of microbiologically confirmed TB pericarditis compared with the adenosine deaminase (ADA) assay and the 
Xpert MTB/RIF test.563 In a meta-analysis, values of uIFN-γ in the pericardial fluid from studies using thresholds of 14–200 pg/mL showed very 
high sensitivity (97%) and specificity (99%) for the diagnosis of TB pericarditis, with a positive likelihood ratio of 187 and a negative likelihood 
ratio of 0.03.565 On the other hand, the tuberculin skin test and IFN-γ 
release assays are of limited value, especially in areas with a high burden 
of TB, since they cannot discriminate between previous exposure to 
Mycobacterium and active disease.566 A detailed approach is outlined 
in Supplementary data online, Table S12. 
Recommendation Table 19 — Recommendations for 
inflammatory cardiomyopathy (see Evidence Table 19) 
Recommendations 
Classa 
Levelb  
Guideline-directed heart failure treatments are 
recommended in patients with inflammatory 
cardiomyopathy to improve and/or stabilize left 
ventricular function. 
I 
C 
Specific medical therapy for the potentially 
underlying systemic disease is recommended in 
inflammatory cardiomyopathy. 
I 
C 
Immunosuppressive therapy, guided by 
endomyocardial biopsy, should be considered in 
virus-negative inflammatory cardiomyopathies to 
suppress the autoimmune response.34,131,551–555 
IIa 
B 
© ESC 2025
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 57 -->

### Page 57

11.1.3. Therapy 
Medical treatment consists of a regimen including rifampicin, isoniazid, 
pyrazinamide, and ethambutol for at least 2 months, followed by isoniazid and rifampicin for an additional 4 months, which is effective in 
treating extrapulmonary TB.1,567 Treatment for ≥9 months gives no 
better results and has the disadvantages of increased cost and poor 
compliance.567 
However, it should be emphasized that, excluding isoniazid, poor 
drug penetration into the pericardial space is a matter of concern, 
also considering the emerging evidence of intrapericardial bacillary 
load and mortality.568 
With the prompt use of antitubercular medications, steroids (oral 
or intrapericardial), and the widespread use of pericardial drainage 
with or without intrapericardial fibrinolysis, the currently reported 
rates of CP are between 5% and 25%.569 Moreover, contemporary 
treatment has accounted for a 20% reduction in all-cause mortality.567,569–572 
Pericardial drainage by any means (pericardiocentesis or pericardial 
window) is recommended as an essential part of the work-up in patients with suspected TB pericarditis, both for diagnostic and therapeutic purposes.1 
Constriction generally develops in up to 50% of patients within 6 months of presentation prior to the introduction of effective TB therapy.1 Appropriate antibiotic therapy is essential to 
prevent this progression.570 In addition, two interventions 
may reduce the incidence of constriction: (i) intrapericardial 
urokinase; and (ii) high-dose adjunctive prednisolone for 
6 weeks.569,573 
However, the coexistence of TB and HIV infection requires special attention. Prednisolone was associated with an increased risk of 
HIV-associated malignancies.569 On this basis, it may be reasonable 
to use adjunctive corticosteroids in patients with TB pericarditis 
without HIV infection and to avoid them in HIV-infected 
individuals.569 
Figure 18 Stages of tuberculous pericarditis.  
Recommendation Table 20 — Recommendations for 
tuberculous pericarditis (see Evidence Table 20) 
Recommendations 
Classa 
Levelb  
Diagnosis and treatment of tuberculous pericarditis and effusion 
Diagnostic pericardiocentesis is recommended in all 
patients with suspected tuberculous pericarditis 
when diagnosis is not confirmed by non-invasive tests 
to identify the aetiological agent in pericardial fluid.570 
I 
C 
Empirical antituberculosis chemotherapy is 
recommended in patients living in endemic areas 
with exudative pericardial effusion after excluding 
other causes to treat the most likely cause.567,570 
I 
C 
Standard antituberculosis multidrug treatment for 
6 months is recommended in patients with 
tuberculous pericarditis for the prevention of 
pericardial constriction.570 
I 
C 
Pericardiectomy is recommended in patients with 
tuberculous pericarditis if the condition is not improving 
or is deteriorating after 4–8 weeks of antituberculosis 
therapy to change the course of disease. 
I 
C 
Adjunctive steroid therapy should be considered in 
HIV-negative cases to prevent the development of 
constrictive TB pericarditis.569 
IIa 
C 
In non-endemic areas a pericardial biopsy may be 
considered in patients with >3 weeks of illness 
without aetiologic diagnosis. 
IIb 
C 
Empirical antituberculosis treatment is not 
recommended in patients living in non-endemic areas. 
III 
C 
© ESC 2025
HIV, human immunodeficiency virus; TB, tuberculosis. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               57


<!-- PAGE 58 -->

### Page 58

11.2. Pericardial involvement in neoplastic 
disease 
11.2.1. Presentation 
Neoplastic pericardial involvement is occasionally manifested by pericarditis or, more commonly, an isolated PEff (usually moderate to 
large, or CTP) with or without evident masses on imaging. It is usually 
related to metastatic lymphatic involvement (especially for lung cancer) or haematogenous spread (especially for breast cancer). In addition, lymphomas, leukaemias, and melanoma may affect the 
pericardium, as may cancer of contiguous organs (e.g. oesophageal 
cancer).574,575 Primary neoplastic disease of the pericardium is rare. 
Pericardial mesothelioma is the most common form, and it may present as ECP or CP in advanced cases. On this basis, the term ‘neoplastic pericarditis’ is often used incorrectly instead of ‘neoplastic 
pericardial effusion’. 
11.2.2. Diagnosis 
The definitive diagnosis is based on the confirmation of malignant infiltration within the pericardial fluid by cytology (pericardiocentesis) 
or pericardial biopsy. A probable diagnosis may be achieved by the 
detection of tumour markers in the pericardial fluid (e.g. CEA, 
CYFRA 21-1, NSE, CA-19-9, CA-72-4, SCC, GATA3, and VEGF), although none of these tumour markers has been proven to be accurate enough for distinguishing malignant from benign effusions.576,577 
Evidence of malignant disease elsewhere and concomitant pericarditis or PEff is also suggestive, although in almost two-thirds of patients 
with documented malignancy, pericardial involvement is caused by 
non-malignant diseases,15 e.g. radiation,578,579 chemotherapy,580 or 
infections. Cytological analyses of pericardial fluid are mandatory 
for the confirmation of malignant pericardial disease.581 Analyses 
of pericardial fluid and less commonly pericardial or epicardial biopsies are essential for the confirmation of malignant pericardial 
disease. 
11.2.3. Therapy 
The management of these patients requires a multidisciplinary approach involving oncologists, cardiologists, and radiotherapists, as 
well as other specific subspecialty experts according to the type of 
cancer. 
General principles of treatment include systemic antineoplastic 
treatment as baseline therapy. Local antineoplastic treatment is based 
on tailored intrapericardial therapy according to the type of tumour 
(e.g. cisplatin is efficacious in lung cancer, thiotepa in breast cancer),582 
and intrapericardial instillation of cytostatic/sclerosing agents to prevent recurrences. Malignant PEffs show a high recurrence rate 
(>50%). Extended pericardial drainage can be necessary in patients 
with suspected or definite neoplastic PEff to prevent effusion recurrence and provide a route for intrapericardial therapy. Additional interventions for recurrent effusions may include pericardiotomy, 
pericardial window, and percutaneous balloon pericardiotomy. All 
techniques are palliative and aimed at improving the quality of life of patients with a poor short-term outcome. 
Radiation therapy is very effective in controlling malignant PEff in patients with radiosensitive tumours, such as lymphomas and leukaemias. 
In clinical practice, management is often palliative at late stages with 
advanced disease, and it is aimed only at the relief of symptoms rather 
than treatment of the underlying disease, considering the prognosis, 
and the overall quality of life of the patient. 
11.3. Post-cardiac injury syndrome 
The term PCIS is an umbrella term indicating a group of inflammatory pericardial syndromes, including late post-acute myocardial 
infarction (post-AMI) pericarditis (or Dressler syndrome), post- 
pericardiotomy syndrome (PPS), and post-traumatic pericarditis 
with or without bleeding. Currently several post-traumatic cases 
are iatrogenic and related to cardiovascular interventions.585,586 
Nowadays, Dressler syndrome appears in <1% of cases, mainly in 
larger infarctions and/or late reperfusion, typically 1–2 weeks after 
AMI.587 Notably, patients with a post-AMI PEff of >10 mm at end- 
diastole should be investigated for a possible subacute heart 
rupture.588,589 
In contrast, cases developing after cardiac device implantation or arrhythmia ablation (e.g. pericarditis appears in ∼10% of cases after AF 
ablation) are becoming increasingly common due to the growing 
number of invasive procedures.586,587,590,591 
Such syndromes are presumed to have an autoimmune pathogenesis 
triggered by pericardial bleeding and/or pleura incision.47,592 An 
immune-mediated pathogenesis is supported by a latent period, 
Recommendation Table 21 — Recommendations for 
neoplastic 
pericardial 
involvement 
(see 
Evidence 
Table 21) 
Recommendations 
Classa 
Levelb  
Pericardiocentesis is recommended for patients with 
cardiac tamponade to relieve symptoms and 
establish the diagnosis of malignant pericardial 
effusion.576,583 
I 
C 
Extended pericardial drainage (3–6 days) is 
recommended in patients with suspected or definite 
neoplastic pericardial effusion to prevent effusion 
recurrence.576,583 
I 
B 
Cytological analysis of pericardial fluid is 
recommended in patients with neoplastic pericarditis 
for the confirmation of malignant pericardial 
disease.581 
I 
C 
Systemic antineoplastic treatment is recommended 
in confirmed cases of neoplastic aetiology to treat 
the primary and secondary metastatic neoplastic 
involvement.582 
I 
C 
Pericardiocentesis should be considered in patients 
with moderate to large pericardial effusion to 
establish the diagnosis of malignant pericardial 
effusion when the diagnosis cannot be reached by 
multimodality imaging.584 
IIa 
C 
Pericardial or epicardial biopsy may be considered in 
patients with suspected malignant pericardial disease 
when the diagnosis cannot be reached by 
multimodality imaging or cytological analysis, to 
confirm the diagnosis. 
IIb 
C 
Intrapericardial therapy, in agreement with the 
oncologist, may be considered in cases refractory to 
systemic antineoplastic treatment. 
IIb 
C 
© ESC 2025
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 59 -->

### Page 59

generally a few weeks, until the appearance of the first manifestations, 
the positive response to anti-inflammatory drugs, and the possibility of 
recurrences. 
11.3.1. Diagnosis 
According to proposed diagnostic criteria, the diagnosis of PCIS may be 
reached in the presence of at least two of the following five criteria: (i) 
fever without alternative causes; (ii) pericardial or pleuritic chest pain; 
(iii) pericardial or pleural rubs; (iv) evidence of PEff; and/or (v) pleural 
effusion with elevated C-reactive protein.593–595 
The rationale for proposing specific criteria is that these syndromes 
may have concomitant pleuro-pericardial involvement and possible pulmonary infiltrates, and are not simply pericarditis.595 Moreover, it is 
sometimes difficult to differentiate PCIS from the simple mechanical 
consequences of surgery (such as early pericardial or pleural effusion). 
The demonstration of inflammatory activity (e.g. C-reactive protein elevation) is essential to establish the diagnosis. Multimodality imaging can 
be helpful for the diagnosis of complicated cases (e.g. loculated effusions, evidence of inflammation). 
11.3.2. Therapy 
The same therapeutic scheme adopted for AP, essentially based on empirical anti-inflammatory therapy, is effective for all forms of PCIS, and 
may improve remission rates and reduce the risk of recurrences. In 
early post-AMI pericarditis, a 5–7-day course of aspirin seems the 
most reasonable option, in association with colchicine.587 
Different treatment strategies (namely aspirin, methylprednisolone, 
dexamethasone, and colchicine) have been adopted for the primary 
prevention of PPS, and the effects of such treatments have been addressed in a meta-analysis that showed that only colchicine was associated with a decreased risk of PPS (OR 0.38), sometimes, however, 
with an increased risk of gastrointestinal side effects.593,594,596–600 
Preventive administration of colchicine can be given after cardiac surgery using weight-adjusted doses (i.e. 0.5 mg once for patients 
≤70 kg and 0.5 mg twice daily for patients >70 kg) and without a loading dose for the prevention of PPS and continued for 1 month.596 
In this guideline document, the LOE for colchicine recommendation 
for the prevention of PPS is based on analysis of the available evidence 
from more than one RCT, systematic reviews and the consensus opinion of the TF members. 
Neither NSAIDs nor colchicine have to be administered for post- 
operative effusions in the absence of systemic inflammation.601,602 
Early post-operative PEffs are relatively common after cardiac surgery, 
and usually disappear spontaneously in 7–10 days.1 Asymptomatic small 
PEffs do not require treatment; however, moderate to large effusions 
(observed in one-third of cases) can progress to CTP at a rate of 
10% within 1 month after surgery and need pericardial decompression.603 Treatment of these asymptomatic effusions by NSAIDs has 
been shown to be ineffective [e.g. diclofenac in the Post-Operative 
Pericardial Effusion (POPE) trial], and may be associated with an increased risk of side effects.601 
The prognosis of PPS is generally good.600 In the largest published 
series on PPS patients after cardiac surgery, complication rates were 
low: <4% for recurrences; <2% for CTP; and no cases of constriction, 
although hospital stay may be prolonged in these patients.592 
Moreover, the development of CP has been reported in ∼3% of 
cases.347 Both early post-AMI pericarditis and Dressler syndrome are 
markers of larger infarct size, but without independent prognostic 
significance.587 
11.4. Pericarditis and autoinflammatory 
diseases 
Compared with the previous guidelines, it has become evident that some 
inflammatory forms of RP share similarities with genetic autoinflammatory diseases characterized by periodic fevers, e.g. FMF and TRAPS.50,51 
These are genetic disorders characterized by mutations of genes involved in the regulation of the inflammatory response, without involvement of specific T cells or autoantibodies.605 These disorders are 
usually detected in the paediatric population, although some patients experience disease onset during adulthood. The most common monogenic 
autoinflammatory syndromes include FMF, in which serositis episodes last 
only 1–3 days, and TRAPS, in which fever and symptoms last for weeks.605 
Mutations associated with these disorders have been reported in up to 
10% of patients with multiple recurrences, especially with a positive family 
history, and a poor response to colchicine.152 Recently, rare deleterious 
MEFV variants were observed more frequently in idiopathic RP than 
in ancestry-matched controls (allele frequency 9/200 vs 2932/129 200, 
P = 0.040).50 These conditions are characterized by the exaggerated production of IL-1 by the inflammasome. Familial occurrence of pericarditis 
has been reported among the relatives of idiopathic RP patients, ranging 
from 4%50 to 10%.113 These data suggest a genetic predisposition in at 
least a subset of patients; counselling may be warranted in these cases. 
11.5. Purulent pericarditis 
Purulent pericarditis, namely the most serious manifestation of bacterial pericarditis, is characterized by the macro- or microscopic presence 
of purulent PEff. It is an exceedingly rare form of pericarditis in the 
Western world, accounting for <1% of AP cases.606 It has a high mortality in untreated cases while, in optimally treated patients, the reported survival rate is approximately 15%–40%.606 
In developed countries, the most common organisms isolated in 
purulent pericarditis include staphylococci and streptococci, while 
Recommendation Table 22 — Recommendations for 
post-cardiac injury syndrome (see Evidence Table 22) 
Recommendations 
Classa 
Levelb  
Anti-inflammatory therapy is recommended in 
patients with PCIS to hasten symptom remission and 
reduce recurrences.292,600 
I 
B 
IL-1 antagonists are recommended in patients with 
refractory PCIS to prevent recurrences and 
progression to constriction.604 
I 
B 
High-dose aspirin is recommended as the first-choice 
anti-inflammatory therapy for post-myocardial 
infarction pericarditis and in patients being already on 
antiplatelet therapy. 
I 
C 
Colchicine, started 48 to 72 h before cardiac surgery, 
should be considered for 1 month in patients after 
cardiac surgery for the prevention of PCIS if there 
are no contraindications and if it is tolerated.594,596 
IIa 
A 
Careful follow-up should be considered in patients 
with PCIS to exclude possible evolution towards 
constrictive pericarditis.347 
IIa 
C 
© ESC 2025
IL, interleukin; PCIS, post-cardiac injury syndrome. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               59


<!-- PAGE 60 -->

### Page 60

the predominant associated lesions are empyema (50%) or pneumonia 
(33%). In immunosuppressed patients or following thoracic surgery, the 
most frequently encountered bacterial/fungal agents are Staphylococcus 
aureus (30%) and fungi (20%), while anaerobic bacteria, originating from 
the oropharynx, have also been reported.607,608 
It should be stressed that in the modern era of iatrogenic and 
HIV-associated immunosuppression, more unusual organisms may account for pericardial infection.1,607 
11.5.1. Presentation 
Purulent pericarditis has generally manifested as a serious febrile disease, 
and the underlying sepsis may predominate, including septic shock.606–608 
Constrictive pericarditis complicates 20%–30% of cases.347 
11.5.2. Diagnosis 
Suspicion of purulent pericarditis is an indication for pericardial drainage 
independently from the haemodynamic status. Surgical pericardial drainage is recommended to allow complete removal of the fluid and prevent 
its organization and progression to constriction. Low pericardial-to-serum 
glucose ratio (mean 0.3) and elevated pericardial fluid white cell count 
with a high proportion of neutrophils (mean cell count 2.8/mL, 92% neutrophils) differentiate purulent from tuberculous (glucose ratio 0.7, mean 
cell count 1.7/mL, 50% neutrophils) and neoplastic pericarditis (glucose 
ratio 0.8, mean cell count 3.3/mL, 55% neutrophils). 
Fluid must be sent for bacterial, fungal, and tuberculous studies along 
with blood and tissue samples, as guided by the clinical presentation.1 
11.5.3. Therapy 
Intravenous antimicrobial therapy should be started empirically until 
microbiological results are available. Afterwards, pathogen-directed antibiotic therapy is warranted based on antibiotic susceptibility.1 The duration of antibiotic therapy should be individualized until fever and clinical 
signs resolve, with the minimum period of administration being 3 weeks. 
Purulent effusions are often heavily loculated and likely to rapidly reaccumulate. Subxiphoid pericardiotomy and rinsing of the pericardial cavity should be considered.15 This allows more complete drainage of the 
effusion, since loculations can be manually lysed. Intrapericardial fibrinolysis is a possible treatment for cases of loculated effusions to achieve adequate drainage.609 Fibrinolysis has been shown to prevent complications 
in approximately 86% of cases without fatal complications.573,609,610 In 
the unfortunate case that percutaneous measures fail to control infection, and worsening HF occurs along with constrictive physiology features, referral to surgical pericardiectomy is advised.610 
11.6. Incessant and recurrent pericarditis 
The TF proposes to adopt the term ‘incessant’ for cases of persistent 
symptoms without clear remission, and thus also to include cases of 
symptom persistence/recurrence during drug tapering. Recognition of 
these cases is of paramount importance, since they can directly progress 
to CP within a few months.104 Recurrent pericarditis is defined as a relapse after a documented first episode of AP, a symptom-free interval, 
complete discontinuation of anti-inflammatory therapy, and evidence 
of subsequent recurrence of pericarditis. Recurrence usually occurs within 18 months from the index episode, and is the most common and 
problematic complication of AP, ranging from 15% to 30% of cases after 
a first episode of pericarditis. It may increase to 50% after a first recurrence in patients with inadequate treatment of the first episode (e.g. 
too fast tapering, not treated with colchicine, treated with corticosteroids).25,611 In developed countries, the aetiology of recurrences is poorly 
known, and most cases are labelled as idiopathic. Historically, most cases 
were probably related to an autoinflammatory/autoimmune pathogenesis. This is based on the inflammatory/non-inflammatory phenotype, 
the latency from the acute attack (several weeks after the index episode), 
the presence of autoantibodies, and the response to anti-inflammatory/ 
immunosuppressive treatments.52,283,284,287 
11.7. Inflammatory and non-inflammatory 
pericardial effusion 
The normal pericardial sac contains 10–50 mL of pericardial fluid, a 
plasma ultrafiltrate that acts as a lubricant between the pericardial 
layers. Any pathological process that causes pericardial inflammation increases the amount of fluid, causing PEff (exudate). Alternative mechanisms causing PEff include decreased reabsorption following increased 
systemic venous pressure, as observed in congestive HF or pulmonary 
hypertension (transudate) or alternatively, decreased lymphatic drainage.612 The regimen of pressures in the epicardium and pericardial cavity is shown in Supplementary data online, Figure S4. 
11.7.1. Classification and aetiology 
The reported incidence and prevalence of PEff in developed countries is 
estimated at 3% and 6%–9%, respectively, based on echocardiographic 
laboratory records.613 Pericardial effusion was detected in 14% of subjects in a prospective registry of consecutive patients who underwent 
chest CT.198 
The classification of PEff is shown in Table 10. Echocardiography provides semiquantitative assessment of the effusion size, which is useful for 
estimating the risk of having a non-idiopathic aetiology and complications 
(see Supplementary data online, Figure S5).105 In the past three decades, 
six major surveys have been published on the characteristics of moderate 
to large PEff (see Supplementary data online, Table S13).556,614–618 
According to these series, many cases remain idiopathic in developed 
countries (up to 50%), while additional aetiologies include cancer 
(10%–32%), infections (15%–30%), iatrogenic causes (15%–20%), and 
connective tissue diseases (5%–15%), whereas TB is the dominant cause 
in developing countries (>60%), where TB is endemic.558 
11.7.2. Presentation 
A significant proportion of patients with PEff are asymptomatic, and PEff is 
an incidental finding during routine examination. The clinical presentation 
of PEff varies according to the speed of accumulation of fluid (see  
Supplementary data online, Figure S4). Classic symptoms include exertional 
dyspnoea progressing to orthopnoea, chest pain, and feeling of fullness. 
Recommendation Table 23 — Recommendations for 
purulent pericarditis (see Evidence Table 23) 
Recommendations 
Classa 
Levelb  
Urgent pericardiocentesis and/or a surgical window 
is recommended in patients with suspicion of 
purulent pericarditis to establish a diagnosis.606 
I 
C 
Intrapericardial fibrinolysis should be considered in 
patients with purulent pericarditis to allow complete 
drainage of purulent fluid and to prevent 
constriction.573,610 
IIa 
B 
© ESC 2025
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 61 -->

### Page 61

Additional symptoms due to the compression of adjacent structures include nausea (diaphragm), dysphagia (oesophagus), hoarseness (recurrent laryngeal nerve), and hiccups (phrenic nerve).118,619 
11.7.3. Diagnosis 
Physical examination may be normal in patients without haemodynamic 
compromise. Echocardiography is the primary diagnostic tool for 
diagnosis, sizing, assessment of haemodynamic effects, and follow-up 
(see Supplementary data online, Figure S5).115,124 Advanced imaging 
(CT and CMR) provides valuable information concerning local inflammation, masses, associated chest abnormalities (e.g. pectus excavatum), 
loculated effusions, and systemic diseases.196,198,620 Pericardial effusion 
is often associated with known or unknown medical conditions (e.g. 
hypothyroidism) in up to 60% of cases, especially if moderate/large.615 
A practical routine evaluation for the triage of PEff is presented in  
Figure 19.1 
Concomitant pericarditis
Treat as pericarditis
Associated systemic disease 
Pericardiocentesis with drainage
Empiric anti-inﬂammatory therapy
Improvement
Outpatient follow-up and treatment 
according to 
speciﬁc aetiology
Pericardial eﬀusion
First-line assessment with history, physical examination, ECG,
chest X-ray transthoracic echocardiography, laboratory assessment 
Cardiac tamponade, symptomatic moderate to large pericardial eﬀusion with suspicion of neoplastic or bacterial aetiology
Admission, 
pericardiocentesis and aetiology search
Large (>20 mm) and chronic (>3 months) eﬀusion
Pericardial window
Treat the systemic 
condition
Symptomatic
Oupatient follow-up
Symptomatic
Fluid re-accumulation
Outpatient follow-up and treatment according to speciﬁc aetiology
Figure 19 Triage and management of pericardial effusion. ECG, electrocardiogram; N, no; Y, yes.   
ESC Guidelines                                                                                                                                                                                               61


<!-- PAGE 62 -->

### Page 62

Patients presenting with PEff without inflammatory marker elevation 
have an increased risk of a neoplastic aetiology (likelihood ratio 2.9).615 
In chronic effusions with no definite aetiology, and without inflammatory markers, empirical anti-inflammatory treatment is futile.1,621 In 
worsening large effusions without evidence of systemic inflammation, 
the exclusion of cancer with advanced imaging (mainly CT) is warranted.196 C-reactive protein should be measured before pericardiocentesis, since it can increase after the procedure.622 Notably, the 
classical Light criteria used for the classification of pleural effusions 
should not be applied to PEff due to the high rate of misclassification 
of fluids as exudates, since pericardial fluid is rich in mesothelial cells, 
proteins, albumin, and lactate dehydrogenase (LDH).623,624 
11.7.4. Therapy 
The treatment of PEff is shown in Figure 19. Therapy of PEff should be 
targeted at the aetiology, as much as possible. In the absence of pericardial inflammation (namely in the absence of C-reactive protein elevation 
and evidence of pericardial inflammation by an imaging technique) anti- 
inflammatory treatment is not recommended. According to recent 
data, the usefulness of pericardial drainage in asymptomatic or oligosymptomatic, large, chronic, idiopathic effusions without evidence of 
pericarditis has been revised.49,621 Conservative treatment improves 
outcomes, the risk of CTP being only 2.2%/year without reported 
deaths.625 In addition, survival after recurrence or complications is 
significantly better in patients treated conservatively without interventions. Nevertheless, if during follow-up the PEff becomes symptomatic 
and haemodynamic impairment is observed by echocardiography, 
drainage is warranted. 
11.7.5. Prognosis and follow-up 
The prognosis of PEff is essentially related to its aetiology.626 Moderate 
to large effusions are more common for specific aetiologies.105,615 In 
general, PEff should be considered as a marker of the severity of the 
underlying disease.584 Small, idiopathic, asymptomatic PEff have an 
overall good prognosis with a very low risk of complications, although 
not all studies concur.613 Those individuals should be reassured about 
the benign nature of the condition, and should not restrict their physical 
activity if C-reactive protein is normal.11 The follow-up of PEff is mainly 
based on the evaluation of symptoms, using focused echocardiography 
to assess size changes, and haemodynamic issues, as well as C-reactive 
protein. Asymptomatic patients with mild idiopathic effusions do not 
generally require specific monitoring. In asymptomatic patients with 
at least moderate effusions, a reasonable follow-up is every 6 months, 
ideally in specialized centres. The latter patients should be instructed to 
seek medical advice in case of symptom appearance, such as dyspnoea 
or fatigue, and/or chest pain suggesting pericarditis. 
11.8. Cardiac tamponade 
Cardiac tamponade is a pericardial syndrome occurring when PEff impairs diastolic filling of the heart until cardiac output is reduced. The 
size of the effusion as well as its distribution may vary. Since the pericardium is relatively stiff, if pericardial fluid collects quickly, such as in haemopericardium, the limit of pericardial stretching is reached quickly with 
volumes of 200–300 mL. In contrast, slowly accumulating PEff may reach 
1 to 2 L before the development of CTP (Supplementary data online,  
Figure S4). This pathophysiology explains that CTP is a last-drop phenomenon. Thus, a small increase of pericardial volume may precipitate the 
syndrome, and the aspiration of small amounts of pericardial fluid with 
pericardiocentesis may greatly improve the clinical condition.118 
Pericardial effusions are usually circumferential, but after trauma or 
cardiac surgery, they may be loculated and even be responsible for localized compression and the development of CTP. 
11.8.1. Presentation 
Beck identified a triad of signs, consisting of hypotension, increased JVP, 
and quiet heart sounds as presenting symptoms.118,619 
This triad was classically identified in ‘surgical tamponade’ with acute 
CTP due to intrapericardial haemorrhage because of trauma, or myocardial/aortic rupture. Beck’s triad may be lacking in patients with ‘medical tamponade’ with slowly accumulating pericardial fluid. Acute CTP is 
usually associated with tachycardia and low blood pressure 
(<90 mmHg) that is only slightly reduced in subacute, chronic tamponade.118,619 On physical examination, classical signs include neck vein distention with elevated JVP, pulsus paradoxus, and diminished heart 
sounds. Pulsus paradoxus is defined as an inspiratory reduction of the 
systolic blood pressure by at least 10 mmHg.118,619 Pulsus paradoxus 
is due to exaggerated ventricular interdependence occurring in CTP, 
when the overall volume of ventricles becomes unable to expand, 
and any change in the volume on one side of the heart causes opposite 
changes on the other side. On ECG, the patient usually shows tachycardia, low QRS voltages, and electrical alternans due to the damping effect 
of pericardial fluid and swinging heart.118,619 
11.8.2. Aetiology and diagnosis 
Cardiac tamponade shares the same causes of PEff. In clinical practice, 
the most common aetiologies include cancer, TB, purulent infections, 
trauma, iatrogenic complications of cardiovascular interventions (e.g. 
ablation of arrhythmias, device implantation, PCIS), acute aortic disease, 
systemic inflammatory diseases, and renal failure.118 In the setting of AP 
with a viral or idiopathic aetiology, CTP is rare (1%–2% of cases) and is 
more common with pericarditis associated with a non-idiopathic aetiology (20%).347 The diagnosis of CTP is a clinical diagnosis based on 
the combination of a suggestive history, symptoms, signs, and imaging 
confirmation by echocardiography (Table 17).118 
Table 17 Echocardiographic signs of cardiac tamponade 
Echocardiographic feature 
Sensitivity 
Specificity  
Large pericardial effusion with swinging 
heart 
n.a. 
n.a. 
Diastolic collapse of the RA 
50%–100% 
33%–100% 
Duration of diastolic collapse of the RA as 
a ratio of the cardiac cycle length >0.34 
>90% 
100% 
Diastolic collapse of the RV 
48%–100% 
72%–100% 
Respiratory changes of the mitral E 
velocity >25%–30%, tricuspid E velocity 
>40%–60% 
n.a. 
n.a. 
Inferior vena cava plethora (dilatation 
>20 mm and <50% reduction of diameter 
with respiratory phases), as well as hepatic 
vein dilatation 
97% 
40% 
© ESC 2025
n.a., not available; RA, right atrium, RV, right ventricle.


<!-- PAGE 63 -->

### Page 63

The diagnosis of CTP identifies high-risk patients with an increased 
risk of complications during follow-up and a high probability of a non- 
viral aetiology. The patients should be admitted for therapy and 
monitoring.1,105 
The definitive therapy is pericardiocentesis, which should be performed urgently according to the clinical presentation. 
11.8.3. Therapy 
The treatment for CTP is drainage of the pericardial fluid, preferably by 
needle pericardiocentesis with the use of echocardiographic or fluoroscopic guidance, and should be performed without delay in unstable patients. Alternatively, drainage is performed by a surgical approach, 
especially in situations such as purulent pericarditis, or urgent situations 
with bleeding into the pericardium. 
Pericardiocentesis should be performed by experienced operators 
trained/certified in acute cardiovascular care and carries a variable 
risk of complications from 4% to 10%, depending on type of monitoring, operator’s skill, and setting (emergent vs urgent vs elective). The 
most common complications include arrhythmias, coronary artery or 
cardiac chamber puncture, haemothorax, pneumothorax, pneumopericardium, and hepatic injury.1 Mechanical ventilation with positive airway pressure should be avoided in CTP. In addition, diuretic therapy 
should be avoided, and temporary fluid administration can be helpful 
to stabilize the patient while waiting for urgent pericardiocentesis. 
11.8.4. Outcomes and prognosis 
The prognosis of CTP is essentially related to its aetiology. Cardiac tamponade in patients with cancer and metastatic involvement of the pericardium has a bad short-term prognosis, since this is a sign of advanced 
disease. In contrast, patients with CTP and a final diagnosis of idiopathic 
pericarditis generally have a good long-term prognosis.1,105 
11.9. Pericardial constriction and 
constrictive pericarditis (calcified and 
non-calcified) 
11.9.1. Introduction 
Pericardial constriction is a chronic condition usually characterized by a 
thickened, fibrotic, and often calcified pericardium that leads to impaired diastolic filling of the heart. Constrictive pericarditis is 
constriction associated with pericarditis.114,119,347 There is a high risk 
of progression in bacterial pericarditis (20%–30%), especially purulent 
pericarditis, intermediate risk in immune-mediated pericarditis and 
neoplastic pericardial diseases (2%–5%), and a low risk in viral and idiopathic pericarditis (<1%).347 Cases of CP after pericardiectomy have 
been reported, especially after partial pericardiectomy.627–630 In developed countries, the most common reported causes are: viral or idiopathic (42%–49%); post-cardiac surgery (11%–37%); post-radiation 
therapy, mostly for breast cancer or Hodgkin’s disease (9%–31%); connective tissue disorders (3%–7%); post-infectious causes (purulent pericarditis or TB in 3%–6%); and miscellaneous causes (<10%). TB is a 
major cause of CP in developing countries.630,631 
11.9.2. Presentation 
The classical clinical presentation comprises signs and symptoms of 
right HF with preserved biventricular function without previous or concomitant myocardial disease. Subacute/chronic inflammatory pericarditis can evolve into CP, and the duration of progression from initial 
pericardial inflammation and the onset of constriction is variable.347 
Systolic dysfunction due to myocardial fibrosis or atrophy can aggravate 
the haemodynamic impairment in more advanced cases. 
In up to 20% of cases, constriction might be present with normal 
pericardial thickness, while advanced and classic cases demonstrate 
prominent pericardial thickening and calcifications.119 
11.9.3. Diagnosis 
The diagnosis is made by multimodality imaging methods, such as echocardiography, CT, and CMR (Figure 13). Cardiac catheterization should 
be considered only if non-invasive multimodality imaging methods are 
inconclusive.115,124,632,633 The Mayo Clinic has proposed specific diagnostic criteria, based on echocardiography to diagnose CP, that have 
been confirmed by other centres. They include the presence of septal 
bounce or ventricular septal shift with either medial e’ of >8 cm/s or 
hepatic vein expiratory diastolic reversal ratio of >0.78 (sensitivity 
87%, specificity 91%; specificity may increase to 97% if all criteria are 
present with a corresponding decrease of sensitivity to 64%). In addition, respirophasic variation E-wave mitral inflow of >25%/tricuspid inflow of >40% can be recorded in these patients632,634 (see  
Supplementary data online, Figures S1, S5, and Table S14). The main reported constrictive syndromes are shown in Table 18. 
Table 18 Definitions and therapy of main constrictive pericardial syndromes 
Syndrome 
Definition 
Therapy  
Transient constriction  
(d.d. permanent constrictive pericarditis, restrictive CMP) 
Reversible pattern of constriction following 
spontaneous recovery or anti-inflammatory 
therapy 
A 3–6 month course of empirical 
anti-inflammatory medical therapy 
Effusive–constrictive pericarditis 
(d.d. cardiac tamponade, constrictive pericarditis) 
Failure of the right atrial pressure to fall by 50% or 
to a level <10 mmHg after pericardiocentesis 
May be diagnosed also by non-invasive imaging 
Pericardiocentesis followed by medical therapy 
Surgery for persistent cases 
Chronic constriction  
(d.d. transient constriction, restrictive CMP) 
Persistent constriction after 3–6 months 
Radical pericardiectomy, medical therapy for 
advanced cases or high risk of surgery or mixed 
forms with myocardial involvement 
© ESC 2025
CMP, cardiomyopathy; d.d., differential diagnosis.   
ESC Guidelines                                                                                                                                                                                               63


<!-- PAGE 64 -->

### Page 64

11.9.4. Therapy 
Medical therapy is considered for specific aetiologies, such as TB, 
to prevent progression to constriction.558 Antituberculosis drugs 
may significantly reduce the risk of constriction from >80% 
to <10%.569 Anti-inflammatory therapy may help to resolve transient constriction in 10%–20% of cases of AP.121,122 In such cases, 
to identify patients with potentially reversible forms of constriction, pericarditis should be excluded by testing markers of inflammation (e.g. C-reactive protein) or looking for imaging evidence of 
pericardial inflammation (e.g. pericardial oedema and/or LGE on 
CMR). 
In advanced cases, medical therapy is supportive of controlling symptoms of congestion, but surgery should never be delayed to improve 
outcomes. 
Pericardiectomy is the standard therapy for symptomatic chronic 
constriction without inflammation or not responding to anti- 
inflammatory therapy (see Section 6.4.2). For milder disease or more 
advanced disease, or for those with radiation-induced disease, reduced 
EF, or advanced renal disease, caution is necessary. Radical pericardiectomy rather than anterior phrenic-to-phrenic pericardiectomy is warranted for the best outcomes.311,635–637 
In general, pericardiectomy has been seen as a high-risk surgery with 
operative mortality of 6%–10%. However, recent studies show better 
results for early surgery in high-volume centres. The risk is related to 
the aetiologies and other comorbidities. Idiopathic causes have the lowest risk of <1.5%.638–640 
11.10. Effusive–constrictive pericarditis 
11.10.1. Introduction 
In ECP, pericardial fluid is present, and the scarred pericardium puts 
pericardial fluid under increased pressure, constricts the cardiac volumes, and leads to signs of CTP.116,117 Classically it is defined haemodynamically as failure of the RAP to fall by 50% or to a level below 
10 mmHg after pericardiocentesis.117 Modern multimodality imaging 
allows a non-invasive diagnosis without cardiac catheterization. 
11.10.2. Aetiology 
Limited data have been published on ECP, and it appears to be a common condition in developing countries.117 Idiopathic cases are most 
commonly found in developed countries, while TB appears to be the 
most common cause in developing countries. The other reported 
causes are neoplasia, radiation, chemotherapy, infections (mainly TB 
and purulent type), and post-surgical pericardial disease.641 
11.10.3. Presentation 
Clinical features of either CP or CTP, or sometimes both, are typically 
present in patients with ECP. In patients who appear to have uncomplicated CTP, the diagnosis usually becomes evident during pericardiocentesis.117 Tricuspid regurgitation or right HF may cause persistently 
elevated RAP after efficient pericardiocentesis. 
11.10.4. Diagnosis 
To diagnose ECP, non-invasive imaging may be valuable.641 Thickening of 
the epicardial–pericardial layer is responsible for the constrictive component. After pericardiocentesis for CTP, careful detection of constriction 
on Doppler findings can be reported.124 Without haemodynamic monitoring, ECP can also be suspected on echocardiography and CMR (see  
Supplementary data online, Table S14). Cardiovascular magnetic resonance may provide helpful information, especially in differentiating constriction from RCM (Table S14). An accurate evaluation of ventricular 
interdependence and septal bounce can be made by assessing ventricular 
coupling with echocardiography and/or real-time cine CMR.115 
Echo-Doppler findings indicating effusive constriction may be detected 
prior to pericardiocentesis.116,124 Currently, the diagnosis can be made 
using multimodality imaging without cardiac catheterization. 
11.10.5. Treatment 
Effusive constriction can often resolve spontaneously or be treated with 
anti-inflammatory therapies in the case of evidence of transient constriction.641 In resistant cases, visceral pericardiectomy must be performed, 
since the epicardial layer is responsible for constricting the heart. The visceral 
component of pericardiectomy requires sharp dissection of many small fragments until ventricular motion is improved. Only pericardial centres with experience and competency should perform pericardiectomy for CP. 
12. Age- and sex-related aspects in 
inflammatory myopericardial 
syndrome 
12.1. Sex distribution 
Acute myocarditis is more prevalent in males (75%–84%).17,28,73,78,642 
On the contrary, the male-to-female ratio is similar in fulminant cases 
(46% females).56,75,643 Sex differences in pericarditis are less evident, 
Recommendation Table 24 — Recommendations for 
constrictive pericarditis (see Evidence Table 24) 
Recommendations 
Classa 
Levelb  
Diagnosis 
Multimodality imaging is recommended in all 
patients with suspected constrictive pericarditis to 
make the diagnosis and assess pericardial 
thickening, calcifications, and active  
inflammation.632 
I 
C 
Cardiac catheterization for haemodynamic 
assessment should be considered in patients with 
suspected constrictive pericarditis when 
multimodality imaging is inconclusive.633 
IIa 
C 
Therapy 
Anti-inflammatory therapy is recommended in 
haemodynamically stable patients with a transient or 
new diagnosis of constriction with concomitant 
evidence of pericardial inflammationc to prevent 
progression to constriction and avoid 
pericardiectomy.122,123 
I 
C 
Pericardiectomy is recommended in patients with 
permanent constriction if there is no active 
inflammation or anti-inflammatory treatment is not 
successful after 3–6 months.635,636 
I 
C 
© ESC 2025
CMR, cardiovascular magnetic resonance. 
aClass of recommendation. 
bLevel of evidence. 
ci.e. C-reactive protein elevation or pericardial enhancement on CMR.


<!-- PAGE 65 -->

### Page 65

with some studies showing a mild prevalence in males of 59% in AP.37 
Males aged 16–65 years are at higher risk of pericarditis (relative risk 
2.02) than females. On the other hand, the probability of pericarditis 
recurrence is higher in females (HR 1.67), probably due to the higher 
frequency of specific causes (e.g. autoimmune diseases).105 
12.2. Paediatric patients 
12.2.1. Myocarditis 
The annual incidence of myocarditis during childhood is between 1 and 
2 cases per 100 000 children.21,644,645 In children <6 years of age, the 
sex distribution was balanced, 50% each,20 but boys had a significantly 
higher incidence at ages 6 to 15 years.21 
The proposed diagnostic approach in adults applies also for children, 
including CMR (e.g. in the MYKKE registry).646 
There are conflicting data regarding the complication rates of EMB in 
children, with some studies reporting similar incidence of complications 
as in adults, both around 5%, mainly from RV sampling.40,63 Particular 
care should be taken in children aged <1 year and in the case of LV biopsies with reported complication rates up to 30%.213 
In particular, very young children are predisposed to severe myocarditis. Critically ill children admitted to the intensive care unit (ICU) 
mostly survived, if receiving high-resource therapies, including 
MCS.647 In a prospective multicentre registry it was shown that in acute 
HF and FM, MCS including VAD improved survival.648 Similar results 
have also been reported from Japan.649 
In infants, enteroviruses, such as Coxsackievirus, were found more 
commonly than in adults.649 A presumed viral aetiology was identified 
in 11%–50%,40,63 with a death or HT rate of 2%, similar to adults.21 In 
biopsy-proven myocarditis, the HT rate rises to 7%, and the mortality 
rate increases to 4%–6%.40 
Therapy for myocarditis in children is not well defined. In a 
meta-analysis evaluating corticosteroids, no mortality reduction was 
observed, but a significant improvement in LVEF was reached with 
the use of steroids in other studies.650–652 In a meta-analysis evaluating 
IVIG,628 treatment was not associated with better survival. This was 
also supported by a prospective trial653 and a multicentre cohort 
study.654 On the contrary, another meta-analysis655 in FM concluded 
that IVIG therapy (usually 1–2 g/kg over 24–48 h) significantly reduced 
in-hospital mortality and improved LVEF. 
Genetic evaluation might help in the future in differentiating subsets 
of children and tailoring therapies.93 
12.2.2. Pericarditis 
In children aged 12 years or less, the incidence of AP was 2.8/100 000 in a 
population study from 2009 to 2021.644 The diagnostic criteria (see  
Table 4), aetiologies, and risk of recurrences (see Tables S2 and S3) are 
similar to those reported in adults (see Supplementary data online,  
Table S1). Most paediatric cases of pericarditis are related to PPS, particularly after atrial septal defect closure. Compared with adults, children more 
commonly have an inflammatory phenotype.656 Non-steroidal anti- 
inflammatory drugs remain the mainstay of therapy at high dosages (see  
Supplementary data online, Table S15). Most paediatricians avoid aspirin. 
Colchicine halved recurrences in children, similarly as for adults.656,657 
The use of corticosteroids should be restricted even more than in adults, 
given that their side effects (including striae rubrae and growth impairment) are particularly deleterious in growing children. Anti-interleukin-1 
agents have been used for the first time in children with autoinflammatory 
diseases and then adopted for RP in them, representing a new therapeutic 
option, especially if they are corticosteroid-dependent. However, it is 
often difficult to withdraw these drugs when clinical remission is achieved; 
for instance, in one study only 15% of children were able to stop anti-IL-1 
agents after a mean follow-up of 2.6 years.658 Few paediatric patients were 
enrolled in RCTs testing anakinra and rilonacept.283,284 
12.3. Pregnancy, lactation, and 
reproductive issues 
There is very limited published evidence on this topic. There are only 
case reports for myocarditis,659–663 and one case series describing 
pregnant women with RP.664 Pregnancy-associated myocarditis is described in Section 9.7. Pericardial effusion is the most common manifestation of pericardial diseases during pregnancy. Effusions during 
pregnancy are typically benign, mild or moderate, and well tolerated, 
with spontaneous resolution after delivery, and no specific treatment 
is required in such cases. However, PEff may be associated with pre- 
eclampsia.665 Acute pericarditis is the second most common condition. 
Pre-conception counselling is essential in women of childbearing age 
with RP or previous myocarditis. In such cases, pregnancy should be 
planned in a phase of disease remission, and therapy should be reviewed. Pre-conception assessment should include multidisciplinary 
evaluation. Echocardiography is the preferred imaging method, while 
X-ray, CT scan, and CMR can be used in selected cases.666 
In patients with IMPS, vaginal delivery is not excluded in uncomplicated cases, while Caesarean section may be required in the presence 
of haemodynamic instability.666 Appropriate follow-up with a multidisciplinary team with experience in the field is recommended throughout 
pregnancy to ensure good maternal and foetal outcomes. 
High-dose aspirin or NSAIDs, such as ibuprofen and indomethacin, 
can be used up to the 20th week of gestation. Corticosteroids at the 
minimal effective dose can be given in patients with active pericarditis 
throughout pregnancy along with NSAIDs and in selected cases colchicine. Azathioprine and IVIG are compatible with pregnancy and breastfeeding. All these medications, apart from high-dose aspirin, may be 
used during lactation. Colchicine is compatible with pregnancy and 
breastfeeding, and it can be continued throughout pregnancy to prevent recurrences.664,667–669 The use of IL-1 blockers during pregnancy 
is controversial. Available literature data seem encouraging; however, 
the relevant studies are scant and retrospective. Despite the limited evidence, anakinra may be continued through conception, pregnancy, and 
lactation in women with rheumatic and musculoskeletal diseases who 
are not able to use alternative therapies.668–670 More details regarding 
drug dosages can be found in Supplementary data online, Table S16. 
There are no specific limitations for men with pericarditis who are 
planning to have children because they can safely continue 
therapy.667,668 
Recommendation Table 25 — Recommendations for 
pregnancy, lactation, and reproductive issues (see  
Evidence Table 25) 
Recommendations 
Classa 
Levelb  
Pre-conception counselling is recommended in 
women with recurrent pericarditis or myocarditis to 
assess disease activity and to review therapy. 
I 
C 
NSAIDs should be considered in pregnant patients 
with pericarditis until the 20th week to treat an 
incessant/recurrent course.664 
IIa 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                               65


<!-- PAGE 66 -->

### Page 66

12.4. The elderly 
Myocarditis is more prevalent in young people, with a median age between 20 and 40 years.28,55,63,73 In a Swedish study, 64% patients 
were younger than 50 years of age. In this study, HF/DCM and deaths 
occurred more commonly in patients aged >50 years.17 Myocarditis is 
probably more commonly related to drugs in the elderly, e.g. ICIs28,495 
and clozapine.508 Age- and sex-based differences have been evaluated in 
two studies with AP, and one study with RP.45,102,671 In these studies, 
elderly patients less often had chest pain, fever, ST elevation, and PR depression. They had lower C-reactive protein values but dyspnoea, AF, 
and PEff were more common. Moreover, they received glucocorticoids 
more commonly, and had a lower risk of recurrences compared with 
younger patients. In the elderly, therapy compliance may be problematic, because of cognitive impairment and comorbidities, but the strongest predictor of non-adherence is the number of medications.672 
Non-steroidal anti-inflammatory drugs should be used cautiously; dosing should be adapted (e.g. colchicine dose should be halved in some 
cases), and attention should be paid to evaluate renal impairment and 
drug interactions. 
12.5. Physical activity in inflammatory 
myopericardial syndrome 
Patients with active IMPS are advised to restrict physical activity. It has 
been proposed that exercise can aggravate myocardial and pericardial 
inflammation through several mechanisms, including a tachycardia- 
mediated process. The importance of controlling heart rate is confirmed by observational studies, in which the empirical use of 
β-blockers to control heart rate in patients with pericarditis improved 
symptom control.274 Previous recommendations have made distinctions between athletes and non-athletes, providing arbitrary times for 
abstention from 3 to 6 months. This TF recommends an individualized 
approach, based on remission times. A complete clinical remission 
should be considered in athletes/non-athletes with normalization of 
symptoms, biomarkers, and imaging. 
During the acute stage of myocarditis, patients are advised to rest 
completely, since exercise has been associated with arrhythmias and 
SCD. To ensure resolution of the disease, recovery should be monitored, including clinical assessment, rhythm control, laboratory analysis, 
and multimodality imaging (see Table 15). A personalized prescription 
of exercise should be performed, based on the patient (athletes, non- 
athletes), and type of exercise. 
12.5.1. Mental health effect of restricting exercise 
Exercise restriction can affect patient mental health, especially in children and young adults. It can lead to frustration, sadness, and depression in patients. Freedom to exercise should be approached with 
shared decision-making, taking into account the risk vs benefit ratio in 
the single case. 
12.6. Multidisciplinary teams for the 
management of inflammatory 
myopericardial syndrome 
It is recommended to have a multidisciplinary team for high-risk cases 
with IMPS. The team should be composed of a clinical cardiologist, a 
CMR imaging specialist with expertise in IMPS, a pathologist with expertise in cardiovascular diseases, and additionally, depending on the 
case, a rheumatologist (or clinical immunologist), an infectious disease 
specialist, a geneticist (or a cardiologist with expertise in genetics), 
interventional cardiologists (including electrophysiologists), and a cardiac intensive care specialist. A cardiac surgeon might be involved subsequently when interventional or surgical decisions are anticipated. 
More details are given in Figure 20. It is of paramount importance 
that physicians develop competence and skills in IMPS to allow timely 
diagnosis and therapy for patients, since mixed forms are common in 
clinical practice. Patient involvement is important, particularly when 
the evidence is scarce to foster shared decision-making.375,673,674 
Anti-inflammatory therapies should be considered in 
patients with pericarditis during lactation to treat and 
prevent pericarditis with timing adjusted to reduce 
drug exposure of the breastfed infant. 
IIa 
C 
During pregnancy and breastfeeding, corticosteroids 
at the minimal effective dose (preferably up to 20 mg 
prednisone daily) should be considered in patients 
with active pericarditis, despite NSAID (if feasible), to 
prevent an incessant/recurrent course.664 
IIa 
C 
Colchicine may be considered in pregnant patients 
with pericarditis, especially in patients already 
receiving this drug to prevent recurrences. 
IIb 
C 
Anakinra may be considered through pregnancy and 
lactation in pregnant patients with recurrent 
pericarditis who are not able to use alternative 
therapies to prevent an incessant/recurrent course. 
IIb 
C 
© ESC 2025
NSAID, non-steroidal anti-inflammatory drug. 
aClass of recommendation. 
bLevel of evidence.  
Recommendation Table 26 — Recommendations for 
physical activity and myocarditis/pericarditis (see  
Evidence Table 26) 
Recommendation 
Classa 
Levelb  
Restriction of physical exercise until remission, for at 
least 1 month, is recommended in athletes and 
non-athletes after IMPS using an individualized 
approach to accelerate recovery. 
I 
C 
© ESC 2025
IMPS, inflammatory myopericardial syndrome. 
aClass of recommendation. 
bLevel of evidence.  
Recommendation Table 27 — Recommendations for 
multidisciplinary teams in myopericardial syndromes 
(see Evidence Table 27) 
Recommendations 
Classa 
Levelb  
A multidisciplinary team discussion at a referral 
centre is recommended in patients with high-risk/ 
complicated IMPS to provide a patient-tailored 
approach.375,673 
I 
C 
© ESC 2025
IMPS, inflammatory myopericardial syndrome. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 67 -->

### Page 67

### 13 Advice for patients

Specific patient education is mandatory for patients with IMPS. Advice 
should address the causes, rationale for treatment, possible complications, and outcomes. Inflammatory myopericardial syndrome affects 
young patients and may severely affect their quality of life. Specific advice should be provided on the need for rest during the acute phase of 
the disease, and the timing for return to physical activity and work, as 
well as benefits and risks associated with tailored immunosuppressive/immunomodulatory therapies, and when to contact the multidisciplinary team. Advice must be tailored to the specific social situation. 
Suitable language should be used, recognizing the patient’s educational 
status. Clarification based on images is preferrable. Care should be taken not to aggravate anxiety unnecessarily. An additional description 
and advice for patients with IMPS is provided in Supplementary data 
online, Section 8, Figure S6, and Table S17. A separate document dedicated to patients has been developed. 
14. Tertiary referral centres for 
inflammatory myopericardial 
syndrome: feature and volume of 
activity 
14.1. Tertiary care centres 
Tertiary care centres of excellence are extensive, renowned healthcare 
facilities that house specialized cardiology departments equipped to 
manage patients with IMPS. Leading institutions are recognized for their 
cardiovascular expertise and often handle patients with complex disease.674 Such centres have significant expertise in the diagnosis and 
therapy of myocarditis and pericarditis and are actively involved in research. They should be the referral centre of choice for complicated 
cases that cannot be managed by regional centres. Endomyocardial biopsy referral centres for deep investigation of EMB samples, including 
immunochemistry and molecular testing, should be identified at regional or national level. 
14.2. Inflammatory myopericardial 
syndrome in regional centres 
Most uncomplicated cases can be handled by regional centres, and depending on the healthcare systems, in outpatient departments. 
However, the crucial factor is the local expertise. At the same time, 
those with more severe pericarditis or myocarditis might need treatment at a hospital or tertiary care referral centre that has advanced 
multimodality imaging capacity and access to new therapeutic 
agents.674 
14.3. Hub-and-spoke model 
These centres should be capable of managing all care levels and adopt a 
hub-and-spoke model. Regardless of where care is provided, the goal is 
to sustain communication and collaboration throughout all healthcare 
system levels. The hub-and-spoke model aims to ease patient access 
to suitable care levels, promote care co-ordination, and drive quality 
enhancement for all patients with IMPS.674,675 









	






	

	

Figure 20 Multidisciplinary teams for inflammatory myopericardial syndrome. aFull team—tailored to the specific case.   
ESC Guidelines                                                                                                                                                                                               67


<!-- PAGE 68 -->

### Page 68

14.4. Teamwork, competencies, and 
advances in imaging techniques 
Building a contemporary multidisciplinary team requires knowledge of 
recent advancements in imaging techniques, as well as evidence-based 
strategies for drug, interventional, and surgical therapies.63,674–676 
The conventional organization of academic or practice departments often operates in isolation, hindering the requirements of diseases that 
demand the insights and skills of a diverse expert panel. These centres 
should endorse a comprehensive team setup that encourages regular, 
ongoing communication among all members. The role of physician-led 
vs nurse-led tertiary centres should be explored further674,675 in view 
of the increasing number and complexity of these patients, and the utility of monitoring inflammatory markers and serial monitoring of cardiac 
imaging, even in an outpatient setting. 
15. Key messages 
The recognition of the whole spectrum of IMPS is increasing within the 
medical community. This is based on a deeper understanding leading to 
a more systematic evaluation, as well as more data being generated by 
prospective trials. Although these entities have been explored for some 
time, the COVID-19 pandemic was the main trigger to increase the 
awareness on the spectrum of disease. Advanced multimodality imaging 
technologies, including CMR, allow a patient-tailored diagnostic and 
therapeutic approach. A major diagnostic paradigm change is the capability of reaching a clinical diagnosis of certainty by non-invasive multimodality imaging (CMR for myocarditis), while EMB remains important 
in selected intermediate- and high-risk cases, if a targeted specific therapy, based on specific histotypes or aetiologies, is needed. 
15.1. Aetiology 
Inflammatory myopericardial syndrome is a spectrum of inflammatory 
diseases with some common aetiologies, either infectious or non- 
infectious, that can affect either the myocardium (myocarditis) or pericardium (pericarditis) in isolated forms, or combined (myopericarditis 
and perimyocarditis). 
15.2. Clinical presentation and diagnosis 
In a large percentage of cases, myocarditis and pericarditis have a chest 
pain presentation, and generally preserved biventricular function with 
good outcomes. For myocarditis, complicated forms include those presenting with severe HF and arrhythmias. Nevertheless, uncomplicated 
presentations may also develop life-threatening complications, albeit 
less commonly, and therefore also may need fast management. 
For pericarditis, complicated cases include those with an incessant or 
recurrent course. Many cases with persistent symptoms may show 
constrictive physiology, which can be reversible after appropriate medical therapy. The diagnosis of non-high-risk cases is based on clinical 
evaluation, including ECG and biomarkers, with non-invasive confirmation of the clinical suspicion by evidence of inflammatory involvement 
using multimodality imaging (mainly echocardiography and CMR). 
Endomyocardial biopsy is recommended for intermediate- and high- 
risk cases on a case-by-case decision, only when results are expected 
to change management. 
15.3. Therapy 
The treatment of uncomplicated IMPS is empirical, aiming at the control 
of symptoms and prevention of complications. Anti-inflammatory 
drugs and colchicine are useful to control chest pain, while additional 
therapies should be guideline-directed for specific complicated courses. 
If a specific aetiology is identified, treatment should be targeted at the 
specific cause. In all cases of IMPS, restriction of physical activity is recommended in the acute phase, while return to work and physical activity should be individualized according to clinical remission times. 
15.4. Prognosis and outcomes 
The prognosis of IMPS varies. Most patients presenting with chest pain 
have a favourable outcome, although recurrences, especially for pericarditis, may severely affect the quality of life of patients and require 
long-term follow-up. For complicated cases of myocarditis with HF 
and arrhythmias, a tailored and individualized approach is warranted. 
Such patients require long-term follow-up, usually lifetime monitoring. 
15.5. Multidisciplinary team 
Management of patients with IMPS should usually be guided by a multidisciplinary team, which should be tailored to the specific patient. This 
team should be composed of different clinicians, all with expertise in 
cardiovascular diseases (e.g. imaging experts, a pathologist, a rheumatologist, an infectious disease specialist, a geneticist, interventional cardiologists, intensive care specialists, and surgeons). It is of paramount 
importance that physicians develop competence and skills either in 
myocarditis or pericarditis to allow timely diagnosis and therapy for patients, because mixed forms are common in clinical practice. 
16. Gaps in evidence 
The field of IMPS has significant knowledge gaps across all aspects, from 
pathogenesis to therapy. However, growing awareness has led to numerous ongoing studies. Advances in multimodality imaging have enabled a more comprehensive and non-invasive understanding of 
disease progression, opening the way to patient-tailored approaches. 
Despite these advancements, large-scale prospective multicentre trials 
with predefined outcome measures are lacking. These uncertainties are 
especially pronounced in chronic conditions, as well as in specific patient groups, such as children, women of childbearing age, during pregnancy, lactating women, and in the elderly. 
A further challenge is the handling of the return to work and physical 
activity as there is a need for a patient-specific approach, taking into 
consideration the individual risk. Lessons learned from other diseases 
should lead to less restrictive guidance in comparison with previous 
advice. 
16.1. Myocarditis 
Knowledge about myocarditis has evolved during recent years, as the 
different mechanisms are better understood. Several causes, such as 
viral and toxic ones, including chemotherapy, as well as systemic disorders, have been investigated, and targeted therapeutic approaches 
were proposed. However, further research into specific therapy is 
needed based on advanced diagnostic approaches. 
Nevertheless, a specific challenge for myocarditis is related to the 
low frequency of complications and the high rate of spontaneous remission. On this basis, clinical trials on medical therapy for myocarditis 
might be currently underpowered to assess the clinical benefit of a specific treatment with small sample sizes. In addition, many antiviral therapies are off-label for myocarditis and controlled trials are missing.


<!-- PAGE 69 -->

### Page 69

Currently, quantitative immunohistochemistry criteria for the diagnosis of LM are under discussion among cardio-pathologists to present 
more definite criteria for EMB. 
Furthermore, a better understanding of the pathogenic and prognostic role of viral loads is needed (e.g. active/causative vs latent/innocent 
bystanders in cardiac viral infections). 
Moreover, the role of genetic predisposition in recurrent myocarditis is not thoroughly clarified. Research into the role of genetic predisposition is evolving to change the classification of disease and may 
influence therapeutic pathways in the future. An increase of ‘overlapping’ conditions, especially DCM and ARVC, can be expected and 
may change our understanding of the disease in the future. 
That means, more research is warranted on the prognosis and SCD 
risk stratification. 
16.2. Pericarditis 
There are significant knowledge gaps in individualized treatment and 
pathogenesis of various types of pericarditis, as well as the understanding of the interaction among genetic background, inflammation, and 
autoimmune mechanisms. Better knowledge of the pathogenesis of recurrences may also help to develop more targeted and individualized 
therapies. 
The genetic background requires further evaluation in complicated, 
recurrent cases and could be helpful to elucidate the mechanisms leading to incessant/recurrent forms. New therapeutic options should also 
be considered and evaluated in clinical trials to explore new drugs for 
more complicated, incessant, or recurrent cases to develop a more individualized and efficacious approach for the treatment of pericarditis. 
A significant management issue is the treatment of patients not responding to colchicine and anti-IL-1 agents, as well as the causes of 
drug dependence to maintain stable clinical remission, such as for corticosteroids and anti-IL-1 agents. 
Additional research is also warranted to understand the prognostic 
significance of persistent LGE of the pericardium. 
There are limited data to support the best timing of return to work 
and physical activity, and further research is needed on this topic with 
appropriate clinical trials or observational studies. 
17. Sex differences 
There is limited published evidence on this topic. Inflammatory myopericardial syndrome seems to affect males more than females from 
a young age. Myocarditis complicated by VA is more common in males, 
while in females, a relatively higher proportion of cases presents with 
complicated forms compared with males, and systemic autoimmune 
disorders are more commonly diagnosed. This was addressed in the 
relevant sections. The diagnostic approaches are similar, but care 
should be taken when applying normal values, especially in imaging. 
Medication should be adapted in women of childbearing age, pregnancy, 
and during lactation (more details are specified in specific sections). 
18. ‘What to do’ and ‘What not to 
do’ messages from the Guidelines 
Table 19 lists all Class I and Class III recommendations from the text 
alongside their level of evidence. 
Table 19 ‘What to do’ and ‘What not to do’ 
Recommendations 
Classa 
Levelb  
Recommendations for clinical evaluation of myocarditis and pericarditis 
Complete clinical evaluation, including history, physical examination, chest X-ray, biomarkers, ECG, and echocardiography is recommended 
in all patients with a suspicion of myocarditis and/or pericarditis for the initial diagnostic assessment. 
I 
C 
CMR is recommended in patients with the clinical suspicion of myocarditis (using updated LL criteria) and/or pericarditis for the 
non-invasive diagnosis of inflammatory reaction. 
I 
B 
Hospital admission is recommended for patients with high-risk pericarditis for monitoring and treatment. 
I 
B 
Hospital admission is recommended for patients with moderate- to high-risk myocarditis for monitoring and treatment. 
I 
C 
EMB is recommended in patients with high-risk myocarditis and/or haemodynamic instability, and/or in patients with intermediate-risk 
myocarditis not responding to conventional therapy in order to detect a specific histologic subtype and to assess the presence of viral 
genome for treatment. 
I 
C 
Invasive coronary angiography or coronary CT, depending on clinical likelihood, is recommended in patients with IMPS if an acute coronary 
syndrome is suspected to rule out obstructive coronary artery disease. 
I 
C 
Routine serology is not recommended in patients with myocarditis and/or pericarditis for the evaluation of viral aetiology except for 
hepatitis C, HIV and Lyme disease. 
III 
C 
Recommendations for genetic testing 
It is recommended to obtain family history including pedigrees in cases of recurrent IMPS to provide clues to the underlying aetiology, 
determine inheritance pattern, and identify relatives at risk. 
I 
C 
Recommendations for the use of cardiovascular magnetic resonance imaging 
Myocarditis 
CMR is recommended in patients with suspected myocarditis to reach a clinical diagnosis and to determine the cause of acute myocardial 
injury, including assessment of oedema, ischaemia, and necrosis/fibrosis/scarring. 
I 
B                       
Continued  
ESC Guidelines                                                                                                                                                                                               69


<!-- PAGE 70 -->

### Page 70

CMR is recommended for follow-up at least within the first 6 months in patients with myocarditis to identify a healed or ongoing process, 
for risk stratification and personalized therapy, and to enable a return to exercise. 
I 
C 
Pericarditis 
CMR is recommended in patients with suspected pericarditis when a diagnosis cannot be made using clinical criteria to assess evidence of 
pericardial thickening, oedema, LGE, and to assess the persistence of disease during follow-up in selected cases. 
I 
B 
Recommendations for computed tomography 
CT is recommended to evaluate pericardial thickness, calcifications, masses, and loculated pericardial effusions, as well as concomitant 
pleuropulmonary diseases and chest abnormalities. 
I 
C 
Recommendations for endomyocardial biopsy 
EMB is recommended in patients with high-risk myocarditis, and/or haemodynamic instability, and/or in patients with intermediate-risk 
myocarditis not responding to conventional therapy in order to detect a specific histologic subtype and to assess the presence of viral 
genome for treatment. 
I 
C 
Recommendations for autopsy 
Comprehensive autopsy is recommended in all patients <50 years of age with SCD to evaluate the presence of acute myocarditis as a cause 
and to detect potential underlying inherited cardiac diseases. 
I 
B 
Retaining samples suitable for DNA extraction and consulting a cardiac pathologist is recommended in cases of SCD, when an inherited 
cause is suspected, or the cause of death remains unexplained. 
I 
B 
Recommendations for medical therapy in myocarditis 
Management of heart failure 
Adherence to the ESC HF guidelines is recommended in cases of myocarditis with LV systolic dysfunction and/or HF to reduce symptoms 
and to improve LV function. 
I 
C 
Immunosuppressive therapy 
Routine use of immunosuppressive therapy is not recommended in acute myocarditis with preserved LV function because no outcome 
benefit has been shown. 
III 
C 
Recommendations for medical therapy in pericarditis 
Colchicine is recommended as first-line therapy in patients with pericarditis as an adjunct to aspirin/NSAID or corticosteroid therapy to 
reduce subsequent recurrences. 
I 
A 
Anti-IL-1 agents (anakinra or rilonacept) are recommended for patients with recurrent pericarditis after failure of first-line therapies and 
corticosteroids, and elevation of C-reactive protein levels to reduce recurrences and allow corticosteroid withdrawal. 
I 
A 
High-dose aspirin or NSAIDs with proton pump inhibitors are recommended as first-line therapy in patients with pericarditis to control 
symptoms and reduce recurrences. 
I 
B 
Corticosteroids are not recommended as the first option for patients with pericarditis therapy without a specific indication. 
III 
C 
Recommendations for interventional techniques, including circulatory support in myocarditis 
A timely and dedicated Shock Team discussion is recommended in patients with myocarditis in the presence of haemodynamic 
compromise, to decide on the need for escalation to MCS and to determine a long-term management plan. 
I 
C 
Recommendations for interventional techniques in pericarditis 
Pericardiocentesis (echocardiography CT-, or fluoroscopy-guided) is recommended for cardiac tamponade, or suspected bacterial or 
neoplastic pericarditis, or symptomatic moderate to large pericardial effusion despite medical therapy. 
I 
C 
Surgical pericardial drainage is recommended in patients with pericardial effusion when percutaneous pericardiocentesis is not feasible or 
with purulent pericardial effusion to allow complete drainage and to prevent constriction. 
I 
C 
Surgical pleuro-pericardial window is recommended in patients with relapsing pericardial effusion despite medical therapy. 
I 
C 
Recommendations for surgical therapy 
Surgical pericardiectomy is recommended in patients with chronic pericardial constriction or persistent constrictive pericarditis despite 
medical therapy to improve symptoms and survival. 
I 
C 
Tricuspid valve repair is recommended in patients with pericardial constriction and severe tricuspid valve regurgitation to improve 
symptoms and survival. 
I 
C 
Recommendations for management of arrhythmias and prevention of sudden cardiac death in myocarditis 
ICD in myocarditis—secondary prevention 
ICD implantation is recommended in patients with non-active myocarditis and haemodynamically not-tolerated sustained VT to prevent 
SCD. 
I 
C                         
Continued


<!-- PAGE 71 -->

### Page 71

Recommendations for risk stratification, complications, and outcomes of inflammatory myopericardial syndrome 
Follow-up with clinical assessment, biomarkers, ECG, exercise test, Holter-ECG monitoring, echocardiography, and CMR at least within 
6 months after the index hospitalization is recommended in all patients with myocarditis to identify a potential progression or new risk 
factors. 
I 
C 
Long-term follow-up is recommended for patients with complicated myocarditis to identify a potential progression or new complications. 
I 
C 
Long-term follow-up is recommended for patients with incessant or recurrent pericarditis to identify a potential progression and new 
complications. 
I 
C 
Recommendations for giant-cell myocarditis 
EMB is recommended in patients with suspected GCM due to unexplained new-onset HF of up to 2 weeks associated with a normal or 
dilated left ventricle and new ventricular arrhythmias, second- or third-degree AVB, or failure to respond to usual care within 1 to 2 weeks 
to initiate specific treatment. 
I 
C 
Combined immunosuppressive therapy is recommended in patients with a diagnosed GCM. 
I 
C 
Recommendations for myocarditis in sarcoidosis 
Diagnosis 
CMR, using tissue characterization techniques, is recommended in patients with suspected CS to assess cardiac inflammation and 
myocardial involvement. 
I 
B 
18F-FDG-PET is recommended for the diagnostic work-up, including detection of inflammation, as well as for follow-up and assessment of 
therapeutic response in patients with CS. 
I 
B 
Therapy 
ICD implantation is recommended in patients with CS and sustained ventricular arrhythmia (VT/VF) or aborted CA to prevent SCD. 
I 
B 
ICD implantation is recommended in patients with CS and LVEF ≤35% to prevent SCD. 
I 
C 
Recommendations for immune checkpoint inhibitor-associated myocarditis 
Diagnostic triage within 24 h is recommended in patients with suspected myocarditis induced by ICI to initiate treatment rapidly. 
I 
C 
Immediate disruption of ICI and administration of high-dosage corticosteroids are recommended in patients with ICI-associated myocarditis 
in order to stop the inflammatory reaction and stabilize the patient. 
I 
C 
Recommendations for inflammatory cardiomyopathy 
Guideline-directed HF treatments are recommended in patients with inflammatory cardiomyopathy to improve and/or stabilize left 
ventricular function. 
I 
C 
Specific medical therapy for the potentially underlying systemic disease is recommended in inflammatory cardiomyopathy. 
I 
C 
Recommendations for tuberculous pericarditis 
Diagnosis and treatment of tuberculous pericarditis and effusion 
Diagnostic pericardiocentesis is recommended in all patients with suspected tuberculous pericarditis when diagnosis is not confirmed by 
non-invasive tests to identify the aetiological agent in pericardial fluid. 
I 
C 
Empirical antituberculosis chemotherapy is recommended in patients living in endemic areas with exudative pericardial effusion after 
excluding other causes to treat the most likely cause. 
I 
C 
Standard antituberculosis multidrug treatment for 6 months is recommended in patients with tuberculous pericarditis for the prevention of 
pericardial constriction. 
I 
C 
Pericardiectomy is recommended in patients with tuberculous pericarditis if the condition is not improving or is deteriorating after 
4–8 weeks of antituberculosis therapy to change the course of disease. 
I 
C 
Empirical antituberculosis treatment is not recommended in patients living in non-endemic areas. 
III 
C 
Recommendations for neoplastic pericardial involvement 
Pericardiocentesis is recommended for patients with cardiac tamponade to relieve symptoms and establish the diagnosis of malignant 
pericardial effusion. 
I 
C 
Extended pericardial drainage (3–6 days) is recommended in patients with suspected or definite neoplastic pericardial effusion to prevent 
effusion recurrence. 
I 
B 
Cytological analysis of pericardial fluid is recommended in patients with neoplastic pericarditis for the confirmation of malignant pericardial 
disease. 
I 
C 
Systemic antineoplastic treatment is recommended in confirmed cases of neoplastic aetiology to treat the primary and secondary metastatic 
neoplastic involvement. 
I 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                               71


<!-- PAGE 72 -->

### Page 72

### 19 Evidence tables

Evidence tables are available at the European Heart Journal online. 
20. Data availability statement 
No new data were generated or analysed in support of this research. 
21. Author information 
Author/Task Force Member Affiliations: Valentino Collini, 
Cardiology, 
Cardiothoracic 
Department, 
Santa 
Maria 
della 
Misericordia University Hospital, Udine, Italy; Jan Gröschel, Charité 
—Universitätsmedizin Berlin, corporate member of Freie Universität 
Berlin and Humboldt-Universität zu Berlin, ECRC Experimental and 
Clinical Research Center, Berlin, Germany, and DZHK (German 
Centre for Cardiovascular Research), partner site Berlin, Berlin, 
Germany, and Deutsches Herzzentrum der Charité, Klinik für 
Kardiologie, Angiologie und Intensivmedizin, Berlin, Germany; 
Yehuda Adler, Sackler Medical School, Tel Aviv University, Tel 
Aviv, Israel; Antonio Brucato, Department of biomedical and clinical sciences, University of Milano, Fatebenefratelli Hospital, Milano, 
Italy; Vanessa Christian (United Kingdom), ESC Patient Forum, 
Sophia Antipolis, France; Vanessa M. Ferreira, Oxford Centre 
for Clinical Magnetic Resonance Research (OCMR), University of 
Oxford, Oxford, United Kingdom; Estelle Gandjbakhch, 
Cardiology Departement, Sorbonne Université, APHP, Hôpital 
Pitié Salpêtrière, Paris, France, and Referral Center for Inherited 
Cardiac Diseases, APHP, Hôpital Pitié Salpêtrière, Paris, France, 
and Inserm 1166, IHU ICAN, Paris, France; Bettina Heidecker, 
Deutsches Herzzentrum der Charité, Universitätsmedizin Berlin, 
Berlin, Germany, and Berlin Institute of Health (BIH), Charité, 
Universitätsmedizin Berlin, Berlin, Germany, and DZHK (German 
Centre for Cardiovascular Research), partner site Berlin, Berlin, 
Germany; Mathieu Kerneis, Sorbonne Université, Paris, France, 
and ACTION Group, Paris, France, and UMRS 1166 Inserm, Paris, 
France, and Institute of Cardiology, Hôpital Pitié-Salpêtrière,  
Recommendations for post-cardiac injury syndrome 
Anti-inflammatory therapy is recommended in patients with PCIS to hasten symptom remission and reduce recurrences. 
I 
B 
IL-1 antagonists are recommended in patients with refractory PCIS to prevent recurrences and progression to constriction. 
I 
B 
High-dose aspirin is recommended as the first-choice anti-inflammatory therapy for post-myocardial infarction pericarditis and in patients 
already on antiplatelet therapy. 
I 
C 
Recommendations for purulent pericarditis 
Urgent pericardiocentesis and/or a surgical window is recommended in patients with suspicion of purulent pericarditis to establish a 
diagnosis. 
I 
C 
Recommendations for constrictive pericarditis 
Diagnosis 
Multimodality imaging is recommended in all patients with suspected constrictive pericarditis to make the diagnosis and assess pericardial 
thickening, calcifications, and active inflammation. 
I 
C 
Therapy 
Anti-inflammatory therapy is recommended in haemodynamically stable patients with a transient or new diagnosis of constriction with 
concomitant evidence of pericardial inflammation to prevent progression to constriction and avoid pericardiectomy. 
I 
C 
Pericardiectomy is recommended in patients with permanent constriction if there is no active inflammation or anti-inflammatory treatment 
is not successful after 3–6 months. 
I 
C 
Recommendations for pregnancy, lactation, and reproductive issues 
Pre-conception counselling is recommended in women with recurrent pericarditis or myocarditis to assess disease activity and to review 
therapy. 
I 
C 
Recommendations for physical activity and myocarditis/pericarditis 
Restriction of physical exercise until remission, for at least 1 month, is recommended in athletes and non-athletes after IMPS using an 
individualized approach to accelerate recovery. 
I 
C 
Recommendations for multidisciplinary teams in myopericardial syndromes 
A multidisciplinary team discussion at a referral centre is recommended in patients with high-risk/complicated IMPS to provide a 
patient-tailored approach. 
I 
C 
© ESC 2025
AVB, atrioventricular block; CA, cardiac arrest; CMR, cardiovascular magnetic resonance; CS, cardiac sarcoidosis; CT, computed tomography; DNA, deoxyribonucleic acid; ECG, 
electrocardiogram; EMB, endomyocardial biopsy; ESC, European Society of Cardiology; 18F-FDG-PET, [18F]-fluorodeoxyglucose positron emission tomography; GCM, giant-cell 
myocarditis; HF, heart failure; HIV, human immunodeficiency virus; ICD, implantable cardioverter-defibrillator; ICI, immune checkpoint inhibitor; IL, interleukin; IMPS; inflammatory 
myopericardial syndrome; LGE, late gadolinium enhancement; LV, left ventricle; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; NSAID, non-steroidal 
anti-inflammatory drug; PCIS, post-cardiac injury syndrome; SCD; sudden cardiac death; VF, ventricular fibrillation; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 73 -->

### Page 73

Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Allan 
L. Klein, Center for the diagnosis of pericardial disease, department 
of cardiovascular medicine, heart, vascular and thoracic institute, 
Cleveland clinic, Cleveland, Ohio, United States of America; Karin 
Klingel, Institute for Pathology and Neuropathology, University 
Hospital Tuebingen, Tuebingen, Germany; George Lazaros, 
Cardiology, School of medicine, Hippokration General Hospital, 
National and Kapodistrian University of Athens, Athens, Greece; 
Roberto Lorusso, Cardio-Thoracic Surgery, Maastricht University 
Medical Centre, Maastricht, Netherlands, and Cardiovascular Research 
Institute Maastricht, Maastricht, Netherlands; Elena G. Nesukay, 
Department of non-coronary heart diseases, rheumatology and therapy, 
National scientific center “The M.D. Strazhesko institute of cardiology, 
clinical and regenerative medicine”, Kiev, Ukraine; Kazem Rahimi, 
Nuffield department of women’s and reproductive health, University 
of Oxford, Oxford, United Kingdom; Arsen D. Ristić, Department 
of Cardiology, University Clinical Center of Serbia, Belgrade, Serbia, 
and Faculty of Medicine, Belgrade University, Belgrade, Serbia; Marcin 
Rucinski (Poland), ESC Patient Forum, Sophia Antipolis, France; 
Leyla Elif Sade, School of Medicine, University of Pittsburgh, 
Pittsburgh, PA, United States of America, and Department of 
Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, 
United States of America; Hannah Schaubroeck, Intensive Care 
Unit, Ghent University Hospital, Ghent, Belgium; Anne Grete 
Semb, Department of research and innovation, REMEDY centre, 
Diakonhjemmet Hospital, Oslo, Norway; Gianfranco Sinagra, 
Center 
for 
Diagnosis 
and 
Treatment 
of 
Cardiomyopathies, 
Cardiothoracovascular Department, Azienda Sanitaria Universitaria 
Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy; Jens 
Jakob Thune, Department of cardiology, Copenhagen University 
Hospital—Bispebjerg and Frederiksberg, Copenhagen, Denmark, and 
Department of clinical medicine, University of Copenhagen, 
Copenhagen, Denmark. 
22. Appendix 
ESC Scientific Document Group 
Includes Document Reviewers and ESC National Cardiac Societies. 
Document 
Reviewers: 
Elena 
Arbelo 
(CPG 
Review 
Co-ordinator) (Spain), Cristina Basso (CPG Review Co-ordinator) 
(Italy), Marianna Adamo (Italy), Suleman Aktaa (United Kingdom), 
Enrico Ammirati (Italy), Lisa Anderson (United Kingdom), Eloisa 
Arbustini (Italy), Emanuele Bobbio (Sweden), Giuseppe Boriani (Italy), 
Margarita Brida (Croatia), Robert A. Byrne (Ireland), Alida L.P. 
Caforio (Italy), Gh.-Andrei Dan (Romania), Fernando Domínguez 
(Spain), Suzanne Fredericks (Canada), Geeta Gulati (Norway), Borja 
Ibanez (Spain), Stefan James (Sweden), Alexander Kharlamov 
(Netherlands), 
Sabine 
Klaassen 
(Germany), 
Jolanda 
Kluin 
(Netherlands), Konstantinos C. Koskinas (Switzerland), Petr 
Kuchynka (Czech Republic), Vijay Kunadian (United Kingdom), Ulf 
Landmesser (Germany), Gregory Y.H. Lip (United Kingdom), 
Bernhard 
Maisch 
(Germany), 
Federica 
Marelli-Berg 
(United 
Kingdom), Pilar Martin (Spain), John William McEvoy (Ireland), 
Borislava Mihaylova (United Kingdom), Richard Mindham (United 
Kingdom), Inge Moelgaard (Denmark), Saidi A. Mohiddin (United 
Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet 
(Belgium), Giovanni Peretto (Italy), Kalliopi Pilichou (Italy), Nicolas 
Piriou (France), Eva Prescott (Denmark), Amina Rakisheva 
(Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Anna 
Sannino (Germany), Franziska Seidel (Germany), Felix C. Tanner 
(Switzerland), Witold Zbyszek Tomkowski (Poland), Ilonca 
Vaartjes (Netherlands), Sophie Van Linthout (Germany), Christiaan 
Vrints (Belgium), Romuald Wojnicz (Poland), Katja Zeppenfeld 
(Netherlands) 
ESC National Cardiac Societies actively involved in the review 
process of the ESC Guidelines for the management of myocarditis and 
pericarditis: 
Albania: Albanian Society of Cardiology, Albana Doko Banushi; 
Algeria: Algerian Society of Cardiology, Mohammed Chettibi; 
Armenia: Armenian Cardiologists Association, Hamayak S. Sisakian; 
Azerbaijan: Azerbaijan Society of Cardiology, Ogtay Musayev; 
Belgium: Belgian Society of Cardiology, Bernard P. Paelinck; Bosnia 
and Herzegovina: Association of Cardiologists of Bosnia and 
Herzegovina, Alden Begić; Bulgaria: Bulgarian Society of Cardiology, 
Yvaylo Daskalov; Croatia: Croatian Cardiac Society, Bosko Skoric; 
Cyprus: Cyprus Society of Cardiology, Marios Ioannides; Czechia: 
Czech Society of Cardiology, Tomas Palecek; Denmark: Danish 
Society of Cardiology, Kasper Rossing; Egypt: Egyptian Society of 
Cardiology, Haytham Soliman Ghareeb; Estonia: Estonian Society of 
Cardiology, Ulvi Hinto; Finland: Finnish Cardiac Society, Markku 
Kupari; France: French Society of Cardiology, Emmanuelle 
Berthelot; Georgia: Georgian Society of Cardiology, Vaja Agladze; 
Germany: German Cardiac Society, Brenda Gerull; Greece: 
Hellenic Society of Cardiology, Alexandros Kasiakogias; Hungary: 
Hungarian Society of Cardiology, Hajnalka Vágó; Iceland: Icelandic 
Society of Cardiology, Inga Jóna Ingimarsdóttir; Ireland: Irish 
Cardiac Society, Emer Joyce; Israel: Israel Heart Society, Sorel 
Goland; Italy: Italian Federation of Cardiology, Enrico Fabris; 
Kazakhstan: Association of Cardiologists of Kazakhstan, Murat 
Amanzholovich Mukarov; Kosovo (Republic of): Kosovo Society 
of Cardiology, Ibadete Bytyçi; Kyrgyzstan: Kyrgyz Society 
of Cardiology, Erkin Mirrakhimov, Latvia: Latvian Society of 
Cardiology, Ginta Kamzola; Lebanon: Lebanese Society of 
Cardiology, Naji J. Abirached; Libya: Libyan Cardiac Society, Aiman 
M. Smer; Lithuania: Lithuanian Society of Cardiology, Vaida 
Mizariene; Luxembourg: Luxembourg Society of Cardiology, 
Andrei Codreanu; Malta: Maltese Cardiac Society, Tiziana Felice; 
Moldova (Republic of): Moldavian Society of Cardiology, 
Eleonora Boris Vataman; Morocco: Moroccan Society of 
Cardiology, Aida Soufiani; Netherlands: Netherlands Society of 
Cardiology, Geertruida Petronella Bijvoet; North Macedonia: 
National Society of Cardiology of North Macedonia, Irena Mitevska; 
Norway: Norwegian Society of Cardiology, Haavard Ravnestad; 
Poland: Polish Cardiac Society, Karol Kamiński; Portugal: 
Portuguese Society of Cardiology, Nuno Cardim; Romania: 
Romanian Society of Cardiology, Oliviana Geavlete; San Marino: 
San Marino Society of Cardiology, Emidio Troiani; Serbia: 
Cardiology Society of Serbia, Marija Zdravkovic; Slovakia: Slovak 
Society of Cardiology, Marcela Dankova; Slovenia: Slovenian Society 
of Cardiology, Andreja Černe Čerček; Spain: Spanish Society 
of Cardiology, Fernando Domínguez; Sweden: Swedish Society of 
Cardiology, Gabriel Arefalk; Switzerland: Swiss Society of 
Cardiology, 
Philip 
Haaf; 
Syrian 
Arab 
Republic: 
Syrian 
Cardiovascular Association, Mohammed Yassin Bani Marjeh; 
Türkiye: Turkish Society of Cardiology, Baris Kilicaslan; Ukraine: 
Ukrainian Association of Cardiology, Sergii Cherniuk; United 
Kingdom of Great Britain and Northern Ireland: British 
Cardiovascular Society, Saidi A. Mohiddin, Uzbekistan: Association 
of Cardiologists of Uzbekistan, Amayak Kevorkov  
ESC Guidelines                                                                                                                                                                                               73


<!-- PAGE 74 -->

### Page 74

ESC Clinical Practice Guidelines (CPG) Committee: Ulf 
Landmesser (Chairperson) (Germany), Stefan James (Co-Chairperson) 
(Sweden), Marianna Adamo (Italy), Suleman Aktaa (United Kingdom), 
Folkert W. Asselbergs (Netherlands), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Giuseppe Boriani (Italy), Margarita Brida 
(Croatia), Robert A. Byrne (Ireland), Estelle Gandjbakhch (France), 
Bettina Heidecker (Germany), Anja Hennemuth (Germany), Borja 
Ibanez (Spain), Peter Jüni (United Kingdom), Gregory Y.H. Lip (United 
Kingdom), John William McEvoy (Ireland), Borislava Mihaylova (United 
Kingdom), Inge Moelgaard (Denmark), Lis Neubeck (United Kingdom), 
Eva Prescott (Denmark), Bianca Rocca (Italy), Xavier Rossello (Spain), 
Anna Sannino (Germany), Felix C. Tanner (Switzerland), Wojtek 
Wojakowski (Poland), Katja Zeppenfeld (Netherlands) 
Contributor either withdrew or was engaged in only a part of the review process: Gerhard Poelzl  (Austria) 
23. References 
1. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC 
Guidelines for the diagnosis and management of pericardial diseases: the task force for 
the diagnosis and management of pericardial diseases of the European Society of 
Cardiology (ESC) Endorsed by: the European Association for Cardio-Thoracic 
Surgery (EACTS). Eur Heart J 2015;36:2921–64. https://doi.org/10.1093/eurheartj/ 
ehv318 
2. Adamopoulos S, Miliopoulos D, Karavidas A, Nikolaou M, Lazaros G, Gkouziouta A, 
et al. HEllenic Registry on Myocarditis SyndromES on behalf of Hellenic Heart 
Failure Association: the HERMES-HF registry. ESC Heart Fail 2020;7:3676–84.  
https://doi.org/10.1002/ehf2.12894 
3. Aquaro GD, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C, et al. Cardiac 
MR with late gadolinium enhancement in acute myocarditis with preserved systolic 
function: ITAMY study. J Am Coll Cardiol 2017;70:1977–87. https://doi.org/10.1016/j. 
jacc.2017.08.044 
4. Imazio M, Brucato A, Barbieri A, Ferroni F, Maestroni S, Ligabue G, et al. Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study. Circulation 2013;128:42–9. https://doi.org/10. 
1161/CIRCULATIONAHA.113.001531 
5. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes 
of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1265–73. https://doi.org/10. 
1001/jamacardio.2020.3557 
6. Keren A, Asleh R, Birati EY, Ben Gal T, Arad M. Definition and diagnosis of acute myocarditis: a position statement of the Israel Heart Society. Isr Med Assoc J 2023;25: 
519–24. 
7. Montera MW, Marcondes-Braga FG, Simões MV, Moura LAZ, Fernandes F, Mangine S, 
et al. Brazilian Society of Cardiology guideline on myocarditis—2022. Arq Bras Cardiol 
2022;119:143–211. https://doi.org/10.36660/abc.20220412 
8. Nagai T, Inomata T, Kohno T, Sato T, Tada A, Kubo T, et al. JCS 2023 guideline on the 
diagnosis and treatment of myocarditis. Circ J 2023;87:674–754. https://doi.org/10. 
1253/circj.CJ-22-0696 
9. Writing Committee; Drazner MH, Bozkurt B, Cooper LT, Aggarwal NR, Basso C, et al. 
2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis: a report of the American College of Cardiology 
Solution Set Oversight Committee. J Am Coll Cardiol 2025;85:391–431. https://doi.org/ 
10.1016/j.jacc.2024.10.080 
10. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. 
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group 
on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636–48, 2648a–48d.  
https://doi.org/10.1093/eurheartj/eht210 
11. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines 
on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 
2021;42:17–96. https://doi.org/10.1093/eurheartj/ehaa605 
12. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 
heart failure. Eur Heart J 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ 
ehab368 
13. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 
44:3503–626. https://doi.org/10.1093/eurheartj/ehad194 
14. Law YM, Lal AK, Chen S, Čiháková D, Cooper LT, Deshpande S, et al. Diagnosis and 
management of myocarditis in children: a scientific statement from the American 
Heart Association. Circulation 2021;144:e123–35. https://doi.org/10.1161/CIR. 
0000000000001001 
15. Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y, et al. Guidelines on 
the diagnosis and management of pericardial diseases executive summary: the task 
force on the diagnosis and management of pericardial diseases of the European 
Society of Cardiology. Eur Heart J 2004;25:587–610. https://doi.org/10.1016/j.ehj. 
2004.02.002 
16. Patriki D, Gresser E, Manka R, Emmert MY, Lüscher TF, Heidecker B. Approximation 
of the incidence of myocarditis by systematic screening with cardiac magnetic resonance imaging. JACC Heart Fail 2018;6:573–9. https://doi.org/10.1016/j.jchf.2018.03.002 
17. Fu M, Kontogeorgos S, Thunström E, Zverkova Sandström T, Kroon C, Bollano E, et al. 
Trends in myocarditis incidence, complications and mortality in Sweden from 2000 to 
2014. Sci Rep 2022;12:1810. https://doi.org/10.1038/s41598-022-05951-z 
18. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. 
Global burden of cardiovascular diseases and risk factors, 1990–2019: update from 
the GBD 2019 study. J Am Coll Cardiol 2020;76:2982–3021. https://doi.org/10.1016/j. 
jacc.2020.11.010 
19. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases 
and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden 
of Disease Study 2013. Lancet 2015;386:743–800. https://doi.org/10.1016/S0140- 
6736(15)60692-4 
20. Messroghli DR, Pickardt T, Fischer M, Opgen-Rhein B, Papakostas K, Böcker D, et al. 
Toward evidence-based diagnosis of myocarditis in children and adolescents: rationale, 
design, and first baseline data of MYKKE, a multicenter registry and study platform. Am 
Heart J 2017;187:133–44. https://doi.org/10.1016/j.ahj.2017.02.027 
21. Arola A, Pikkarainen E, Sipilä JO, Pykäri J, Rautava P, Kytö V. Occurrence and features 
of childhood myocarditis: a nationwide study in Finland. J Am Heart Assoc 2017;6: 
e005306. https://doi.org/10.1161/JAHA.116.005306 
22. Imazio M, Cecchi E, Demichelis B, Chinaglia A, Ierna S, Demarie D, et al. 
Myopericarditis versus viral or idiopathic acute pericarditis. Heart 2008;94:498–501.  
https://doi.org/10.1136/hrt.2006.104067 
23. Kytö V, Sipilä J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation 2014;130:1601–6. https://doi.org/10.1161/ 
CIRCULATIONAHA.114.010376 
24. Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, et al. A randomized 
trial of colchicine for acute pericarditis. N Engl J Med 2013;369:1522–8. https://doi. 
org/10.1056/NEJMoa1208536 
25. Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, et al. Efficacy and safety of 
colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet 2014;383:2232–7.  
https://doi.org/10.1016/S0140-6736(13)62709-9 
26. Charpentier S, Beaune S, Joly LM, Khoury A, Duchateau F-X, Briot R, et al. 
Management of chest pain in the French emergency healthcare system: the prospective observational EPIDOULTHO study. Eur J Emerg Med 2018;25:404–10. https://doi. 
org/10.1097/MEJ.0000000000000481 
27. Sexson Tejtel SK, Munoz FM, Al-Ammouri I, Savorgnan F, Guggilla RK, Khuri-Bulos N, 
et al. Myocarditis and pericarditis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2022;40:1499–511. https:// 
doi.org/10.1016/j.vaccine.2021.11.074 
28. Ammirati E, Cipriani M, Moro C, Raineri C, Pini D, Sormani P, et al. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis: 
Multicenter Lombardy Registry. Circulation 2018;138:1088–99. https://doi.org/10. 
1161/CIRCULATIONAHA.118.035319 
29. Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 
ESC Guidelines for the management of endocarditis. Eur Heart J 2023;44: 
3948–4042. https://doi.org/10.1093/eurheartj/ehad193 
30. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. 
Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert 
recommendations. J Am Coll Cardiol 2018;72:3158–76. https://doi.org/10.1016/j.jacc. 
2018.09.072 
31. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol 1987;18:619–24. https://doi.org/ 
10.1016/s0046-8177(87)80363-5 
32. Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. 
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol 2021;18:169–93. https://doi.org/10.1038/s41569-020-00435-x 
33. Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, et al. 2011 Consensus 
statement on endomyocardial biopsy from the Association for European 
Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc 
Pathol 2012;21:245–74. https://doi.org/10.1016/j.carpath.2011.10.001 
34. Caforio ALP, Giordani AS, Baritussio A, Marcolongo D, Vicenzetto C, Tarantini G, 
et al. Long-term efficacy and safety of tailored immunosuppressive therapy in immune- 
mediated biopsy-proven myocarditis: a propensity-weighted study. Eur J Heart Fail 
2024;26:1175–85. https://doi.org/10.1002/ejhf.3220


<!-- PAGE 75 -->

### Page 75

35. Imazio M, Squarotti GB, Andreis A, Agosti A, Millesimo M, Frea S, et al. Diagnostic and 
prognostic role of the electrocardiogram in patients with pericarditis. Heart 2022;108: 
1474–8. https://doi.org/10.1136/heartjnl-2021-320443 
36. Imazio M, Brucato A, Maestroni S, Cumetti D, Dominelli A, Natale G, et al. Prevalence 
of C-reactive protein elevation and time course of normalization in acute pericarditis: 
implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation 2011; 
123:1092–7. https://doi.org/10.1161/CIRCULATIONAHA.110.986372 
37. Pisacreta AM, Mascolo R, Nivuori M, Dominioni CC, Gabiati C, Trotta L, et al. Acute 
pericarditis with pleuropulmonary involvement, fever and elevated C-reactive protein: 
a systemic autoinflammatory disease? A cohort study. Eur J Intern Med 2023;113:45–8.  
https://doi.org/10.1016/j.ejim.2023.03.034 
38. Tombetti E, Casarin F, Bizzi E, Bezer S, Mascolo R, Pallini G, et al. Relapsing pericarditis: 
peripheral blood neutrophilia, lymphopenia and high neutrophil-to-lymphocyte ratio 
herald acute attacks, high-grade inflammation, multiserosal involvement, and predict 
multiple recurrences. Int J Rheum Dis 2023;26:337–43. https://doi.org/10.1111/1756- 
185X.14523 
39. Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al. 
Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail 2020;13:e007405. https://doi.org/10.1161/ 
CIRCHEARTFAILURE.120.007405 
40. Seidel F, Opgen-Rhein B, Rentzsch A, Boehne M, Wannenmacher B, Boecker D, et al. 
Clinical characteristics and outcome of biopsy-proven myocarditis in children—results 
of the German prospective multicentre registry ‘MYKKE’. Int J Cardiol 2022;357: 
95–104. https://doi.org/10.1016/j.ijcard.2022.03.026 
41. Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with 
‘idiopathic’ left ventricular dysfunction. Circulation 2005;111:887–93. https://doi.org/ 
10.1161/01.CIR.0000155616.07901.35 
42. Ukimura A, Satomi H, Ooi Y, Kanzaki Y. Myocarditis associated with influenza A 
H1N1pdm2009. Influenza Res Treat 2012;2012:351979. https://doi.org/10.1155/ 
2012/351979 
43. Lazarou E, Lazaros G, Antonopoulos AS, Imazio M, Vasileiou P, Karavidas A, et al. A 
risk score for pericarditis recurrence. Eur J Clin Invest 2021;51:e13602. https://doi. 
org/10.1111/eci.13602 
44. Imazio M, Andreis A, Lubian M, Lazaros G, Lazarou E, Brucato A, et al. The Torino 
Pericarditis Score: a new-risk stratification tool to predict complicated pericarditis. 
Intern Emerg Med 2021;16:1921–6. https://doi.org/10.1007/s11739-021-02803-y 
45. Lazaros G, Antonopoulos AS, Lazarou E, Vlachopoulos C, Vogiatzi G, Vassilopoulos D, 
et al. Age- and sex-based differences in patients with acute pericarditis. Eur J Clin Invest 
2021;51:e13392. https://doi.org/10.1111/eci.13392 
46. Vecchié A, Chiabrando JG, Dell MS, Bonaventura A, Mauro AG, Wohlford G, et al. 
Clinical presentation and outcomes of acute pericarditis in a large urban hospital in 
the United States of America. Chest 2020;158:2556–67. https://doi.org/10.1016/j. 
chest.2020.07.039 
47. Gouriet F, Levy P-Y, Casalta J-P, Zandotti C, Collart F, Lepidi H, et al. Etiology of pericarditis in a prospective cohort of 1162 cases. Am J Med 2015;128:784.e1–e8. https:// 
doi.org/10.1016/j.amjmed.2015.01.040 
48. Mayosi BM, Wiysonge CS, Ntsekhe M, Volmink JA, Gumedze F, Maartens G, et al. 
Clinical characteristics and initial management of patients with tuberculous pericarditis 
in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI 
Africa) registry. BMC Infect Dis 2006;6:2. https://doi.org/10.1186/1471-2334-6-2 
49. Conte E, Tamanini S, Bizzi E, Maestroni S, Cumetti D, Novembre ML, et al. 
Post-cardiac injury syndrome and pericardial effusion recurrence after pericardial effusion drainage in chronic idiopathic pericardial effusion. Eur J Intern Med 2024;123: 
132–7. https://doi.org/10.1016/j.ejim.2024.01.024 
50. Peet CJ, Rowczenio D, Omoyinmi E, Papadopoulou C, Mapalo BRR, Wood MR, et al. 
Pericarditis and autoinflammation: a clinical and genetic analysis of patients with idiopathic recurrent pericarditis and monogenic autoinflammatory diseases at a national 
referral center. J Am Heart Assoc 2022;11:e024931. https://doi.org/10.1161/JAHA. 
121.024931 
51. Imazio M, Faletra F, Zucco J, Mio C, Carraro M, Gava AM, et al. Genetic variants in patients with recurrent pericarditis. J Cardiovasc Med (Hagerstown) 2024;25:799–804.  
https://doi.org/10.2459/JCM.0000000000001669 
52. Caforio ALP, Brucato A, Doria A, Brambilla G, Angelini A, Ghirardello A, et al. 
Anti-heart and anti-intercalated disk autoantibodies: evidence for autoimmunity in 
idiopathic recurrent acute pericarditis. Heart 2010;96:779–84. https://doi.org/10. 
1136/hrt.2009.187138 
53. Basso C. Myocarditis. N Engl J Med 2022;387:1488–500. https://doi.org/10.1056/ 
NEJMra2114478 
54. Ammirati E, Moslehi JJ. Diagnosis and treatment of acute myocarditis: a review. JAMA 
2023;329:1098–113. https://doi.org/10.1001/jama.2023.3371 
55. Younis A, Matetzky S, Mulla W, Masalha E, Afel Y, Chernomordik F, et al. Epidemiology 
characteristics and outcome of patients with clinically diagnosed acute myocarditis. Am 
J Med 2020;133:492–9. https://doi.org/10.1016/j.amjmed.2019.10.015 
56. Ammirati E, Veronese G, Brambatti M, Merlo M, Cipriani M, Potena L, et al. Fulminant 
versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2019;74:299–311. https://doi.org/10.1016/j.jacc.2019.04.063 
57. Huang F, Ammirati E, Ponnaiah M, Montero S, Raimbault V, Abrams D, et al. Fulminant 
myocarditis proven by early biopsy and outcomes. Eur Heart J 2023;44:5110–24.  
https://doi.org/10.1093/eurheartj/ehad707 
58. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 
ESC Guidelines for the management of patients with ventricular arrhythmias and 
the prevention of sudden cardiac death: developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac 
death of the European Society of Cardiology (ESC) Endorsed by the Association for 
European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2022;43: 
3997–4126. https://doi.org/10.1093/eurheartj/ehac262 
59. Berg J, Kottwitz J, Baltensperger N, Kissel CK, Lovrinovic M, Mehra T, et al. Cardiac 
magnetic resonance imaging in myocarditis reveals persistent disease activity despite 
normalization of cardiac enzymes and inflammatory parameters at 3-month follow-up. 
Circ Heart Fail 2017;10:e004262. https://doi.org/10.1161/CIRCHEARTFAILURE.117. 
004262 
60. Schwuchow-Thonke S, Göbel S, Emrich T, Schmitt VH, Fueting F, Klank C, et al. 
Increased C reactive protein, cardiac troponin I and GLS are associated with myocardial inflammation in patients with non-ischemic heart failure. Sci Rep 2021;11:3008.  
https://doi.org/10.1038/s41598-021-82592-8 
61. Krumm P, Brendel JM, Klingel K, Müller KAL, Kübler J, Gräni C, et al. Using multiparametric cardiac magnetic resonance to phenotype and differentiate biopsy-proven 
chronic from healed myocarditis and dilated cardiomyopathy. J Clin Med 2022;11: 
5047. https://doi.org/10.3390/jcm11175047 
62. Anzini M, Merlo M, Sabbadini G, Barbati G, Finocchiaro G, Pinamonti B, et al. 
Long-term evolution and prognostic stratification of biopsy-proven active myocarditis. 
Circulation 
2013;128:2384–94. 
https://doi.org/10.1161/CIRCULATIONAHA.113. 
003092 
63. Caforio ALP, Kaski JP, Gimeno JR, Elliott PM, Laroche C, Tavazzi L, et al. 
Endomyocardial biopsy: safety and prognostic utility in paediatric and adult myocarditis 
in the European Society of Cardiology EURObservational Research Programme 
Cardiomyopathy and Myocarditis Long-Term Registry. Eur Heart J 2024;45: 
2548–69. https://doi.org/10.1093/eurheartj/ehae169 
64. Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, Lopez-Cuenca D, 
Sanchez-Munoz JJ, Oliva-Sandoval MJ, et al. Genetics of myocarditis in arrhythmogenic 
right ventricular dysplasia. Heart Rhythm 2015;12:766–73. https://doi.org/10.1016/j. 
hrthm.2015.01.001 
65. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC 
Guidelines for the management of acute coronary syndromes in patients presenting 
without persistent ST-segment elevation. Eur Heart J 2021;42:1289–367. https://doi. 
org/10.1093/eurheartj/ehaa575 
66. Caforio ALP, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, et al. A prospective 
study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007;28:1326–33. https://doi.org/10.1093/ 
eurheartj/ehm076 
67. Buiatti A, Merlo M, Pinamonti B, De Biasio M, Bussani R, Sinagra G. Clinical presentation and long-term follow-up of perimyocarditis. J Cardiovasc Med (Hagerstown) 2013; 
14:235–41. https://doi.org/10.2459/JCM.0b013e328351da6e 
68. Abdel-Aty H, Boyé P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, et al. 
Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 
2005;45:1815–22. https://doi.org/10.1016/j.jacc.2004.11.069 
69. Zagrosek A, Abdel-Aty H, Boyé P, Wassmuth R, Messroghli D, Utz W, et al. Cardiac 
magnetic resonance monitors reversible and irreversible myocardial injury in myocarditis. JACC Cardiovasc Imaging 2009;2:131–8. https://doi.org/10.1016/j.jcmg.2008.09. 
014 
70. Gröschel J, Bhoyroo Y, Blaszczyk E, Trauzeddel RF, Viezzer D, Saad H, et al. Different 
impacts on the heart after COVID-19 infection and vaccination: insights from cardiovascular magnetic resonance. Front Cardiovasc Med 2022;9:916922. https://doi.org/10. 
3389/fcvm.2022.916922 
71. Gentile P, Merlo M, Peretto G, Ammirati E, Sala S, Della Bella P, et al. Post-discharge 
arrhythmic risk stratification of patients with acute myocarditis and life-threatening 
ventricular tachyarrhythmias. Eur J Heart Fail 2021;23:2045–54. https://doi.org/10. 
1002/ejhf.2288 
72. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC 
Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44: 
3720–826. https://doi.org/10.1093/eurheartj/ehad191 
73. Baritussio A, Schiavo A, Basso C, Giordani AS, Cheng C-Y, Pontara E, et al. Predictors 
of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies. Eur J Heart Fail 2022;24:1033–44.  
https://doi.org/10.1002/ejhf.2496  
ESC Guidelines                                                                                                                                                                                               75


<!-- PAGE 76 -->

### Page 76

74. Ammirati E, Cipriani M, Lilliu M, Sormani P, Varrenti M, Raineri C, et al. Survival and left 
ventricular function changes in fulminant versus nonfulminant acute myocarditis. 
Circulation 2017;136:529–45. https://doi.org/10.1161/CIRCULATIONAHA.117.026386 
75. Kondo T, Okumura T, Shibata N, Imaizumi T, Dohi K, Izawa H, et al. Differences in 
prognosis and cardiac function according to required percutaneous mechanical circulatory support and histological findings in patients with fulminant myocarditis: insights 
from the CHANGE PUMP 2 study. J Am Heart Assoc 2022;11:e023719. https://doi.org/ 
10.1161/JAHA.121.023719 
76. Peretto G, Sala S, Rizzo S, De Luca G, Campochiaro C, Sartorelli S, et al. Arrhythmias in 
myocarditis: state of the art. Heart Rhythm 2019;16:793–801. https://doi.org/10.1016/j. 
hrthm.2018.11.024 
77. Imazio M, Lazaros G, Picardi E, Vasileiou P, Orlando F, Carraro M, et al. Incidence and 
prognostic significance of new onset atrial fibrillation/flutter in acute pericarditis. Heart 
2015;101:1463–7. https://doi.org/10.1136/heartjnl-2014-307398 
78. Shah Z, Mohammed M, Vuddanda V, Ansari MW, Masoomi R, Gupta K. National 
trends, gender, management, and outcomes of patients hospitalized for myocarditis. 
Am J Cardiol 2019;124:131–6. https://doi.org/10.1016/j.amjcard.2019.03.036 
79. Rosier L, Zouaghi A, Barré V, Martins R, Probst V, Marijon E, et al. High risk of sustained 
ventricular arrhythmia recurrence after acute myocarditis. J Clin Med 2020;9:848.  
https://doi.org/10.3390/jcm9030848 
80. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated 
with cardiac sarcoidosis. Heart Rhythm 2014;11:1305–23. https://doi.org/10.1016/j. 
hrthm.2014.03.043 
81. Bobbio E, Hjalmarsson C, Björkenstam M, Polte CL, Oldfors A, Lindström U, et al. 
Diagnosis, management, and outcome of cardiac sarcoidosis and giant cell myocarditis: 
a Swedish single center experience. BMC Cardiovasc Disord 2022;22:192. https://doi. 
org/10.1186/s12872-022-02639-0 
82. Cooper LT, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis—natural history 
and treatment. N Engl J Med 1997;336:1860–66. https://doi.org/10.1056/ 
NEJM199706263362603 
83. Peretto G, Sala S, Rizzo S, Palmisano A, Esposito A, De Cobelli F, et al. Ventricular arrhythmias in myocarditis: characterization and relationships with myocardial inflammation. J Am Coll Cardiol 2020;75:1046–57. https://doi.org/10.1016/j.jacc.2020.01.036 
84. Peretto G, Sala S, Basso C, Rizzo S, Radinovic A, Frontera A, et al. Inflammation as a 
predictor of recurrent ventricular tachycardia after ablation in patients with myocarditis. J Am Coll Cardiol 2020;76:1644–56. https://doi.org/10.1016/j.jacc.2020.08.012 
85. van der Linde MR. Lyme carditis: clinical characteristics of 105 cases. Scand J Infect Dis 
Suppl 1991;77:81–4. https://doi.org/10.3109/inf.1991.23.suppl-77.01 
86. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 
ESC guidelines on cardiac pacing and cardiac resynchronization therapy: developed by 
the Task Force on cardiac pacing and cardiac resynchronization therapy of the 
European Society of Cardiology (ESC) With the special contribution of the 
European Heart Rhythm Association (EHRA). Eur Heart J 2021;42:3427–520.  
https://doi.org/10.1093/eurheartj/ehab364 
87. Bhatia RT, Finocchiaro G, Westaby J, Chatrath N, Behr ER, Papadakis M, et al. 
Myocarditis and sudden cardiac death in the community: clinical and pathological insights from a national registry in the United Kingdom. Circ Arrhythm Electrophysiol 
2023;16:e012129. https://doi.org/10.1161/CIRCEP.123.012129 
88. Lynge TH, Nielsen TS, Gregers Winkel B, Tfelt-Hansen J, Banner J. Sudden cardiac 
death caused by myocarditis in persons aged 1–49 years: a nationwide study of 14  
294 deaths in Denmark. Forensic Sci Res 2019;4:247–56. https://doi.org/10.1080/ 
20961790.2019.1595352 
89. Peretto G, Mazzone P, Paglino G, Marzi A, Tsitsinakis G, Rizzo S, et al. Continuous electrical monitoring in patients with arrhythmic myocarditis: insights from a referral center. J Clin Med 2021;10:5142. https://doi.org/10.3390/jcm10215142 
90. Baritussio A, Cheng C-Y, Simeti G, Ocagli H, Lorenzoni G, Giordani AS, et al. CMR 
predictors of favorable outcome in myocarditis: a single-center experience. J Clin 
Med 2024;13:1229. https://doi.org/10.3390/jcm13051229 
91. Ammirati E, Raimondi F, Piriou N, Sardo Infirri L, Mohiddin SA, Mazzanti A, et al. Acute 
myocarditis associated with desmosomal gene variants. JACC Heart Fail 2022;10: 
714–27. https://doi.org/10.1016/j.jchf.2022.06.013 
92. Kontorovich AR, Tang Y, Patel N, Georgievskaya Z, Shadrina M, Williams N, et al. 
Burden of cardiomyopathic genetic variation in lethal pediatric myocarditis. Circ 
Genom Precis Med 2021;14:e003426. https://doi.org/10.1161/CIRCGEN.121.003426 
93. Seidel F, Holtgrewe M, Al-Wakeel-Marquard N, Opgen-Rhein B, Dartsch J, Herbst C, 
et al. Pathogenic variants associated with dilated cardiomyopathy predict outcome in 
pediatric myocarditis. Circ Genom Precis Med 2021;14:e003250. https://doi.org/10. 
1161/CIRCGEN.120.003250 
94. Lota AS, Hazebroek MR, Theotokis P, Wassall R, Salmi S, Halliday BP, et al. Genetic 
architecture of acute myocarditis and the overlap with inherited cardiomyopathy. 
Circulation 2022;146:1123–34. https://doi.org/10.1161/CIRCULATIONAHA.121. 
058457 
95. Monda E, Bakalakos A, Cannie D, O’Mahony C, Syrris P, Kaski JP, et al. Prevalence of 
pathogenic variants in cardiomyopathy-associated genes in acute myocarditis: a 
systematic review and meta-analysis. JACC Heart Fail 2024;12:1101–11. https://doi. 
org/10.1016/j.jchf.2024.02.012 
96. Belkaya S, Kontorovich AR, Byun M, Mulero-Navarro S, Bajolle F, Cobat A, et al. 
Autosomal recessive cardiomyopathy presenting as acute myocarditis. J Am Coll 
Cardiol 2017;69:1653–65. https://doi.org/10.1016/j.jacc.2017.01.043 
97. Smith ED, Lakdawala NK, Papoutsidakis N, Aubert G, Mazzanti A, McCanta AC, et al. 
Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy 
distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. 
Circulation 2020;141:1872–84. https://doi.org/10.1161/CIRCULATIONAHA.119. 
044934 
98. Peretto G, De Luca G, Villatore A, Di Resta C, Sala S, Palmisano A, et al. Multimodal 
detection and targeting of biopsy-proven myocardial inflammation in genetic cardiomyopathies: a pilot report. JACC Basic Transl Sci 2023;8:755–65. https://doi.org/10. 
1016/j.jacbts.2023.02.018 
99. Bariani R, Cipriani A, Rizzo S, Celeghin R, Bueno Marinas M, Giorgi B, et al. ‘Hot phase’ 
clinical presentation in arrhythmogenic cardiomyopathy. Europace 2021;23:907–17.  
https://doi.org/10.1093/europace/euaa343 
100. Bariani R, Rigato I, Cipriani A, Bueno Marinas M, Celeghin R, Basso C, et al. 
Myocarditis-like episodes in patients with arrhythmogenic cardiomyopathy: a systematic review on the so-called hot-phase of the disease. Biomolecules 2022;12:1324.  
https://doi.org/10.3390/biom12091324 
101. Bassetto G, Merlo M, Dal Ferro M, Setti M, Paldino A, Collesi C, et al. Apoptosis, a useful marker in the management of hot-phase cardiomyopathy? Eur J Heart Fail 2024;26: 
590–7. https://doi.org/10.1002/ejhf.3173 
102. Collini V, Siega Vignut L, Angriman F, Braidotti G, De Biasio M, Imazio M. Age-stratified 
patterns in clinical presentation, treatment and outcomes in acute pericarditis: a retrospective cohort study. Heart 2024;110:1139–44. https://doi.org/10.1136/heartjnl- 
2024-324214 
103. Lazaros G, Antonopoulos AS, Imazio M, Solomou E, Lazarou E, Vassilopoulos D, et al. 
Clinical significance of pleural effusions and association with outcome in patients hospitalized with a first episode of acute pericarditis. Intern Emerg Med 2019;14:745–51.  
https://doi.org/10.1007/s11739-019-02041-3 
104. Imazio M, Pivetta E, Andreis A, Serra C, Carbone F, Masoero M, et al. Incessant pericarditis as a risk factor for complicated pericarditis and hospital admission. Circulation 
2021;143:401–2. https://doi.org/10.1161/CIRCULATIONAHA.120.051156 
105. Imazio M, Cecchi E, Demichelis B, Ierna S, Demarie D, Ghisio A, et al. Indicators of 
poor prognosis of acute pericarditis. Circulation 2007;115:2739–44. https://doi.org/ 
10.1161/CIRCULATIONAHA.106.662114 
106. Imazio M, Brucato A, Cumetti D, Brambilla G, Demichelis B, Ferro S, et al. 
Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation. Circulation 2008;118:667–71. https://doi.org/10.1161/CIRCULATIONAHA. 
107.761064 
107. Lazaros G, Antonopoulos AS, Vlachopoulos C, Oikonomou E, Karavidas A, 
Chrysochoou C, et al. Predictors of switching from nonsteroidal anti-inflammatory 
drugs to corticosteroids in patients with acute pericarditis and impact on clinical outcome. Hellenic J Cardiol 2019;60:357–63. https://doi.org/10.1016/j.hjc.2018.04.001 
108. Melendo-Viu M, Marchán-Lopez Á, Guarch CJ-L, Roubín SR, Abu-Assi E, Meneses RT, 
et al. A systematic review and meta-analysis of randomized controlled trials evaluating 
pharmacologic therapies for acute and recurrent pericarditis. Trends Cardiovasc Med 
2023;33:319–26. https://doi.org/10.1016/j.tcm.2022.02.001 
109. Artom G, Koren-Morag N, Spodick DH, Brucato A, Guindo J, Bayes-de-Luna A, et al. 
Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing 
recurrent pericarditis: a multi-centre all-case analysis. Eur Heart J 2005;26:723–27.  
https://doi.org/10.1093/eurheartj/ehi197 
110. Klein AL, Wang TKM, Cremer PC, Abbate A, Adler Y, Asher C, et al. Pericardial diseases: international position statement on new concepts and advances in multimodality cardiac imaging. JACC Cardiovasc Imaging 2024;17:937–88. https://doi.org/10.1016/j. 
jcmg.2024.04.010 
111. Chiabrando JG, Bonaventura A, Vecchié A, Wohlford GF, Mauro AG, Jordan JH, et al. 
Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll 
Cardiol 2020;75:76–92. https://doi.org/10.1016/j.jacc.2019.11.021 
112. Cremer PC, Tariq MU, Karwa A, Alraies MC, Benatti R, Schuster A, et al. Quantitative 
assessment of pericardial delayed hyperenhancement predicts clinical improvement in 
patients with constrictive pericarditis treated with anti-inflammatory therapy. Circ 
Cardiovasc Imaging 2015;8:e003125. https://doi.org/10.1161/CIRCIMAGING.114. 
003125 
113. Brucato A, Brambilla G, Moreo A, Alberti A, Munforti C, Ghirardello A, et al. 
Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am J 
Cardiol 2006;98:267–71. https://doi.org/10.1016/j.amjcard.2006.01.086 
114. Imazio M, Brucato A, Adler Y, Brambilla G, Artom G, Cecchi E, et al. Prognosis of idiopathic recurrent pericarditis as determined from previously published reports. Am J 
Cardiol 2007;100:1026–8. https://doi.org/10.1016/j.amjcard.2007.04.047 
115. Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B, et al. American Society 
of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for 
Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed


<!-- PAGE 77 -->

### Page 77

Tomography. J Am Soc Echocardiogr 2013;26:965–1012.e15. https://doi.org/10.1016/j. 
echo.2013.06.023 
116. Miranda WR, Newman DB, Sinak LJ, Espinosa RE, Anavekar NS, Goel K, et al. Pre- and 
post-pericardiocentesis echo-Doppler features of effusive-constrictive pericarditis 
compared with cardiac tamponade and constrictive pericarditis. Eur Heart J 
Cardiovasc Imaging 2019;20:298–306. https://doi.org/10.1093/ehjci/jey081 
117. Sagristà-Sauleda J, Angel J, Sánchez A, Permanyer-Miralda G, Soler-Soler J. 
Effusive-constrictive pericarditis. N Engl J Med 2004;350:469–75. https://doi.org/10. 
1056/NEJMoa035630 
118. Ristić AD, Imazio M, Adler Y, Anastasakis A, Badano LP, Brucato A, et al. Triage strategy for urgent management of cardiac tamponade: a position statement of the 
European Society of Cardiology Working Group on Myocardial and Pericardial 
Diseases. Eur Heart J 2014;35:2279–84. https://doi.org/10.1093/eurheartj/ehu217 
119. Talreja DR, Edwards WD, Danielson GK, Schaff HV, Tajik AJ, Tazelaar HD, et al. 
Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. 
Circulation 2003;108:1852–7. https://doi.org/10.1161/01.CIR.0000087606.18453.FD 
120. Sagristà-Sauleda J, Permanyer-Miralda G, Candell-Riera J, Angel J, Soler-Soler J. 
Transient cardiac constriction: an unrecognized pattern of evolution in effusive acute 
idiopathic pericarditis. Am J Cardiol 1987;59:961–6. https://doi.org/10.1016/0002- 
9149(87)91134-9 
121. Haley JH, Tajik AJ, Danielson GK, Schaff HV, Mulvagh SL, Oh JK. Transient constrictive 
pericarditis: causes and natural history. J Am Coll Cardiol 2004;43:271–75. https://doi. 
org/10.1016/j.jacc.2003.08.032 
122. Sato K, Ayache A, Kumar A, Cremer PC, Griffin B, Popovic ZB, et al. Improvement in 
left ventricular mechanics following medical treatment of constrictive pericarditis. 
Heart 2021;107:828–35. https://doi.org/10.1136/heartjnl-2020-317304 
123. Feng D, Glockner J, Kim K, Martinez M, Syed IS, Araoz P, et al. Cardiac magnetic resonance imaging pericardial late gadolinium enhancement and elevated inflammatory 
markers can predict the reversibility of constrictive pericarditis after antiinflammatory 
medical therapy: a pilot study. Circulation 2011;124:1830–7. https://doi.org/10.1161/ 
CIRCULATIONAHA.111.026070 
124. Cosyns B, Plein S, Nihoyanopoulos P, Smiseth O, Achenbach S, Andrade MJ, et al. 
European Association of Cardiovascular Imaging (EACVI) position paper: multimodality imaging in pericardial disease. Eur Heart J Cardiovasc Imaging 2015;16:12–31. https:// 
doi.org/10.1093/ehjci/jeu128 
125. Lopalco G, Venerito V, Brucato A, Emmi G, Giacomelli R, Cauli A, et al. Anakinra effectiveness in refractory polyserositis: an Italian multicenter study. Joint Bone Spine 
2022;89:105299. https://doi.org/10.1016/j.jbspin.2021.105299 
126. Kilic A, Varkal MA, Durmus MS, Yildiz I, Yıldırım ZNY, Turunc G, et al. Relationship 
between clinical findings and genetic mutations in patients with familial 
Mediterranean fever. Pediatr Rheumatol Online J 2015;13:59. https://doi.org/10.1186/ 
s12969-015-0057-1 
127. Kumar S, Khubber S, Reyaldeen R, Agrawal A, Cremer PC, Imazio M, et al. Advances in 
imaging and targeted therapies for recurrent pericarditis: a review. JAMA Cardiol 2022; 
7:975–85. https://doi.org/10.1001/jamacardio.2022.2584 
128. Habib G, Bucciarelli-Ducci C, Caforio ALP, Cardim N, Charron P, Cosyns B, et al. 
Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus 
document in collaboration with the ‘Working group on myocardial and pericardial diseases’ of the European Society of Cardiology Endorsed by The Indian Academy of 
Echocardiography. Eur Heart J Cardiovasc Imaging 2017;18:1090–121. https://doi.org/ 
10.1093/ehjci/jex034 
129. Imazio M, Pivetta E, Palacio Restrepo S, Sormani P, Pedrotti P, Quarta G, et al. 
Usefulness of cardiac magnetic resonance for recurrent pericarditis. Am J Cardiol 
2020;125:146–51. https://doi.org/10.1016/j.amjcard.2019.09.026 
130. Imazio M, Demichelis B, Parrini I, Giuggia M, Cecchi E, Gaschino G, et al. Day-hospital 
treatment of acute pericarditis: a management program for outpatient therapy. J Am 
Coll Cardiol 2004;43:1042–46. https://doi.org/10.1016/j.jacc.2003.09.055 
131. Chimenti C, Russo MA, Frustaci A. Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial. Eur Heart J 2022; 
43:3463–73. https://doi.org/10.1093/eurheartj/ehac348 
132. Rao K, De Silva K, Sood A, Denniss AR, Hsu C-J. Predicting patients with troponin positive chest pain and unobstructed coronary arteries with electrocardiogram, troponin 
kinetics and GRACE score. Heart Lung Circ 2022;31:1219–27. https://doi.org/10.1016/ 
j.hlc.2022.05.040 
133. De Lazzari M, Zorzi A, Baritussio A, Siciliano M, Migliore F, Susana A, et al. Relationship 
between T-wave inversion and transmural myocardial edema as evidenced by cardiac 
magnetic resonance in patients with clinically suspected acute myocarditis: clinical and 
prognostic implications. J Electrocardiol 2016;49:587–95. https://doi.org/10.1016/j. 
jelectrocard.2016.04.002 
134. Nucifora G, Miani D, Di Chiara A, Piccoli G, Artico J, Puppato M, et al. Infarct-like acute 
myocarditis: relation between electrocardiographic findings and myocardial damage as 
assessed by cardiac magnetic resonance imaging. Clin Cardiol 2013;36:146–52. https:// 
doi.org/10.1002/clc.22088 
135. Wang Z, Wang Y, Lin H, Wang S, Cai X, Gao D. Early characteristics of fulminant myocarditis vs non-fulminant myocarditis: a meta-analysis. Medicine (Baltimore) 2019;98: 
e14697. https://doi.org/10.1097/MD.0000000000014697 
136. Ukena C, Mahfoud F, Kindermann I, Kandolf R, Kindermann M, Böhm M. Prognostic 
electrocardiographic parameters in patients with suspected myocarditis. Eur J Heart 
Fail 2011;13:398–405. https://doi.org/10.1093/eurjhf/hfq229 
137. Jhamnani S, Fuisz A, Lindsay J. The spectrum of electrocardiographic manifestations of 
acute myocarditis: an expanded understanding. J Electrocardiol 2014;47:941–7. https:// 
doi.org/10.1016/j.jelectrocard.2014.07.018 
138. Baritussio A, Cheng C-Y, Lorenzoni G, Basso C, Rizzo S, De Gaspari M, et al. A 
machine-learning model for the prognostic role of C-reactive protein in myocarditis. 
J Clin Med 2022;11:7068. https://doi.org/10.3390/jcm11237068 
139. Lazaros G, Vlachakis PK, Theofilis P, Dasoula FE, Imazio M, Lazarou E, et al. D-dimer as 
a diagnostic and prognostic plasma biomarker in patients with a first episode of acute 
pericarditis. Eur J Intern Med 2023;19:2133–9. https://doi.org/10.1016/j.ejim.2023.06. 
017 
140. Mauro A, Bizzi E, Wu MA, Mascolo R, Chirico C, Conte E, et al. D-dimer and procalcitonin in patients with recurrent pericarditis: a prospective study. Intern Emerg Med 
2024;19:2133–9. https://doi.org/10.1007/s11739-024-03712-6 
141. Blanco-Domínguez R, Sánchez-Díaz R, de la Fuente H, Jiménez-Borreguero LJ, 
Matesanz-Marín A, Relaño M, et al. A novel circulating microRNA for the detection 
of acute myocarditis. N Engl J Med 2021;384:2014–27. https://doi.org/10.1056/ 
NEJMoa2003608 
142. Caforio ALP, De Luca G, Baritussio A, Seguso M, Gallo N, Bison E, et al. Serum organ- 
specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers 
of cardiac involvement in systemic sclerosis: frequency, clinical and prognostic correlates. 
Diagnostics (Basel) 2021;11:2165. https://doi.org/10.3390/diagnostics11112165 
143. Coronado MJ, Bruno KA, Blauwet LA, Tschöpe C, Cunningham MW, Pankuweit S, 
et al. Elevated sera sST2 is associated with heart failure in men ≤50 years old with myocarditis. J Am Heart Assoc 2019;8:e008968. https://doi.org/10.1161/JAHA.118.008968 
144. Müller I, Vogl T, Kühl U, Krannich A, Banks A, Trippel T, et al. Serum alarmin S100A8/ 
S100A9 levels and its potential role as biomarker in myocarditis. ESC Heart Fail 2020;7: 
1442–51. https://doi.org/10.1002/ehf2.12760 
145. Müller I, Vogl T, Pappritz K, Miteva K, Savvatis K, Rohde D, et al. Pathogenic role of the 
damage-associated molecular patterns S100A8 and S100A9 in Coxsackievirus 
B3-induced myocarditis. Circ Heart Fail 2017;10:e004125. https://doi.org/10.1161/ 
CIRCHEARTFAILURE.117.004125 
146. Ader F, Surget E, Charron P, Redheuil A, Zouaghi A, Maltret A, et al. Inherited cardiomyopathies revealed by clinically suspected myocarditis: highlights from genetic testing. 
Circ Genom Precis Med 2020;13:e002744. https://doi.org/10.1161/CIRCGEN.119. 
002744 
147. Poller W, Haas J, Klingel K, Kühnisch J, Gast M, Kaya Z, et al. Familial recurrent myocarditis triggered by exercise in patients with a truncating variant of the desmoplakin 
gene. J Am Heart Assoc 2020;9:e015289. https://doi.org/10.1161/JAHA.119.015289 
148. Ollitrault P, Al Khoury M, Troadec Y, Calcagno Y, Champ-Rigot L, Ferchaud V, et al. 
Recurrent acute myocarditis: an under-recognized clinical entity associated with the 
later diagnosis of a genetic arrhythmogenic cardiomyopathy. Front Cardiovasc Med 
2022;9:998883. https://doi.org/10.3389/fcvm.2022.998883 
149. Piriou N, Marteau L, Kyndt F, Serfaty JM, Toquet C, Le Gloan L, et al. Familial screening 
in case of acute myocarditis reveals inherited arrhythmogenic left ventricular cardiomyopathies. ESC Heart Fail 2020;7:1520–33. https://doi.org/10.1002/ehf2.12686 
150. Artico J, Merlo M, Delcaro G, Cannatà A, Gentile P, De Angelis G, et al. Lymphocytic 
myocarditis: a genetically predisposed disease? J Am Coll Cardiol 2020;75:3098–100.  
https://doi.org/10.1016/j.jacc.2020.04.048 
151. Verdonschot JAJ, Heymans SRB. Dilated cardiomyopathy: second hits knock-down the 
heart. Eur Heart J 2024;45:500–1. https://doi.org/10.1093/eurheartj/ehad778 
152. Cantarini L, Lucherini OM, Brucato A, Barone L, Cumetti D, Iacoponi F, et al. Clues to 
detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among 
patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin 
Res Cardiol 2012;101:525–31. https://doi.org/10.1007/s00392-012-0422-8 
153. Brucato A, Shinar Y, Brambilla G, Robbiolo L, Ferrioli G, Patrosso MC, et al. Idiopathic 
recurrent acute pericarditis: familial Mediterranean fever mutations and disease evolution in a large cohort of Caucasian patients. Lupus 2005;14:670–4. https://doi.org/10. 
1191/0961203305lu2197oa 
154. Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL, et al. 
Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 
2000;36:227–32. https://doi.org/10.1016/s0735-1097(00)00690-2 
155. Pinamonti B, Alberti E, Cigalotto A, Dreas L, Salvi A, Silvestri F, et al. Echocardiographic 
findings in myocarditis. Am J Cardiol 1988;62:285–91. https://doi.org/10.1016/0002- 
9149(88)90226-3 
156. Uppu SC, Shah A, Weigand J, Nielsen JC, Ko HH, Parness IA, et al. Two-dimensional 
speckle-tracking-derived segmental peak systolic longitudinal strain identifies regional 
myocardial involvement in patients with myocarditis and normal global left ventricular 
systolic function. Pediatr Cardiol 2015;36:950–9. https://doi.org/10.1007/s00246-015- 
1105-9 
157. Sperlongano S, D’Amato A, Tagliamonte E, Russo V, Desiderio A, Ilardi F, et al. Acute 
myocarditis: prognostic role of speckle tracking echocardiography and comparison 
with cardiac magnetic resonance features. Heart Vessels 2022;37:121–31. https://doi. 
org/10.1007/s00380-021-01893-0  
ESC Guidelines                                                                                                                                                                                               77


<!-- PAGE 78 -->

### Page 78

158. Ben-Joya D, Kaplan A, Baruch G, Rothschild E, Beer G, Banai S, et al. The prevalence of 
abnormal right ventricle speckle strain in the setting of acute myocarditis and preserved left ventricle function. Int J Cardiovasc Imaging 2023;39:1231–8. https://doi. 
org/10.1007/s10554-023-02829-7 
159. Meindl C, Paulus M, Poschenrieder F, Hamer OW, Zeman F, Maier LS, et al. Left atrial 
strain parameters derived by echocardiography are impaired in patients with acute 
myocarditis and preserved systolic left ventricular function. Int J Cardiovasc Imaging 
2023;39:1157–65. https://doi.org/10.1007/s10554-023-02827-9 
160. Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, et al. Colchicine in 
addition to conventional therapy for acute pericarditis: results of the COlchicine for 
acute PEricarditis (COPE) trial. Circulation 2005;112:2012–6. https://doi.org/10. 
1161/CIRCULATIONAHA.105.542738 
161. Iles LM, Ellims AH, Llewellyn H, Hare JL, Kaye DM, McLean CA, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging 2015;16:14–22. https://doi.org/10.1093/ 
ehjci/jeu182 
162. Miller CA, Naish JH, Bishop P, Coutts G, Clark D, Zhao S, et al. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging 2013;6:373–83. https://doi.org/10. 
1161/CIRCIMAGING.112.000192 
163. Voigt A, Elgeti T, Durmus T, Idiz ME, Butler C, Beling M, et al. Cardiac magnetic resonance imaging in dilated cardiomyopathy in adults—towards identification of myocardial inflammation. Eur Radiol 2011;21:925–35. https://doi.org/10.1007/s00330- 
010-1985-2 
164. Lurz P, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M, et al. Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the 
MyoRacer-Trial. J Am Coll Cardiol 2016;67:1800–11. https://doi.org/10.1016/j.jacc. 
2016.02.013 
165. Zurick AO, Bolen MA, Kwon DH, Tan CD, Popovic ZB, Rajeswaran J, et al. Pericardial 
delayed hyperenhancement with CMR imaging in patients with constrictive pericarditis 
undergoing surgical pericardiectomy: a case series with histopathological correlation. 
JACC Cardiovasc Imaging 2011;4:1180–91. https://doi.org/10.1016/j.jcmg.2011.08.011 
166. Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E. 
Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson 2020;22:17. https://doi.org/10.1186/s12968-020- 
00607-1 
167. Muehlberg F, Blaszczyk E, Will K, Wilczek S, Brederlau J, Schulz-Menger J. 
Characterization of critically ill patients with septic shock and sepsis-associated cardiomyopathy using cardiovascular MRI. ESC Heart Fail 2022;9:2147–56. https://doi.org/10. 
1002/ehf2.13938 
168. Gröschel J, Ammann C, Zange L, Viezzer D, Forman C, Schmidt M, et al. Fast acquisition of left and right ventricular function parameters applying cardiovascular magnetic 
resonance in clinical routine—validation of a 2-shot compressed sensing cine sequence. Scand Cardiovasc J 2022;56:266–75. https://doi.org/10.1080/14017431.2022. 
2099010 
169. Mileva N, Paolisso P, Gallinoro E, Fabbricatore D, Munhoz D, Bergamaschi L, et al. 
Diagnostic and prognostic role of cardiac magnetic resonance in MINOCA: systematic 
review and meta-analysis. JACC Cardiovasc Imaging 2023;16:376–89. https://doi.org/10. 
1016/j.jcmg.2022.12.029 
170. Machanahalli Balakrishna A, Ismayl M, Thandra A, Walters R, Ganesan V, Anugula D, 
et al. Diagnostic value of cardiac magnetic resonance imaging and intracoronary optical 
coherence tomography in patients with a working diagnosis of myocardial infarction 
with non-obstructive coronary arteries—a systematic review and meta-analysis. 
Curr Probl Cardiol 2023;48:101126. https://doi.org/10.1016/j.cpcardiol.2022.101126 
171. Hausvater A, Smilowitz NR, Li B, Redel-Traub G, Quien M, Qian Y, et al. Myocarditis in 
relation to angiographic findings in patients with provisional diagnoses of MINOCA. 
JACC Cardiovasc Imaging 2020;13:1906–13. https://doi.org/10.1016/j.jcmg.2020.02.037 
172. Tornvall P, Gerbaud E, Behaghel A, Chopard R, Collste O, Laraudogoitia E, et al. 
Myocarditis or ‘true’ infarction by cardiac magnetic resonance in patients with a clinical 
diagnosis of myocardial infarction without obstructive coronary disease: a 
meta-analysis of individual patient data. Atherosclerosis 2015;241:87–91. https://doi. 
org/10.1016/j.atherosclerosis.2015.04.816 
173. Bohnen S, Radunski UK, Lund GK, Kandolf R, Stehning C, Schnackenburg B, et al. 
Performance of T1 and T2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging 
2015;8:e003073. https://doi.org/10.1161/CIRCIMAGING.114.003073 
174. Khanna S, Amarasekera AT, Li C, Bhat A, Chen HHL, Gan GCH, et al. The utility of 
cardiac magnetic resonance imaging in the diagnosis of adult patients with acute myocarditis: a systematic review and meta-analysis. Int J Cardiol 2022;363:225–39. https:// 
doi.org/10.1016/j.ijcard.2022.06.047 
175. Jia Z, Wang L, Jia Y, Liu J, Zhao H, Huo L, et al. Detection of acute myocarditis using T1 
and T2 mapping cardiovascular magnetic resonance: a systematic review and 
meta-analysis. J Appl Clin Med Phys 2021;22:239–48. https://doi.org/10.1002/acm2. 
13365 
176. Blissett S, Chocron Y, Kovacina B, Afilalo J. Diagnostic and prognostic value of cardiac 
magnetic resonance in acute myocarditis: a systematic review and meta-analysis. Int J 
Cardiovasc Imaging 2019;35:2221–9. https://doi.org/10.1007/s10554-019-01674-x 
177. Pan JA, Lee YJ, Salerno M. Diagnostic performance of extracellular volume, native T1, 
and T2 mapping versus Lake Louise criteria by cardiac magnetic resonance for detection of acute myocarditis: a meta-analysis. Circ Cardiovasc Imaging 2018;11:e007598.  
https://doi.org/10.1161/CIRCIMAGING.118.007598 
178. Wei S, Fu J, Chen L, Yu S. Performance of cardiac magnetic resonance imaging for diagnosis of myocarditis compared with endomyocardial biopsy: a meta-analysis. Med Sci 
Monit 2017;23:3687–96. https://doi.org/10.12659/msm.902155 
179. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, et al. 
Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. 
Lancet 2012;379:453–60. https://doi.org/10.1016/S0140-6736(11)61335-4 
180. Greenwood JP, Ripley DP, Berry C, McCann GP, Plein S, Bucciarelli-Ducci C, et al. 
Effect of care guided by cardiovascular magnetic resonance, myocardial perfusion scintigraphy, or NICE guidelines on subsequent unnecessary angiography rates: the 
CE-MARC 2 randomized clinical trial. JAMA 2016;316:1051–60. https://doi.org/10. 
1001/jama.2016.12680 
181. Nagel E, Greenwood JP, McCann GP, Bettencourt N, Shah AM, Hussain ST, et al. 
Magnetic resonance perfusion or fractional flow reserve in coronary disease. N Engl 
J Med 2019;380:2418–28. https://doi.org/10.1056/NEJMoa1716734 
182. Arai AE, Schulz-Menger J, Berman D, Mahrholdt H, Han Y, Bandettini WP, et al. 
Gadobutrol-enhanced cardiac magnetic resonance imaging for detection of coronary 
artery disease. J Am Coll Cardiol 2020;76:1536–47. https://doi.org/10.1016/j.jacc.2020. 
07.060 
183. Kwong RY, Ge Y, Steel K, Bingham S, Abdullah S, Fujikura K, et al. Cardiac magnetic 
resonance stress perfusion imaging for evaluation of patients with chest pain. J Am 
Coll Cardiol 2019;74:1741–55. https://doi.org/10.1016/j.jacc.2019.07.074 
184. Bohm P, Scharhag J, Meyer T. Data from a nationwide registry on sports-related sudden cardiac deaths in Germany. Eur J Prev Cardiol 2016;23:649–56. https://doi.org/10. 
1177/2047487315594087 
185. Pelliccia A, Solberg EE, Papadakis M, Adami PE, Biffi A, Caselli S, et al. 
Recommendations for participation in competitive and leisure time sport in athletes 
with cardiomyopathies, myocarditis, and pericarditis: position statement of the 
Sport Cardiology Section of the European Association of Preventive Cardiology 
(EAPC). Eur Heart J 2019;40:19–33. https://doi.org/10.1093/eurheartj/ehy730 
186. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NAM, et al. 
Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific 
statement from the American Heart Association and American College of Cardiology. 
Circulation 2015;132:e273–80. https://doi.org/10.1161/CIR.0000000000000239 
187. Sechtem U, Tscholakoff D, Higgins CB. MRI of the normal pericardium. AJR Am J 
Roentgenol 1986;147:239–44. https://doi.org/10.2214/ajr.147.2.239 
188. Stark DD, Higgins CB, Lanzer P, Lipton MJ, Schiller N, Crooks LE, et al. Magnetic resonance imaging of the pericardium: normal and pathologic findings. Radiology 1984; 
150:469–74. https://doi.org/10.1148/radiology.150.2.6691103 
189. Tscholakoff D, Sechtem U, de Geer G, Schmidt H, Higgins CB. Evaluation of pleural 
and pericardial effusions by magnetic resonance imaging. Eur J Radiol 1987;7:169–74. 
190. Power JA, Thompson DV, Rayarao G, Doyle M, Biederman RWW. Cardiac magnetic 
resonance radiofrequency tissue tagging for diagnosis of constrictive pericarditis: a 
proof of concept study. J Thorac Cardiovasc Surg 2016;151:1348–55. https://doi.org/ 
10.1016/j.jtcvs.2015.12.035 
191. Gastl M, Sokolska JM, Polacin M, Gotschy A, von Spiczak Brzezinski J, Alkadhi H, et al. 
Parametric mapping CMR for the measurement of inflammatory reactions of the pericardium. Open Heart 2022;9:e001919. https://doi.org/10.1136/openhrt-2021-001919 
192. Conte E, Agalbato C, Lauri G, Mushtaq S, Cia AD, Bonomi A, et al. Cardiac MRI after 
first episode of acute pericarditis: a pilot study for better identification of high risk patients. Int J Cardiol 2022;354:63–7. https://doi.org/10.1016/j.ijcard.2022.03.007 
193. Young PM, Glockner JF, Williamson EE, Morris MF, Araoz PA, Julsrud PR, et al. MR imaging findings in 76 consecutive surgically proven cases of pericardial disease with CT 
and pathologic correlation. Int J Cardiovasc Imaging 2012;28:1099–109. https://doi.org/ 
10.1007/s10554-011-9916-0 
194. Taylor AM, Dymarkowski S, Verbeken EK, Bogaert J. Detection of pericardial inflammation with late-enhancement cardiac magnetic resonance imaging: initial results. Eur 
Radiol 2006;16:569–74. https://doi.org/10.1007/s00330-005-0025-0 
195. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 
ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur 
Heart J 2020;41:407–77. https://doi.org/10.1093/eurheartj/ehz425 
196. Maggiolini S, De Carlini CC, Ferri LA, Colombo GI, Gentile G, Meles E, et al. The role of 
early contrast-enhanced chest computed tomography in the aetiological diagnosis of 
patients presenting with cardiac tamponade or large pericardial effusion. Eur Heart J 
Cardiovasc Imaging 2016;17:421–8. https://doi.org/10.1093/ehjci/jev225 
197. Lee Y-H, Kim SM, Kim EK, Park S-J, Lee S-C, Park SW, et al. Pattern of pericardial calcification determines mid-term postoperative outcomes after pericardiectomy in


<!-- PAGE 79 -->

### Page 79

chronic constrictive pericarditis. Int J Cardiol 2023;387:131133. https://doi.org/10. 
1016/j.ijcard.2023.131133 
198. Conte E, Agalbato C, Lauri G, Mushtaq S, Carollo C, Bonomi A, et al. Prevalence and 
prognosis of pericardial effusion in patients affected by pectus excavatum: a case- 
control study. Int J Cardiol 2021;344:179–83. https://doi.org/10.1016/j.ijcard.2021.10. 
005 
199. Bogaert J, Meyns B, Dymarkowski S, Sinnaeve P, Meuris B. Calcified constrictive pericarditis: prevalence, distribution patterns, and relationship to the myocardium. JACC 
Cardiovasc Imaging 2016;9:1013–4. https://doi.org/10.1016/j.jcmg.2015.08.011 
200. Azzu A, Morosin M, Antonopoulos AS, Capoccia M, Rosendahl U, Mohiaddin R. 
Cardiac decompression by pericardiectomy for constrictive pericarditis: multimodality 
imaging to identify patients at risk for prolonged inotropic support. J Cardiovasc Imaging 
2021;29:361–72. https://doi.org/10.4250/jcvi.2020.0223 
201. Peretto G, Busnardo E, Ferro P, Palmisano A, Vignale D, Esposito A, et al. Clinical applications of FDG-PET scan in arrhythmic myocarditis. JACC Cardiovasc Imaging 2022; 
15:1771–80. https://doi.org/10.1016/j.jcmg.2022.02.029 
202. Palmisano A, Vignale D, Peretto G, Busnardo E, Calcagno C, Campochiaro C, et al. 
Hybrid FDG-PET/MR or FDG-PET/CT to detect disease activity in patients with persisting arrhythmias after myocarditis. JACC Cardiovasc Imaging 2021;14:288–92. https:// 
doi.org/10.1016/j.jcmg.2020.03.009 
203. Hanneman K, Kadoch M, Guo HH, Jamali M, Quon A, Iagaru A, et al. Initial experience with 
simultaneous 18F-FDG PET/MRI in the evaluation of cardiac sarcoidosis and myocarditis. 
Clin Nucl Med 2017;42:e328–34. https://doi.org/10.1097/RLU.0000000000001669 
204. Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, et al. 
Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in 
cardiac sarcoid detection and therapy monitoring. J Nucl Med 2017;58:1341–53.  
https://doi.org/10.2967/jnumed.117.196287 
205. Salomäki SP, Hohenthal U, Kemppainen J, Pirilä L, Saraste A. Visualization of pericarditis by fluorodeoxyglucose PET. Eur Heart J Cardiovasc Imaging 2014;15:291. https:// 
doi.org/10.1093/ehjci/jet179 
206. Nensa F, Kloth J, Tezgah E, Poeppel TD, Heusch P, Goebel J, et al. Feasibility of 
FDG-PET in myocarditis: comparison to CMR using integrated PET/MRI. J Nucl 
Cardiol 2018;25:785–94. https://doi.org/10.1007/s12350-016-0616-y 
207. Basso C, Calabrese F, Angelini A, Carturan E, Thiene G. Classification and histological, 
immunohistochemical, and molecular diagnosis of inflammatory myocardial disease. 
Heart Fail Rev 2013;18:673–81. https://doi.org/10.1007/s10741-012-9355-6 
208. Murphy L, McGuckin M, Giblin G, Keogh A, McGovern B, Fabre A, et al. The role of 
endomyocardial biopsy in suspected myocarditis in the contemporary era: a 10-year 
National Transplant Centre experience. Cardiovasc Pathol 2021;54:107366. https:// 
doi.org/10.1016/j.carpath.2021.107366 
209. Lu ZA, Aubry MC, Fallon JT, Fishbein MC, Giordano C, Klingel K, et al. Myocarditis and 
endomyocardial biopsy: achieving consensus diagnosis on 100 cases. Cardiovasc Pathol 
2023;62:107492. https://doi.org/10.1016/j.carpath.2022.107492 
210. Seferović PM, Tsutsui H, McNamara DM, Ristić AD, Basso C, Bozkurt B, et al. Heart 
Failure Association of the ESC, Heart Failure Society of America and Japanese Heart 
Failure Society position statement on endomyocardial biopsy. Eur J Heart Fail 2021; 
23:854–71. https://doi.org/10.1002/ejhf.2190 
211. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, et al. 
Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 2010;122:900–9.  
https://doi.org/10.1161/CIRCULATIONAHA.109.924167 
212. van der Boon R, den Dekker W, Meuwese CL, Lorusso R, von der Thüsen J, 
Constantinescu AC, et al. Safety of endomyocardial biopsy in new-onset acute heart 
failure requiring veno-arterial extracorporeal membrane oxygenation. Circ Heart Fail 
2021;14:e008387. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008387 
213. Mueller GC, Michel-Behnke I, Knirsch W, Haas NA, Abdul-Khaliq H, Gitter R, et al. 
Feasibility, safety and diagnostic impact of endomyocardial biopsies for the diagnosis 
of myocardial disease in children and adolescents. EuroIntervention 2018;14: 
1089–95. https://doi.org/10.4244/EIJ-D-18-00128 
214. De Gaspari M, Larsen BT, d’Amati G, Kreutz K, Basso C, Michaud K, et al. Diagnosing 
myocarditis in endomyocardial biopsies: survey of current practice. Cardiovasc Pathol 
2023;64:107494. https://doi.org/10.1016/j.carpath.2022.107494 
215. Gartshteyn Y, Tamargo M, Fleischer S, Kapoor T, Li J, Askanase A, et al. 
Endomyocardial biopsies in the diagnosis of myocardial involvement in systemic lupus 
erythematosus. Lupus 2020;29:199–204. https://doi.org/10.1177/0961203319897116 
216. Heymans S, Lakdawala NK, Tschöpe C, Klingel K. Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches. Lancet 2023;402:998–1011.  
https://doi.org/10.1016/S0140-6736(23)01241-2 
217. Kandolin R, Lehtonen J, Salmenkivi K, Räisänen-Sokolowski A, Lommi J, Kupari M. 
Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined 
immunosuppression. 
Circ 
Heart 
Fail 
2013;6:15–22. 
https://doi.org/10.1161/ 
CIRCHEARTFAILURE.112.969261 
218. Casella M, Dello Russo A, Bergonti M, Catto V, Conte E, Sommariva E, et al. Diagnostic 
yield of electroanatomic voltage mapping in guiding endomyocardial biopsies. Circulation 
2020;142:1249–60. https://doi.org/10.1161/CIRCULATIONAHA.120.046900 
219. Casella M, Pizzamiglio F, Dello Russo A, Carbucicchio C, Al-Mohani G, Russo E, et al. 
Feasibility of combined unipolar and bipolar voltage maps to improve sensitivity of endomyocardial biopsy. Circ Arrhythm Electrophysiol 2015;8:625–32. https://doi.org/10. 
1161/CIRCEP.114.002216 
220. Ezzeddine FM, Kapa S, Rosenbaum A, Blauwet L, Deshmukh AJ, AbouEzzeddine OF, 
et al. Electrogram-guided endomyocardial biopsy yield in patients with suspected cardiac sarcoidosis and relation to outcomes. J Cardiovasc Electrophysiol 2021;32:2486–95.  
https://doi.org/10.1111/jce.15191 
221. Vaidya VR, Abudan AA, Vasudevan K, Shantha G, Cooper LT, Kapa S, et al. The efficacy 
and safety of electroanatomic mapping-guided endomyocardial biopsy: a systematic 
review. J Interv Card Electrophysiol 2018;53:63–71. https://doi.org/10.1007/s10840- 
018-0410-7 
222. Pelargonio G, Pinnacchio G, Narducci ML, Pieroni M, Perna F, Bencardino G, et al. long- 
term arrhythmic risk assessment in biopsy-proven myocarditis. JACC Clin Electrophysiol 
2020;6:574–82. https://doi.org/10.1016/j.jacep.2019.12.010 
223. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ, et al. 
Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 
1987;1:3–14. 
224. Schnitt SJ, Ciano PS, Schoen FJ. Quantitation of lymphocytes in endomyocardial biopsies: use and limitations of antibodies to leukocyte common antigen. Hum Pathol 1987; 
18:796–800. https://doi.org/10.1016/s0046-8177(87)80053-9 
225. Linder J, Cassling RS, Rogler WC, Wilson JE, Markin RS, Sears TD, et al. 
Immunohistochemical characterization of lymphocytes in uninflamed ventricular myocardium. Implications for myocarditis. Arch Pathol Lab Med 1985;109:917–20. 
226. Ohta-Ogo K, Sugano Y, Ogata S, Nakayama T, Komori T, Eguchi K, et al. Myocardial 
T-lymphocytes as a prognostic risk-stratifying marker of dilated cardiomyopathy—results of the multicenter registry to investigate inflammatory cell infiltration in dilated 
cardiomyopathy in tissues of endomyocardial biopsy (INDICATE study). Circ J 2022; 
86:1092–101. https://doi.org/10.1253/circj.CJ-21-0529 
227. Katzmann JL, Schlattmann P, Rigopoulos AG, Noutsias E, Bigalke B, Pauschinger M, 
et al. Meta-analysis on the immunohistological detection of inflammatory cardiomyopathy in endomyocardial biopsies. Heart Fail Rev 2020;25:277–94. https://doi.org/10. 
1007/s10741-019-09835-9 
228. Pelzl L, Mantino S, Sauter M, Manuylova T, Vogel U, Klingel K. Lymphocytic myocarditis 
in children with parvovirus B19 infection: pathological and molecular insights. 
Biomedicines 2024;12:1909. https://doi.org/10.3390/biomedicines12081909 
229. Stiermaier T, Föhrenbach F, Klingel K, Kandolf R, Boudriot E, Sandri M, et al. 
Biventricular endomyocardial biopsy in patients with suspected myocarditis: feasibility, 
complication rate and additional diagnostic value. Int J Cardiol 2017;230:364–70.  
https://doi.org/10.1016/j.ijcard.2016.12.103 
230. Mahfoud F, Gärtner B, Kindermann M, Ukena C, Gadomski K, Klingel K, et al. Virus 
serology in patients with suspected myocarditis: utility or futility? Eur Heart J 2011; 
32:897–903. https://doi.org/10.1093/eurheartj/ehq493 
231. Heidecker B, Williams SH, Jain K, Oleynik A, Patriki D, Kottwitz J, et al. Virome sequencing in patients with myocarditis. Circ Heart Fail 2020;13:e007103. https://doi.org/10. 
1161/CIRCHEARTFAILURE.120.007103 
232. Maisch B, Rupp H, Ristic A, Pankuweit S. Pericardioscopy and epi- and pericardial biopsy—a new window to the heart improving etiological diagnoses and permitting targeted intrapericardial therapy. Heart Fail Rev 2013;18:317–28. https://doi.org/10.1007/ 
s10741-013-9382-y 
233. Ding Z, Yang M, Wang Y, Wu S, Qiu X, Liu Q. Retrospective analysis of 769 cases of 
sudden cardiac death from 2006 to 2015: a forensic experience in China. Forensic Sci 
Med Pathol 2017;13:336–41. https://doi.org/10.1007/s12024-017-9888-z 
234. Vassalini M, Verzeletti A, Restori M, De Ferrari F. An autopsy study of sudden cardiac 
death in persons aged 1–40 years in Brescia (Italy). J Cardiovasc Med (Hagerstown) 2016; 
17:446–53. https://doi.org/10.2459/JCM.0000000000000234 
235. Wu Y, Ai M, Bardeesi ASA, Zhang L, Wu Q, Yin K, et al. The forensic pathological analysis of sport-related sudden cardiac death in Southern China. Forensic Sci Res 2020;5: 
47–54. https://doi.org/10.1080/20961790.2017.1319785 
236. Wang H, Yao Q, Zhu S, Zhang G, Wang Z, Li Z, et al. The autopsy study of 553 cases of 
sudden cardiac death in Chinese adults. Heart Vessels 2014;29:486–95. https://doi.org/ 
10.1007/s00380-013-0388-0 
237. Doolan A, Langlois N, Semsarian C. Causes of sudden cardiac death in young 
Australians. Med J Aust 2004;180:110–2. https://doi.org/10.5694/j.1326-5377.2004. 
tb05830.x 
238. Harris KM, Mackey-Bojack S, Bennett M, Nwaudo D, Duncanson E, Maron BJ. Sudden 
unexpected death due to myocarditis in young people, including athletes. Am J Cardiol 
2021;143:131–4. https://doi.org/10.1016/j.amjcard.2020.12.028 
239. Basso C, Aguilera B, Banner J, Cohle S, d’Amati G, de Gouveia RH, et al. Guidelines for 
autopsy investigation of sudden cardiac death: 2017 update from the Association for 
European Cardiovascular Pathology. Virchows Arch 2017;471:691–705. https://doi.org/ 
10.1007/s00428-017-2221-0 
240. Ekström K, Lehtonen J, Nordenswan H-K, Mäyränpää MI, Räisänen-Sokolowski A, 
Kandolin R, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical 
and cause-of-death registries. Eur Heart J 2019;40:3121–8. https://doi.org/10.1093/ 
eurheartj/ehz428  
ESC Guidelines                                                                                                                                                                                               79


<!-- PAGE 80 -->

### Page 80

241. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA 
expert consensus statement on the state of genetic testing for the channelopathies 
and cardiomyopathies. This document was developed as a partnership between the 
Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). 
Heart Rhythm 2011;8:1308–39. https://doi.org/10.1016/j.hrthm.2011.05.020 
242. Wilhelm M, Bolliger SA, Bartsch C, Fokstuen S, Gräni C, Martos V, et al. Sudden cardiac 
death in forensic medicine—Swiss recommendations for a multidisciplinary approach. 
Swiss Med Wkly 2015;145:w14129. https://doi.org/10.4414/smw.2015.14129 
243. de Noronha SV, Behr ER, Papadakis M, Ohta-Ogo K, Banya W, Wells J, et al. The importance of specialist cardiac histopathological examination in the investigation of 
young sudden cardiac deaths. Europace 2014;16:899–907. https://doi.org/10.1093/ 
europace/eut329 
244. De Gaspari M, Fedeli U, Saia M, Carturan E, Pilichou K, Corrado D, et al. Rate and cause 
of sudden cardiac death in the young during the COVID-19 pandemic and vaccination. 
Circulation 
2023;148:2069–71. 
https://doi.org/10.1161/CIRCULATIONAHA.123. 
066270 
245. du Long R, Fronczek J, Niessen HWM, van der Wal A, de Boer H. The histopathological spectrum of myocardial inflammation in relation to circumstance of death: a retrospective cohort study in clinical and forensic autopsies. Forensic Sci Res 2022;7:238–46.  
https://doi.org/10.1080/20961790.2021.1989793 
246. Li L, Zhang Y, Burke A, Xue A, Zhao Z, Fowler D, et al. Demographic, clinical and 
pathological features of sudden deaths due to myocarditis: results from a state-wide 
population-based autopsy study. Forensic Sci Int 2017;272:81–6. https://doi.org/10. 
1016/j.forsciint.2016.12.037 
247. Gulino SP, Burns K, Gunther WM, MacLeod H. Improving forensic pathologic investigation of sudden death in the young: tools, guidance, and methods of cardiovascular 
dissection from the sudden death in the young case registry. Acad Forensic Pathol 
2018;8:347–91. https://doi.org/10.1177/1925362118782077 
248. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC 
guidelines for the management of chronic coronary syndromes. Eur Heart J 2024; 
45:3415–537. https://doi.org/10.1093/eurheartj/ehae177 
249. Nowatzke J, Guedeney P, Palaskas N, Lehmann L, Ederhy S, Zhu H, et al. Coronary 
artery disease and revascularization associated with immune checkpoint blocker myocarditis: report from an international registry. Eur J Cancer 2022;177:197–205. https:// 
doi.org/10.1016/j.ejca.2022.07.018 
250. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 2020;142:2299–311. https://doi.org/10.1161/CIRCULATIONAHA.120. 
049981 
251. Zöller B, Ji J, Sundquist J, Sundquist K. Risk of coronary heart disease in patients with 
cancer: a nationwide follow-up study from Sweden. Eur J Cancer 2012;48:121–8.  
https://doi.org/10.1016/j.ejca.2011.09.015 
252. Jain CC, Miranda WR, El Sabbagh A, Nishimura RA. A simplified method for the diagnosis of constrictive pericarditis in the cardiac catheterization laboratory. JAMA Cardiol 
2022;7:100–4. https://doi.org/10.1001/jamacardio.2021.3478 
253. Casella M, Gasperetti A, Compagnucci P, Narducci ML, Pelargonio G, Catto V, et al. 
Different phases of disease in lymphocytic myocarditis: clinical and electrophysiological 
characteristics. JACC Clin Electrophysiol 2023;9:314–26. https://doi.org/10.1016/j.jacep. 
2022.10.004 
254. Hoogendoorn JC, Sramko M, Venlet J, Siontis KC, Kumar S, Singh R, et al. 
Electroanatomical voltage mapping to distinguish right-sided cardiac sarcoidosis 
from arrhythmogenic right ventricular cardiomyopathy. JACC Clin Electrophysiol 
2020;6:696–707. https://doi.org/10.1016/j.jacep.2020.02.008 
255. Peretto G, Sala S, Basso C, Della Bella P. Programmed ventricular stimulation in patients with active vs previous arrhythmic myocarditis. J Cardiovasc Electrophysiol 
2020;31:692–701. https://doi.org/10.1111/jce.14374 
256. Haanschoten DM, Adiyaman A, ‘t Hart NA, Jager PL, Elvan A. Value of 3D mapping- 
guided endomyocardial biopsy in cardiac sarcoidosis: case series and narrative review 
on the value of electro-anatomic mapping-guided endomyocardial biopsies. Eur J Clin 
Invest 2021;51:e13497. https://doi.org/10.1111/eci.13497 
257. Muser D, Santangeli P, Liang JJ, Castro SA, Magnani S, Hayashi T, et al. Characterization 
of the electroanatomic substrate in cardiac sarcoidosis: correlation with imaging findings of scar and inflammation. JACC Clin Electrophysiol 2018;4:291–303. https://doi.org/ 
10.1016/j.jacep.2017.09.175 
258. Liang JJ, Hebl VB, DeSimone CV, Madhavan M, Nanda S, Kapa S, et al. Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy 
for suspected cardiac sarcoidosis and myocarditis. JACC Heart Fail 2014;2:466–73.  
https://doi.org/10.1016/j.jchf.2014.03.015 
259. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 
Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute 
and chronic heart failure. Eur Heart J 2023;44:3627–39. https://doi.org/10.1093/ 
eurheartj/ehad195 
260. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 
Heart J 2024;45:3314–414. https://doi.org/10.1093/eurheartj/ehae176 
261. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomström-Lundqvist C, et al. 2019 
ESC guidelines for the management of patients with supraventricular tachycardia. The 
Task Force for the management of patients with supraventricular tachycardia of the 
European Society of Cardiology (ESC). Eur Heart J 2020;41:655–720. https://doi.org/ 
10.1093/eurheartj/ehz467 
262. Berg J, Lovrinovic M, Baltensperger N, Kissel CK, Kottwitz J, Manka R, et al. 
Non-steroidal anti-inflammatory drug use in acute myopericarditis: 12-month clinical 
follow-up. Open Heart 2019;6:e000990. https://doi.org/10.1136/openhrt-2018-000990 
263. Collini V, De Martino M, Andreis A, De Biasio M, Gaspard F, Paneva E, et al. Efficacy and 
safety of colchicine for the treatment of myopericarditis. Heart 2024;110:735–9.  
https://doi.org/10.1136/heartjnl-2023-323484 
264. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T, et al. 
Predictors of outcome in patients with suspected myocarditis. Circulation 2008;118: 
639–48. https://doi.org/10.1161/CIRCULATIONAHA.108.769489 
265. Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, et al. Epidemiology, 
pathophysiology and contemporary management of cardiogenic shock—a position 
statement from the Heart Failure Association of the European Society of 
Cardiology. Eur J Heart Fail 2020;22:1315–41. https://doi.org/10.1002/ejhf.1922 
266. Heymans S, Van Linthout S, Kraus SM, Cooper LT, Ntusi NAB. Clinical characteristics 
and mechanisms of acute myocarditis. Circ Res 2024;135:397–411. https://doi.org/10. 
1161/CIRCRESAHA.124.324674 
267. Pappritz K, Lin J, El-Shafeey M, Fechner H, Kühl U, Alogna A, et al. Colchicine prevents 
disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the 
cardiosplenic axis. ESC Heart Fail 2022;9:925–41. https://doi.org/10.1002/ehf2.13845 
268. Kerneis M, Cohen F, Combes A, Amoura Z, Pare C, Brugier D, et al. Rationale and design of the ARAMIS trial: anakinra versus placebo, a double blind randomized controlled trial for the treatment of acute myocarditis. Arch Cardiovasc Dis 2023;116: 
460–6. https://doi.org/10.1016/j.acvd.2023.07.004 
269. Li Y, Yu Y, Chen S, Liao Y, Du J. Corticosteroids and intravenous immunoglobulin in 
pediatric myocarditis: a meta-analysis. Front Pediatr 2019;7:342. https://doi.org/10. 
3389/fped.2019.00342 
270. Chen HS, Wang W, Wu SN, Liu JP. Corticosteroids for viral myocarditis. Cochrane 
Database Syst Rev 2013;2013:CD004471. https://doi.org/10.1002/14651858. 
CD004471.pub3 
271. Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic 
myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol 2017;70: 
2363–75. https://doi.org/10.1016/j.jacc.2017.09.023 
272. Mason JW, O’Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, et al. 
A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995;333: 
269–75. https://doi.org/10.1056/NEJM199508033330501 
273. Schultheiss H-P, Piper C, Sowade O, Waagstein F, Kapp J-F, Wegscheider K, et al. 
Betaferon in chronic viral cardiomyopathy (BICC) trial: effects of interferon-β treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol 2016;105: 
763–73. https://doi.org/10.1007/s00392-016-0986-9 
274. Imazio M, Andreis A, Agosti A, Piroli F, Avondo S, Casula M, et al. Usefulness of beta- 
blockers to control symptoms in patients with pericarditis. Am J Cardiol 2021;146: 
115–9. https://doi.org/10.1016/j.amjcard.2021.01.032 
275. Avondo S, Andreis A, Casula M, Biondi-Zoccai G, Imazio M. Pharmacologic treatment 
of acute and recurrent pericarditis: a systematic review and meta-analysis of controlled 
clinical trials. Panminerva Med 2021;63:314–23. https://doi.org/10.23736/S0031-0808. 
21.04263-4 
276. Lutschinger LL, Rigopoulos AG, Schlattmann P, Matiakis M, Sedding D, Schulze PC, 
et al. Meta-analysis for the value of colchicine for the therapy of pericarditis and of 
postpericardiotomy syndrome. BMC Cardiovasc Disord 2019;19:207. https://doi.org/ 
10.1186/s12872-019-1190-4 
277. Li Y-L, Qiao S-B, Wang J-Y, Chen Y-M, Luo J, Zhang H-F. Colchicine in addition to conventional therapy for pericarditis recurrence: an update meta-analysis. Herz 2016;41: 
630–8. https://doi.org/10.1007/s00059-016-4410-z 
278. Papageorgiou N, Briasoulis A, Lazaros G, Imazio M, Tousoulis D. Colchicine for prevention and treatment of cardiac diseases: a meta-analysis. Cardiovasc Ther 2017;35: 
10–18. https://doi.org/10.1111/1755-5922.12226 
279. Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018;3: 
231–41. https://doi.org/10.1016/S2468-1253(18)30037-2 
280. Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 
American College of Rheumatology guideline for the prevention and treatment of 
glucocorticoid-induced osteoporosis. Arthritis Rheumatol 2023;75:2088–102. https:// 
doi.org/10.1002/art.42646 
281. Sambola A, Roca Luque I, Mercé J, Alguersuari J, Francisco-Pascual J, García-Dorado D, 
et al. Colchicine administered in the first episode of acute idiopathic pericarditis: a randomized multicenter open-label study. Rev Esp Cardiol (Engl Ed) 2019;72:709–16.  
https://doi.org/10.1016/j.rec.2018.11.016 
282. Imazio M, Andreis A, Piroli F, Lazaros G, Gattorno M, Lewinter M, et al. 
Anti-interleukin 1 agents for the treatment of recurrent pericarditis: a systematic


<!-- PAGE 81 -->

### Page 81

review and meta-analysis. Heart 2021;107:1240–5. https://doi.org/10.1136/heartjnl- 
2020-318869 
283. Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, et al. Phase 3 trial of 
interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med 2021;384:31–41.  
https://doi.org/10.1056/NEJMoa2027892 
284. Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, et al. Effect of 
anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA 2016;316: 
1906–12. https://doi.org/10.1001/jama.2016.15826 
285. Brucato A, Wheeler A, Luis SA, Abbate A, Cremer PC, Zou L, et al. Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis. 
Heart 2023;109:297–304. https://doi.org/10.1136/heartjnl-2022-321328 
286. Collini V, Andreis A, De Biasio M, De Martino M, Isola M, Croatto N, et al. Efficacy of 
colchicine in addition to anakinra in patients with recurrent pericarditis. Open Heart 
2024;11:e002599. https://doi.org/10.1136/openhrt-2023-002599 
287. Vianello F, Cinetto F, Cavraro M, Battisti A, Castelli M, Imbergamo S, et al. Azathioprine 
in isolated recurrent pericarditis: a single centre experience. Int J Cardiol 2011;147: 
477–8. https://doi.org/10.1016/j.ijcard.2011.01.027 
288. Imazio M, Lazaros G, Picardi E, Vasileiou P, Carraro M, Tousoulis D, et al. Intravenous 
human immunoglobulins for refractory recurrent pericarditis: a systematic review of 
all published cases. J Cardiovasc Med (Hagerstown) 2016;17:263–9. https://doi.org/10. 
2459/JCM.0000000000000260 
289. Marcolongo R, Russo R, Laveder F, Noventa F, Agostini C. Immunosuppressive therapy prevents recurrent pericarditis. J Am Coll Cardiol 1995;26:1276–9. https://doi.org/ 
10.1016/0735-1097(95)00302-9 
290. Lazaros G, Antonopoulos AS, Antonatou K, Skendros P, Ritis K, Hadziyannis E, et al. 
Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic recurrent pericarditis: a pilot observational prospective study. Int J Cardiol 2020;311: 
77–82. https://doi.org/10.1016/j.ijcard.2020.03.069 
291. Lotrionte M, Biondi-Zoccai G, Imazio M, Castagno D, Moretti C, Abbate A, et al. 
International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences. Am Heart J 2010;160: 
662–70. https://doi.org/10.1016/j.ahj.2010.06.015 
292. Horneffer PJ, Miller RH, Pearson TA, Rykiel MF, Reitz BA, Gardner TJ. The effective 
treatment of postpericardiotomy syndrome after cardiac operations. A randomized 
placebo-controlled trial. J Thorac Cardiovasc Surg 1990;100:292–6. https://doi.org/10. 
1016/S0022-5223(19)35571-0 
293. Atluri P, Ullery BW, MacArthur JW, Goldstone AB, Fairman AS, Hiesinger W, et al. 
Rapid onset of fulminant myocarditis portends a favourable prognosis and the ability 
to bridge mechanical circulatory support to recovery. Eur J Cardiothorac Surg 2013; 
43:379–82. https://doi.org/10.1093/ejcts/ezs242 
294. Montero S, Aissaoui N, Tadié J-M, Bizouarn P, Scherrer V, Persichini R, et al. Fulminant 
giant-cell myocarditis on mechanical circulatory support: management and outcomes 
of a French multicentre cohort. Int J Cardiol 2018;253:105–12. https://doi.org/10.1016/ 
j.ijcard.2017.10.053 
295. Bernhardt AM, Copeland H, Deswal A, Gluck J, Givertz MM; Task Force 1; et al. The 
International Society for Heart and Lung Transplantation/Heart Failure Society of 
America Guideline on Acute Mechanical Circulatory Support. J Heart Lung 
Transplant 2023;42:e1–e64. https://doi.org/10.1016/j.healun.2022.10.028 
296. Lorusso R, Shekar K, MacLaren G, Schmidt M, Pellegrino V, Meyns B, et al. ELSO interim 
guidelines for venoarterial extracorporeal membrane oxygenation in adult cardiac patients. ASAIO J 2021;67:827–44. https://doi.org/10.1097/MAT.0000000000001510 
297. Lorusso R, Centofanti P, Gelsomino S, Barili F, Di Mauro M, Orlando P, et al. 
Venoarterial extracorporeal membrane oxygenation for acute fulminant myocarditis 
in adult patients: a 5-year multi-institutional experience. Ann Thorac Surg 2016;101: 
919–26. https://doi.org/10.1016/j.athoracsur.2015.08.014 
298. Mirabel M, Luyt C-E, Leprince P, Trouillet J-L, Léger P, Pavie A, et al. Outcomes, long- 
term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support. Crit Care Med 2011;39:1029–35. https://doi. 
org/10.1097/CCM.0b013e31820ead45 
299. Diddle JW, Almodovar MC, Rajagopal SK, Rycus PT, Thiagarajan RR. Extracorporeal 
membrane oxygenation for the support of adults with acute myocarditis. Crit Care 
Med 2015;43:1016–25. https://doi.org/10.1097/CCM.0000000000000920 
300. Nunez JI, Grandin EW, Reyes-Castro T, Sabe M, Quintero P, Motiwala S, et al. 
Outcomes with peripheral venoarterial extracorporeal membrane oxygenation for 
suspected acute myocarditis: 10-year experience from the extracorporeal life support 
organization registry. Circ Heart Fail 2023;16:e010152. https://doi.org/10.1161/ 
CIRCHEARTFAILURE.122.010152 
301. Strobbe A, Adriaenssens T, Bennett J, Dubois C, Desmet W, McCutcheon K, et al. 
Etiology and long-term outcome of patients undergoing pericardiocentesis. J Am 
Heart Assoc 2017;6:e007598. https://doi.org/10.1161/JAHA.117.007598 
302. Maisch B, Ristić AD, Pankuweit S, Neubauer A, Moll R. Neoplastic pericardial effusion. 
Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J 2002;23: 
1625–31. https://doi.org/10.1053/euhj.2002.3328 
303. Martinoni A, Cipolla CM, Cardinale D, Civelli M, Lamantia G, Colleoni M, et al. 
Long-term results of intrapericardial chemotherapeutic treatment of malignant 
pericardial effusions with thiotepa. Chest 2004;126:1412–6. https://doi.org/10.1378/ 
chest.126.5.1412 
304. Colleoni M, Martinelli G, Beretta F, Marone C, Gallino A, Fontana M, et al. Intracavitary 
chemotherapy with thiotepa in malignant pericardial effusions: an active and well- 
tolerated regimen. J Clin Oncol 1998;16:2371–6. https://doi.org/10.1200/JCO.1998. 
16.7.2371 
305. Kunitoh H, Tamura T, Shibata T, Imai M, Nishiwaki Y, Nishio M, et al. A randomised 
trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer 
(JCOG9811). Br J Cancer 2009;100:464–9. https://doi.org/10.1038/sj.bjc.6604866 
306. Shepherd FA, Morgan C, Evans WK, Ginsberg JF, Watt D, Murphy K. Medical management of malignant pericardial effusion by tetracycline sclerosis. Am J Cardiol 1987;60: 
1161–6. https://doi.org/10.1016/0002-9149(87)90411-5 
307. Beckmann E, Ismail I, Cebotari S, Busse A, Martens A, Shrestha M, et al. Right-sided 
heart failure and extracorporeal life support in patients undergoing pericardiectomy 
for constrictive pericarditis: a risk factor analysis for adverse outcome. Thorac 
Cardiovasc Surg 2017;65:662–70. https://doi.org/10.1055/s-0036-1593817 
308. Busch C, Penov K, Amorim PA, Garbade J, Davierwala P, Schuler GC, et al. Risk factors 
for mortality after pericardiectomy for chronic constrictive pericarditis in a large 
single-centre cohort. Eur J Cardiothorac Surg 2015;48:e110–6. https://doi.org/10. 
1093/ejcts/ezv322 
309. Vondran M, Rylski B, Berezowski M, Polycarpou A, Born F, Guenther S, et al. 
Preemptive extracorporeal life support for surgical treatment of severe constrictive 
pericarditis. Ann Thorac Surg 2019;108:1376–81. https://doi.org/10.1016/j.athoracsur. 
2019.03.105 
310. Saxena P, Joyce LD, Daly RC, Kushwaha SS, Schirger JA, Rosedahl J, et al. Cardiac transplantation for radiation-induced cardiomyopathy: the Mayo Clinic experience. Ann 
Thorac Surg 2014;98:2115–21. https://doi.org/10.1016/j.athoracsur.2014.06.056 
311. Al-Kazaz M, Klein AL, Oh JK, Crestanello JA, Cremer PC, Tong MZ, et al. Pericardial 
diseases and best practices for pericardiectomy: JACC state-of-the-art review. J Am 
Coll Cardiol 2024;84:561–80. https://doi.org/10.1016/j.jacc.2024.05.048 
312. Vistarini N, Chen C, Mazine A, Bouchard D, Hebert Y, Carrier M, et al. Pericardiectomy 
for constrictive pericarditis: 20 years of experience at the Montreal Heart Institute. Ann 
Thorac Surg 2015;100:107–13. https://doi.org/10.1016/j.athoracsur.2015.02.054 
313. Lee S, Lee J, Joo S, Park YK, Kim KM, Jung JC, et al. Impact of pericardial calcification on 
early postoperative outcomes after pericardiectomy: a retrospective observational 
study. J Cardiothorac Surg 2024;19:449. https://doi.org/10.1186/s13019-024-02842-4 
314. Yamamoto N, Ohara K, Nie M, Torii S, Inoue N, Miyaji K. For what type of constrictive 
pericarditis is the waffle procedure effective? Asian Cardiovasc Thorac Ann 2011;19: 
115–8. https://doi.org/10.1177/0218492311399496 
315. Matsuura K, Mogi K, Takahara Y. Off-pump waffle procedure using an ultrasonic scalpel for constrictive pericarditis. Eur J Cardiothorac Surg 2015;47:e220–2. https://doi.org/ 
10.1093/ejcts/ezu554 
316. Calderon-Rojas RD, Greason KL, King KS, Luis SA, Oh JK, Stulak JM, et al. Outcomes of 
tricuspid valve operation at the time of pericardiectomy for constrictive pericarditis. 
Ann Thorac Surg 2021;111:1252–7. https://doi.org/10.1016/j.athoracsur.2020.06.106 
317. Li T-T, Cheng J. Clinical analysis of temporary pacemaker implantation in 13 children. 
Transl Pediatr 2022;11:174–82. https://doi.org/10.21037/tp-21-586 
318. Suarez K, Banchs JE. A review of temporary permanent pacemakers and a comparison 
with conventional temporary pacemakers. J Innov Card Rhythm Manag 2019;10: 
3652–61. https://doi.org/10.19102/icrm.2019.100506 
319. Braun MU, Rauwolf T, Bock M, Kappert U, Boscheri A, Schnabel A, et al. Percutaneous 
lead implantation connected to an external device in stimulation-dependent patients 
with systemic infection—a prospective and controlled study. Pacing Clin 
Electrophysiol 2006;29:875–9. https://doi.org/10.1111/j.1540-8159.2006.00454.x 
320. Zei PC, Eckart RE, Epstein LM. Modified temporary cardiac pacing using transvenous 
active fixation leads and external re-sterilized pulse generators. J Am Coll Cardiol 2006; 
47:1487–9. https://doi.org/10.1016/j.jacc.2006.01.006 
321. Chung MK, Patton KK, Lau C-P, Forno ARJD, Al-Khatib SM, Arora V, et al. 2023 HRS/ 
APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm 2023;20:e17–91. https://doi.org/10.1016/j.hrthm. 
2023.03.1538 
322. Casella M, Bergonti M, Narducci ML, Persampieri S, Gasperetti A, Conte E, et al. Prior 
myocarditis and ventricular arrhythmias: the importance of scar pattern. Heart Rhythm 
2021;18:589–96. https://doi.org/10.1016/j.hrthm.2020.12.016 
323. Rav-Acha M, Shah K, Hasin T, Gumuser E, Tovia-Brodie O, Shauer A, et al. Incidence 
and predictors for recurrence of ventricular arrhythmia presenting during acute myocarditis: a multicenter study. JACC Clin Electrophysiol 2024;10:1161–74. https://doi.org/ 
10.1016/j.jacep.2024.02.027 
324. Sasko B, Patschan D, Nordbeck P, Seidlmayer L, Andresen H, Jänsch M, et al. Secondary 
prevention of potentially life-threatening arrhythmia using implantable cardioverter 
defibrillators in patients with biopsy-proven viral myocarditis and preserved ejection 
fraction. Cardiology 2021;146:213–21. https://doi.org/10.1159/000511120 
325. Peretto G, Sala S, Carturan E, Rizzo S, Villatore A, De Luca G, et al. Clinical profiling and 
outcomes of viral myocarditis manifesting with ventricular arrhythmias. Eur Heart J 
Open 2023;3:oead132. https://doi.org/10.1093/ehjopen/oead132  
ESC Guidelines                                                                                                                                                                                               81


<!-- PAGE 82 -->

### Page 82

326. Ekström K, Lehtonen J, Kandolin R, Räisänen-Sokolowski A, Salmenkivi K, Kupari M. 
Incidence, risk factors, and outcome of life-threatening ventricular arrhythmias in giant 
cell myocarditis. Circ Arrhythm Electrophysiol 2016;9:e004559. https://doi.org/10.1161/ 
CIRCEP.116.004559 
327. Tscholl V, Wielander D, Kelch F, Stroux A, Attanasio P, Tschöpe C, et al. Benefit of a 
wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis. ESC Heart Fail 2021;8:2428–37. https://doi.org/10.1002/ehf2. 
13353 
328. Blaschke F, Lacour P, Dang PL, Parwani AS, Hohendanner F, Walter T, et al. Wearable 
cardioverter-defibrillator: friend or foe in suspected myocarditis? ESC Heart Fail 2021; 
8:2591–6. https://doi.org/10.1002/ehf2.13340 
329. Wäßnig NK, Günther M, Quick S, Pfluecke C, Rottstädt F, Szymkiewicz SJ, 
et al. Experience with the wearable cardioverter-defibrillator in patients at high risk 
for sudden cardiac death. Circulation 2016;134:635–43. https://doi.org/10.1161/ 
CIRCULATIONAHA.115.019124 
330. El-Battrawy I, Koepsel K, Tenbrink D, Kovacs B, Dreher TC, Blockhaus C, et al. Use of 
the wearable cardioverter-defibrillator among patients with myocarditis and reduced 
ejection fraction or ventricular tachyarrhythmia: data from a multicenter registry. J Am 
Heart Assoc 2023;12:e030615. https://doi.org/10.1161/JAHA.123.030615 
331. Peretto G, Gulletta S, Slavich M, Campochiaro C, Vignale D, De Luca G, et al. Exercise 
stress test late after arrhythmic versus nonarrhythmic presentation of myocarditis. 
J Pers Med 2022;12:1702. https://doi.org/10.3390/jpm12101702 
332. Yang F, Wang J, Li W, Xu Y, Wan K, Zeng R, et al. The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis: systematic review and meta-analysis. Eur Radiol 2020;30:2616–26. https://doi.org/10.1007/s00330- 
019-06643-5 
333. Georgiopoulos G, Figliozzi S, Sanguineti F, Aquaro GD, di Bella G, Stamatelopoulos K, 
et al. Prognostic impact of late gadolinium enhancement by cardiovascular magnetic 
resonance in myocarditis. Circ Cardiovasc Imaging 2021;14:e011492. https://doi.org/ 
10.1161/CIRCIMAGING.120.011492 
334. Schumm J, Greulich S, Wagner A, Grün S, Ong P, Bentz K, et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. 
J Cardiovasc Magn Reson 2014;16:14. https://doi.org/10.1186/1532-429X-16-14 
335. Salamanca J, Díez-Villanueva P, Martínez P, Cecconi A, González de Marcos B, Reyes G, 
et al. COVID-19 ‘fulminant myocarditis’ successfully treated with temporary mechanical circulatory support. JACC Cardiovasc Imaging 2020;13:2457–9. https://doi.org/10. 
1016/j.jcmg.2020.05.003 
336. Pavlicek V, Kindermann I, Wintrich J, Mahfoud F, Klingel K, Böhm M, et al. Ventricular 
arrhythmias and myocardial inflammation: long-term follow-up of patients with suspected myocarditis. Int J Cardiol 2019;274:132–7. https://doi.org/10.1016/j.ijcard. 
2018.07.142 
337. Imazio M, Brucato A, Spodick DH, Adler Y. Prognosis of myopericarditis as determined from previously published reports. J Cardiovasc Med (Hagerstown) 2014;15: 
835–9. https://doi.org/10.2459/JCM.0000000000000082 
338. Castrichini M, Porcari A, Baggio C, Gagno G, Maione D, Barbati G, et al. Sex differences 
in natural history of cardiovascular magnetic resonance- and biopsy-proven lymphocytic myocarditis. ESC Heart Fail 2022;9:4010–9. https://doi.org/10.1002/ehf2.14102 
339. Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, et al. Long-term 
follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete 
recovery. J Am Coll Cardiol 2012;59:1604–15. https://doi.org/10.1016/j.jacc.2012.01. 
007 
340. Ammirati E, Varrenti M, Sormani P, Bernasconi D, Moro C, Grosu A, et al. Long-term 
prognostic performance of cardiac magnetic resonance imaging markers versus complicated clinical presentation after an acute myocarditis. Int J Cardiol 2024;417:132567.  
https://doi.org/10.1016/j.ijcard.2024.132567 
341. Greulich S, Seitz A, Müller KAL, Grün S, Ong P, Ebadi N, et al. Predictors of mortality in 
patients with biopsy-proven viral myocarditis: 10-year outcome data. J Am Heart Assoc 
2020;9:e015351. https://doi.org/10.1161/JAHA.119.015351 
342. Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, et al. 
Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. 
Circulation 
2006;114:1581–90. 
https://doi.org/10.1161/CIRCULATIONAHA.105. 
606509 
343. Narducci ML, Pelargonio G, La Rosa G, Inzani F, d’Amati G, Novelli V, et al. Role of 
extensive diagnostic workup in young athletes and nonathletes with complex ventricular arrhythmias. Heart Rhythm 2020;17:230–7. https://doi.org/10.1016/j.hrthm.2019. 
08.022 
344. Maleszewski JJ, Orellana VM, Hodge DO, Kuhl U, Schultheiss H-P, Cooper LT. 
Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J 
Cardiol 2015;115:1733–8. https://doi.org/10.1016/j.amjcard.2015.03.023 
345. Kim M-J, Jung HO, Kim H, Bae Y, Lee SY, Jeon DS. 10-Year survival outcome after clinically suspected acute myocarditis in adults: a nationwide study in the pre-COVID-19 
era. PLoS One 2023;18:e0281296. https://doi.org/10.1371/journal.pone.0281296 
346. Kytö V, Sipilä J, Rautava P. Rate and patient features associated with recurrence of 
acute myocarditis. Eur J Intern Med 2014;25:946–50. https://doi.org/10.1016/j.ejim. 
2014.11.001 
347. Imazio M, Brucato A, Maestroni S, Cumetti D, Belli R, Trinchero R, et al. Risk of constrictive pericarditis after acute pericarditis. Circulation 2011;124:1270–5. https://doi. 
org/10.1161/CIRCULATIONAHA.111.018580 
348. Yesilyaprak A, Kumar AK, Agrawal A, Furqan MM, Verma BR, Syed AB, et al. Predicting 
long-term clinical outcomes of patients with recurrent pericarditis. J Am Coll Cardiol 
2024;84:1193–204. https://doi.org/10.1016/j.jacc.2024.05.072 
349. Caforio ALP, Adler Y, Agostini C, Allanore Y, Anastasakis A, Arad M, et al. Diagnosis 
and management of myocardial involvement in systemic immune-mediated diseases: a 
position statement of the European Society of Cardiology Working Group on 
Myocardial and Pericardial Disease. Eur Heart J 2017;38:2649–62. https://doi.org/10. 
1093/eurheartj/ehx321 
350. Cheng C-Y, Baritussio A, Giordani AS, Iliceto S, Marcolongo R, Caforio ALP. 
Myocarditis in systemic immune-mediated diseases: prevalence, characteristics and 
prognosis. A systematic review. Autoimmun Rev 2022;21:103037. https://doi.org/10. 
1016/j.autrev.2022.103037 
351. Mavrogeni S, Bratis K, Sfendouraki E, Papadopoulou E, Kolovou G. Myopericarditis, 
as the first sign of rheumatoid arthritis relapse, evaluated by cardiac magnetic resonance. Inflamm Allergy Drug Targets 2013;12:206–11. https://doi.org/10.2174/ 
1871528111312030008 
352. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71: 
1400–12. https://doi.org/10.1002/art.40930 
353. Jia E, Geng H, Liu Q, Xiao Y, Zhang Y, Xie J, et al. Cardiac manifestations of Han 
Chinese patients with systemic lupus erythematosus: a retrospective study. Ir J Med 
Sci 2019;188:801–6. https://doi.org/10.1007/s11845-018-1934-7 
354. Tanwani J, Tselios K, Gladman DD, Su J, Urowitz MB. Lupus myocarditis: a single center 
experience and a comparative analysis of observational cohort studies. Lupus 2018;27: 
1296–302. https://doi.org/10.1177/0961203318770018 
355. Thomas G, Cohen Aubart F, Chiche L, Haroche J, Hié M, Hervier B, et al. Lupus myocarditis: initial presentation and longterm outcomes in a multicentric series of 29 patients. J Rheumatol 2017;44:24–32. https://doi.org/10.3899/jrheum.160493 
356. Mathian A, Mouries-Martin S, Dorgham K, Devilliers H, Yssel H, Garrido Castillo L, 
et al. Ultrasensitive serum interferon-α quantification during SLE remission identifies 
patients at risk for relapse. Ann Rheum Dis 2019;78:1669–76. https://doi.org/10. 
1136/annrheumdis-2019-215571 
357. Mathian A, Mouries-Martin S, Dorgham K, Devilliers H, Barnabei L, Ben Salah E, et al. 
Monitoring disease activity in systemic lupus erythematosus with single-molecule array 
digital enzyme-linked immunosorbent assay quantification of serum interferon-α. 
Arthritis Rheumatol 2019;71:756–65. https://doi.org/10.1002/art.40792 
358. du Toit R, Herbst PG, Ackerman C, Pecoraro AJ, Claassen D, Cyster HP, et al. 
Outcome of clinical and subclinical myocardial injury in systemic lupus erythematosus—a prospective cohort study. Lupus 2021;30:256–68. https://doi.org/10.1177/ 
0961203320976960 
359. Hinojar R, Foote L, Sangle S, Marber M, Mayr M, Carr-White G, et al. Native T1 and T2 
mapping by CMR in lupus myocarditis: disease recognition and response to treatment. 
Int J Cardiol 2016;222:717–26. https://doi.org/10.1016/j.ijcard.2016.07.182 
360. Sacré K, Brihaye B, Hyafil F, Serfaty J-M, Escoubet B, Zennaro M-C, et al. Asymptomatic 
myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study. Arthritis Rheum 2010;62:2093–100. https://doi.org/10. 
1002/art.27488 
361. Pineton de Chambrun M, Larcher R, Pène F, Argaud L, Mayaux J, Jamme M, et al. 
In-hospital mortality-associated factors in patients with thrombotic antiphospholipid 
syndrome requiring ICU admission. Chest 2020;157:1158–66. https://doi.org/10. 
1016/j.chest.2019.11.010 
362. Yong WC, Sanguankeo A, Upala S. Association between primary Sjogren’s syndrome, 
arterial stiffness, and subclinical atherosclerosis: a systematic review and meta-analysis. 
Clin Rheumatol 2019;38:447–55. https://doi.org/10.1007/s10067-018-4265-1 
363. Lazzerini PE, Murthy Ginjupalli VK, Srivastava U, Bertolozzi I, Bacarelli MR, Verrengia 
D, et al. Anti-Ro/SSA antibodies blocking calcium channels as a potentially reversible 
cause of atrioventricular block in adults. JACC Clin Electrophysiol 2023;9:1631–48.  
https://doi.org/10.1016/j.jacep.2023.03.007 
364. Bruni C, Buch MH, Furst DE, De Luca G, Djokovic A, Dumitru RB, et al. Primary systemic sclerosis heart involvement: a systematic literature review and preliminary data- 
driven, consensus-based WSF/HFA definition. J Scleroderma Relat Disord 2022;7:24–32.  
https://doi.org/10.1177/23971983211053246 
365. Krumm P, Mueller KAL, Klingel K, Kramer U, Horger MS, Zitzelsberger T, et al. 
Cardiovascular magnetic resonance patterns of biopsy proven cardiac involvement 
in systemic sclerosis. J Cardiovasc Magn Reson 2016;18:70. https://doi.org/10.1186/ 
s12968-016-0289-3 
366. De Luca G, Campochiaro C, De Santis M, Sartorelli S, Peretto G, Sala S, et al. Systemic 
sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. Rheumatology (Oxford) 2020;59:2523–33. https://doi. 
org/10.1093/rheumatology/kez658 
367. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic 
sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian


<!-- PAGE 83 -->

### Page 83

patients. Medicine (Baltimore) 2002;81:139–53. https://doi.org/10.1097/00005792- 
200203000-00004 
368. Bruni C, Buch MH, Djokovic A, De Luca G, Dumitru RB, Giollo A, et al. Consensus on 
the assessment of systemic sclerosis-associated primary heart involvement: World 
Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, 
and follow-up assessment. J Scleroderma Relat Disord 2023;8:169–82. https://doi.org/ 
10.1177/23971983231163413 
369. Fairley JL, Wicks I, Peters S, Day J. Defining cardiac involvement in idiopathic inflammatory myopathies: a systematic review. Rheumatology (Oxford) 2021;61:103–20. https:// 
doi.org/10.1093/rheumatology/keab573 
370. Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients 
with idiopathic inflammatory myopathies according to clinical features: a longitudinal 
study of 162 cases. Medicine (Baltimore) 2004;83:35–42. https://doi.org/10.1097/01. 
md.0000109755.65914.5e 
371. Allanore Y, Vignaux O, Arnaud L, Puéchal X, Pavy S, Duboc D, et al. Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related 
myocarditis evaluated by magnetic resonance imaging. Ann Rheum Dis 2006;65: 
249–52. https://doi.org/10.1136/ard.2005.038679 
372. Zhang L, Wang G, Ma L, Zu N. Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review. Clin Cardiol 2012;35:686–91. https://doi.org/10.1002/clc. 
22026 
373. Groh M, Masciocco G, Kirchner E, Kristen A, Pellegrini C, Varnous S, et al. Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg– 
Strauss syndrome). J Heart Lung Transplant 2014;33:842–50. https://doi.org/10.1016/ 
j.healun.2014.02.023 
374. Bojkova D, Wagner JUG, Shumliakivska M, Aslan GS, Saleem U, Hansen A, et al. 
SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. 
Cardiovasc Res 2020;116:2207–15. https://doi.org/10.1093/cvr/cvaa267 
375. Peretto G, Villatore A, Rizzo S, Esposito A, De Luca G, Palmisano A, et al. The spectrum of COVID-19-associated myocarditis: a patient-tailored multidisciplinary approach. J Clin Med 2021;10:1974. https://doi.org/10.3390/jcm10091974 
376. Weckbach LT, Curta A, Bieber S, Kraechan A, Brado J, Hellmuth JC, et al. Myocardial 
inflammation and dysfunction in COVID-19-associated myocardial injury. Circ 
Cardiovasc Imaging 2021;14:e012220. https://doi.org/10.1161/CIRCIMAGING.120. 
011713 
377. Basso C, Leone O, Rizzo S, De Gaspari M, van der Wal A, Aubry M-C, et al. 
Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J 2020;41:3827–35. https://doi.org/10.1093/ 
eurheartj/ehaa664 
378. Halushka MK, Vander Heide RS. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc Pathol 2021;50: 
107300. https://doi.org/10.1016/j.carpath.2020.107300 
379. Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, et al. 
Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy 
cases. JAMA Cardiol 2020;5:1281–5. https://doi.org/10.1001/jamacardio.2020.3551 
380. Aquaro GD, Licordari R, Todiere G, Ianni U, Dellegrotaglie S, Restivo L, et al. Incidence 
of acute myocarditis and pericarditis during the coronavirus disease 2019 pandemic: 
comparison with the prepandemic period. J Cardiovasc Med (Hagerstown) 2022;23: 
447–53. https://doi.org/10.2459/JCM.0000000000001330 
381. Boehmer TK, Kompaniyets L, Lavery AM, Hsu J, Ko JY, Yusuf H, et al. Association between COVID-19 and myocarditis using hospital-based administrative data—United 
States, March 2020–January 2021. MMWR Morb Mortal Wkly Rep 2021;70:1228–32.  
https://doi.org/10.15585/mmwr.mm7035e5 
382. Daniels CJ, Rajpal S, Greenshields JT, Rosenthal GL, Chung EH, Terrin M, et al. 
Prevalence of clinical and subclinical myocarditis in competitive athletes with recent 
SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry. JAMA 
Cardiol 2021;6:1078–87. https://doi.org/10.1001/jamacardio.2021.2065 
383. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. 
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. 
Lancet Rheumatol 2020;2:e325–31. https://doi.org/10.1016/S2665-9913(20)30127-2 
384. REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol 
AD, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N 
Engl J Med 2021;384:1491–502. https://doi.org/10.1056/NEJMoa2100433 
385. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association 
between early treatment with tocilizumab and mortality among critically ill patients 
with COVID-19. JAMA Intern Med 2021;181:41–51. https://doi.org/10.1001/ 
jamainternmed.2020.6252 
386. Klingel K, Hohenadl C, Canu A, Albrecht M, Seemann M, Mall G, et al. Ongoing 
enterovirus-induced myocarditis is associated with persistent heart muscle infection: 
quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl 
Acad Sci U S A 1992;89:314–8. https://doi.org/10.1073/pnas.89.1.314 
387. Schowengerdt KO, Ni J, Denfield SW, Gajarski RJ, Bowles NE, Rosenthal G, et al. 
Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation 1997;96: 
3549–54. https://doi.org/10.1161/01.cir.96.10.3549 
388. Bock C-T, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J 
Med 2010;362:1248–9. https://doi.org/10.1056/NEJMc0911362 
389. Huang C-H, Vallejo JG, Kollias G, Mann DL. Role of the innate immune system in acute 
viral myocarditis. Basic Res Cardiol 2009;104:228–37. https://doi.org/10.1007/s00395- 
008-0765-5 
390. Corsten MF, Papageorgiou A, Verhesen W, Carai P, Lindow M, Obad S, et al. 
MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury 
and dysfunction during acute viral myocarditis. Circ Res 2012;111:415–25. https://doi. 
org/10.1161/CIRCRESAHA.112.267443 
391. Goldberg L, Tirosh-Wagner T, Vardi A, Abbas H, Pillar N, Shomron N, et al. Circulating 
microRNAs: a potential biomarker for cardiac damage, inflammatory response, and 
left ventricular function recovery in pediatric viral myocarditis. J Cardiovasc Transl 
Res 2018;11:319–28. https://doi.org/10.1007/s12265-018-9814-0 
392. Mueller KAL, Mueller II, Eppler D, Zuern CS, Seizer P, Kramer U, et al. Clinical and 
histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. PLoS One 2015;10:e0126707. https://doi.org/10.1371/journal.pone. 
0126707 
393. Wakafuji S, Okada R. Twenty year autopsy statistics of myocarditis incidence in Japan. 
Jpn Circ J 1986;50:1288–93. https://doi.org/10.1253/jcj.50.1288 
394. Vaideeswar P, Cooper LT. Giant cell myocarditis: clinical and pathological features in 
an Indian population. Cardiovasc Pathol 2013;22:70–4. https://doi.org/10.1016/j. 
carpath.2012.06.003 
395. Caforio ALP, Angelini A, Blank M, Shani A, Kivity S, Goddard G, et al. Passive transfer of 
affinity-purified anti-heart autoantibodies (AHA) from sera of patients with myocarditis induces experimental myocarditis in mice. Int J Cardiol 2015;179:166–77. https://doi. 
org/10.1016/j.ijcard.2014.10.165 
396. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as 
causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm 
Electrophysiol 2011;4:303–9. https://doi.org/10.1161/CIRCEP.110.959254 
397. Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation 2016;134:e579–e646. https:// 
doi.org/10.1161/CIR.0000000000000455 
398. Liu S, Zheng L, Shen L, Wu L, Yao Y. Clinical identification and characteristic analysis of 
giant cell myocarditis in 12 cases. Front Cardiovasc Med 2021;8:649094. https://doi.org/ 
10.3389/fcvm.2021.649094 
399. Okura Y, Dec GW, Hare JM, Kodama M, Berry GJ, Tazelaar HD, et al. A clinical and 
histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. 
J Am Coll Cardiol 2003;41:322–9. https://doi.org/10.1016/s0735-1097(02)02715-8 
400. Berthelot-Richer M, O’Connor K, Bernier M, Trahan S, Couture C, Dubois M, et al. 
When should we consider the diagnosis of giant cell myocarditis? Revisiting ‘classic’ 
echocardiographic and clinical features of this rare pathology. Exp Clin Transplant 
2014;12:565–8. https://doi.org/10.6002/ect.2013.0218 
401. Ekström K, Lehtonen J, Kandolin R, Räisänen-Sokolowski A, Salmenkivi K, Kupari M. 
Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Fail 
2016;18:1452–8. https://doi.org/10.1002/ejhf.606 
402. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of 
endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and 
the European Society of Cardiology. Endorsed by the Heart Failure Society of America 
and the Heart Failure Association of the European Society of Cardiology. J Am Coll 
Cardiol 2007;50:1914–31. https://doi.org/10.1016/j.jacc.2007.09.008 
403. Cooper LT, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC, et al. 
Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008;102: 
1535–9. https://doi.org/10.1016/j.amjcard.2008.07.041 
404. Patel PM, Saxena A, Wood CT, O’Malley TJ, Maynes EJ, Entwistle JWC, et al. 
Outcomes of mechanical circulatory support for giant cell myocarditis: a systematic 
review. J Clin Med 2020;9:3905. https://doi.org/10.3390/jcm9123905 
405. Bobbio E, Björkenstam M, Nwaru BI, Giallauria F, Hessman E, Bergh N, et al. Short- and 
long-term outcomes after heart transplantation in cardiac sarcoidosis and giant-cell 
myocarditis: a systematic review and meta-analysis. Clin Res Cardiol 2022;111: 
125–40. https://doi.org/10.1007/s00392-021-01920-0 
406. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Bresnitz EA, et al. 
Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir 
Crit Care Med 2001;164:1885–9. https://doi.org/10.1164/ajrccm.164.10.2104046 
407. Lehtonen J, Uusitalo V, Pöyhönen P, Mäyränpää MI, Kupari M. Cardiac sarcoidosis: 
phenotypes, diagnosis, treatment, and prognosis. Eur Heart J 2023;44:1495–510.  
https://doi.org/10.1093/eurheartj/ehad067 
408. Okasha O, Kazmirczak F, Chen K-HA, Farzaneh-Far A, Shenoy C. Myocardial involvement in patients with histologically diagnosed cardiac sarcoidosis: a systematic review 
and meta-analysis of gross pathological images from autopsy or cardiac transplantation 
cases. J Am Heart Assoc 2019;8:e011253. https://doi.org/10.1161/JAHA.118.011253 
409. Iwai K, Tachibana T, Takemura T, Matsui Y, Kitalchi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol 
Jpn 1993;43:372–6. https://doi.org/10.1111/j.1440-1827.1993.tb01148.x  
ESC Guidelines                                                                                                                                                                                               83


<!-- PAGE 84 -->

### Page 84

410. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 
38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995;119: 
167–72. 
411. Philips B, Madhavan S, James CA, te Riele ASJM, Murray B, Tichnell C, et al. 
Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: 
distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol 
2014;7:230–6. https://doi.org/10.1161/CIRCEP.113.000932 
412. Gasperetti A, Rossi VA, Chiodini A, Casella M, Costa S, Akdis D, et al. Differentiating 
hereditary arrhythmogenic right ventricular cardiomyopathy from cardiac sarcoidosis 
fulfilling 2010 ARVC task force criteria. Heart Rhythm 2021;18:231–8. https://doi.org/ 
10.1016/j.hrthm.2020.09.015 
413. Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari MD, et al. 
Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria. Int J Cardiol 2020; 
319:106–14. https://doi.org/10.1016/j.ijcard.2020.06.005 
414. Bagwan IN, Hooper LVB, Sheppard MN. Cardiac sarcoidosis and sudden death. The 
heart may look normal or mimic other cardiomyopathies. Virchows Arch 2011;458: 
671–8. https://doi.org/10.1007/s00428-010-1003-8 
415. Athwal PSS, Chhikara S, Ismail MF, Ismail K, Ogugua FM, Kazmirczak F, et al. 
Cardiovascular magnetic resonance imaging phenotypes and long-term outcomes in 
patients with suspected cardiac sarcoidosis. JAMA Cardiol 2022;7:1057–66. https:// 
doi.org/10.1001/jamacardio.2022.2981 
416. Azoulay L-D, Waintraub X, Haroche J, Amoura Z, Cohen Aubart F. Factors associated 
with implantable cardioverter defibrillators appropriate therapy in cardiac sarcoidosis: 
a meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis 2020;37:17–23. https://doi.org/10. 
36141/svdld.v37i1.8271 
417. Sharma R, Kouranos V, Cooper LT, Metra M, Ristic A, Heidecker B, et al. Management 
of cardiac sarcoidosis. Eur Heart J 2024;45:2697–726. https://doi.org/10.1093/ 
eurheartj/ehae356 
418. Selan JC, Michaelson M, Fanburg BL, Estes NAM. Evaluation and management of heart 
rhythm disturbances due to cardiac sarcoidosis. Heart Lung Circ 2014;23:1100–9.  
https://doi.org/10.1016/j.hlc.2014.07.065 
419. Ardehali H, Howard DL, Hariri A, Qasim A, Hare JM, Baughman KL, et al. A positive 
endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients 
with initially unexplained cardiomyopathy. Am Heart J 2005;150:459–63. https://doi. 
org/10.1016/j.ahj.2004.10.006 
420. Kouranos V, Tzelepis GE, Rapti A, Mavrogeni S, Aggeli K, Douskou M, et al. 
Complementary role of CMR to conventional screening in the diagnosis and prognosis 
of cardiac sarcoidosis. JACC Cardiovasc Imaging 2017;10:1437–47. https://doi.org/10. 
1016/j.jcmg.2016.11.019 
421. Adhaduk M, Paudel B, Khalid MU, Ashwath M, Mansour S, Liu K. Comparison of cardiac magnetic resonance imaging and fluorodeoxyglucose positron emission tomography in the assessment of cardiac sarcoidosis: meta-analysis and systematic review. 
J Nucl Cardiol 2023;30:1574–87. https://doi.org/10.1007/s12350-022-03129-8 
422. Orii M, Tanimoto T, Ota S, Takagi H, Tanaka R, Fujiwara J, et al. Diagnostic accuracy of 
cardiac magnetic resonance imaging for cardiac sarcoidosis in complete heart block patients implanted with magnetic resonance-conditional pacemaker. J Cardiol 2020;76: 
191–7. https://doi.org/10.1016/j.jjcc.2020.02.014 
423. Stanton KM, Ganigara M, Corte P, Celermajer DS, McGuire MA, Torzillo PJ, et al. The 
utility of cardiac magnetic resonance imaging in the diagnosis of cardiac sarcoidosis. 
Heart Lung Circ 2017;26:1191–9. https://doi.org/10.1016/j.hlc.2017.02.021 
424. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of 
myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969–77.  
https://doi.org/10.1161/CIRCULATIONAHA.109.851352 
425. Zhang J, Li Y, Xu Q, Xu B, Wang H. Cardiac magnetic resonance imaging for diagnosis 
of cardiac sarcoidosis: a meta-analysis. Can Respir J 2018;2018:7457369. https://doi. 
org/10.1155/2018/7457369 
426. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 
18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241–8. https://doi.org/10. 
2967/jnumed.111.090662 
427. Dweck MR, Abgral R, Trivieri MG, Robson PM, Karakatsanis N, Mani V, et al. Hybrid 
magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac sarcoidosis. JACC Cardiovasc Imaging 2018;11:94–107.  
https://doi.org/10.1016/j.jcmg.2017.02.021 
428. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 
18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989–98.  
https://doi.org/10.2967/jnumed.104.013352 
429. Vita T, Okada DR, Veillet-Chowdhury M, Bravo PE, Mullins E, Hulten E, et al. 
Complementary value of cardiac magnetic resonance imaging and positron emission 
tomography/computed tomography in the assessment of cardiac sarcoidosis. Circ 
Cardiovasc Imaging 2018;11:e007030. https://doi.org/10.1161/CIRCIMAGING.117. 
007030 
430. Agoston-Coldea L, Kouaho S, Sacre K, Dossier A, Escoubet B, Chillon S, et al. High 
mass (>18 g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy-proven extracardiac 
sarcoidosis. Int J Cardiol 2016;222:950–6. https://doi.org/10.1016/j.ijcard.2016.07.233 
431. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc 
Imaging 2013;6:501–11. https://doi.org/10.1016/j.jcmg.2012.10.021 
432. Nadel J, Lancefield T, Voskoboinik A, Taylor AJ. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with 
long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc 
Imaging 2015;16:634–41. https://doi.org/10.1093/ehjci/jeu294 
433. Murtagh G, Laffin LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV, et al. Prognosis of 
myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging 
2016;9:e003738. https://doi.org/10.1161/CIRCIMAGING.115.003738 
434. Coleman GC, Shaw PW, Balfour PC, Gonzalez JA, Kramer CM, Patel AR, et al. 
Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis. 
JACC Cardiovasc Imaging 2017;10:411–20. https://doi.org/10.1016/j.jcmg.2016.05.009 
435. Smedema J-P, van Geuns R-J, Ector J, Heidbuchel H, Ainslie G, Crijns HJGM. Right ventricular involvement and the extent of left ventricular enhancement with magnetic resonance predict adverse outcome in pulmonary sarcoidosis. ESC Heart Fail 2018;5: 
157–71. https://doi.org/10.1002/ehf2.12201 
436. Velangi PS, Chen K-HA, Kazmirczak F, Okasha O, von Wald L, Roukoz H, et al. Right 
ventricular abnormalities on cardiovascular magnetic resonance imaging in patients 
with sarcoidosis. JACC Cardiovasc Imaging 2020;13:1395–405. https://doi.org/10. 
1016/j.jcmg.2019.12.011 
437. Greulich S, Kitterer D, Latus J, Aguor E, Steubing H, Kaesemann P, et al. 
Comprehensive cardiovascular magnetic resonance assessment in patients with sarcoidosis and preserved left ventricular ejection fraction. Circ Cardiovasc Imaging 
2016;9:e005022. https://doi.org/10.1161/CIRCIMAGING.116.005022 
438. Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E. T1 and T2 mapping 
in recognition of early cardiac involvement in systemic sarcoidosis. Radiology 2017;285: 
63–72. https://doi.org/10.1148/radiol.2017162732 
439. Crouser ED, Ruden E, Julian MW, Raman SV. Resolution of abnormal cardiac MRI T2 
signal following immune suppression for cardiac sarcoidosis. J Investig Med 2016;64: 
1148–50. https://doi.org/10.1136/jim-2016-000144 
440. Greulich S, Gatidis S, Gräni C, Blankstein R, Glatthaar A, Mezger K, et al. Hybrid cardiac 
magnetic resonance/fluorodeoxyglucose positron emission tomography to differentiate active from chronic cardiac sarcoidosis. JACC Cardiovasc Imaging 2022;15:445–56.  
https://doi.org/10.1016/j.jcmg.2021.08.018 
441. Crouser ED, Ono C, Tran T, He X, Raman SV. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med 
2014;189:109–12. https://doi.org/10.1164/rccm.201309-1668LE 
442. Cheung E, Ahmad S, Aitken M, Chan R, Iwanochko RM, Balter M, et al. Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the 
diagnosis and prognosis of suspected cardiac sarcoidosis. Eur J Hybrid Imaging 2021; 
5:24. https://doi.org/10.1186/s41824-021-00119-w 
443. Wicks EC, Menezes LJ, Barnes A, Mohiddin SA, Sekhri N, Porter JC, et al. Diagnostic 
accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis. Eur 
Heart J Cardiovasc Imaging 2018;19:757–67. https://doi.org/10.1093/ehjci/jex340 
444. Aitken M, Davidson M, Chan MV, Urzua Fresno C, Vasquez LI, Huo YR, et al. 
Prognostic value of cardiac MRI and FDG PET in cardiac sarcoidosis: a systematic review and meta-analysis. Radiology 2023;307:e222483. https://doi.org/10.1148/radiol. 
222483 
445. Mc Ardle BA, Birnie DH, Klein R, de Kemp RA, Leung E, Renaud J, et al. Is there an 
association between clinical presentation and the location and extent of myocardial 
involvement of cardiac sarcoidosis as assessed by 18F-fluorodoexyglucose positron 
emission tomography? Circ Cardiovasc Imaging 2013;6:617–26. https://doi.org/10. 
1161/CIRCIMAGING.112.000289 
446. Muser D, Santangeli P, Castro SA, Liang JJ, Enriquez A, Werner TJ, et al. Prognostic role 
of serial quantitative evaluation of 18F-fluorodeoxyglucose uptake by PET/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia. Eur J Nucl 
Med Mol Imaging 2018;45:1394–404. https://doi.org/10.1007/s00259-018-4001-8 
447. Ahmed AI, Abebe AT, Han Y, Alnabelsi T, Agrawal T, Kassi M, et al. The prognostic role 
of cardiac positron emission tomography imaging in patients with sarcoidosis: a systematic review. J Nucl Cardiol 2021;28:1545–52. https://doi.org/10.1007/s12350-021- 
02681-z 
448. Flores RJ, Flaherty KR, Jin Z, Bokhari S. The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis. J Nucl Cardiol 2020;27:2003–10. https:// 
doi.org/10.1007/s12350-018-01504-y 
449. Sperry BW, Tamarappoo BK, Oldan JD, Javed O, Culver DA, Brunken R, et al. 
Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F– 
FDG PET scans for suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2018;11: 
336–45. https://doi.org/10.1016/j.jcmg.2017.04.020 
450. Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, et al. 
Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with 
cardiac sarcoidosis. J Nucl Cardiol 2014;21:166–74. https://doi.org/10.1007/s12350- 
013-9828-6


<!-- PAGE 85 -->

### Page 85

451. Birnie D, Beanlands RSB, Nery P, Aaron SD, Culver DA, DeKemp RA, et al. Cardiac 
sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT). Am Heart J 
2020;220:246–52. https://doi.org/10.1016/j.ahj.2019.10.003 
452. Nordenswan H-K, Lehtonen J, Ekström K, Kandolin R, Simonen P, Mäyränpää M, et al. 
Outcome of cardiac sarcoidosis presenting with high-grade atrioventricular block. Circ 
Arrhythm 
Electrophysiol 
2018;11:e006145. 
https://doi.org/10.1161/CIRCEP.117. 
006145 
453. Halawa A, Jain R, Turagam MK, Kusumoto FM, Woldu HG, Gautam S. Outcome of 
implantable cardioverter defibrillator in cardiac sarcoidosis: a systematic review and 
meta-analysis. J Interv Card Electrophysiol 2020;58:233–42. https://doi.org/10.1007/ 
s10840-020-00705-1 
454. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR, et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc 
Electrophysiol 2012;23:925–9. https://doi.org/10.1111/j.1540-8167.2012.02350.x 
455. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. 
Long-term follow-up of patients with cardiac sarcoidosis and implantable 
cardioverter-defibrillators. Heart Rhythm 2012;9:884–91. https://doi.org/10.1016/j. 
hrthm.2012.02.010 
456. Franke KB, Marshall H, Kennewell P, Pham H-D, Tully PJ, Rattanakosit T, et al. Risk and 
predictors of sudden death in cardiac sarcoidosis: a systematic review and 
meta-analysis. Int J Cardiol 2021;328:130–40. https://doi.org/10.1016/j.ijcard.2020.11. 
044 
457. Mathijssen H, Bakker ALM, Balt JC, Akdim F, van Es HW, Veltkamp M, et al. Predictors 
of appropriate implantable cardiac defibrillator therapy in cardiac sarcoidosis. J 
Cardiovasc Electrophysiol 2022;33:1272–80. https://doi.org/10.1111/jce.15484 
458. Crawford T, Mueller G, Sarsam S, Prasitdumrong H, Chaiyen N, Gu X, et al. Magnetic 
resonance imaging for identifying patients with cardiac sarcoidosis and preserved or 
mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ 
Arrhythm Electrophysiol 2014;7:1109–15. https://doi.org/10.1161/CIRCEP.113.000156 
459. Shafee MA, Fukuda K, Wakayama Y, Nakano M, Kondo M, Hasebe Y, et al. Delayed 
enhancement on cardiac magnetic resonance imaging is a poor prognostic factor in patients with cardiac sarcoidosis. J Cardiol 2012;60:448–53. https://doi.org/10.1016/j.jjcc. 
2012.08.002 
460. Mehta D, Mori N, Goldbarg SH, Lubitz S, Wisnivesky JP, Teirstein A. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 2011;4:43–8. https://doi.org/10.1161/ 
CIRCEP.110.958322 
461. Okada DR, Smith J, Derakhshan A, Gowani Z, Zimmerman SL, Misra S, et al. 
Electrophysiology study for risk stratification in patients with cardiac sarcoidosis and 
abnormal cardiac imaging. Int J Cardiol Heart Vasc 2019;23:100342. https://doi.org/10. 
1016/j.ijcha.2019.03.002 
462. Adhaduk M, Paudel B, Liu K, Ashwath M, Giudici M. The role of electrophysiology 
study in risk stratification of cardiac sarcoidosis patients: meta-analyses and systemic 
review. Int J Cardiol 2022;349:55–61. https://doi.org/10.1016/j.ijcard.2021.11.061 
463. Zipse MM, Tzou WS, Schuller JL, Aleong RG, Varosy PD, Tompkins C, et al. 
Electrophysiologic testing for diagnostic evaluation and risk stratification in patients 
with suspected cardiac sarcoidosis with preserved left and right ventricular systolic 
function. J Cardiovasc Electrophysiol 2019;30:1939–48. https://doi.org/10.1111/jce. 
14058 
464. Tandon P, Mosleh T, Mustafa A, Miodownik H, Miller M, Morgenthau AS. Utility of 
electrophysiologic testing for sudden death risk stratification in cardiac sarcoidosis patients with mildly impaired left ventricular function. Respir Med 2022;191:106712.  
https://doi.org/10.1016/j.rmed.2021.106712 
465. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329–36. https://doi.org/10. 
1016/j.jacc.2013.09.022 
466. Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, et al. Efficacy and safety of 
implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients 
with cardiac sarcoidosis. Europace 2013;15:347–54. https://doi.org/10.1093/europace/ 
eus316 
467. Stevenson A, Bray JJH, Tregidgo L, Ahmad M, Sharma A, Ng A, et al. Prognostic value of 
late gadolinium enhancement detected on cardiac magnetic resonance in cardiac sarcoidosis. JACC Cardiovasc Imaging 2023;16:345–57. https://doi.org/10.1016/j.jcmg.2022. 
10.018 
468. Veronese G, Ammirati E, Brambatti M, Merlo M, Cipriani M, Potena L, et al. Viral genome search in myocardium of patients with fulminant myocarditis. Eur J Heart Fail 
2020;22:1277–80. https://doi.org/10.1002/ejhf.1738 
469. Sinagra G, Porcari A, Gentile P, Artico J, Fabris E, Bussani R, et al. Viral presence-guided 
immunomodulation in lymphocytic myocarditis: an update. Eur J Heart Fail 2021;23: 
211–6. https://doi.org/10.1002/ejhf.1969 
470. Moimas S, Zacchigna S, Merlo M, Buiatti A, Anzini M, Dreas L, et al. Idiopathic dilated 
cardiomyopathy and persistent viral infection: lack of association in a controlled study 
using a quantitative assay. Heart Lung Circ 2012;21:787–93. https://doi.org/10.1016/j. 
hlc.2012.07.013 
471. Stewart GC, Lopez-Molina J, Gottumukkala RVSRK, Rosner GF, Anello MS, Hecht JL, 
et al. Myocardial parvovirus B19 persistence: lack of association with clinicopathologic 
phenotype in adults with heart failure. Circ Heart Fail 2011;4:71–8. https://doi.org/10. 
1161/CIRCHEARTFAILURE.110.958249 
472. Robinson J, Hartling L, Vandermeer B, Sebastianski M, Klassen TP. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane 
Database Syst Rev 2020;8:CD004370. https://doi.org/10.1002/14651858.CD004370. 
pub4 
473. Kühl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, et al. 
Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular 
function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003;107:2793–8. https://doi.org/10.1161/01.CIR.0000072766. 
67150.51 
474. Kühl U, Lassner D, von Schlippenbach J, Poller W, Schultheiss H-P. Interferon-beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol 2012;60: 
1295–6. https://doi.org/10.1016/j.jacc.2012.06.026 
475. Schultheiss H-P, Bock C-T, Aleshcheva G, Baumeier C, Poller W, Escher F. 
Interferon-β suppresses transcriptionally active parvovirus B19 infection in viral cardiomyopathy: a subgroup analysis of the BICC-trial. Viruses 2022;14:444. https://doi. 
org/10.3390/v14020444 
476. Cobas M, Abbo L, Santos M, Baccini-Jauregui C, Pham S. Successful management of 
fulminant influenza A subtype H1N1 myocarditis. BMJ Case Rep 2010;2010: 
bcr0220102763. https://doi.org/10.1136/bcr.02.2010.2763 
477. Baik SH, Jeong HS, Kim SJ, Yoon YK, Sohn JW, Kim MJ. A case of influenza associated 
fulminant myocarditis successfully treated with intravenous peramivir. Infect 
Chemother 2015;47:272–7. https://doi.org/10.3947/ic.2015.47.4.272 
478. Jahns F-P, Ben-Hamouda N, Kirsch M, Roumy A, Liaudet L. Intravenous zanamivir for 
influenza myocarditis and enteral malabsorption. Crit Care 2018;22:332. https://doi. 
org/10.1186/s13054-018-2263-y 
479. Mazzitelli M, Garofalo E, Bruni A, Barreca GS, Quirino A, Giancotti A, et al. Severe 
myocarditis due to influenza A(H1N1)pdm09 viral infection in a young woman successfully treated with intravenous zanamivir: a case report. Clin Case Rep 2019;7: 
2336–40. https://doi.org/10.1002/ccr3.2499 
480. Yoshimizu N, Tominaga T, Ito T, Nishida Y, Wada Y, Sohmiya K, et al. Repetitive fulminant influenza myocarditis requiring the use of circulatory assist devices. Intern Med 
2014;53:109–14. https://doi.org/10.2169/internalmedicine.53.1117 
481. Khouzam RN, Parizianu C, Hafiz AM, Chawla S, Schwartz R. Fulminant myocarditis associated with novel H1N1 influenza A. Heart Lung 2011;40:566–8. https://doi.org/10. 
1016/j.hrtlng.2011.01.004 
482. Ito N, Sato M, Momoi N, Aoyagi Y, Endo K, Chishiki M, et al. Influenza A H1N1 
pdm09-associated myocarditis during zanamivir therapy. Pediatr Int 2015;57:1172–4.  
https://doi.org/10.1111/ped.12712 
483. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of highly active 
antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000; 
40:282–4. https://doi.org/10.1053/jinf.2000.0672 
484. Steere AC, Batsford WP, Weinberg M, Alexander J, Berger HJ, Wolfson S, et al. Lyme 
carditis: cardiac abnormalities of Lyme disease. Ann Intern Med 1980;93:8–16. https:// 
doi.org/10.7326/0003-4819-93-1-8 
485. Besant G, Wan D, Yeung C, Blakely C, Branscombe P, Suarez-Fuster L, et al. Suspicious 
index in Lyme carditis: systematic review and proposed new risk score. Clin Cardiol 
2018;41:1611–6. https://doi.org/10.1002/clc.23102 
486. Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, 
Auwaerter PG, et al. Clinical Practice Guidelines by the Infectious Diseases Society 
of America (IDSA), American Academy of Neurology (AAN), and American 
College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and 
treatment of Lyme disease. Arthritis Care Res (Hoboken) 2021;73:1–9. https://doi.org/ 
10.1002/acr.24495 
487. Costello JM, Alexander ME, Greco KM, Perez-Atayde AR, Laussen PC. Lyme carditis in 
children: presentation, predictive factors, and clinical course. Pediatrics 2009;123: 
e835–841. https://doi.org/10.1542/peds.2008-3058 
488. Nunes MCP, Badano LP, Marin-Neto JA, Edvardsen T, Fernández-Golfín C, 
Bucciarelli-Ducci C, et al. Multimodality imaging evaluation of Chagas disease: an expert consensus of Brazilian Cardiovascular Imaging Department (DIC) and the 
European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc 
Imaging 2018;19:459–60. https://doi.org/10.1093/ehjci/jex154 
489. Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A, Rosas F, et al. 
Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med 
2015;373:1295–306. https://doi.org/10.1056/NEJMoa1507574 
490. Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, 
López-Velez R. Use of benznidazole to treat chronic Chagas’ disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009;64:1139–47. https://doi.org/10. 
1093/jac/dkp357 
491. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006;144:724–34. https://doi.org/10. 
7326/0003-4819-144-10-200605160-00006  
ESC Guidelines                                                                                                                                                                                               85


<!-- PAGE 86 -->

### Page 86

492. Chadalawada S, Rassi A, Samara O, Monzon A, Gudapati D, Vargas Barahona L, et al. 
Mortality risk in chronic Chagas cardiomyopathy: a systematic review and 
meta-analysis. ESC Heart Fail 2021;8:5466–81. https://doi.org/10.1002/ehf2.13648 
493. Carmo AAL, de Sousa MR, Agudelo JF, Boersma E, Rocha MOC, Ribeiro ALP, et al. 
Implantable cardioverter-defibrillator in Chagas heart disease: a systematic review 
and meta-analysis of observational studies. Int J Cardiol 2018;267:88–93. https://doi. 
org/10.1016/j.ijcard.2018.05.091 
494. Rassi FM, Minohara L, Rassi A, Correia LCL, Marin-Neto JA, Rassi A, et al. Systematic 
review and meta-analysis of clinical outcome after implantable cardioverter- 
defibrillator therapy in patients with Chagas heart disease. JACC Clin Electrophysiol 
2019;5:1213–23. https://doi.org/10.1016/j.jacep.2019.07.003 
495. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. 
Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 
2018;71:1755–64. https://doi.org/10.1016/j.jacc.2018.02.037 
496. Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. 
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19:1579–89.  
https://doi.org/10.1016/S1470-2045(18)30608-9 
497. Suzuki Y, Kaneko H, Tamura Y, Okada A, Fujiu K, Michihata N, et al. Cardiovascular 
events after the initiation of immune checkpoint inhibitors. Heliyon 2023;9:e16373.  
https://doi.org/10.1016/j.heliyon.2023.e16373 
498. Nguyen LS, Cooper LT, Kerneis M, Funck-Brentano C, Silvain J, Brechot N, et al. 
Systematic analysis of drug-associated myocarditis reported in the World Health 
Organization pharmacovigilance database. Nat Commun 2022;13:25. https://doi.org/ 
10.1038/s41467-021-27631-8 
499. Liu M, Cheng X, Ni R, Zheng B, Huang S, Yang J. Cardiotoxicity of immune checkpoint 
inhibitors: a frequency network meta-analysis. Front Immunol 2022;13:1006860.  
https://doi.org/10.3389/fimmu.2022.1006860 
500. Pradhan R, Nautiyal A, Singh S. Diagnosis of immune checkpoint inhibitor-associated 
myocarditis: a systematic review. Int J Cardiol 2019;296:113–21. https://doi.org/10. 
1016/j.ijcard.2019.07.025 
501. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 
European Hematology Association (EHA), the European Society for Therapeutic 
Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society 
(IC-OS). Eur Heart J 2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244 
502. Salem J-E, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, et al. 
Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov 2023;13: 
1100–15. https://doi.org/10.1158/2159-8290.CD-22-1180 
503. L’Orphelin J-M, Dollalille C, Akroun J, Alexandre J, Dompmartin A. Cardiovascular immunotoxicity associated with immune checkpoint inhibitors in metastatic melanoma. 
Cancers (Basel) 2023;15:2170. https://doi.org/10.3390/cancers15072170 
504. Tocchetti CG, Farmakis D, Koop Y, Andres MS, Couch LS, Formisano L, et al. 
Cardiovascular toxicities of immune therapies for cancer—a scientific statement of 
the Heart Failure Association (HFA) of the ESC and the ESC Council of 
Cardio-Oncology. Eur J Heart Fail 2024;26:2055–76. https://doi.org/10.1002/ejhf.3340 
505. Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 2020;6:865–71. https://doi.org/10.1001/jamaoncol.2020.0726 
506. Clapham E, Reutfors J, Linder M, Brandt L, Sundström J, Bodén R. The association between exposure to clozapine, olanzapine, and quetiapine and the outcomes perimyocarditis and heart failure: a population-based cohort study. Psychiatry Res 2023;326: 
115336. https://doi.org/10.1016/j.psychres.2023.115336 
507. Sandarsh S, Bishnoi RJ, Shashank RB, Miller BJ, Freudenreich O, McEvoy JP. Monitoring 
for myocarditis during treatment initiation with clozapine. Acta Psychiatr Scand 2021; 
144:194–200. https://doi.org/10.1111/acps.13328 
508. Siskind D, Sidhu A, Cross J, Chua Y-T, Myles N, Cohen D, et al. Systematic review and 
meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy. Aust N 
Z J Psychiatry 2020;54:467–81. https://doi.org/10.1177/0004867419898760 
509. Seree-aphinan C, Assanangkornchai N, Nilmoje T. Prolonged extracorporeal membrane oxygenation support in a patient with drug reaction with eosinophilia and systemic symptoms syndrome-associated fulminant myocarditis—a case report and 
literature review. Heart Int 2020;14:112–7. https://doi.org/10.17925/HI.2020.14.2.112 
510. Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, et al. The Brighton 
Collaboration: addressing the need for standardized case definitions of adverse events 
following immunization (AEFI). Vaccine 2002;21:298–302. https://doi.org/10.1016/ 
s0264-410x(02)00449-8 
511. Engler RJM, Montgomery JR, Spooner CE, Nelson MR, Collins LC, Ryan MA, et al. 
Myocarditis and pericarditis recovery following smallpox vaccine 2002–2016: a comparative observational cohort study in the military health system. PLoS One 2023;18: 
e0283988. https://doi.org/10.1371/journal.pone.0283988 
512. Parmar K, Subramanyam S, Del Rio-Pertuz G, Sethi P, Argueta-Sosa E. Cardiac adverse 
events after vaccination—a systematic review. Vaccines (Basel) 2022;10:700. https:// 
doi.org/10.3390/vaccines10050700 
513. Thanjan MT, Ramaswamy P, Lai WW, Lytrivi ID. Acute myopericarditis after multiple 
vaccinations in an adolescent: case report and review of the literature. Pediatrics 2007; 
119:e1400–3. https://doi.org/10.1542/peds.2006-2605 
514. Dilber E, Karagöz T, Aytemir K, Ozer S, Alehan D, Oto A, et al. Acute myocarditis associated with tetanus vaccination. Mayo Clin Proc 2003;78:1431–3. https://doi.org/10. 
4065/78.11.1431-a 
515. Boccara F, Benhaiem-Sigaux N, Cohen A. Acute myopericarditis after diphtheria, tetanus, and polio vaccination. Chest 2001;120:671–2. https://doi.org/10.1378/chest.120. 
2.671 
516. Barton M, Finkelstein Y, Opavsky MA, Ito S, Ho T, Ford-Jones LE, et al. Eosinophilic 
myocarditis temporally associated with conjugate meningococcal C and hepatitis B 
vaccines in children. Pediatr Infect Dis J 2008;27:831–5. https://doi.org/10.1097/INF. 
0b013e31816ff7b2 
517. Lu J, Zhang X, Xu H, Li Z. Inspiration to mRNA-based COVID-19 vaccination: serious 
adverse case reports with hepatitis B vaccine in real-world. Front Pediatr 2022;10: 
888686. https://doi.org/10.3389/fped.2022.888686 
518. Nagano N, Yano T, Fujita Y, Koyama M, Hasegawa R, Nakata J, et al. Hemodynamic 
collapse after influenza vaccination: a vaccine-induced fulminant myocarditis? Can J 
Cardiol 2020;36:1554.e5–e7. https://doi.org/10.1016/j.cjca.2020.05.005 
519. Jain SS, Anderson SA, Steele JM, Wilson HC, Muniz JC, Soslow JH, et al. Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in 
the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) 
multicenter study. EClinicalMedicine 2024;76:102809. https://doi.org/10.1016/j.eclinm. 
2024.102809 
520. Peretto G, Micaglio E, Ciconte G, Maia M, Luzzi M, Cariello M, et al. The ‘arrhythmic’ 
presentation of peripartum cardiomyopathy: case series and critical review of the literature. Front Cardiovasc Med 2024;11:1362692. https://doi.org/10.3389/fcvm.2024. 
1362692 
521. Hoevelmann J, Engel ME, Muller E, Hohlfeld A, Böhm M, Sliwa K, et al. A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic 
review and meta-analysis. Eur J Heart Fail 2022;24:1719–36. https://doi.org/10.1002/ 
ejhf.2603 
522. Gunderson EP, Croen LA, Chiang V, Yoshida CK, Walton D, Go AS. Epidemiology of 
peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol 
2011;118:583–91. https://doi.org/10.1097/AOG.0b013e318229e6de 
523. Karaye KM, Ishaq NA, Sa’idu H, Balarabe SA, Talle MA, Isa MS, et al. Incidence, clinical 
characteristics, and risk factors of peripartum cardiomyopathy in Nigeria: results from 
the PEACE Registry. ESC Heart Fail 2020;7:235–43. https://doi.org/10.1002/ehf2.12562 
524. Goli R, Li J, Brandimarto J, Levine LD, Riis V, McAfee Q, et al. Genetic and phenotypic 
landscape of peripartum cardiomyopathy. Circulation 2021;143:1852–62. https://doi. 
org/10.1161/CIRCULATIONAHA.120.052395 
525. Mallikethi-Reddy S, Akintoye E, Trehan N, Sharma S, Briasoulis A, Jagadeesh K, et al. 
Burden of arrhythmias in peripartum cardiomyopathy: analysis of 9841 hospitalizations. Int J Cardiol 2017;235:114–7. https://doi.org/10.1016/j.ijcard.2017.02.084 
526. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current 
state of knowledge on aetiology, diagnosis, management, and therapy of peripartum 
cardiomyopathy: a position statement from the Heart Failure Association of the 
European Society of Cardiology Working Group on peripartum cardiomyopathy. 
Eur J Heart Fail 2010;12:767–78. https://doi.org/10.1093/eurjhf/hfq120 
527. Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, Parker JD, et al. B-type natriuretic 
peptide in pregnant women with heart disease. J Am Coll Cardiol 2010;56:1247–53.  
https://doi.org/10.1016/j.jacc.2010.02.076 
528. Esbrand FD, Zafar S, Panthangi V, Cyril Kurupp AR, Raju A, Luthra G, et al. Utility of 
N-terminal (NT)-brain natriuretic peptide (proBNP) in the diagnosis and prognosis of 
pregnancy associated cardiovascular conditions: a systematic review. Cureus 2022;14: 
e32848. https://doi.org/10.7759/cureus.32848 
529. Li W, Li H, Long Y. Clinical characteristics and long-term predictors of persistent left 
ventricular systolic dysfunction in peripartum cardiomyopathy. Can J Cardiol 2016;32: 
362–8. https://doi.org/10.1016/j.cjca.2015.07.733 
530. Arora NP, Mahajan N, Mohamad T, Kottam A, Afonso LC, Danrad R, et al. Cardiac 
magnetic resonance imaging in peripartum cardiomyopathy. Am J Med Sci 2014;347: 
112–7. https://doi.org/10.1097/MAJ.0b013e31828155e3 
531. Ordovas KG, Baldassarre LA, Bucciarelli-Ducci C, Carr J, Fernandes JL, Ferreira VM, 
et al. Cardiovascular magnetic resonance in women with cardiovascular disease: position statement from the Society for Cardiovascular Magnetic Resonance (SCMR). J 
Cardiovasc Magn Reson 2021;23:52. https://doi.org/10.1186/s12968-021-00746-z 
532. Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI 
exposure during pregnancy and fetal and childhood outcomes. JAMA 2016;316: 
952–61. https://doi.org/10.1001/jama.2016.12126 
533. Schelbert EB, Elkayam U, Cooper LT, Givertz MM, Alexis JD, Briller J, et al. Myocardial 
damage detected by late gadolinium enhancement cardiac magnetic resonance is uncommon in peripartum cardiomyopathy. J Am Heart Assoc 2017;6:e005472. https:// 
doi.org/10.1161/JAHA.117.005472 
534. Cooper LT, Mather PJ, Alexis JD, Pauly DF, Torre-Amione G, Wittstein IS, et al. 
Myocardial recovery in peripartum cardiomyopathy: prospective comparison with


<!-- PAGE 87 -->

### Page 87

recent onset cardiomyopathy in men and nonperipartum women. J Card Fail 2012;18: 
28–33. https://doi.org/10.1016/j.cardfail.2011.09.009 
535. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study 
(investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol 2015;66: 
905–14. https://doi.org/10.1016/j.jacc.2015.06.1309 
536. Biteker M, Özlek B, Özlek E, Çil C, Çelik O, Doğan V, et al. Predictors of early and delayed recovery in peripartum cardiomyopathy: a prospective study of 52 patients. J 
Matern Fetal Neonatal Med 2020;33:390–7. https://doi.org/10.1080/14767058.2018. 
1494146 
537. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin 
Proc 2005;80:1602–6. https://doi.org/10.4065/80.12.1602 
538. Moulig V, Pfeffer TJ, Ricke-Hoch M, Schlothauer S, Koenig T, Schwab J, et al. Long-term 
follow-up in peripartum cardiomyopathy patients with contemporary treatment: low 
mortality, high cardiac recovery, but significant cardiovascular co-morbidities. Eur J 
Heart Fail 2019;21:1534–42. https://doi.org/10.1002/ejhf.1624 
539. Sliwa K, Azibani F, Baard J, Osman A, Zühlke L, Lachmann A, et al. Reducing late maternal death due to cardiovascular disease—a pragmatic pilot study. Int J Cardiol 2018; 
272:70–6. https://doi.org/10.1016/j.ijcard.2018.07.140 
540. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, Veltmann C, Coats AJS, Crespo-Leiro MG, 
et al. Current management of patients with severe acute peripartum cardiomyopathy: 
practical guidance from the Heart Failure Association of the European Society of 
Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2016;18: 
1096–105. https://doi.org/10.1002/ejhf.586 
541. Fu K, Zhang H, Chen N, Hu Y, Xiao J, Zhang X, et al. Risk factors for intracardiac 
thrombus in peripartum cardiomyopathy: a retrospective study in China. ESC Heart 
Fail 2023;10:148–58. https://doi.org/10.1002/ehf2.14158 
542. Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, et al. 
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 2017;38:2671–9. https://doi.org/10.1093/eurheartj/ehx355 
543. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema J-P, Becker A, et al. Evaluation of 
bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a 
proof-of-concept pilot study. Circulation 2010;121:1465–73. https://doi.org/10.1161/ 
CIRCULATIONAHA.109.901496 
544. Kumar A, Ravi R, Sivakumar RK, Chidambaram V, Majella MG, Sinha S, et al. Prolactin 
inhibition in peripartum cardiomyopathy: systematic review and meta-analysis. Curr 
Probl Cardiol 2023;48:101461. https://doi.org/10.1016/j.cpcardiol.2022.101461 
545. Trongtorsak A, Kittipibul V, Mahabir S, Ibrahim M, Saint Croix GR, Hernandez GA, 
et al. Effects of bromocriptine in peripartum cardiomyopathy: a systematic review 
and meta-analysis. Heart Fail Rev 2022;27:533–43. https://doi.org/10.1007/s10741- 
021-10185-8 
546. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal 
of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019;393: 
61–73. https://doi.org/10.1016/S0140-6736(18)32484-X 
547. Codsi E, Rose CH, Blauwet LA. Subsequent pregnancy outcomes in patients with peripartum cardiomyopathy. Obstet Gynecol 2018;131:322–7. https://doi.org/10.1097/ 
AOG.0000000000002439 
548. Meng M-L, Arendt KW, Banayan JM, Bradley EA, Vaught AJ, Hameed AB, et al. 
Anesthetic care of the pregnant patient with cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2023;147:e657–73. https://doi. 
org/10.1161/CIR.0000000000001121 
549. De Backer J, Haugaa K. 2025 ESC Guidelines for the management of cardiovascular 
disease and pregnancy. Eur Heart J. 2011;32:3147–97. https://doi.org/10.1093/ 
eurheartj/ehr218 
550. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, et al. Report 
of the 1995 World Health Organization/International Society and Federation of 
Cardiology Task Force on the definition and classification of cardiomyopathies. 
Circulation 1996;93:841–2. https://doi.org/10.1161/01.cir.93.5.841 
551. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the 
TIMIC study. Eur Heart J 2009;30:1995–2002. https://doi.org/10.1093/eurheartj/ 
ehp249 
552. Escher F, Kühl U, Lassner D, Poller W, Westermann D, Pieske B, et al. Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. Clin Res Cardiol 2016;105:1011–20.  
https://doi.org/10.1007/s00392-016-1011-z 
553. Merken J, Hazebroek M, Van Paassen P, Verdonschot J, Van Empel V, Knackstedt C, 
et al. Immunosuppressive therapy improves both short- and long-term prognosis in 
patients with virus-negative nonfulminant inflammatory cardiomyopathy. Circ Heart 
Fail 2018;11:e004228. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004228 
554. De Luca G, Campochiaro C, Sartorelli S, Peretto G, Sala S, Palmisano A, et al. Efficacy 
and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: a prospective cohort study. J Autoimmun 2020;106:102330. https://doi.org/10. 
1016/j.jaut.2019.102330 
555. Peretto G, Sala S, De Luca G, Marcolongo R, Campochiaro C, Sartorelli S, et al. 
Immunosuppressive therapy and risk stratification of patients with myocarditis presenting with ventricular arrhythmias. JACC Clin Electrophysiol 2020;6:1221–34. https:// 
doi.org/10.1016/j.jacep.2020.05.013 
556. Reuter H, Burgess LJ, Doubell AF. Epidemiology of pericardial effusions at a large academic hospital in South Africa. Epidemiol Infect 2005;133:393–9. https://doi.org/10. 
1017/s0950268804003577 
557. Mayosi BM, Wiysonge CS, Ntsekhe M, Gumedze F, Volmink JA, Maartens G, et al. 
Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. S Afr 
Med J 2008;98:36–40. 
558. Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation 2005;112: 
3608–16. https://doi.org/10.1161/CIRCULATIONAHA.105.543066 
559. Isiguzo G, Du Bruyn E, Howlett P, Ntsekhe M. Diagnosis and management of tuberculous pericarditis: what is new? Curr Cardiol Rep 2020;22:2. https://doi.org/10.1007/ 
s11886-020-1254-1 
560. Ntsekhe M, Mayosi BM. Tuberculous pericarditis with and without HIV. Heart Fail Rev 
2013;18:367–73. https://doi.org/10.1007/s10741-012-9310-6 
561. Noubiap JJ, Agbor VN, Ndoadoumgue AL, Nkeck JR, Kamguia A, Nyaga UF, et al. 
Epidemiology of pericardial diseases in Africa: a systematic scoping review. Heart 
2019;105:180–8. https://doi.org/10.1136/heartjnl-2018-313922 
562. Xie DL, Cheng B, Sheng Y, Jin J. Diagnostic accuracy of adenosine deaminase for tuberculous pericarditis: a meta-analysis. Eur Rev Med Pharmacol Sci 2015;19:4411–8. https:// 
doi.org/10.18632/eurrev_2015_19_22_4411 
563. Pandie S, Peter JG, Kerbelker ZS, Meldau R, Theron G, Govender U, et al. Diagnostic 
accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared 
to adenosine deaminase and unstimulated interferon-γ in a high burden setting: a prospective study. BMC Med 2014;12:101. https://doi.org/10.1186/1741-7015-12-101 
564. Yu G, Ye B, Chen D, Zhong F, Chen G, Yang J, et al. Comparison between the diagnostic validities of Xpert MTB/RIF and interferon-γ release assays for tuberculous pericarditis using pericardial tissue. PLoS One 2017;12:e0188704. https://doi.org/10.1371/ 
journal.pone.0188704 
565. Liu C, Cui Y-L, Ding C-M, Wu Y-H, Li H-L, Liu X-F, et al. Diagnostic accuracy of 
interferon-gamma in pericardial effusions for tuberculous pericarditis: a meta-analysis. 
J Thorac Dis 2018;10:854–60. https://doi.org/10.21037/jtd.2017.12.107 
566. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, et al. 
Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in 
HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune 
Defic Syndr 2011;56:230–38. https://doi.org/10.1097/QAI.0b013e31820b07ab 
567. Wiysonge CS, Ntsekhe M, Thabane L, Volmink J, Majombozi D, Gumedze F, et al. 
Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev 2017; 
9:CD000526. https://doi.org/10.1002/14651858.CD000526.pub2 
568. Pasipanodya JG, Mubanga M, Ntsekhe M, Pandie S, Magazi BT, Gumedze F, et al. 
Tuberculous pericarditis is multibacillary and bacterial burden drives high mortality. 
EBioMedicine 2015;2:1634–9. https://doi.org/10.1016/j.ebiom.2015.09.034 
569. Mayosi BM, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F, et al. Prednisolone and 
Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med 2014;371: 
1121–30. https://doi.org/10.1056/NEJMoa1407380 
570. Reuter H, Burgess LJ, Louw VJ, Doubell AF. The management of tuberculous pericardial effusion: experience in 233 consecutive patients. Cardiovasc J S Afr 2007;18:20–5. 
571. Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. 
Lancet 1987;2:1418–22. https://doi.org/10.1016/s0140-6736(87)91127-5 
572. Strang JIG, Nunn AJ, Johnson DA, Casbard A, Gibson DG, Girling DJ. Management of 
tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up. QJM 2004;97:525–35. https://doi.org/10.1093/qjmed/hch086 
573. Cui H-B, Chen X-Y, Cui C-C, Shou X-L, Liu X, Yao X-W, et al. Prevention of pericardial constriction by transcatheter intrapericardial fibrinolysis with urokinase. Chin Med 
Sci J 2005;20:5–10. https://doi.org/10.1016/j.chinmedsci.2005.01.002 
574. Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in 
patients with neoplastic disease. Prog Cardiovasc Dis 2010;53:157–63. https://doi.org/ 
10.1016/j.pcad.2010.06.003 
575. Imazio M, Demichelis B, Parrini I, Favro E, Beqaraj F, Cecchi E, et al. Relation of acute 
pericardial disease to malignancy. Am J Cardiol 2005;95:1393–4. https://doi.org/10. 
1016/j.amjcard.2005.01.094 
576. Pawlak Cieślik A, Szturmowicz M, Fijałkowska A, Gątarek J, Gralec R, 
Błasińska-Przerwa K, et al. Diagnosis of malignant pericarditis: a single centre experience. Kardiol Pol 2012;70:1147–53. https://doi.org/10.33963/v.kp.79064 
577. Karatolios K, Pankuweit S, Maisch B. Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion. Heart Fail Rev 2013;18:337–44. https:// 
doi.org/10.1007/s10741-012-9327-x 
578. Wang K, Eblan MJ, Deal AM, Lipner M, Zagar TM, Wang Y, et al. Cardiac toxicity after 
radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation 
trials delivering 70 to 90 Gy. J Clin Oncol 2017;35:1387–94. https://doi.org/10.1200/ 
JCO.2016.70.0229 
579. Takata N, Kataoka M, Hamamoto Y, Tsuruoka S, Kanzaki H, Uwatsu K, et al. Risk factors for pericardial effusion after chemoradiotherapy for thoracic esophageal cancer-  
ESC Guidelines                                                                                                                                                                                               87


<!-- PAGE 88 -->

### Page 88

comparison of four-field technique and traditional two opposed fields technique. J 
Radiat Res 2018;59:291–7. https://doi.org/10.1093/jrr/rry029 
580. Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al. 
Evaluation and management of cancer patients presenting with acute cardiovascular 
disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC Council of Cardio-Oncology—Part 1: acute coronary syndromes 
and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care 2021;10:947–59.  
https://doi.org/10.1093/ehjacc/zuab056 
581. Saab J, Hoda RS, Narula N, Hoda SA, Geraghty BE, Nasar A, et al. Diagnostic yield of 
cytopathology in evaluating pericardial effusions: clinicopathologic analysis of 419 specimens. Cancer Cytopathol 2017;125:128–37. https://doi.org/10.1002/cncy.21790 
582. Numico G, Cristofano A, Occelli M, Sicuro M, Mozzicafreddo A, Fea E, et al. Prolonged 
drainage and intrapericardial bleomycin administration for cardiac tamponade secondary to cancer-related pericardial effusion. Medicine (Baltimore) 2016;95:e3273. https:// 
doi.org/10.1097/MD.0000000000003273 
583. Kim SR, Kim EK, Cho J, Chang S-A, Park S-J, Lee S-C, et al. Effect of anti-inflammatory 
drugs on clinical outcomes in patients with malignant pericardial effusion. J Am Coll 
Cardiol 2020;76:1551–61. https://doi.org/10.1016/j.jacc.2020.08.003 
584. De Filippo O, Gatti P, Rettegno S, Iannaccone M, D’Ascenzo F, Lazaros G, et al. Is pericardial effusion a negative prognostic marker? Meta-analysis of outcomes of pericardial 
effusion. J Cardiovasc Med (Hagerstown) 2019;20:39–45. https://doi.org/10.2459/JCM. 
0000000000000720 
585. Gatzoulis K, Archontakis S, Tsiachris D, Lazaros G, Apostolopoulos T, Zervopoulos G, 
et al. Post-cardiac injury syndrome after permanent electronic cardiac device implantation. Incidence, presentation, management and long-term prognosis. Int J Cardiol 
2014;174:163–4. https://doi.org/10.1016/j.ijcard.2014.03.170 
586. Nakhla S, Mentias A, Rymer C, Hussein A, Wazni O, Rickard J, et al. Acute pericarditis 
after atrial fibrillation ablation: incidence, characteristics, and risk factors. Heart Rhythm 
2022;3:248–51. https://doi.org/10.1016/j.hroo.2022.02.008 
587. Imazio M, Negro A, Belli R, Beqaraj F, Forno D, Giammaria M, et al. Frequency and 
prognostic significance of pericarditis following acute myocardial infarction treated 
by primary percutaneous coronary intervention. Am J Cardiol 2009;103:1525–9.  
https://doi.org/10.1016/j.amjcard.2009.01.366 
588. Figueras J, Juncal A, Carballo J, Cortadellas J, Soler JS. Nature and progression of pericardial effusion in patients with a first myocardial infarction: relationship to age and free 
wall rupture. Am Heart J 2002;144:251–8. https://doi.org/10.1067/mhj.2002.123840 
589. Figueras J, Barrabés JA, Serra V, Cortadellas J, Lidón R-M, Carrizo A, et al. Hospital 
outcome of moderate to severe pericardial effusion complicating ST-elevation 
acute myocardial infarction. Circulation 2010;122:1902–9. https://doi.org/10. 
1161/CIRCULATIONAHA.109.934968 
590. Mohanty S, Mohanty P, Kessler D, Gianni C, Baho KK, Morris T, et al. Impact of colchicine monotherapy on the risk of acute pericarditis following atrial fibrillation ablation. JACC Clin Electrophysiol 2023;9:1051–9. https://doi.org/10.1016/j.jacep.2023.01. 
037 
591. Lehto J, Kiviniemi T, Gunn J, Airaksinen J, Rautava P, Kytö V. Occurrence of postpericardiotomy syndrome: association with operation type and postoperative mortality 
after open-heart operations. J Am Heart Assoc 2018;7:e010269. https://doi.org/10. 
1161/JAHA.118.010269 
592. Imazio M, Brucato A, Rovere ME, Gandino A, Cemin R, Ferrua S, et al. Contemporary 
features, risk factors, and prognosis of the post-pericardiotomy syndrome. Am J Cardiol 
2011;108:1183–7. https://doi.org/10.1016/j.amjcard.2011.06.025 
593. Finkelstein Y, Shemesh J, Mahlab K, Abramov D, Bar-El Y, Sagie A, et al. Colchicine for 
the prevention of postpericardiotomy syndrome. Herz 2002;27:791–4. https://doi.org/ 
10.1007/s00059-002-2376-5 
594. Imazio M, Trinchero R, Brucato A, Rovere ME, Gandino A, Cemin R, et al. COlchicine 
for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J 2010;31:2749–54. https:// 
doi.org/10.1093/eurheartj/ehq319 
595. Imazio M, Brucato A, Ferrazzi P, Spodick DH, Adler Y. Postpericardiotomy syndrome: 
a proposal for diagnostic criteria. J Cardiovasc Med (Hagerstown) 2013;14:351–3.  
https://doi.org/10.2459/JCM.0b013e328353807d 
596. Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the 
COPPS-2 randomized clinical trial. JAMA 2014;312:1016–23. https://doi.org/10. 
1001/jama.2014.11026 
597. Gill PJ, Forbes K, Coe JY. The effect of short-term prophylactic acetylsalicylic acid on 
the incidence of postpericardiotomy syndrome after surgical closure of atrial septal 
defects. Pediatr Cardiol 2009;30:1061–7. https://doi.org/10.1007/s00246-009-9495-1 
598. Mott AR, Fraser CD, Kusnoor AV, Giesecke NM, Reul GJ, Drescher KL, et al. The effect of short-term prophylactic methylprednisolone on the incidence and severity of 
postpericardiotomy syndrome in children undergoing cardiac surgery with cardiopulmonary bypass. J Am Coll Cardiol 2001;37:1700–6. https://doi.org/10.1016/s0735- 
1097(01)01223-2 
599. Bunge JJH, van Osch D, Dieleman JM, Jacob KA, Kluin J, van Dijk D, et al. Dexamethasone 
for the prevention of postpericardiotomy syndrome: a DExamethasone for Cardiac 
Surgery substudy. Am Heart J 2014;168:126–31.e1. https://doi.org/10.1016/j.ahj.2014. 
03.017 
600. Imazio M, Brucato A, Markel G, Cemin R, Trinchero R, Spodick DH, et al. Meta-analysis 
of randomized trials focusing on prevention of the postpericardiotomy syndrome. Am J 
Cardiol 2011;108:575–9. https://doi.org/10.1016/j.amjcard.2011.03.087 
601. Meurin P, Tabet JY, Thabut G, Cristofini P, Farrokhi T, Fischbach M, et al. Nonsteroidal 
anti-inflammatory drug treatment for postoperative pericardial effusion: a multicenter 
randomized, double-blind trial. Ann Intern Med 2010;152:137–43. https://doi.org/10. 
7326/0003-4819-152-3-201002020-00004 
602. Meurin P, Lelay-Kubas S, Pierre B, Pereira H, Pavy B, Iliou MC, et al. Colchicine for postoperative pericardial effusion: a multicentre, double-blind, randomised controlled trial. 
Heart 2015;101:1711–6. https://doi.org/10.1136/heartjnl-2015-307827 
603. Meurin P, Weber H, Renaud N, Larrazet F, Tabet JY, Demolis P, et al. Evolution of the 
postoperative pericardial effusion after day 15: the problem of the late tamponade. 
Chest 2004;125:2182–7. https://doi.org/10.1378/chest.125.6.2182 
604. Andreis A, Imazio M, Giustetto C, Brucato A, Adler Y, De Ferrari GM. Anakinra for 
constrictive pericarditis associated with incessant or recurrent pericarditis. Heart 
2020;106:1561–5. https://doi.org/10.1136/heartjnl-2020-316898 
605. Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, et al. Classification 
criteria for autoinflammatory recurrent fevers. Ann Rheum Dis 2019;78:1025–32.  
https://doi.org/10.1136/annrheumdis-2019-215048 
606. Sagristà-Sauleda J, Barrabés JA, Permanyer-Miralda G, Soler-Soler J. Purulent pericarditis: review of a 20-year experience in a general hospital. J Am Coll Cardiol 1993;22: 
1661–5. https://doi.org/10.1016/0735-1097(93)90592-o 
607. Rubin RH, Moellering RC. Clinical, microbiologic and therapeutic aspects of purulent 
pericarditis. Am J Med 1975;59:68–78. https://doi.org/10.1016/0002-9343(75)90323-x 
608. Brook I, Frazier EH. Microbiology of acute purulent pericarditis. A 12-year experience 
in a military hospital. Arch Intern Med 1996;156:1857–60. https://doi.org/10.1001/ 
archinte.1996.00440150113013 
609. Wiyeh AB, Ochodo EA, Wiysonge CS, Kakia A, Awotedu AA, Ristic A, et al. A systematic review of the efficacy and safety of intrapericardial fibrinolysis in patients with pericardial effusion. Int J Cardiol 2018;250:223–8. https://doi.org/10.1016/j.ijcard.2017.10. 
049 
610. Augustin P, Desmard M, Mordant P, Lasocki S, Maury J-M, Heming N, et al. Clinical review: intrapericardial fibrinolysis in management of purulent pericarditis. Crit Care 
2011;15:220. https://doi.org/10.1186/cc10022 
611. Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med 2011;155:409–14.  
https://doi.org/10.7326/0003-4819-155-7-201110040-00359 
612. Vogiatzidis K, Zarogiannis SG, Aidonidis I, Solenov EI, Molyvdas P-A, Gourgoulianis KI, 
et al. Physiology of pericardial fluid production and drainage. Front Physiol 2015;6:62.  
https://doi.org/10.3389/fphys.2015.00062 
613. Mitiku TY, Heidenreich PA. A small pericardial effusion is a marker of increased mortality. Am Heart J 2011;161:152–7. https://doi.org/10.1016/j.ahj.2010.10.007 
614. Corey GR, Campbell PT, Van Trigt P, Kenney RT, O’Connor CM, Sheikh KH, et al. 
Etiology of large pericardial effusions. Am J Med 1993;95:209–13. https://doi.org/10. 
1016/0002-9343(93)90262-n 
615. Sagristà-Sauleda J, Mercé J, Permanyer-Miralda G, Soler-Soler J. Clinical clues to the 
causes of large pericardial effusions. Am J Med 2000;109:95–101. https://doi.org/10. 
1016/s0002-9343(00)00459-9 
616. Levy P-Y, Corey R, Berger P, Habib G, Bonnet J-L, Levy S, et al. Etiologic diagnosis of 
204 pericardial effusions. Medicine (Baltimore) 2003;82:385–91. https://doi.org/10. 
1097/01.md.0000101574.54295.73 
617. Ma W, Liu J, Zeng Y, Chen S, Zheng Y, Ye S, et al. Causes of moderate to large pericardial effusion requiring pericardiocentesis in 140 Han Chinese patients. Herz 2012; 
37:183–7. https://doi.org/10.1007/s00059-011-3428-5 
618. Abdallah R, Atar S. Etiology and characteristics of large symptomatic pericardial effusion in a community hospital in the contemporary era. QJM 2014;107:363–8. https:// 
doi.org/10.1093/qjmed/hct255 
619. Roy CL, Minor MA, Brookhart MA, Choudhry NK. Does this patient with a pericardial 
effusion have cardiac tamponade? JAMA 2007;297:1810–8. https://doi.org/10.1001/ 
jama.297.16.1810 
620. Cremer PC, Kumar A, Kontzias A, Tan CD, Rodriguez ER, Imazio M, et al. Complicated 
pericarditis: understanding risk factors and pathophysiology to inform imaging and 
treatment. J Am Coll Cardiol 2016;68:2311–28. https://doi.org/10.1016/j.jacc.2016.07. 
785 
621. Lazaros G, Antonopoulos AS, Lazarou E, Vlachopoulos C, Foukarakis E, Androulakis A, 
et al. Long-term outcome of pericardial drainage in cases of chronic, large, hemodynamically insignificant, C-reactive protein negative, idiopathic pericardial effusions. 
Am J Cardiol 2020;126:89–93. https://doi.org/10.1016/j.amjcard.2020.03.035 
622. Lazaros G, Oikonomou V, Oikonomou E, Aznaouridis K, Vlachopoulos C, Vogiatzi G, 
et al. Recurrence of pericardial effusion after pericardiocentesis: does catheter- 
induced acute pericardial inflammation play a role? Am J Med Sci 2021;361:676–8.  
https://doi.org/10.1016/j.amjms.2020.10.012


<!-- PAGE 89 -->

### Page 89

623. Buoro S, Tombetti E, Ceriotti F, Simon C, Cugola D, Seghezzi M, et al. What is the normal composition of pericardial fluid? Heart 2021;107:1584–90. https://doi.org/10. 
1136/heartjnl-2020-317966 
624. Imazio M, Biondo A, Ricci D, Boffini M, Pivetta E, Brucato A, et al. Contemporary biochemical analysis of normal pericardial fluid. Heart 2020;106:541–4. https://doi.org/10. 
1136/heartjnl-2018-314574 
625. Imazio M, Lazaros G, Valenti A, De Carlini CC, Maggiolini S, Pivetta E, et al. Outcomes 
of idiopathic chronic large pericardial effusion. Heart 2019;105:477–81. https://doi.org/ 
10.1136/heartjnl-2018-313532 
626. Fröhlich GM, Keller P, Schmid F, Wolfrum M, Osranek M, Falk C, et al. 
Haemodynamically irrelevant pericardial effusion is associated with increased mortality 
in patients with chronic heart failure. Eur Heart J 2013;34:1414–23. https://doi.org/10. 
1093/eurheartj/eht006 
627. Porta-Sánchez A, Sagristà-Sauleda J, Ferreira-González I, Torrents-Fernández A, 
Roca-Luque I, García-Dorado D. Constrictive pericarditis: etiologic spectrum, patterns of clinical presentation, prognostic factors, and long-term follow-up. Rev Esp 
Cardiol (Engl Ed) 2015;68:1092–100. https://doi.org/10.1016/j.rec.2014.12.018 
628. Ling LH, Oh JK, Schaff HV, Danielson GK, Mahoney DW, Seward JB, et al. Constrictive 
pericarditis in the modern era: evolving clinical spectrum and impact on outcome after 
pericardiectomy. Circulation 1999;100:1380–6. https://doi.org/10.1161/01.cir.100.13.1380 
629. Bertog SC, Thambidorai SK, Parakh K, Schoenhagen P, Ozduran V, Houghtaling PL, 
et al. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. J Am Coll Cardiol 2004;43:1445–52. https://doi.org/10.1016/j.jacc.2003.11.048 
630. Mutyaba AK, Balkaran S, Cloete R, du Plessis N, Badri M, Brink J, et al. Constrictive pericarditis requiring pericardiectomy at Groote Schuur Hospital, Cape Town, South 
Africa: causes and perioperative outcomes in the HIV era (1990–2012). J Thorac 
Cardiovasc Surg 2014;148:3058–65.e1. https://doi.org/10.1016/j.jtcvs.2014.07.065 
631. Yang J, Xiang W, He R, Zhang P. Tuberculous constrictive pericarditis: ‘armored heart’. 
QJM 2024;117:679–80. https://doi.org/10.1093/qjmed/hcae101 
632. Welch TD, Ling LH, Espinosa RE, Anavekar NS, Wiste HJ, Lahr BD, et al. 
Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circ 
Cardiovasc Imaging 2014;7:526–34. https://doi.org/10.1161/CIRCIMAGING.113.001613 
633. Talreja DR, Nishimura RA, Oh JK, Holmes DR. Constrictive pericarditis in the modern 
era: novel criteria for diagnosis in the cardiac catheterization laboratory. J Am Coll 
Cardiol 2008;51:315–9. https://doi.org/10.1016/j.jacc.2007.09.039 
634. Qamruddin S, Alkharabsheh SK, Sato K, Kumar A, Cremer PC, Chetrit M, et al. 
Differentiating constriction from restriction (from the Mayo Clinic echocardiographic 
criteria). Am J Cardiol 2019;124:932–8. https://doi.org/10.1016/j.amjcard.2019.06.002 
635. Saito T, Fukushima S, Yamasaki T, Kawamoto N, Tadokoro N, Kakuta T, et al. 
Pericardiectomy for constrictive pericarditis at a single Japanese center: 20 years of experience. Gen Thorac Cardiovasc Surg 2022;70:430–8. https://doi.org/10.1007/s11748- 
021-01718-x 
636. Choi MS, Jeong DS, Oh JK, Chang S-A, Park S-J, Chung S. Long-term results of radical 
pericardiectomy for constrictive pericarditis in Korean population. J Cardiothorac Surg 
2019;14:32. https://doi.org/10.1186/s13019-019-0845-7 
637. George TJ, Arnaoutakis GJ, Beaty CA, Kilic A, Baumgartner WA, Conte JV. 
Contemporary etiologies, risk factors, and outcomes after pericardiectomy. Ann 
Thorac Surg 2012;94:445–51. https://doi.org/10.1016/j.athoracsur.2012.03.079 
638. Tzani A, Doulamis IP, Tzoumas A, Avgerinos DV, Koudoumas D, Siasos G, et al. 
Meta-analysis of population characteristics and outcomes of patients undergoing pericardiectomy for constrictive pericarditis. Am J Cardiol 2021;146:120–7. https://doi.org/ 
10.1016/j.amjcard.2021.01.033 
639. Faiza Z, Prakash A, Namburi N, Johnson B, Timsina L, Lee LS. Fifteen-year experience 
with pericardiectomy at a tertiary referral center. J Cardiothorac Surg 2021;16:180.  
https://doi.org/10.1186/s13019-021-01561-4 
640. Gillaspie EA, Stulak JM, Daly RC, Greason KL, Joyce LD, Oh J, et al. A 20-year experience with isolated pericardiectomy: analysis of indications and outcomes. J Thorac 
Cardiovasc Surg 2016;152:448–58. https://doi.org/10.1016/j.jtcvs.2016.03.098 
641. Ntsekhe M, Shey Wiysonge C, Commerford PJ, Mayosi BM. The prevalence and outcome of effusive constrictive pericarditis: a systematic review of the literature. 
Cardiovasc J Afr 2012;23:281–5. https://doi.org/10.5830/CVJA-2011-072 
642. Thevathasan T, Kenny MA, Gaul AL, Paul J, Krause FJ, Lech S, et al. Sex and age characteristics in acute or chronic myocarditis. a descriptive, multicenter cohort study. 
JACC Adv 2024;3:100857. https://doi.org/10.1016/j.jacadv.2024.100857 
643. Kanaoka K, Onoue K, Terasaki S, Nakano T, Nakai M, Sumita Y, et al. Features and outcomes of histologically proven myocarditis with fulminant presentation. Circulation 
2022;146:1425–33. https://doi.org/10.1161/CIRCULATIONAHA.121.058869 
644. Conte E, Leoni O, Ammirati E, Imazio M, Brucato A. Incidence of myocarditis and pericarditis considered as separate clinical events over the years and post-SARS-CoV2 vaccination in adults and children. Eur J Intern Med 2023;115:140–2. https://doi.org/10. 
1016/j.ejim.2023.06.002 
645. Klugman D, Berger JT, Sable CA, He J, Khandelwal SG, Slonim AD. Pediatric patients 
hospitalized with myocarditis: a multi-institutional analysis. Pediatr Cardiol 2010;31: 
222–8. https://doi.org/10.1007/s00246-009-9589-9 
646. Pitak B, Opgen-Rhein B, Schubert S, Reineker K, Wiegand G, Boecker D, et al. 
Cardiovascular magnetic resonance in children with suspected myocarditis: current 
practice and applicability of adult protocols. Cardiol Young 2022;32:1957–65. https:// 
doi.org/10.1017/S1047951121005291 
647. Peng DM, Kwiatkowski DM, Lasa JJ, Zhang W, Banerjee M, Mikesell K, et al. 
Contemporary care and outcomes of critically-ill children with clinically diagnosed 
myocarditis. J Card Fail 2023;30:350–8. https://doi.org/10.1016/j.cardfail.2023.04.010 
648. Schubert S, Opgen-Rhein B, Boehne M, Weigelt A, Wagner R, Müller G, et al. Severe 
heart failure and the need for mechanical circulatory support and heart transplantation 
in pediatric patients with myocarditis: results from the prospective multicenter registry 
‘MYKKE’. Pediatr Transplant 2019;23:e13548. https://doi.org/10.1111/petr.13548 
649. Matsuura H, Ichida F, Saji T, Ogawa S, Waki K, Kaneko M, et al. Clinical features of acute 
and fulminant myocarditis in children – 2nd Nationwide Survey by Japanese Society of 
Pediatric Cardiology and Cardiac Surgery. Circ J 2016;80:2362–8. https://doi.org/10. 
1253/circj.CJ-16-0234 
650. Yao Q, Zhan S. Corticosteroid in anti-inflammatory treatment of pediatric acute myocarditis: a systematic review and meta-analysis. Ital J Pediatr 2023;49:30. https://doi.org/ 
10.1186/s13052-023-01423-w 
651. Camargo PR, Snitcowsky R, da Luz PL, Mazzieri R, Higuchi ML, Rati M, et al. Favorable 
effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis. Pediatr Cardiol 1995;16:61–8. https://doi.org/10.1007/BF00796819 
652. Aziz KU, Patel N, Sadullah T, Tasneem H, Thawerani H, Talpur S. Acute viral myocarditis: role of immunosuppression: a prospective randomised study. Cardiol Young 2010; 
20:509–15. https://doi.org/10.1017/S1047951110000594 
653. Lin M-S, Tseng Y-H, Chen M-Y, Chung C-M, Tsai M-H, Wang P-C, et al. In-hospital and 
post-discharge outcomes of pediatric acute myocarditis underwent after high-dose 
steroid or intravenous immunoglobulin therapy. BMC Cardiovasc Disord 2019;19:10.  
https://doi.org/10.1186/s12872-018-0981-3 
654. Butts RJ, Boyle GJ, Deshpande SR, Gambetta K, Knecht KR, Prada-Ruiz CA, et al. 
Characteristics of clinically diagnosed pediatric myocarditis in a contemporary multi- 
center cohort. Pediatr Cardiol 2017;38:1175–82. https://doi.org/10.1007/s00246-017- 
1638-1 
655. Huang X, Sun Y, Su G, Li Y, Shuai X. Intravenous immunoglobulin therapy for acute 
myocarditis in children and adults. Int Heart J 2019;60:359–65. https://doi.org/10. 
1536/ihj.18-299 
656. Imazio M, Brucato A, Pluymaekers N, Breda L, Calabri G, Cantarini L, et al. Recurrent 
pericarditis in children and adolescents: a multicentre cohort study. J Cardiovasc Med 
(Hagerstown) 2016;17:707–12. https://doi.org/10.2459/JCM.0000000000000300 
657. Alsabri M, Elsayed SM, Elsnhory AB, Abouelmagd K, Ayyad M, Alqeeq BF, et al. Efficacy 
and safety of colchicine in pediatric pericarditis: a systematic review and future directions. Pediatr Cardiol 2024; https://doi.org/10.1007/s00246-024-03606-6 
658. Caorsi R, Insalaco A, Bovis F, Martini G, Cattalini M, Chinali M, et al. Pediatric recurrent 
pericarditis: appropriateness of the standard of care and response to IL-1 blockade. J 
Pediatr 2023;256:18–26.e8. https://doi.org/10.1016/j.jpeds.2022.11.034 
659. Sunohara D, Motoki H, Saigusa T, Ebisawa S, Okada A, Ando H, et al. Biopsy detection 
and clinical management of acute lymphocytic myocarditis in pregnancy. J Cardiol Cases 
2019;20:164–7. https://doi.org/10.1016/j.jccase.2019.07.010 
660. Veronese G, Nonini S, Cannata A, Aresta F, Olivieri G, Montrasio E, et al. Fulminant 
lymphocytic myocarditis during pregnancy treated with temporary mechanical circulatory supports and aggressive immunosuppression. Circ Heart Fail 2022;15: 
e009810. https://doi.org/10.1161/CIRCHEARTFAILURE.122.009810 
661. Moore RC, Briery CM, Rose CH, Skelton TN, Martin JN. Lymphocytic myocarditis 
presenting as nausea, vomiting, and hepatic dysfunction in the first trimester of pregnancy. Obstet Gynecol 2006;108:815–7. https://doi.org/10.1097/01.AOG.0000216016. 
91685.52 
662. Marceau A, McGinnis JM, Derakhshan F, Liu YA, Sathananthan G, Sosa Cazales AC, 
et al. Interdisciplinary approach to an unusual case of myocarditis in pregnancy. CJC 
Open 2019;1:103–5. https://doi.org/10.1016/j.cjco.2019.02.001 
663. Movva R, Brown SB, Morris DL, Figueredo VM. Anakinra for myocarditis in juvenile 
idiopathic arthritis. Tex Heart Inst J 2013;40:623–5. 
664. Brucato A, Pluymaekers N, Tombetti E, Rampello S, Maestroni S, Lucianetti M, et al. 
Management of idiopathic recurrent pericarditis during pregnancy. Int J Cardiol 2019; 
282:60–5. https://doi.org/10.1016/j.ijcard.2019.02.003 
665. Pouta AM, Räsänen JP, Airaksinen KE, Vuolteenaho OJ, Laatikainen TJ. Changes in maternal heart dimensions and plasma atrial natriuretic peptide levels in the early puerperium of normal and pre-eclamptic pregnancies. Br J Obstet Gynaecol 1996;103: 
988–92. https://doi.org/10.1111/j.1471-0528.1996.tb09548.x 
666. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková 
R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165–241. https://doi.org/10.1093/ 
eurheartj/ehy340 
667. Schreiber K, Frishman M, Russell MD, Dey M, Flint J, Allen A, et al. British Society for 
Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice. Rheumatology 2023;62: 
e89–e104. https://doi.org/10.1093/rheumatology/keac552 
668. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin 
MD, et al. 2020 American College of Rheumatology Guideline for the management  
ESC Guidelines                                                                                                                                                                                               89


<!-- PAGE 90 -->

### Page 90

of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 
2020;72:529–56. https://doi.org/10.1002/art.41191 
669. Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers 
C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795–810. https:// 
doi.org/10.1136/annrheumdis-2015-208840 
670. Russell MD, Dey M, Flint J, Davie P, Allen A, Crossley A, et al. British Society for 
Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology 2023;62: 
e48–e88. https://doi.org/10.1093/rheumatology/keac551 
671. Bizzi E, Cavaleri F, Mascolo R, Conte E, Maggiolini S, Decarlini CC, et al. Recurrent pericarditis in older adults: clinical and laboratory features and outcome. J Am Geriatr Soc 
2024;72:3467–75. https://doi.org/10.1111/jgs.19150 
672. Pasina L, Brucato AL, Falcone C, Cucchi E, Bresciani A, Sottocorno M, et al. Medication 
non-adherence among elderly patients newly discharged and receiving polypharmacy. 
Drugs Aging 2014;31:283–9. https://doi.org/10.1007/s40266-014-0163-7 
673. Peretto G, De Luca G, Campochiaro C, Palmisano A, Busnardo E, Sartorelli S, et al. 
Telemedicine in myocarditis: evolution of a mutidisciplinary ‘disease unit’ at the time 
of COVID-19 pandemic. Am Heart J 2020;229:121–6. https://doi.org/10.1016/j.ahj. 
2020.07.015 
674. Aldajani A, Bérubé M, Mardigyan V. How and why to set up a pericardial disease clinic. 
Can J Cardiol 2023;39:1149–51. https://doi.org/10.1016/j.cjca.2023.04.028 
675. Mizia-Stec K, Charron P, Gimeno Blanes JR, Elliott P, Kaski JP, Maggioni AP, et al. 
Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis 
of cardiomyopathy: the ESC EORP cardiomyopathy/myocarditis registry. Eur Heart J 
Cardiovasc Imaging 2021;22:781–9. https://doi.org/10.1093/ehjci/jeaa329 
676. Kaski JP, Norrish G, Gimeno Blanes JR, Charron P, Elliott P, Tavazzi L, et al. 
Cardiomyopathies in children and adolescents: aetiology, management, and outcomes 
in the European Society of Cardiology EURObservational Research Programme 
Cardiomyopathy and Myocarditis Registry. Eur Heart J 2024;45:1443–54. https://doi. 
org/10.1093/eurheartj/ehae109
